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Abstract 
The discovery of new treatments for chronic pain relies on the detection of pre-clinical targets 
and the progression to successful clinical trials. In order to improve this transition reliable 
translational models must be identified, based on mechanisms that underlie the symptoms of 
chronic pain. This thesis aimed to validate the use of 3 potential translational models: topical 
capsaicin, ultraviolet irradiation (UVB) and UVB rekindling. Furthermore, using a mechanism 
based approach to treatment, the modulation of capsaicin induced sensitisation was explored 
in animals and humans. 
In order to characterise the models in rats, in vivo electrophysiological recordings were made 
from single unit dorsal horn wide dynamic range neurones. Evoked responses to thermal, 
mechanical and electrical stimulation were quantified. To complement the animal studies, full 
QST  profiling  was  undertaken  on  healthy  human  volunteers.  Assessments  of  the  pain 
thresholds were made, as well as numerical ratings to sub and supra threshold stimuli, in 
order to best compare these results with rodent data. 
All of the models tested evoked similar sensory changes across species, and the symptoms 
induced in each of the models were used to infer the peripheral and central components. 
Sensory changes evoked by capsaicin included mechanical hypersensitivity accompanied by a 
facilitation of responses in the Aδ fibre range. These are reflective of both a peripheral and 
central sensitisation. Furthermore, these changes were prevented by pre-treatment with the 
adenosine receptor 1 (A1R) agonist, CPA. UVB appeared to be a strictly peripheral model, 
resulting in no secondary changes or receptive field expansion. On the other hand, the UVB 
rekindling model showed clear signs of engaging both peripheral and central mechanisms, 
including thermal allodynia, secondary brush hypersensitivity and a facilitation of Aβ fibre 
responses. 
Overall, we confirmed that similar short-term sensory consequences, that may mimic certain 
pathophysiologies, could be engaged and quantified in rats and human volunteers in response 
to topical capsaicin, UVB irradiation and UVB rekindling. The UVB rekindling model induced 
signs of the engagement of a number of clinically relevant phenomena, such as peripheral 
inflammation/ sensitisation driving central modifications. As such this model will be useful in 
investigating  mechanisms  of  inflammatory  pain  and  assessing  analgesic  efficacy  of  novel 
medications. 
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1.  Introduction   22 
 
1.1.   Overview of Pain 
Around 1664 Descartes proposed his alarm bell type model of pain. He postulated that the 
afferent nerve functioned like a tiny rope; the end triggered by damage in the skin and a 
sensor pulling on the cord located in a ‘pain centre’ in the brain: 
“…ainsi que tirant l’un des bouts d’une corde on fait sonner en même temps la cloche qui pend à 
l’autre bout.” 
Although rather simplistic, this biomedical model conjures a wonderful image and captures 
the essence of the protective nature of pain. The somatosensory phenomenon can indeed 
result  from  the  transmission  of  signals  from  peripheral  nociceptors,  initiated  by  tissue 
damage.  A  signal  that  is  relayed  through  the  spinal  cord  and  reaches  the  somatosensory 
cortex in the brain, where it may be interpreted as painful. However, it is now well recognised 
that pain also incorporates psychological, social, and behavioural aspects. Furthermore, whilst 
this kind of alarm bell warning signal is necessary for survival, when the pain outlasts the 
initiating stimuli and becomes chronic it leads to great suffering. 
 
Figure 1-1 ‘Traité de l'Homme’. Descartes’ original proposition of the pain pathway. 
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1.1.1.  Pain defined: A complex aetiology with multiple co-morbidities 
Aristotle described pain as “the passion of the soul”, an early description which begins to hint 
at the subjective, conscious nature of the experience. Pain usually results from a nociceptive 
input,  which  is  subsequently  modified  by  a  number  of  affective  emotional  and  cognitive 
evaluative factors. The initial intensity of a given sensory stimulus is therefore not necessarily 
proportional to what is perceived by the subject. Whilst nociception is generally accepted to 
describe the neuronal activity, pain refers to the additional integration of complex emotional 
factors.  This  is  reflected  in  the  International  Association  for  the  Study  of  Pain  (IASP) 
definition, which describes pain as “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage” (Merskey and 
Bogduk 1994). In recent years it has become apparent that pain is also influenced by genetic 
factors,  which  contribute  to  the  variation  in  perception  between  individuals  (Mogil  et  al. 
1999; Binder et al. 2011; Sikandar et al. 2013). This variable relationship between stimulus 
and percept often creates difficulties not only with regards to measurement, but also more 
importantly  to  the  management  and  treatment  of  pain,  particularly  for  those  affected  by 
chronic conditions.  
Pain can be classified in a number of ways.  Whilst clinicians sometimes use a disease-based 
classification, scientists more often try to classify pain on the basis of underlying mechanisms 
(Jensen  and  Baron  2003).  Thus,  several  broad  categories  are  recognised.  These  are:  
nociceptive pain, inflammatory pain, neuropathic pain (and syndromes that combine these), 
and  a  less  well  understood  category  referred  to  as  ‘dysfunctional’  or  ‘generalised’  pain. 
Nociceptive  pain  is  that  which  transiently  activates  the  nociceptive  system,  for  instance 
stubbing  one’s  toe.  Inflammatory  pain  is  associated  with  the  release  into  tissues  of 
inflammatory mediators, which not only activate but also sensitise the pain signalling system. 
It includes conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA), as well as 
post-operative pain. Neuropathic pain is usually the result of a lesion or disease located at any 
point of the neuraxis – from the peripheral to the central nervous system (CNS). This category 
commonly  includes  disorders  of  the  peripheral  nervous  system  such  as  post  herpetic 
neuralgia (PHN), diabetic neuropathy (DPN), or human immunodeficiency virus (HIV) related 
neuropathies.  In  all  these  cases,  the  pain  appears  to  be  related  to  damage  of  peripheral 
nerves. Neuropathic pain can however also arise following damage to the CNS; such as spinal 
cord  injury,  multiple  sclerosis,  and  stroke.  Cancer  pain  often  includes  a  mixture  of 
mechanisms  with  a  contribution  of  space-occupying  tumours,  a  release  of  inflammatory 
mediators and compression or invasion of nerves (Sikandar et al. 2013). Finally, generalised 24 
 
pain  refers  to  conditions  that  have  no  obvious  tissue  or  nerve  damage,  and  includes 
fibromyalgia, irritable bowel syndrome (IBS), and tension headaches.  
All classifications of pain may be acute or chronic, the latter being defined as pain persisting 
for  3  (or  6)  months,  in  duration  (McMahon  et  al.  2013).  Although  it  may  be  considered 
pathological when it outlasts a nociceptive stimulation, or is present in the absence of external 
stimuli, it may equally arise from a defined stimulus such as in OA, RA or nerve injury. Acute 
pain is necessary for survival, in order to drive protective reflexes and help avoid harm. This 
function  provides  considerable  benefit,  as  evidenced  for  instance  by  the  rare  cases  of 
congenital insensitivity to pain (resulting from mutations in genes such as SCN9A and those 
encoding NK1 receptors), which are potentially fatal since sufferers are particularly prone to 
burns, fractures and other such physical injuries (Cox et al. 2006; Sikandar et al. 2013). While 
pain may therefore be considered an adaptive behaviour, the development into a chronic state 
on the other hand may certainly be deemed maladaptive. When the acute responses outlast 
the initiating stimuli, and persevere long beyond the time that such sensations serve any 
useful purpose, unrelenting suffering can occur with a consequential decrease in quality of 
life.  Chronic  pain  involves  the  emergence  of changes  in  normal  pain  processing  and  thus 
involves different mechanisms to those in normal pain sensing. As a result it may be more 
difficult to manage and treatments are often associated with greater side effects.  
In healthy volunteers, stimuli applied to peripheral tissues such as skin or muscle produce 
pain typically when the stimulus intensity rises to a level that might damage tissues, such as 
skin  temperatures  above  45C.  With  even  stronger  stimuli,  the  perceived  pain  rises 
monotonically with stimulus strength. However, many chronic pain patients show stimulus 
response relationships that are shifted leftwards and upwards. In other words, for a given 
degree of painful stimulus, the chronic pain patient feels more intense pain than they would if 
healthy. The term for this phenomenon is hyperalgesia. Allodynia is a term that refers to the 
condition where a normally non-painful stimulus begins to evoke the sensations of pain. For 
example, the simple process of brushing ones hair becomes exquisitely painful. Allodynia is 
not simply an extension of hyperalgesia since it may reflect activity in innocuous sensory 
receptors being abnormally interpreted as pain.  
Whilst  chronic  pain  serves  as  an  umbrella  term,  encompassing  a  wide  variety  of  clinical 
features such as hyperalgesia and allodynia, these features can be broken down further into 
the modality affected. It is clear that different symptoms are the manifestation of distinct 
underlying  mechanisms.  For  example,  hyperalgesia  to  thermal  stimuli  may  have  different 25 
 
mechanisms  to  mechanical  hyperalgesia,  and  cold  allodynia  most  certainly  differs  in  its 
origins from dynamic mechanical allodynia (DMA) (Dworkin et al. 2003; Baron 2006; Baron et 
al.  2010).  Furthermore,  although  there  may  be  an  association  between  mechanisms  and 
symptoms, there is not necessarily any one specific mechanism which can be assigned to a 
single symptom and there are likely to be a number of mechanisms which can lead to the 
same  symptom  (Jensen  and  Baron  2003).  Different  symptoms  therefore  have  different 
pharmacological sensitivities and as such it is unrealistic to attempt to find one treatment that 
will suffice for all chronic pain sufferers.  Moreover, it seems likely that a mechanism-based 
approach to treatment will bring more success into helping patients improve their quality of 
life.  
These mechanisms will be discussed in further detail throughout this thesis, however as it 
stands we still do not have a full understanding of the mechanisms underpinning chronic pain 
and as such many patients find their treatment inadequate. It is estimated up to one in five of 
the adult population in Europe suffer (Breivik et al. 2006). Similar figures were found in a 
more recent evaluation of non-cancer related moderate-severe pain in Europe, where it was 
established  that  19%  of  the  population  were  affected  (Reid  et  al.  2011).  In  Britain  it  is 
believed that up to 10 million suffer from pain each day (BPS 2005). Furthermore, it was 
shown that up to 40% of the patients studied receive inadequate treatment, highlighting the 
large  gap  in  pharmacological  and  non-pharmacological  interventions  for  such  conditions 
(Breivik et al. 2006; Attal et al. 2011). 
This  treatment  shortfall  may  have  a  direct  impact  on  patient’s  everyday  lives,  inhibiting 
normal  daily  activities  such  as  going  to  work  and  socialising,  eventually  leaving  some 
completely disabled. In addition to this suffering, many clinical studies have shown there to be 
a correlation with affective disorders in patients suffering from chronic conditions. Common 
co-morbidities  include  anxiety,  depression  and  sleep  disturbances  (Gormsen  et  al.  2010; 
Rehm  et  al.  2010),  with  up  to  36%  of  patients  reporting  that  chronic  pain  has  a  further 
negative  impact  on  their  family  and  friends  (Baker  2010).  Furthermore,  the  direct  and 
indirect cost to the economy as a result of chronic pain is estimated to be up to €200 billion in 
Europe  alone  (Baker  2010).  Thus,  there  are  a  number  of  pressing  reasons  for  better 
management  and  treatment  of  chronic  pain.  Knowledge  of  the  underlying  mechanisms  is 
imperative for the development of such pharmaceuticals and as such this thesis will focus on 
the exploring translational models with mechanisms that are likely to contribute to chronic 
pain.  26 
 
1.1.2.  Pain is detected by a specific set of primary sensory neurones 
Pain is most commonly initiated by excitation of specialised peripheral afferent fibres (PAFs), 
named nociceptors  (Sherrington 1900). These  sensory  neurones  detect  noxious stimuli  of 
chemical, mechanical and thermal nature. They include unmyelinated C fibres and myelinated 
Aδ fibres (Burgess and Perl 1967; Bessou and Perl 1969; Meyer et al. 2006) and under certain 
pathological conditions it is believed that myelinated Aβ fibres may also contribute to the 
sensation of pain (Treede and Cole 1993; Latremoliere and Woolf 2009). The thick myelinated 
Aβ  fibres  are  the  fastest  conductors,  with  velocities  (in  humans)  of  around  30-80  m/s, 
whereas the thinly myelinated Aδ fibres conduct around 6-30 m/s, and finally C fibres are the 
slowest with velocities around 0.5-2 m/s. These somatosensory afferents innervate virtually 
all tissues of the body. Their cell bodies are found mainly within the dorsal root ganglia (DRG), 
or the trigeminal ganglion. They have bifuricating axons, allowing branching into peripheral 
tissues and into the dorsal horn (DH) of spinal cord (or brainstem) where they synapse with 
second order projection neurones. The action potentials arising from nociceptor terminals are 
relayed to the CNS where they are integrated and interpreted in a manner that motivates 
behaviour aimed at limiting the damaging influence of the noxious stimulus.  
Fibres may be classified by their distinct functions or expression patterns. C fibres are the 
smallest  of  the  primary  afferents  and  unmyelinated,  which  renders  them  the  slowest  in 
conducting. Activation of C fibres results in a burning, pricking, tingling or warm sensation 
(Mouraux et al. 2010).  Studies of rodent cutaneous nociceptors suggest they can be broadly 
split into two classes depending on the genes they express and therefore their peripheral 
sensitivity, and their central termination patterns (Snider and McMahon 1998). These two 
groups,  roughly  equally  numerous,  are  commonly  referred  to  as  peptidergic  and  non 
peptidergic,  as  the  former  but  not  the  latter  normally  express  neuropeptides  such  as 
substance P, calcitonin gene related peptide (CGRP) and somatostatin (Snider and McMahon 
1998).  Non-peptidergic  neurones  contain  fluoride-resistant  acid  phosphotase  and  stain 
positively  for  the  plant  binding  lectin  isolectin  B4  (IB4)  (Silverman  and  Kruger  1988). 
Peptidergic neurones are also characterised by their expression of the high affinity receptor 
for nerve growth factor (NGF), tyrosine kinase A receptor (TrkA), whereas non peptidergic 
are generally found to express glial cell line-derived neurotrophic factor receptors such as 
GFRα1-4 and receptor tyrosine kinase Ret (Averill et al. 1995; Bennett et al. 1998; Orozco et 
al. 2001). More recently it has become clear that there is a significant population of low-27 
 
threshold C fibres that are more common in proximal body sites that may mediate pleasant 
touch sensations (Löken et al. 2009).  
Aδ fibre stimulation can lead to tingling and pricking sensations, as well as that of light touch 
(Mouraux et al. 2010). All of these afferents are believed to express neurofilament-200 and 
the brain-derived neurotrophic factor (BDNF) receptor (Priestley et al. 2002). These fibres 
can also be split into two subgroups, which are both thinly myelinated; type I are generally 
found to respond to heat greater than 50°C, whereas type II have a lower threshold around 
42-45°C (Treede et al. 1995). The high threshold Aδ and C fibres are collectively thought of as 
nociceptors.  The  differences  in  neurotransmitters/neuromodulators,  receptors  and 
sensitivities  of  nociceptors  suggests  that  they  all  contribute  to  pain  signalling  in  slightly 
different ways and each have their own specific subtle functions.  
 
1.1.3.  Stimuli are transduced via specific receptors on nociceptor peripheral terminals 
The  ability  to  detect  and  transduce  potentially  damaging  external  stimuli  is  required  for 
survival. This process is carried out by a myriad of receptors (detailed in table 1-1), which are 
found on the unencapsulated nerve endings of peripheral nociceptors. Transduction converts 
stimuli  into  an  electrical  signal  known  as  a  generator  potential,  which  can  drive  action 
potentials,  and  allow  the  message  to  be  relayed  to  the  spinal  cord  and  higher  centres. 
Although there are a number of ways in which nociceptors can be classified, one way to do so 
is by the range of stimuli that the peripheral afferent responds to. This classification system 
includes: polymodal nociceptors (responding to mechanical, thermal and chemical stimuli); C-
heat, C-mechano-heat, C-mechano-cold fibres; mechanically insensitive afferents (do not, at 
least in normal conditions, respond to mechanical stimuli) (Meyer and Campbell 1988; Davis 
et al. 1993; Schmidt et al. 1995; Weidner et al. 1999).  
Polymodal afferents express a number of receptors detailed in the table 1-1 below. They may 
be ionotropic or metabotropic and activation generates either inward or outward currents, 
resulting  in  a  depolarisation  or  hyperpolarisation  of  the  afferent,  respectively.  Ionotropic 
receptors allow either an influx or efflux of certain ions, whereas  metabotropic G protein 
coupled receptors activate specific signalling cascades and second messengers. It is important 
to note that with regards to mechanotransduction, the receptors remain poorly defined (Coste 
et al. 2012).  
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Stimulus Type  Stimuli 
Candidate 
Receptor 
Receptor Type 
Thermal 
  
  
>42C, Capsaicin  TRPV1  Ionotropic 
Heat  TRPV2-4  Ionotropic 
Cold, Menthol  TRPM8  Ionotropic 
Mechanical    
Unknown 
ASIC?  TRP?  Piezo 
1-2?   
Chemical  
  
  
  
  
  
  
  
H+  TRPV1/ASIC  Ionotropic 
Ci;8nnamaldehyde, 
Mustard Oil, Formalin  TRPA1  Ionotropic 
ATP/ADP  P2X  Ionotropic 
Adenosine  A1-4  Metabotropic 
Bradykinin  BK1-2  Metabotropic 
Prostaglandins  EP1-4  Metabotropic 
Histamine  H1  Metabotropic 
Serotonin  5HT3  Ionotropic 
 
Table  1-1  The  major  mammalian  receptor  types  located  on  peripheral  afferent  nociceptors. 
Thermosensation is governed almost exclusively by TRP channels, whilst chemosensitivity is dictated by the 
expression of a number of different channels. Suggested candidate mechanotransducer molecules includes TRPs, 
potassium channels, Piezos, and ASICs, although this process is not yet fully understood (Basbaum et al. 2009). 
 
1.1.4.  TRP Channels 
Transient receptor potential (TRP) channels are one of the largest families of ion channels and 
have  a  wide  variety  of  functional  roles.  In  1969  Cosens  and  Manning  isolated  a  mutant 
photoreceptor  from  the  drosophila,  which  caused  the  specimen  to  become  blind  upon 
exposure to bright light (Cosens and Manning 1969).  This was the first TRP channel to be 
discovered and since then 28 mammalian isoforms have been identified, which are split into 7 
different subfamilies (Clapham 2003; Venkatachalam and Montell 2007). They are made up of 
6 transmembrane domain (TMD) polypeptide subunits, which assemble as tetramers that can 
form pores in the cell membrane (Ramsey et al. 2006).  29 
 
Currently, they are one of the most extensively studied families of ion channels present in 
sensory neurones. The seven sub-families include: TRPV, TRPC, TRPM, TRP TRPML, TRPA and 
TRPP (Venkatachalam and Montell 2007). TRPM8 and A1 are thought to be involved in cold 
sensing (McKemy et al. 2002; Story et al. 2003), whereas seven others are activated by heat, 
over a distinct range of temperatures: TRPV1-4, TRPM2, TRPM4 and TRPM5 (Venkatachalam 
and Montell 2007). Collectively, these nine channels are expressed on A and C fibres and are 
known as thermoTRPs. They are activated at different ranges of temperature, both noxious 
and non-noxious (Venkatachalam and Montell 2007). It has been suggested that TRPV1 and 
TRPM8/TRPA1  are  the  first  to  detect  noxious  hot  and  cold  stimuli,  respectively,  with 
activation thresholds of 42°C for TRPV1 and 14°C for TRPA1 (McKemy et al. 2002; Dhaka et al. 
2006), thus activation of one of these receptors is proposed to lead to the perception of hot or 
cold thermal pain. TRPV2 on the other hand appears to be expressed on A rather than C 
fibres, and has the highest threshold for activation (over 52°C) and contributes to noxious 
heat perception (Caterina et al. 1999). 
 
1.1.5.  The TRPV1 Receptor 
The transient receptor potential vanilloid type 1 (TRPV1) receptor is a non-selective ligand 
gated  ion  channel.  It  is  an  integrator  of  many  physical  and  chemical  stimuli,  including 
capsaicin  and  noxious  heat  (>43  °C),  as  well  as  being  activated  by  protons  (pH  <5.2), 
endogenous  lipids  and  certain  inflammatory  mediators  (Szallasi  and  Blumberg  1999).  All 
compounds are lipophilic and therefore act at intracellular binding sites. Stimuli are detected 
and transduced through opening of the ion channel, which results in entry of cations such as 
Na+ and Ca2+ to the neurone; it has been shown that although the channel is non-selective, it 
has a high permeability to Ca2+ (Caterina et al. 1997). 
TRPV1 is believed to exist as a homo or heteromeric complex consisting of 4 subunits, with a 
pore-forming hydrophobic stretch between TMDs 5 -6 (Caterina et al. 1997; Moiseenkova-Bell 
et  al.  2008).  The  presence  of  specific  amino  acid  residues  are  required  for  sensitivity  to 
different  stimuli;  it  is  believed  that  Y511  and  S512  located  between  TMDs  2-3  dictate 
vanilloid/capsaicin  sensitivity  since  mutations  to  tyrosine  or  alanine  render  the  channel 
capsaicin insensitive (Jordt and Julius 2002). 
The  receptors are  known  to  be  expressed on  primary sensory  neurones. They have  been 
detected on terminals of small- to medium- diameter nociceptors, such as peptidergic and 30 
 
non-peptidergic  C  fibres,  as  well  as  some  Aδ  fibres  (Caterina  et  al.  1997).  Caterina  and 
colleagues  demonstrated  that  capsaicin  sensitivity  is  eliminated  in  TRPV1-/-  mice,  though 
interestingly they only display impaired heat detection and reduced thermal hypersensitivity 
in response to inflammatory agents (Caterina et al. 2000).  This highlights the importance of 
TRPV1 for heat sensing and the induction of thermal hyperalgesia in inflammatory states, 
whilst suggesting there may be other receptors also involved. 
Recently, the function of TRPV1 expressing afferents has been explored with the profiling of 
TRPV1-DTA mice, generated by Mishra and colleagues. As noted, it was previously shown that 
TRPV1 knockout (KO) mice maintained some thermosensation, which was only impaired over 
50°C  (Caterina  et  al.  2000).  However,  these  mice,  whose  TRPV1  afferents  are  completely 
ablated, have no response to capsaicin and are also totally insensitive to both hot and cold 
(Mishra and Hoon 2011). The lack of cold sensitivity is believed to be due to co-expression of 
the  channels early on in development, which is  normally lost during adulthood  (McKemy 
2011). The mice also exhibited no hypothermia in response to intraplantar capsaicin, which is 
seen  in  normal  animals.  This  suggests  that  the  group  of  TRPV1  positive  afferents  are 
imperative in the detection of noxious heat and thermoregulation. 
 
1.1.6.  The TRPM8 Receptor 
Another member of the  TRP  family, TRPM8, may be  more  important for the  detection  of 
cooling (30-15°C) and noxious cold (<15°C) (McKemy et al. 2002). TRPM8 is activated by 
menthol, which has been shown to cause cooling and eventually irritation and pain when 
applied to the skin of human volunteers (Wasner et al. 2004). TRPM8 is a non-selective cation 
channel and activation generates currents required for cold sensing. TRPM8 KO mice show 
deficiencies  in  cold  detection,  as  well  as  impaired  development  of  cold  hypersensitivity, 
suggesting that the receptor is indeed involved in cold sensing and the pathological sensations 
(Bautista et al. 2007; Colburn et al. 2007; Dhaka et al. 2007). 
A second channel suggested to take part in detection of cold stimuli is TRPA1, which does not 
appear to have any co-localisation with TRPM8 and thus may contribute to cold sensing in a 
separate set of neurones (Story et al. 2003; Kwan et al. 2006). However, the data is conflicting 
as although some studies have shown cold induced Ca2+ influx through TRPA1, others were 
unable to reproduce this and thus the full contribution of TRPA1 in cold sensing remains 
controversial (Story et al. 2003; Jordt et al. 2004). Since there are also a number of neurones 31 
 
which do not express either TRPM8 or TRPA1, but are cold sensitive, this suggests that other 
channels must also be involved in cold sensing (Munns et al. 2007). 
Together TRPV1 and TRPM8 can sense temperatures from 42°C+ and <15-30°C (Caterina et 
al. 1997; McKemy et al. 2002); a range which may be expanded under certain pathological 
conditions. Despite the indicated function in the detection of heat and cold pain, with possible 
involvements in chronic pain, it has also been suggested that when simultaneously activated 
their actions may oppose one another. Premkumar and colleagues found that intraplantar 
injection of both capsaicin and menthol reduced nocifensive behaviour in mice, in comparison 
to capsaicin alone (Premkumar et al. 2005). They suggest that TRPM8 activation may indeed 
be able to counteract that of TRPV1.  
 
1.1.7.  Subsets of peripheral sensory neurones respond to distinct stimuli  
Although it is believed that many nociceptors are polymodal and respond to a number of 
different  stimuli,  it  has  recently  been  suggested  that  in  mice  there  are  a  specific  set  of 
peptidergic  fibres  which  are  important  in  the  detection  of  heat  pain,  and  a  set  of  non-
peptidergic which contribute to mechanical pain (Abrahamsen et al. 2008; Cavanaugh et al. 
2009; Cavanaugh et al. 2011; Minett et al. 2012). These data suggest that modality specific 
pain behaviours are generated by different subsets of nociceptors. In addition they showed 
that each set was carried into a different section of the DH. It was suggested that nociceptors 
that  respond  to  mechanical  stimuli  are  mainly  fed  into  lamina  I  (LI),  whereas  those 
responding to heat were terminating in deeper sections of the DH (Cavanaugh et al. 2011). 
This indicates that perhaps there are segregated pathways for the different stimuli at least at 
the peripheral level (this is not to say that integration will not take place further up the pain 
pathway). 
In  addition  to  this  specificity  in  transmission,  it  was  further  suggested  that  the  sets  of 
nociceptors  have  separate  regulatory  controls  (Cavanaugh  et  al.  2011).  In  addition  to 
modulation by  amino butyric acid (GABA)ergic interneurones, peripheral afferents are also 
under  the  control  of  endogenous  opioids  (Basbaum  and  Fields  1984).  Bausbaum  and 
colleagues  proposed  that  in  mice,  peptidergic  neurones  express  mainly  the  mu  opioid 
receptor  (μOR),  whereas  the  non-peptidergic  express  the  delta  opioid  receptor  (δOR) 
(Cavanaugh et al. 2011). The implication of this is that it would be possible to control for 
different  pain  modalities  by  targeting  these  different  receptors.  For  example,  a  patient 32 
 
suffering from a mechanical hypersensitivity could be treated with a δOR agonist, whereas a 
heat  hypersensitivity  may  respond  better  to  a  μOR  agonist.  However,  as  this  study  was 
conducted only in mice, it is not certain that such specificities would translate into humans. It 
may  be  interesting  to  investigate  this  hypothesis  further  in  human  models  of  heat  and 
mechanical sensitivity to identify any translational hurdles. 
 
1.1.8.  Primary afferent action potentials require voltage gated sodium channels 
Activation of a sensory nerve terminal as a consequence of a stimulus activating receptors at 
the  terminal  membrane  leads  to  membrane  depolarization.  There  has  been  considerable 
speculation  about  the  functional  role  of  different  voltage  gated  ion  channels  in  the 
propagation of noxious stimuli. This has been fuelled in part by the selective expression of 
three sodium channel subunits on nociceptors, Nav 1.7, 1.8 and 1.9 (Dib-Hajj et al. 2010). Nav 
1.7  is  expressed  in  peripheral  sensory  neurones  and  has  fast  activation  and  inactivation 
kinetics  (Toledo-Aral  et  al.  1997);  without  this  inactivation  the  channel  is  predicted  to 
produce prolonged bursts of activity, leading to increased nociceptive signalling. Whilst Nav 
1.9 is believed to be responsible for the resting potential, Nav 1.7 and is believed to amplify 
slow subthreshold generator potentials towards the threshold for an action potential (Dib-
Hajj et al. 2010; Dib-Hajj et al. 2013). This signal recruits Nav 1.8, a channel almost selectively 
expressed in nociceptors, which is crucial for the upstroke of these action potential and thus 
transmission (Stirling et al. 2005; Momin and Wood 2008). Humans carrying null mutations in 
Nav 1.7 exhibit a congenital insensitivity to pain, whilst other mutations affecting the fast 
inactivation can lead to conditions such as paroxysmal extreme pain disorder (Cox et al. 2006; 
Fertleman  et  al.  2006;  Sikandar  et  al.  2013).    These  findings  have  of  course  generated 
considerable evidence in the role of this channel. Although out of scope of this thesis, further 
discussion on the roles of these channels can be found in Dib-Hajj et al. (Dib-Hajj et al. 2013). 
 
1.1.9.  Chemical mediators in the periphery may lead to nociceptor sensitisation 
Evidence supports the general hypothesis that persistent or chronic pain is, in part, due to an 
increase  in the  excitability of the  peripheral  terminals of fine calibre  afferents to  a  given 
stimulus intensity (Baron 2006; Basbaum et al. 2009; Gold and Gebhart 2010; Baron et al. 
2013). This process, dubbed peripheral sensitisation, has been much studied (Basbaum et al. 
2009;  Gold  and  Gebhart  2010).  There  are  a  myriad  of  chemical  stimuli  that  can  activate 33 
 
nociceptor endings, including both endogenous and exogenous substances. The equilibrium of 
chemicals  in  the  environment  surrounding  the  nerve  terminals  determines  the  baseline 
sensitivity and thus the normal phenotype (Basbaum et al. 2009; Gold and Gebhart 2010).  
Inflammation is a complex biological response and classical signs include - dolor (pain), calor 
(heat),  rubor  (redness),  tumor  (swelling),  in  addition  to  a  possible  functio  laesa  (loss  of 
function). Tissue damage is often accompanied by a release of endogenous mediators from 
activated  nociceptors,  as  well  surrounding  non-neural  cells  such  as  mast  cells,  basophils, 
platelets,  macrophages,  neutrophils,  endothelial  cells,  keratinocytes,  and  fibroblasts 
(Basbaum et al. 2009; Gold and Gebhart 2010; Sikandar et al. 2013). Numerous activating and 
sensitising substances can be released in an inflammatory immune response often referred to 
as a cocktail or ‘inflammatory soup’. Recognised components of this ‘soup’ include adenosine 
triphosphate (ATP), bradykinin (BK),  NGF, prostaglandins (PGs), serotonin (5HT), protons 
and other pro-inflammatory cytokines and chemokines such as interleukin-1 (IL-1), tumour 
necrosis  factor-  (TNF-),  chemokine  (C-C  motif)  ligand  3  (CCL3)  and  chemokine  (C-X-C 
motif) ligand 5 (CXCL5) (Zhang and Oppenheim 2005; Jin and Gereau IV 2006; Dawes et al. 
2011; Sikandar et al. 2013). The hallmarks of such sensitisation include decreased activation 
thresholds  and  an  increased  frequency  of  action  potential  discharge  to  suprathreshold 
stimuli. 
That an increase in peripheral excitability is at the root of certain chronic pain syndromes 
raises the possibility that drugs acting on these chemical messages may be developed that 
remain outside CNS, thereby avoiding some of the complications of present therapies. A large 
number  of  non-redundant  mechanisms  have  been  causally  associated  with  increasing  the 
excitability  of  sensory  nerve  terminals  (Pethő  and  Reeh  2012).  Activation  of  certain 
metabotropic receptors, discussed below, can lead to signalling events that converge on a few 
downstream second messengers, which ultimately interact with ion channels.  
Key players include G-protein coupled receptors (GPCRs), TrkA activation and other tyrosine 
kinase  receptors  (RTKs)(Basbaum  et  al.  2009;  Gold  and  Gebhart  2010).  The  second 
messenger  systems  involved  post-activation  of  G  protein  coupled  receptors  are  largely 
regulated  by  adenylate  cyclase  (AC)/protein  kinase  A  (PKA)  and  phospholipase  C  (PLC)/ 
protein  kinase  C  (PKC).  Activation  of  TrkA  receptors  engages  mitogen-activated  protein 
kinase (MAPK), phosphoinositide 3-kinase (PI3K) and PLC signalling pathways, whilst RTKs 
are linked to p38 MAPK, Janus kinase (JAK) and Stat transcription factors. The downstream 
effect  of  these  messengers  involves  transcriptional,  translational  and  post-translational 34 
 
modifications to a number of ion channels (Huang et al. 2006; Basbaum et al. 2009). This may 
include  modulation  of  ion  channels  through  phosphorylation  or  methylation,  Ca2+ 
mobilisation, altered expression of channels, receptors or enzymes. Whilst mediators such as 
BK, PG’s, 5HT and numerous chemokines act at GPCRs (their respective actions depend on the 
type of G protein activated), many cytokines and neurotrophic factors such as NGF, BDNF, IL-1 
and TNF- act at RTKs (Basbaum et al. 2009). 
K+ channels are vital for normal neuronal function; setting the resting potential of the cells 
and regulating action potentials. Downstream messengers that interact with these channels 
may inhibit currents that are at least partially open in the resting state and depolarize the 
membrane, driving it closer to activation threshold. In addition, by inhibiting the channel 
activity,  the  membrane  resistance  would  be  increased.  This  in  turn  may  increase  the 
amplitude of the membrane depolarization for any stimulus that would open depolarizing ion 
channels. Mediators that block K+ channels would therefore not necessarily activate the nerve, 
but  may  shift  the  stimulus-activation  response  curve  leftward  and  upward;  a  process 
consistent with the hypersensitive state. Indeed, numerous K+ channels have been shown to 
be downregulated in models of neuropathic pain, whilst an overexpression of channels such 
as  Kv1.2  can  induce  neuropathic  pain  symptoms  (Kim  et  al.  2002;  Zhao  et  al.  2013). 
Suggesting that dysregulation of K+ channels may contribute to neuronal hyperexcitability. 
On the other hand, a facilitation of voltage gated sodium channel currents would also lead to a 
similar lowering in activation threshold of the neurone and a hypersensitive state - indeed it 
has been shown that Nav 1.7 activity/ expression is increased during some inflammatory and 
neuropathic like states (Black et al. 2004; Shields et al. 2012). Indeed, in the presence of PGE2 
Nav 1.7 may be activated, most likely through lowering of activation thresholds (Vanegas and 
Schaible 2001). For example, MAPK1 and -3 mediated phosphorylation of Nav 1.7 enables 
smaller currents to activate the channel (Vanegas and Schaible 2001; Nassar et al. 2004). 
Interestingly, an R1105W variant  of the  channel  is associated with an increase in  C fibre 
activity, which may render carriers ‘predisposed’ to developing hypersensitive states. This 
variant is already associated with OA, and it may be useful to further explore its role in other 
inflammatory conditions (Reimann et al. 2010; Estacion et al. 2011). Additionally, a gain of 
function  mutation  G1662S  in  Nav  1.8  has  been  found  to  be  associated  with  small  fibre 
neuropathy (Han et al. 2013). Taken together, genetic evidence supports the theory that a 
facilitation of Na+ channel currents may lead to hyperexcitability associated with chronic pain 
conditions. 35 
 
1.1.10.  The role of TRPV1 in enhanced pain sensing 
The  role  of  TRPV1  has  been  extensively  studied  in  persistent  pain  states.  In  general,  the 
thermal  hyperalgesia  that  develops  in  several  pathological  states  depends  critically  on 
sensitisation of TRPV1 (Huang et al. 2006; Kanai et al. 2007). A growing list of peripheral 
mediators  -  including  BK, histamine, NGF, PGs, protons, IL-1, IL-6, CCL2 and CCL3  - can 
modulate TRPV1. TRPV1 actions may be potentiated through phosphorylation of the receptor 
resulting in altered channel kinetics, or by increasing the surface expression of receptors (Ji et 
al. 2002; Moriyama et al. 2005; Huang et al. 2006; Gold and Gebhart 2010). The latter may be 
most clinically relevant and occurs either through an increase in transport or in number of 
receptors produced and inserted into the membrane.  
Protons are able to both directly activate and potentiate activity of TRPV1. During a state of 
tissue injury or ischemia, where proton levels may be elevated, hydrogen ions are thought to 
act at an extracellular site to increase the potential of channel opening (Jordt et al. 2000). PGs 
such as PGE2 and PGI2 act at EP1 or IP receptors respectively. They have been demonstrated 
to  interact  with  TRPV1  through  both  PKC  and  PKA  dependent  pathways,  resulting  in 
phosphorylation of the receptors, and thus lowering of the temperature activation threshold 
to as low as 35°C (Moriyama et al. 2005). BK acts on the B1 and B2 receptors, which are 
believed to activate the diacylglycerol (DAG)-PKC pathway, and thereby the phosphorylation 
of TRPV1 (Vellani et al. 2001; Vellani et al. 2004). ATP is released from injured cells and its 
actions at the P2X/P2Y2 have been implicated in TRPV1 sensitisation via a PKC-dependent 
pathway (Moriyama et al. 2003).  
A second method of potentiating the actions of TRPV1, as mentioned, is by increasing the 
surface expression of receptors either through an increase in trafficking and/ or receptor 
density (i.e. the number of receptors produced or inserted into the membrane) (Ji et al. 2002; 
Zhang et al. 2005). In inflammatory conditions, such as OA, NGF is released and contributes 
towards pain through actions at TrkA receptors, which are expressed  on specific sensory 
neurones such as C and Aδ fibres. NGF is able to recruit a number of intracellular pathways 
and the importance of this mediator is highlighted by the fact that a loss of function of TrkA 
leads  to  an  insensitivity  to  pain  all  together  (Indo  et  al.  1996;  Shu  and  Mendell  1999). 
Injection of complete Freund’s adjuvant (CFA) and the monosodium iodoacetate (MIA) model 
of OA have been shown to result in increased TRPV1 expression in the DH (Ji et al. 2002). 
Zhang  et  al  demonstrated  that  TrkA  induced  activation  of  PI3K/  Src  kinase  causing 
phosphorylation of the Y200 residue, which resulted in increased membrane expression of 36 
 
TRPV1  (Zhang  et  al.  2005).  NGF  also  increases  transcription  of  TRPV1,  and  may  induce 
translation via p38 MAPK activation (Ji et al. 2002; Xue et al. 2007). Peripheral sensitisation of 
TRPV1 receptors, which results in lowering of the activation temperature (perhaps even to 
body temperature), may occur in a number of inflammatory pain conditions. 
Although the real contribution of TRPV1 in chronic pain remains unclear, a small number of 
patients do exhibit heat hypersensitivity (Maier et al. 2010; Soni et al. 2013). Furthermore 
some  patients,  for  instance  those  with  inflammatory  bowel  disease  and  irritable  bowel 
syndrome, have increased expression of the receptor (Akbar et al. 2010). The same has been 
claimed  for  some  chronic  cough  patients,  which  is  known  to  have  similar  underlying 
pathophysiology to chronic pain (Groneberg et al. 2004; Mitchell et al. 2005; O'Neill et al. 
2013). In addition, the fact that chronic cough patients are more sensitive to inhaled capsaicin 
suggests  that  TRPV1  sensitisation  may  be  a  contributing  factor  underlying  some 
hypersensitivity, whilst children carrying the TRPV1 single nucleotide polymorphism (SNP) 
I585V (decreasing channel activity) appear to be at a lower risk of developing asthma related 
cough (Cantero-Recasens et al. 2010). Taken together, these findings suggest TRPV1 could 
hold potential as a therapeutic target for relief of symptoms in chronic pain. Sensitisation of 
TRPV1  can  be  induced  by  application  of  capsaicin.  This  allows  further  study  of  the 
consequences,  mechanisms  and  pharmacological  sensitivity.  As  such  this  model  will  be 
explored further in this thesis in chapters 3 and 4. 
 
1.1.11.  Primary afferents synapse with second order projection neurones in the 
dorsal horn 
PAFs enter the DH of the spinal cord via the dorsal root entry zones, where they synapse with 
cells such as second order neurones or spinal interneurones. DH neurones receive convergent 
sensory input from a number of neurones responding to different modalities (Todd 2010). 
The  distribution  pattern  of  afferents  terminating  within  the  DH  is  determined  by  their 
sensory modality and the body region innervated (Todd 2010). Within the spinal cord the 
signal is integrated and processed - the initial input may be modulated by other incoming 
peripheral fibres, through a number of interneuronal connections both within or between, 
laminae, and additionally by fibres descending from the midbrain (D'Mello and Dickenson 
2008). Non-neuronal cells such as astrocytes and microglia may also impact the output of DH 37 
 
neurones (McMahon and Malcangio 2009). All of these processes that contribute towards the 
modulation of spinal neurone activity are plastic, as will be discussed later.  
The DH is divided into 10 laminae (LI-X), which receive and process inputs. Within the each 
laminae  PAFs  synapse  with  second  order  neurons.  Whilst,  Aδ  and  peptidergic  C  fibres 
terminate  in  LI  of  the  DH  and  the  outermost  part  of  LII  (substantia  gelatinosa),  non 
peptidergic C fibres terminate in the inner part of LII (Todd 2010). The majority of Aβ fibres 
are believed to terminate in the deep DH (LIII-V), and some Aδ also terminate here in LV. 
Furthermore, in addition to local spinal connects there are also indirect connections are made 
between  LI  and  LV,  and  neurones  residing  in  LI  are  able  to  modulate  LV  through  the 
recruitment of descending control mechanisms (Bee and Dickenson 2008). Thus LV receives 
input from all types of sensory fibres and can respond to all types of stimuli from a range of 
non-noxious to noxious, mechanical, chemical and thermal (figure 1-2). 
Depolarisation of peripheral sensory fibres leads to the activation of voltage gated calcium 
channels such as Cav2.2 within their central terminals, which is believed to be pertinent in the 
pain pathway (Woolf and Ma 2007). This further initiates the release of neurotransmitters 
from the presynaptic terminals – in the case of sensory fibres all release glutamate as the 
main excitatory transmitter, but peptidergic  C fibres may also release CGRP, substance P, 
BDNF,  somatostatin  and  galanin  (Dickenson  1995).  Glutamate  activates  post-synaptic  N-
methyl-D-aspartate  (NMDA)  receptors,  as  well  as  alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic  acid  (AMPA)  and  kainate  receptors.  Acute  transmission  of  nociceptive 
information  relies  on  the  ionotropic  AMPA  and  kainate  receptors,  however  the  NMDA 
receptor has been the focus of many pain studies as it has been shown to be upregulated and 
sensitised in many chronic pain states (Brown and Krupp 2006). Activation of post-synaptic 
receptors leads to the activation of second order neurones and allows transmission of the 
nociceptive signal to higher centres. 
Many  DH  neurones  respond  to  noxious  stimuli  applied  to  specific  body  sites.  Cells  that 
respond selectively to noxious stimuli are known as nociceptive specific neurones (NS), whilst 
those that are activated by innocuous as well as noxious stimuli are known as wide dynamic 
range  neurones  (WDR).  Some  of  the  NS  and  WDR  neurones  have  axonal  projections  to 
supraspinal  sites,  while  others  are  interneurones.  These  interneurones  may  be  excitatory 
(releasing glutamate) or inhibitory (releasing GABA or glycine) and play an important role in 
local  processing  of  sensory  information.  NS  cells  are  mainly  located  in  LI,  whilst  LIII-IV 
respond mainly to non-noxious tactile stimuli (D'Mello and Dickenson 2008). The majority of 38 
 
WDR cells are located in LV (D'Mello and Dickenson 2008), which will be the main area of 
study in this thesis. In addition to producing graded responses to a wide range of stimuli, LV 
WDR neurones display a unique characteristic known as wind-up (Dickenson and Sullivan 
1987).   
The  phenomenon  of  wind-up  is  a  frequency  dependent  increase  in  central  neuronal 
responses, whereby repetitive stimulation of peripheral fibres enhances the output of spinal 
cord neurones. Such activity dependent plasticity depends on the co-release of neuropeptides 
from afferent  C fibres, which leads to  a  slow membrane  depolarisation  that summates to 
release the Mg2+ block of the NMDA receptor. Silencing of NMDA receptors is usually mediated 
via Mg2+ block of the ion channel pore. Since wind-up may be blocked by the administration of 
AP5 and ketamine, it is accepted that the process relies on recruitment of the NMDA receptor 
(Davies and Lodge 1987; Dickenson and Sullivan 1987). Notably, wind up is both frequency 
and intensity dependent, since the stimulus must be above C fibre intensity and applied at 
0.3Hz or more (Mendell and Wall 1965). The perceptual correlate of wind up can also be 
measured  in  humans,  whereby  it  is  known  that  brief,  repetitive  stimulation  to  a  train  of 
stimuli results in a greater pain responses at the end (Price et al. 1994; Magerl et al. 1998). 
This is often referred to as temporal summation, and is also blocked by NMDA antagonism 
suggesting  overlapping  mechanisms  (Price  et  al.  1994).  These  features  of  wind-up  and 
intensity coding make WDR cells attractive to study as responses are comparable with human 
pain ratings (Dickenson and Sullivan 1987; LaMotte et al. 1991; Simone et al. 1991; Price et al. 
1994; Sikandar et al. 2013). 
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 Figure 1-2 Primary afferents synapse in the DH of the spinal cord. Afferent fibres enter the DH via the DRG, 
where their cell bodies are located. C fibres mainly terminate in LI-II, as do A although some also extend into 
deeper lamina. In contrast, A principally penetrate into LIII-V. Whilst NS cells receive direct input from A and C 
fibres, WDR cells receive convergent input both directly and indirectly from all primary afferent fibre types. LII 
contains many interneurons, which connect peripheral fibres and WDR cells in addition to governing much of the 
intraspinal processing.  Adapted from (D'Mello and Dickenson 2008; O'Neill et al. 2013) 
 
1.1.12.  GABAergic interneurones control spinal inhibition 
The DH also contains interneurones, which may synapse with both PAF terminals and second 
order projection neurones. These neurones typically serve as inhibitory controls and thus 
contain the transmitters GABA or glycine. Melzack and Wall proposed the gate control theory, 
whereby inhibitory interneurones synapse with peripheral Aβ fibres and NS cells of LI to 
inhibit  them  from  relaying  pain  signals  (Melzack  1965).  These  synapses  are  therefore 
referred  to  as  being  silent  as  they  do  not  activate  second  order  projection  neurones. 
Furthermore,  it  has  been  proposed  that  low  threshold  Aβ  fibres  can  activate  inhibitory 
interneurones, which in turn inhibit release of transmitters from Aδ and C fibres, acting as an 
endogenous modulator of nociceptive signals. 
Yaksh demonstrated that administration of GABA/ glycine antagonists resulted in pain from 
tactile  stimuli  such  as  light  touch;  it  is  therefore  believed  that  loss  of  spinal  inhibition 
contributes to the development of allodynia (Yaksh, 1989). A disinhibition of Aβ fibre input 
and therefore an activation of LI NS cells may result in their conversion to WDR cells. This in 
turn could results in non-noxious tactile stimuli causing a painful sensation (Torsney and 
MacDermott 2006). The proposed mechanisms that may contribute to the development of this 40 
 
phenomenon  include  a  down  regulation  of  the  KKC2  transporter,  or  the  release  of 
endogenous endocannabinoids (Coull et al. 2003; Keller et al. 2007; Pernía-Andrade et al. 
2009).  
The KCC2 transporter is required for the maintenance of internal K+ and Cl- concentrations; Cl- 
is usually found at a higher concentration outside of the neurones and thus upon activation of 
GABAA  receptors,  Cl-  enters  the  cell.  This  results  in  a  hyperpolarisation  of  second  order 
neurones, and on pre-synaptic neurones a decrease in transmitter release. A downregulation 
of this transporter could disrupt the usual ionic balance and result in a higher concentration 
of Cl- inside the cell. Therefore, activation of GABAA would result in an efflux of Cl- from the 
neurone and depolarisation  of the second order neurone  or a  reduction in GABA release. 
Overall, resulting in a reduction in spinal inhibition (Keller et al. 2007).  
Additionally,  it  has  been  suggested  that  peripheral  fibres  may  release  endogenous 
endocannabinoids in the DH, which act at cannabinoid 1 receptors (CB1R) located on both 
glutamatergic and GABAergic interneurones (Pernía-Andrade et al. 2009). Hegyi et al found 
that in LI and LII of the DH around 20% of spinal GABA-ergic interneurones express the CB1R, 
in addition to being located on the post synaptic membrane of second order neurones (Hegyi 
et al. 2009). Activation of CB1R on both the pre and post synaptic membranes may suppress 
GABA  mediated  neurotransmission  and  thus  result  in  a  depression  of  inhibitory  synaptic 
activity. As such, these mechanisms are an important area of study as either could contribute 
to the development of mechanical allodynia experienced by patients, and hold potential for 
future therapies. 
 
1.1.13.  Ongoing input into the DH may result in wind up and central sensitisation 
In the 1980s evidence began to accumulate suggesting that sensory processing of noxious 
stimuli  in  chronic  pain  states  might  not  only  be  amplified  by  the  process  of  peripheral 
sensitisation,  described  above,  but  also  by  parallel  changes  in  central  processing.  These 
plastic changes have been identified and studied at multiple sites within the CNS, including 
the cortex, in descending supraspinal controls (described later) and, most extensively, in the 
spinal processing of painful stimuli. In the spinal cord, the process is often referred to as 
central sensitisation, by analogy with its peripheral  counterpart. It has become clear that 
there are multiple forms of central sensitisation with different features and mechanisms.  41 
 
In its most basic form, ongoing stimulation of peripheral C and Aδ fibres, due to peripheral 
inflammation or nerve injury, can result in the previously mentioned wind up, in addition to 
central sensitisation and long term potentiation (LTP). As with wind up, the increased input 
into the DH causes an increase in release of glutamate and neuropeptides such as substance P 
and CGRP at the synaptic terminal. This in turn results  in an increased activation of post 
synaptic receptors and binding of SP and CGRP to neurokinin 1 (NK1) and CGRP1 receptors, 
respectively, leading to a slow depolarisation of second order neurones, thus relieving the 
usual block of NMDA receptors (Dickenson and Sullivan 1987; Latremoliere and Woolf 2009). 
Sustained depolarisation of projection neurones results in removal of this Mg2+ block, and 
thus Ca2+ entry to the neurone. Therefore, once NMDA and CGRP1 receptors are activated, 
changes may occur within the second order neurone including an increased production and 
surface expression of post synaptic receptors, in addition to enhanced probability of channel 
opening  (Latremoliere  and  Woolf  2009).  This  may  be  due  to  a  number  of  mechanisms 
involving changes in transcription, translation and post-translational modifications.  
Many animal studies have explored the detailed molecular mechanisms underpinning central 
sensitisation (Latremoliere and Woolf 2009; Kuner 2010). One major consequence for the 
second order cell is a mobilisation of calcium and recruitment of multiple second messenger 
systems such as protein kinases, p38 and extracellular signal-regulated kinase (ERK). These 
processes reinforce the central sensitised state both by driving posttranslational changes in 
receptors in the cell and, over a longer time frame, by altering gene expression in second 
order neurones. Such changes lead to a significant increase in synaptic efficacy.  
Intracellular events in the second order neurone lead to the activation of enzymes such as 
PKA, PKC, Ca2+/calmodulin-dependent protein kinase II (CAMKII) and Src kinases. These in 
turn lead to phosphorylation of serine and tyrosine residues in GluR1 and GluR2 subunits of 
AMPA receptors, and NR1 and NR2A/B subunits of NMDA receptors (Zou et al. 2000; Guo and 
Huang  2001;  Guo  et  al.  2002;  Latremoliere  and  Woolf  2009;  Wang  et  al.  2010). 
Phosphorylation of GluR1 targets AMPA receptors to the membrane and increases trafficking, 
whilst  phosphorylation of NR2 subunits  enhances the  probability of channel opening and 
prevents endocytosis  (Latremoliere and  Woolf 2009).  Furthermore,  activation  of enzymes 
such  as  ERK,  result  in  cAMP  response  element-binding  protein  mediated  transcriptional 
changes, increasing the expression of receptors such as NK1 and TrkB, which produce longer 
lasting  changes  in  excitability  (Latremoliere  and  Woolf  2009).    In  addition,  a  number  of 42 
 
heterosynaptic mechanisms may sensitise surrounding cells (including a reduction in spinal 
inhibition and changes in descending controls).  
This  plasticity,  which  causes  hyperexcitability  of  DH  neurones,  is  responsible  for  the 
symptoms that are associated with hyperalgesia and allodynia in humans and pain related 
behaviours in animals (Campbell and Meyer 2006;  Schaible  et al. 2006;  Latremoliere and 
Woolf  2009).  Activation  thresholds  of  spinal  neurones  are  lowered  and  responses  to 
peripheral stimuli are enhanced (Suzuki et al. 2000). Whilst wind up is only a short-term 
homosynpatic phenomenon that is reversible, central sensitisation and LTP induce long-term 
changes across a number of synapses, which may be associated with the development and 
maintenance of chronic pain (Magerl et al. 1998). LTP is specifically associated with protein 
synthesis and thus involves structural changes at the level of the synapse (Bailey et al. 2004). 
The contribution of LTP to chronic pain is debated, since the frequency required for induction 
is very high (Rygh et al. 1999). Further discussion of LTP is out of scope of this thesis, since 
this mechanism is not explored. 
The importance of these mechanisms is highlighted by the fact that receptor antagonism or 
knock-out of GluR1/ NR1 inhibits the development of central sensitisation (Chizh et al. 2001; 
South et al. 2003; Hartmann et al. 2004). Furthermore, as previously mentioned a loss of 
spinal inhibition may also contribute to the state of spinal hyperexcitability. For example, it 
has been shown in OA that there is an inhibition of glycine receptors, which prevents the 
endogenous inhibitory signals (Ahmadi et al. 2001). Persistent noxious stimulation also leads 
to widespread genetic and epigenetic changes in spinal cord (Denk and McMahon 2012; Crow 
et al. 2013) but the significance of these changes remains in large measure only partially 
defined. Many detailed reviews of all the contributing processes identified exist within the 
field and will be discussed further in chapter 6 (Latremoliere and Woolf 2009; Woolf 2011). 
More recently, the proliferation and activation of resident immune cells in the spinal cord 
(microglia)  have  been  identified  as  contributors  to  central  sensitisation  (Marchand  et  al. 
2005; McMahon and Malcangio 2009). These cells are required under normal conditions to 
perform a surveillance function of the tissue they populate, and are only activated when that 
tissue is damaged or compromised in order to participate in innate immunity. However, in 
some  chronic  pain  states  (particularly  neuropathic  states)  it  has  been  shown  that  spinal 
microglia are activated and begin to release a number of inflammatory mediators such as 
TNF- and IL-1 (McMahon and Malcangio 2009). These microglial responses appear to be an 
important regulator of spinal excitability, targeting both pre- and post-synaptic elements (Gao 43 
 
and  Ji  2010;  Trang  et  al.  2012).  Furthermore,  several  strategies  that  block  microglial 
activation, such as broadly acting inhibitors like minocycline or propentophylline or blockers 
of  specific  receptors  on  microglia  such  as  P2X7,  prevent  the  development  of  many 
neuropathic pain symptoms (Guasti et al. 2009; Trang et al. 2012). Since all the current data 
relates to experimental studies in animals the relevance of this process to clinical conditions 
is not yet established, however further discussion on this topic is out of scope of this thesis. 
The presence of central sensitisation is revealed in a number of clinical settings, with the most 
compelling  being  the  case  of  referred  pain  and  hyperalgesia  (Gwilym  et  al.  2011). 
Additionally, in a number of visceral pathologies, such as cardiac ischemia, pain is often felt 
initially deep within the chest, but with time the pain may radiate to superficial structures, 
most often the arm (McMahon 1997). The area of referral can also become hyperalgesic. The 
explanation is that spinal circuits receiving inputs from both visceral and somatic tissues are 
sensitised by the former, so that the sensitivity of the latter is increased. Another example of 
this process in humans is seen when focal experimental painful stimuli (such as noxious heat 
or algogenic chemicals) are applied to the skin of volunteers. The stimuli elicit pain at the site 
of stimulation but in addition, an area surrounding the stimulus where mechanical stimuli are 
perceived  as  being  more  painful  than  normal  (Raja  et  al.  1984).  The  area  of  so-called 
secondary hyperalgesia can be large and arises because activity in nociceptors at the site of 
the stimulus induces a state of spinal hyperexcitability that manifests itself as hyperalgesia. 
Manipulations that block peripheral activity lead to reversal of the hyperexcitable state of this 
type of central sensitisation, although high frequency nociceptor activity can trigger longer 
lasting central hyperexcitability known as spinal long-term potentiation (Sandkühler and Liu 
2001). 
It is important to note that the two pathophysiological phenomena discussed thus far - central 
and peripheral sensitisation - are not mutually exclusive and may exist in tandem. An initial 
peripheral sensitisation may indeed be the driving force behind the development of central 
sensitisation in some instances. As such, it may be difficult to fully dissect the specific central 
and peripheral contributions of underlying symptoms of chronic pain. 
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1.1.14.  Projection neurones carry the signal from the DH to higher centres of the 
CNS 
In order to consciously perceive nociceptive signals as pain these messages must reach higher 
centres in the CNS. Neurones projecting from the DH carry nociceptive signals in ascending 
tracts to specific areas of the brain. These neurones are found in either LI or LIII-VI and their 
axons cross the midline before ascending to centres such as the midbrain, cortical structures 
and  the  thalamus  (Todd  et  al.  2002;  D'Mello  and  Dickenson  2008).  One  feature  of  these 
projection  neurones  is  that  many  express  the  Substance  P  receptor  NK1;  the  highest 
concentration of which is found in LI where around 80% of projection neurones in rats are 
believed to express NK1 (Nakaya et al. 1994; Todd et al. 2002). NK1+ LI projections to the 
brainstem are imperative for the integration of nociceptive information with arousal, mood 
and context in order to mediate changes in perception  (Tracey and Mantyh 2007). These 
neurones are particularly important in controlling spinal excitability, since ablation reduces 
both  formalin  responses  and  CFA  related  hypersensitivity  (Suzuki  et  al.  2002).  Indeed 
hyperalgesia associated with persistent pain states appears to depend critically on these LI 
projections (Mantyh et al. 1997; Suzuki et al. 2002). 
There are a number of pathways through which second order neurones can transmit pain-
related signals from the spinal cord. These include the spinoparabrachial, the spinothalamic 
and spinomesencephalic tracts (Tracey and Mantyh 2007). Most supraspinal projections from 
the spinal cord originate either in LI, or more deeply from LIV, V, and VI. These two systems 
may engage different brain regions, with the latter activating regions of the thalamus, insular, 
anterior  cingulated  cortex,  and  somatosensory  cortex,  which  are  important  for  sensory 
discrimination  (Tracey and Mantyh 2007). On the  other hand, the LI projection neurones 
project to parabrachial nuclei and activate the amygdala, hypothalamus, rostral ventromedial 
medulla  (RVM)  and  periaqueductal  grey  (PAG).  These  areas  are  involved  in  the  affective 
emotional components of pain perception (Tracey and Mantyh 2007).  
 
1.1.15.  Cortical representation of pain 
Functional magnetic resonance imaging (fMRI) studies in humans have identified multiple 
areas  that  are  commonly  active  when  painful  stimuli  are  applied.  These  include  the 
aforementioned  thalamus,  mid/rostral  anterior  cortex,  primary  and  secondary 
somatosensory cortex, insular cortex and prefrontal cortices, as well as numerous brainstem 45 
 
nuclei  and parts  of the  basal ganglia  (Tracey 2011). Originally these  areas  together  were 
referred  to  as  the  ‘Pain  Matrix’,  however  the  term  has  since  been  abandoned  because  of 
continued  debate  about  whether  these  different  areas  are  actually  associated  with 
perceptions or pain (Legrain et al. 2011).  Furthermore, this signature is plastic and can be 
influenced  by  numerous  cognitive,  emotional,  contextual  and  physiological  factors.  Such 
factors are known to influence the reported pain experience and this is reflected in the brain, 
where different situations result in an increase or decrease in activity in particular regions 
(Tracey  and  Dickenson  2012).  Therefore  it  seems  reasonable  to  conclude  that  the  ‘pain 
matrix’ is not only nociceptive-specific activity, but rather is a reflection of brain activities 
involved in processing both nociceptive and non-nociceptive salient sensory input (Iannetti 
and Mouraux 2010; Legrain et al. 2011).  
 
1.1.16.  Descending controls modulate pain processing 
While there has been considerable interest and emphasis on the processes of peripheral and 
central  sensitisation,  it  is  important  not  to  overlook  the  descending  pathways  from  the 
midbrain and brainstem, which also play a pivotal role in the modulation of pain processing. 
Pathways descending from the  PAG, RVM  and the  pontine  nuclei (most  notably the  locus 
coeruleus (LC), but also A5 and A7) have been identified as key players in this modulatory 
system - with the release of 5HT from the RVM playing an overriding pronociceptive role and 
noradrenaline  (NA)  from  the  LC  an  antinociceptive  one  (Bannister  et  al.  2009).  Other 
neurotransmitters such as dopamine, opioids, substance P, dynorphin and GABA may also be 
involved in these processes (Millan 2002). The fine balance between excitatory and inhibitory 
controls may indeed dictate overall excitability of DH neurones.  
This descending modulatory system is believed to be activated through a spino-bulbospinal 
loop, whereby activated NK1 receptor expressing LI/III projection neurones send signals to 
the parabrachial area and onto the limbic system (Suzuki et al. 2002). Inputs driving the 
circuits in the amygdala, hypothalamus, frontal lobe, and anterior cingulate cortex activate 
areas of PAG, which in turn feeds into both the RVM and LC, modulating release of 5HT and 
NA,  respectively.  Removal  of  the  projection  neurone  drive  can  decrease  (via  supraspinal 
circuits)  excitability  of  DH  neurones  in  chronic  pain  states  suggesting  an  overriding 
pronociceptive action of descending controls contributing to hypersensitivity (Suzuki et al. 
2002).  Furthermore,  injection  of  lidocaine  directly  into  the  RVM  reverses  nerve  injury 46 
 
induced behavioural hypersensitivity (Burgess et al. 2002), suggesting that during chronic 
pain states the balance is tipped towards an increase in descending facilitation/ decreased 
descending inhibition. 
This facilitation is largely due to the actions of 5HT at the 5HT3 receptor, which is expressed 
both pre- and post-synaptically on neurones in the DH, in addition to on interneurones. 5HT3 
receptors are excitatory – allowing an influx of cations, which in turn can result in increase in 
second  order  cell  excitability.  Using  ondansetron  to  block  spinal  5HT3  receptors,  it  was 
shown  that  descending  influences  became  facilitatory  in  models  of  neuropathy  and  OA 
(Suzuki et al. 2004; Rahman et al. 2009).  
In opposition to these mechanisms is the release of NA acting at 2 receptors, also expressed 
pre- and post-synaptically and on intrinsic interneurones in the DH. Stimulation of the LC is 
antinociceptive, but the effect is reversed with an 2 antagonists (Jones and Gebhart 1986). 
While the actions of 5HT appear to be enhanced in certain chronic pain states, it would appear 
that the  inhibitory mechanisms  are simultaneously down-regulated  (Rahman et al. 2008). 
Given the networks that exist between the PAG and the limbic brain, it is unsurprising that a 
number of psychosocial factors are able to modulate the pain experience, such as anxiety, 
depression, context and past experiences. Chronic pain is in fact inextricably intertwined with 
co-morbidities such as anxiety, depression and sleep disturbances in a vicious cycle as one 
exacerbates the other (Gormsen et al. 2010; Rehm et al. 2010). It is co-morbidities such as 
these that make the search for adequate treatment even more pressing, and also highlights 
these areas as potential drug targets.  47 
 
 
Figure 1-3 Ascending and descending pain pathways link the spinal cord, midbrain and higher centres. 
Spinal projection neurones carry nociceptive information to the thalamus to allow for sensory discrimination, in 
addition to conveying signals to brainstem structures such as the PAG, involved in emotional pain processing. 
Further connections to limbic areas such as the hypothalamus and amygdala are also involved in the emotional 
component  of  pain.  Serotonergic  and  noradrenergic  descending  controls  arise  mainly  in  the  RVM  and  LC, 
contributing to overall spinal excitability.  Adapted from (O'Neill et al. 2012). 
 
1.1.17.  The transition from acute to chronic pain 
As previously mentioned, chronic pain is generally accepted as pain ongoing for a period 
greater  than  3  months  (McMahon  et  al.  2013).  It  is  clear  there  must  be  some  forms  of 
predisposing factors that render certain individuals more susceptible than others, as only a 
small proportion of patients with peripheral nerve pathologies develop signs of chronic pain 
(Kehlet  et  al.  2006).  Whilst  up  to  26%  of  diabetes  patients  may  develop  a  neuropathy, 
traumatic  nerve  injury  leads  to  neuropathic  pain  in  less  than  5%  (Haanpää  et  al.  2009). 
Predisposing factors may be of genetic origin, though are likely to also have environmental 
influences.  
A number of risk factors for the development of chronic pain have been identified, which are 
outlined in table 1-2, below. These factors can be subdivided into those attributed to the 
psychosocial status of the patient, and those that have medical/physiological underpinnings. 48 
 
It is important to note that psychosocial factors are likely to play a larger role than perhaps 
was  previously  thought  (Macrae  2008)  –  potentially  due  to  the  interaction  with  the 
descending  modulatory  controls.  It  has  been  shown  in  animals  that  the  balance  between 
facilitation and inhibition is a key process in the development of chronic pain, and factors that 
influence this are of course mood, anxiety and sleep (De Felice et al. 2011). 
Psychological Factors  Medical Factors 
Past Experiences  Genotype 
Beliefs/Expectations  Medical History 
Anxiety/Depression  Intensity 
Catastrophising  Surgery 
Social Circumstance  Medications/Anaesthesia 
 
Table 1-2 The potential risk factors associated with chronic pain. There are a number of risk factors, both 
medical and environmental (psychosocial), which may be associated with the development of chronic pain. It is 
difficult to ascertain their distinct contributions, but most likely a number of different factors will be involved in 
each individual case. Adapted from (Macrae 2008). 
Past experiences can shape beliefs and future expectations in either positive or negative ways. 
If a patient has had a negative experience in the past they may be more pessimistic regarding 
future treatment. However, such beliefs can also arise without any previous experience; with 
regards to surgery it has been suggested that feeling post-operative pain may result in the 
patient  believing  something  has  gone  wrong  and  may  blame  the  surgeon.  This  has  been 
associated  with  poor  treatment  response  and  lowering  of  pain  thresholds  (DeGood  and 
Kiernan 1996; Turk and Okifuji 1996). 
Anxiety and depression are likely to play a key role in susceptibility for the progression of 
acute to chronic pain, as previously discussed the neuronal networks and pathways involved 
in both are inextricably intertwined. Catastrophising also appears to correlate with chronic 
pain (Lamé et al. 2005). It is possible that this may be the result of disrupting the balance 
between  descending  facilitation  and  inhibition.    De  Felice  et  al  showed  that  nerve  injury 
induced pain may rely on descending modulation and that inhibition may protect from acute 
pain  progressing  to  chronic  (De  Felice  et  al.  2011).  Therefore,  a  disruption  resulting  in 
decreased inhibition/increased facilitation may be a critical factor in the transition to chronic 49 
 
pain. However, it is unlikely that these psychosocial factors alone are enough to cause this 
transition and thus physiological and genetic mechanisms may act in synchrony.  
Indeed  it  may  be  the  case  that  genetic  make-up  determines  susceptibility,  or  epigenetic 
modulations predispose an individual to chronic pain (Sikandar et al. 2013). Both animal and 
human studies suggest that there are existing genetic factors that influence the development 
of  neuropathic  pain  (Seltzer  et  al.  2001;  De  Felice  et  al.  2011;  Sikandar  et  al.  2013). 
Identification of genetic predisposing or protecting factors dictating who will, or will not, 
develop chronic pain is likely to be critical to determining the success of treatment. Could one 
answer  be  related  to  a  propensity  to  develop  peripheral  sensitisation  mechanisms?  The 
TRPV1  SNP  I585V  variant  renders  the  channel  30%  less  active  and  is  associated  with  a 
decrease in heat and pinprick hyperalgesia (Cantero-Recasens et al. 2010; Binder et al. 2011), 
thus begging the question of whether this leads to an inability to sensitise or provide enough 
drive to lead to further central changes? Maybe the key lies in sodium channel SNPs such as 
R1105, decreasing activity of the afferent fibres? However, given that volunteers who do not 
develop secondary hyperalgesia report the same initial pain upon capsaicin injection as those 
who do, this seems unlikely. Many candidate genes have in fact been identified, however they 
are  yet  to  provide  solid  evidence  of  any  hereditary  variants  that  are  responsible  for 
predisposing individuals to chronic pain. It is likely there are many more important genetic 
variants that may be involved but are yet to be identified – in particular regarding genes 
involved the descending controls. 
It  has  been  suggested  that  some  animal  strains  possess  certain  protective  mechanisms, 
rendering them less susceptible to chronic pain (Mogil et al. 1999; De Felice et al. 2011). After 
two strains of rats were identified, which developed tactile allodynia in significantly different 
proportions (85% vs 50%), De Felice and colleagues could find no outstanding discrepancies 
between the two in terms of markers in either the periphery or the spinal cord. Thus they 
looked to higher centres and found that blocking the RVM in neuropathic rats decreased signs 
of hypersensitivity, whereas in the rats that developed no signs of chronic pain, this block 
actually induced allodynia (De Felice et al. 2011). The results suggest that perhaps there is a 
failure  to  engage/loss  of  descending  inhibitory  pathways,  or  an  excessive  descending 
facilitation, leading to the development of chronic pain symptoms such as tactile allodynia. Or 
perhaps  an  excess  of  descending  inhibition  will  protect  against  the  development.  These 
finding  may  be  useful  groundwork  to  further  assess  these  mechanisms  in  patients  with 
chronic pain.  50 
 
1.2.   Experimental pain models in animals and humans further our 
insights into the mechanistic underpinnings of chronic pain 
A  number  of  experimental  preclinical  models  have  been  developed  to  further  our 
understanding of the pivotal pathophysiological mechanisms involved in the induction and 
maintenance of chronic pain. Such models aid identification of potential drug targets and in 
order  to  investigate  the  efficacy  of  possible  new  pharmacological  interventions.  Animal 
models are one of the most important tools in drug discovery for chronic pain and they range 
from the induction of inflammatory pain, to neuropathic pain, to a combination of the two in 
numerous disease specific states- such as cancer induced pain (Wang and Wang 2003; Mogil 
2009). The models are able to sensitise the pain signalling system at different points through 
a number of different mechanisms, which are likely to be relevant to clinical conditions.  
Broadly speaking there are two approaches to animal models of chronic pain. This includes 
the induction of particular symptoms/ mechanisms believed to be important in the clinic, and 
the induction of specific disease states creating models with ‘face validity’, such as cancer-
induced bone pain (Mantyh 2013). The induction of specific symptoms/ mechanisms may use 
inflammatory or neuropathic like states. Inflammatory pain may be induced through the use 
of substances such as CFA, formalin, carrageenan, MIA, and mustard oil, whereas neuropathic 
pain is induced by injuries to a peripheral nerve such as the L5/L6 spinal nerve ligation (SNL), 
spared nerve injury, chronic constriction injury (CCI) and partial sciatic nerve ligation/ the 
Seltzer  model  (Wang  and  Wang  2003).  Animal  models  such  as  these  have  allowed  the 
elucidation  of  distinct  molecular  and  cellular  mechanisms  underpinning  chronic  pain 
symptoms, including: peripheral sensitisation, central sensitisation, enlargement of receptive 
fields in DH neurones and impaired descending controls (Arendt-Nielsen et al. 2007).  
Another  animal  model,  capsaicin,  is  able  to  induce  short  term  changes  that  mimic  both 
inflammatory and neuropathic like symptoms and as such is also a popular model for chronic 
pain. The chilli pepper derived chemical is able to induce a robust peripheral sensitisation, 
and the barrage of input into the DH also results in central sensitisation.  As such, it has 
already been  a  very useful tool for elucidating a  number of  molecular events involved in 
chronic pain and will be explored further in Chapter 3 of this thesis (for a full review see 
O’Neill et al, 2012).  
More  recently,  the  use  of  disease-specific  models,  with  face  validity,  such  as  HIV-related 
neuropathy, cancer induced bone pain and DPN have become increasingly popular (Ueta et al. 51 
 
2005;  Rice  et  al.  2009;  Schmelz  2010;  Mantyh  2013).  The  reason  behind  this  is  that  the 
different aetiologies are likely to engage different mechanisms at both the stage of induction 
and maintenance of chronic pain, and as such it is important to study specific states to truly 
understand their individual physiological underpinnings and uncover the most suitable drug 
targets. These models have increased our knowledge of conditions such as HIV-associated 
sensory  neuropathy.  The  stavudine  (d4T  –  a  nucleoside  reverse  transcriptase  inhibitor) 
model  has  been  used  to  investigate  the  behavioural  changes  and  specific  neuropathology 
associated with the condition (Huang et al. 2013). Revealing distinct pathologies such as a 
reduction in peripheral and central terminals of DRG neurones and increases in myelinated 
and unmyelinated axon diameters (Huang et al. 2013). Therefore, such studies are critical for 
the future of chronic pain research and drug development. 
In addition to disease specific models, further approaches can be taken in order to increase 
the  clinical  meaningfulness  and  predictive  value  for  patients  of  the  preclinical  studies. 
Surrogate human models are aimed at bridging the gap between basic animal science and the 
clinic.  Experimental  models  allow  activation  and  sensitisation  of  the  pain  system  and 
measurement  of  specific  evoked  responses  (Arendt-Nielsen  et  al.  2007;  Schmelz  2009). 
Similar to the animal models discussed, they imitate the signs and symptoms of chronic pain 
under  highly  controlled  conditions,  whilst  in  addition  exploiting  the  human  capacity  for 
verbal communication and allow further investigation into the intensity and quality of pain 
(see figure 1-4  for the full advantages of surrogate models). These studies obviously face 
many more limitations with regards to ethical and safety concerns and thus can address only 
a few clinically relevant signs and symptoms. Most concentrate on inflammatory models using 
the application of topical or injected algogens such as mustard oil or capsaicin. To avoid the 
use of injections models such as ultraviolet B irradiation (UVB), the thermal burn and freeze 
lesion have also been developed. Such models are able to consistently induce mechanisms 
such as peripheral and central sensitisation in order to study the consequences and possible 
modulation of such phenomenon (Schmelz 2009).   52 
 
 
Figure  1-4  Advantages  of  the  use  of  surrogate  models.  Numerous  advantages  of  adopting  human 
experimental models exist, from the exploitation of verbal capacity and quantitative assessment of responses, to 
comparing responses at different sites and over time.  Adapted from (Arendt-Nielsen et al. 2007). 
However, even using animal and human models it is of course impossible to replicate the 
exact pathophysiologies and the full complexity of chronic pain syndromes. Using animal and 
human studies in tandem is one of the most powerful tools currently available in research. 
Much  of  our  knowledge  around  pain  processing  and  the  mechanisms  of  induction  and 
maintenance of chronic pain states have arisen from years of preclinical research in animals 
and humans and it is undoubtedly true that basic research is required still to further our 
understanding  of  the  complex  pathways  the pathophysiology  of  chronic  pain.  The  human 
studies  are  imperative  for  improving  the  clinical  translation  of  early  work  by  identifying 
mechanisms and modulation relevant to the human pain processing system. In addition they 
exploit the ability of subjects to verbally communicate, which adds a qualitative dimension to 
the studies. On the other hand, many chronic pain syndromes cannot be modelled in humans 
and the cellular and molecular underpinnings can often only be extracted from the animal 
models  (Mogil  2009).  Therefore,  it  is  likely  that  the  most  efficient  studies  will  use  a 
combination of animal and human studies in order to reap the benefits of both (Dawes et al. 
2011).  For  example,  although  it  was  first  noted  in  humans  that  Gabapentin  could  reduce 
symptoms of neuropathic pain, animal studies elucidated the potential mechanisms (Luo et al. 53 
 
2002; Bennett 2010). This thesis aims to characterise translational models of chronic pain in 
order to best exploit the potentials of studies across species. 
 
1.2.1.  The question of translational pain research 
One challenge faced in the field of chronic pain research is to understand the true predictive 
value of preclinical animal models. The value rests upon the degree of overlap between the 
models and patients. The debate has arisen due to the fact that very few analgesics developed 
will ever enter this pain market. In fact it is estimated that only 16% of pain drugs entering 
phase I clinical trials will eventually gain approval for use in patients (Kola and Landis 2004). 
Furthermore, of those that do enter the market, many do not provide adequate treatment; in a 
meta-analysis  of 174 clinical trials  it was  found that from the  therapies that  do exist  the 
majority of patients did not receive adequate pain relief, and (Finnerup et al. 2010; Berge 
2011).  This  limited  success  in  translation  of  basic  discoveries  into  clinical  therapies  has 
therefore raised the question as to what is driving this disparity (Mogil 2009). Although there 
are many explanations that could be behind this, one suggestion is that the preclinical models 
are to blame. Current problems of translating research into patients include potential species-
specific  pain  processes  and  efficacy  of  analgesics,  as  well  as  the  undeniable  difficultly  in 
interpreting  pain  associated  behaviours  in  animals  and  the  wide  variety  of  aetiologies 
responsible for chronic pain in the clinical (Blackburn-Munro 2004; Bennett 2010; Schmelz 
2010). 
It may be argued that at a very basic level, the nervous system is what sets us aside from other 
species.  Indeed,  as  humans,  our  nervous  system  has  developed  into  a  unique  and 
sophisticated  machine  that  has  subtle  differences  from  that  of  say,  a  rat  or a  mouse  and 
indeed this could raise the question of how applicable are the animal studies to the human 
conditions  (Bennett  2010).  However,  it  is  important  to  note that  pain  is  a  basic  function 
necessarily for survival and is unlikely to have changed over time. It is well known that areas 
of the brain involved in pain processing are not necessarily highly evolved brain regions, but 
in fact the  primitive regions  which are conserved  through time,  such as  the  primary and 
secondary  somatosensory  cortices,  the  anterior  cingulated  cortex  and  the  insula  are 
imperative to pain sensing (Iannetti and Mouraux 2010). These areas have been identified 
using human brain imaging, but were previously identified in animals (Bennett 2010). Simple 
behavioural responses are believed to be highly conserved through evolution and as such are 54 
 
most likely comparable in animals and humans. In fact not only has the acute pain system of 
animals and humans shown to have a great deal of overlap, it has also been shown to be 
sensitised and modulated in the same way, therefore suggesting there is a reasonable degree 
of  overlap  (D'Mello  and  Dickenson  2008;  Dawes  et  al.  2011;  O'Neill  et  al.  2012).  Indeed, 
stimulation of the PAG in rats and humans was shown to produce analgesia, thus suggesting 
fundamental  similarities  (Bennett  2010).  It  has  also  been  pointed  out  that  the  nervous 
systems do not need to be identical, but simply display a ‘functional degree of similarity’, 
which  current  data  certainly  suggests  and  thus  warrants  the  study  of  pain  in  preclinical 
animal models (Bennett 2010). 
One  difference  that  presents  a  challenge  to  preclinical  research  is  the  subjective  and 
emotional nature of the pain experience. In humans we can be certain that pain is not simply a 
sensory phenomenon but can in fact be influenced by affective and cognitive processing. Pain 
is a very subjective experience and modulation by higher brain centres may be a function 
unique to humans, or at least its existence is difficult to quantify in animals (Berge 2011). It is 
therefore accepted that we cannot model fully the complex pathophysiology of chronic pain as 
such there is a limited use for animal models as they can only cover certain aspects of the true 
conditions (Arendt-Nielsen et al. 2007; Schmelz 2010; Berge 2011). One important way to get 
around this issue is of course the use of translational models, where the human surrogate may 
also be explored and can provide more information around the full sensory and emotional 
pain experience. 
A second factor which suggests that there may be some species-specific differences in the 
development of chronic pain is that whilst less than 50% of patients with neuropathies will 
develop signs of chronic pain (such as hyperalgesia and allodynia), they are usually present in 
all animal models; suggesting possible differences in the pathologies (Kehlet et al. 2006; Rice 
et  al.  2009;  Dickenson  and  Baron  2011).  The  low  level  of  variability  is  important  for 
standardisation  of  preclinical  models,  but  does  perhaps  suggest  a  disparity  with  the  true 
human conditions. There are a number of risk factors for the development of chronic pain, as 
previously discussed, which may be unique to humans. On the other hand, this disparity may 
simply reflect the reduction in variability of the initial insult responsible for the pain or less 
variability  in  the  animal  genetics  (Rice  et  al.  2009).    Whilst  the  animal  models  are 
standardised and all receive the same severity of injury, this clearly varies between patients. 
However, the important point to note is that it is clear that some patients experiencing a 55 
 
neuropathy will not develop signs of chronic pain and an understanding of the reasons behind 
this will be of great interest. 
The  possibility  of  species-specific  mechanisms,  and  thus  drug  efficacy,  could  impact  the 
design of new drugs may and render some promising candidates useless in the clinic. A prime 
example of this is the NK1 antagonist, which appeared to reduce pain behaviour in pre-clinical 
models, but failed once it reached human clinical trials (Hill 2000). As previously mentioned, 
species-specific pain processes seem to be related to the fact that human pain involves the 
integration of emotional and contextual (Berge 2011). Pain is an experience unique to the 
individual, which is difficult to exactly recreate and measure with animal models alone and 
this limitation must be accepted. Furthermore, this highlights the importance of investigating 
the subjective component of the pain experience. 
An additional issue raised with regards to preclinical animal studies is around the choice of 
model used, as it is questioned to what degree do the mechanisms studied in experimental 
animal models reflect the true pathophysiologies of clinical pain states (Rice et al. 2009; Berge 
2011). Indeed, there are a limited number of preclinical models in use, many of which do not 
in  fact  recreate  the  exact  pathophysiologies occurring  patients  (Rice  et  al.  2009;  Schmelz 
2010). Furthermore, the myriad of aetiologies underlying different chronic pain conditions in 
patients  mean  it  is  difficult  to  relate  the  findings  in  one  particular  model  to  different 
conditions in the clinic. For example, Schmelz suggests that animal models of neuropathic 
pain where a nerve is ligated or injured are unlikely to mimic non-traumatic neuropathic pain 
states  and  certainly  cannot  be  used  as  a  surrogate  for  non-neuropathic  pain  conditions 
(Schmelz 2010). In agreement with this sentiment, Rice notes that models of peripheral nerve 
injury have become an ‘industry standard’, yet only around 9% randomised controlled trials 
are actually conducting in patients with a peripheral nerve injury  (Rice et al. 2009). It is 
important that when choosing a preclinical model, thought is given to the clinical condition 
that will be implicated (Rice et al. 2009). Although disease specific models with greater face 
validity begin to overcome this issue, it is important to note that such an approach is not 
without drawbacks. Whilst some diseases do not have a preclinical model: of those available 
none replicate the true timelines of the disease pathology. Conditions may develop in patients 
over many years, whereas models are induced in a number of weeks. For example, whilst 
disease duration of patients entering trials for PHN is 4 years, the animal models develop over 
a maximum of 10 weeks (Rice et al. 2009).  56 
 
Given the broad range of underlying aetiologies in patients it is unsurprising that there is no 
‘one model fits all’ and it is impossible to suggest that there may be a single model of chronic 
pain which will suffice as a model to predict the mechanisms and efficacy of analgesics for a 
range  of  different  conditions  (Berge  2011).  Rather,  disease  and  symptom  specific  models 
should be used to overcome this issue to investigate mechanisms and modulation relevant to 
specific conditions. It is important to understand which mechanisms each model can address 
and one way to do this is by fully characterising and phenotyping a model in both animals and 
humans, where possible. By gaining knowledge of all the symptoms induced by a specific 
model we can begin to gather insight into the potential mechanisms at play. In the absence of 
being able to recreate disease pathologies, it is useful to develop models that induce particular 
symptoms  for  mechanistic  studies.  This  thesis  aims  to  fully  characterise  a  number  of 
translational  chronic  pain  models  in  order  to  help  understand  their  relevance  to  clinical 
conditions.  
Finally, one may ask can we really measure pain in animals (Blackburn-Munro 2004; Bennett 
2010)? In the absence of the capacity for verbal communication, most animal studies rely on 
reflexes, such as the tail flick or paw withdrawal, which cannot necessarily be equated to the 
human pain sensation and certainly does not mimic a clinical situation. Although they may 
involve a level of supraspinal processing and modulation, on the whole these are thought of as 
spinal phenomenon, which clearly do not engage all areas integral to the full human pain 
experience. In order to initially trigger these reflexes the same peripheral fibres and receptors 
involved  in  the  conscious  pain  experience  are  necessary  and  thus  it  is  at  least  partially 
relevant, however the spinal cord mechanisms may be different and the full affective and 
cognitive processing is not apparent (Mogil 2009; Bennett 2010). In particular, focus falls on 
the engagement of motor neurones that are involved in this reflex, which poses a particular 
problem for drug development since it is possible that certain drugs may interact with these 
interneurones driving the withdrawal reflex, rather than in the pain pathway itself. One way 
to overcome this issue is with the use of additional tests to explore motor function, which 
would indicate if the drug is in fact affecting motor neurones, rather than those integral to 
pain signalling.  
An  additional  downfall  of  these  reflex  measures  is  that  they  often  only  test  a  restricted 
number of modalities (mechanical and thermal) and assess a gain of function. Since patients 
with chronic pain display a range of sensory phenotypes, of which sensory gain is only one 
feature, this limits the usefulness of these reflex measurements (Rice et al. 2009). 57 
 
Behavioural measures of pain are also subject to a high degree of variability. The measures 
are sensitive to a number of extrinsic factors that are often difficult to control for, such as 
habituation and the test environment. Furthermore, there may be a degree of subjectivity 
between experimenters (Chesler et al. 2002). One way to address this issue is to use more 
objective measures, such as electrophysiology. This thesis uses in vivo electrophysiology in 
order to produce more objective characterisation of translational models. 
Additional  measures  explored  in  preclinical  have  also  received  criticism,  since  pain 
behaviours in animals such as guarding and licking may simply be signs of other dysethesias 
and not necessarily what we experience as pain (Blackburn-Munro 2004). As such there is a 
clear need for more operant measures of pain in animals, in addition robust translational 
models  that  allow  the  human  counterpart  to  be  explored  for  the  qualitative  aspects 
confirming the real location and intensity of pain, in addition to capturing the full sensory, 
emotional  and  perceptual  experience.  Furthermore,  these  endpoints  often  measured  in 
animals  differ  from  those  in  the  clinical  trials  (which  involve  pain  questionnaires  and 
reporting’s  of  spontaneous  pain);  it  is  important  to  try  and  make  sure  that  endpoints 
measured in preclinical studies are relevant to those in the clinic (and vice versa) (Rice et al. 
2009). This thesis aims to address the disparity in outcome measures, by using an identical 
range of endpoints in both animal and human models. 
As previously mentioned, much insight has come from preclinical studies. It is without doubt 
that a number of animal models have helped our understanding of mechanisms contributing 
to chronic pain and their respective modulation, which should not be overlooked (D'Mello and 
Dickenson  2008;  Baron  et  al.  2013;  Sikandar  and  Dickenson  2013).  Indeed,  much  of  our 
understanding  of  the  pivotal  mechanisms  underpinning  central  sensitisation  and  the 
importance  of  the  fine  balance  in  descending  controls  has  come  from  preclinical  animal 
models (Bannister et al. 2009; Sikandar and Dickenson 2013). Genetic engineering and the 
use of KO mice has also been particularly fruitful when elucidating the function of particular 
proteins involved in pain signalling.  
Furthermore, drugs are available to patients today that have come from these studies, such as 
the N-type calcium channel blocker ziconotide, which has been shown to be as effective in 
patients as the preclinical studies in animals (Williams et al. 2008). It is particularly effective 
in refractory malignant pain, reducing patient’s pain scores on average by 53.1% (Williams et 
al. 2008). More recently the introduction of tapentadol has the potential for great benefit to 
patients,  since  the  requirement  for  opioids  may  be  lowered  –  which  was  originally 58 
 
demonstrated in acute inflammatory and neuropathic pain models (Prommer 2010). Indeed 
studies have already reported analgesia in patients suffering with lower back pain (Hartrick 
and  Rozek  2011).  It  has  also  been  noted  that  most  successful  analgesics  that  were  not 
discovered through this traditional route do still succeed in reversing thermal and mechanical 
hyperalgesia  in  these  rodent  models  (Kontinen  2002).  Furthermore,  retrospective 
investigation of the mechanisms of certain pain drugs that were discovered by ‘accident’ has 
also benefited from animal studies, such as the elucidation of the actions of gabapentin in 
chronic pain (Luo et al. 2002; Sikandar and Dickenson 2013). Future success will most likely 
be  dependent  on  the  combination  of  animal  and  human  preclinical  studies.  However,  an 
integrated  approach  in  translating  knowledge  obtained  from  animal  models  into  human 
research and clinical trials is imperative for progression in the field of pain management.  
 
1.2.2.  Limitations of human surrogate models  
Although many of the issues raised with the animal studies can be addressed by using human 
models,  they  too  are  not  without  their  own  criticisms.  The  usefulness  of  existing  human 
surrogate models are questioned despite the clear translational benefits and the ability to 
investigate human pain under controlled conditions. Especially since some clinically relevant 
symptoms have not yet been modelled. For example, there are currently there are no reliable 
surrogates  for  symptoms  such  as  spontaneous  pain  and  cold  allodynia/  hyperalgesia. 
Spontaneous pain is one of the most important clinical symptoms that chronic pain patients 
present with, since it is common across virtually all patients regardless of the underlying 
aetiology  (Mogil  2009;  Rice  et  al.  2009).  The  development  of  preclinical  models  that  can 
assess  this  symptom  is  therefore  of  great  importance  for  further  understanding  of  its 
pathophysiology and the screening of candidate analgesics. 
Another limitation is the inability to model nerve injury, as well as other long-term changes. 
While some inflammatory conditions may be modelled in humans (for instance using UVB 
irradiation), neuropathic or disease specific pain states cannot be induced experimentally. 
Instead, existing efforts in human models focus on mimicking sensory signs and symptoms of 
chronic  pain  disorders.  They  supplement  animal  models  with  data  detailing  the  exact 
duration, intensity and quality of pain. However, as such, one major limitation is that the 
current models do not necessarily engage clinically meaningful mechanisms. All the changes 
induced are short-term, for obvious ethical reasons, whereas the pain associated with various 59 
 
conditions appear to manifests over many years. Therefore most models may not necessarily 
reflect the true pathophysiology. That is to say, it is impossible for ethical reasons to induce 
nerve  injuries  and  other  initiating  factors  in  human  volunteers  to  precipitate  long-term 
changes in the spinal cord and supraspinal sites that underpin chronic pain. Even current 
models such as intradermal injection of capsaicin can be very painful, and the UVB-sunburn 
model has the clear risk of inducing heat lesions or blisters on the skin of subjects so must be 
used with caution.  
As a result of these limitations, the current human models are also not necessarily aligned 
with  the  animal  models.  Whilst  inflammatory  mediators  used  in  animal  models  such  as 
formalin, carrageen or CFA induce a robust sensitisation, these are not suitable for use in 
humans due to the risk of damage to nerve fibres. In order to truly benefit from the use of 
animal and human studies in parallel it is useful to initiate the same models, which are likely 
to engage similar mechanisms, where the data collected from each will complement the other.  
Studies to date have shown that there certainly are some clinically meaningful overlapping 
models  resulting  in  chronic  pain  like  symptoms  in  both  animals  and  humans.  This  was 
originally demonstrated with the use of intradermal capsaicin to induce central sensitisation 
in both animals and humans (O'Neill et al. 2012). The basic animal models give a good insight 
into pathophysiological mechanisms that contribute towards the central changes, whereas the 
human surrogate models have confirmed that induction of central sensitisation can mimic 
sensory signs and symptoms of chronic pain and thus may be useful for testing new drug 
candidates. In addition, the UVB model of inflammatory pain has also been shown to have a 
high  translational  impact.  This  second  model  has  come  to  be  one  of  the  most  successful 
translational studies so far, being used in a number of laboratories and producing similar 
effects in both animals and humans (Bishop et al. 2007; Bishop et al. 2009; Dawes et al. 2011). 
It was recently used to identifying a number of candidate molecules that may be involved in 
inflammatory pain such as the chemokine CXCL5 (Dawes et al, 2011).  This model will be 
explored further in this thesis in chapter 5. The success of such studies would suggest that it 
might be useful to develop further human surrogate models that can compliment mechanistic 
animal data. 
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1.2.3.  Poor clinical trial design may impact translation from basic science 
A final concern in the field of translational pain research suggests that preclinical models are 
not completely to blame for the previous drug failures. Misinterpretation of preclinical data 
and the poor design of subsequent clinical trials may also hinder the progress of basic science 
discoveries into clinical practice. If the initial research is carried out in animal models that do 
not  accurately  reflect  the  symptoms  experienced  by  the  group  of  patients  the  drug  is 
subsequently tested in it is unsurprising that no efficacy is found (Woolf 2010). For example, a 
drug target may be identified that demonstrates efficacy alleviating mechanical hyperalgesia 
in the SNL model, whilst progressing forward into clinical trials the drug may then be given to 
a group of patients from various polyneuropathies suffering from a spontaneous ongoing pain 
(Rice et al. 2009).  These two symptoms are of course not comparable and preclinical data 
against one symptom should not be expected to work against another. Any candidate drug 
target  identified  from  preclinical  studies  should  eventually  lead  to  the  development  and 
testing of compounds in patients specifically selected on the basis that they show similar signs 
to the original preclinical model used in order to address this mismatch between preclinical 
models and diseases in clinical trials (Rice et al. 2009).  
Furthermore, most clinical trials currently select groups of patients based on the criterion of 
having a certain disorder or underlying pathology, such PHN or DPN. However, not all of these 
patients will suffer from the same symptoms. Indeed, it has been noted that patients suffering 
from  the  same  disorders  can  be  split  into  subgroups  of  those  suffering  from  the  same 
symptoms (Baron et al. 2009; Maier et al. 2010). Thus, the clinical trials should also focus on 
conducting studies in the group of patients that are suitable for the particular compound of 
interest.  That is to say, clinical trials should organise patients into subgroups who suffer from 
the same collection of symptoms since it is likely that the symptoms may relate to a common 
underlying  mechanisms  (Jensen  and  Baron  2003).  Candidate  analgesics  should  then  be 
allocated to subgroups where it has been proven to show efficacy in the equivalent animal 
model, rather than simply testing on all patients who may suffer from the same disorder but 
between them exhibit a myriad of different symptoms (Jensen and Baron 2003; Rice et al. 
2009; Attal et al. 2011). Poorly designed clinical trials may mean that promising candidate 
drugs are wasted and in fact it is possible that compounds that previously failed in clinical 
trials, may be shown to be more effective than first thought if they were to re-test them and 
examine specific symptoms and modalities. Asking a patient to simply ‘rate’ their pain is an 
incredibly broad measure and a reduction in a particular quality of pain could be masked. 61 
 
 
 
Figure  1-5  Proposed  mechanisms  for  symptoms  associated  with  chronic  pain.  Different  mechanisms 
underlie different symptoms, although each symptom may arise from a number of mechanisms. Adapted from 
(Baron 2006). 62 
 
Although it is out of the scope of this thesis to address the complex issues surrounding the 
clinical trial design, basic recommendations may be adapted. Using preclinical models with 
detailed  phenotypes  will  aid  the  development  of  a  mechanism-based  approach  to  pain 
classification and treatment. Developing preclinical models that mimic specific symptoms/ 
mechanisms  will  enable  the  testing  of  drugs  designed  to  act  against  these  particular 
abnormalities. If we know that a certain drug acts at a specific target that is engaged in a 
particular mechanism, the most appropriate preclinical model can be chosen for the initial 
screening (i.e. a hypothesis driven screening). Furthermore, patients suffering from the same 
symptoms may be selected for the clinical trial based on the fact they would be predicted as 
more likely to respond. The outcome measures used in preclinical studies may also be used in 
clinical trials in order to address this disconnect. Finally, such preclinical work can help select 
the most appropriate endpoints for the clinical trials.  Since the models explored in this thesis 
are  symptom  specific,  rather  than  being  applicable  to  a  particular  disease  state, 
recommendations will only be able to be adapted based on symptom profiles. Overall this 
thesis  aims  to  bring  together  preclinical  data  from  animal  and  human  models  aimed  at 
modelling and treating specific symptoms, in order to improve the path from basic science to 
the clinic and to aid the design of clinical studies. 
In summary, it is clear that animal models based on mechanisms or specific disease states, as 
well as human surrogate models, all have a number of benefits and drawbacks. However, they 
have  all  played  important  roles  in  our  understanding  of  pain  mechanisms  and  the 
development of analgesics. In order to address some of the drawbacks discussed, a combined 
approach  may  be  undertaken  whereby  the  benefits  of  all  may  be  exploited.  Discovery  of 
analgesic targets and analgesic efficacy should be extrapolated based on specific mechanisms 
in order to identify the most suitable patient population who may benefit. 63 
 
1.3.   Objective assessment of nociception and pain in experimental 
models 
As previously mentioned, many in vivo models  rely on  behavioural  outcome measures  of 
reflex  thresholds  to  certain  stimulation  to  infer  pain  in  animals,  however  assessing 
spontaneous (or ongoing) pain is very difficult. Additionally, since is a subjective measure, 
there is the possibility that different results may be obtained depending on the researcher 
undertaking the experiment (Chesler et al. 2002). The same is true of the reporting of pain by 
human test subjects, which can be hugely variable due to individual subjectivity. In order to 
try to combat this, more objective measures of pain are being sought out. In animal models 
this  includes  the  use of  measures  such  as  conditioned  place  preference  (CPP),  which  has 
started to be used to assess spontaneous pain (King et al. 2009; De Felice et al. 2011). This is 
an important step forward in the field of pain research, as it begins to relate basic science 
directly to problems highlighted in the clinic. Other useful techniques include the use of in 
vivo electrophysiology, which is an objective measure of neuronal activity allowing the study 
of both sub and supra threshold stimuli. This process is detailed in the methods and will be 
the main technique used for animal studies in this thesis, as it provides an unbiased and 
quantitative  measure  of  neuronal  activity  in  response  to  a  number  of  different  painful 
conditions/stimuli. 
 
1.3.1.  Advantages of in vivo electrophysiology 
In vivo electrophysiology allows direct objective monitoring of neuronal activity. Recordings 
can be made at any level of the pain signalling system, including evoked potential recordings 
of peripheral nerves, spinal tracts, and cortical areas, extracellular single neurone recordings 
of  action  potential  discharges,  and  intracellular  recordings  of  postsynaptic  potentials  and 
action potentials.  In particular, measuring from neurones in the spinal cord to assess sensory 
processing is of great use as they play a pivotal role in pain signalling (D'Mello and Dickenson 
2008;  Price  2013).  They  are  a  key  site  of  relay  for  nociceptive  information  and  are  the 
integrators  of  both  peripheral  input  and  descending  modulation  (D'Mello  and  Dickenson 
2008). Furthermore, the circuitry of the DH is well known to be subject to plasticity in chronic 
pain states. Electrophysiology enables investigation of the alteration on both physiology and 
pharmacology of spinal cord processing (Stanfa and Dickenson 2004). Indeed, extracellular 
recordings  have  aided  the  characterisation  of  central  changes  and  evoked  responses  in 64 
 
numerous  inflammatory  and  neuropathic  preclinical  models  in  addition  to  enabling  clear 
demonstration  of  distinctive  pharmacological  manipulation  (Dickenson  and Sullivan 1987; 
Dickenson  and  Sullivan  1987;  Stanfa  et  al.  1992;  Chapman  et  al.  1998;  Urch  et  al.  2003; 
Rahman et al. 2009). The ability to measure suprathreshold stimuli is also of great benefit; 
since these are more likely match the clinical reporting’s from patients experiencing intense 
pain  (as  opposed  to  threshold  measures,  which  are  the  equivalent  to  much  lower,  less 
clinically relevant, pain ratings) (Sikandar and Dickenson 2013; Sikandar et al. 2013). 
As previously mentioned, within the DH of the spinal cord there are two main groups of cells 
involved  in  pain  processing:  NS  and  WDR  neurones.  Whilst  NS  neurones  respond  on  the 
whole to high intensity input, WDR neurones receive input from A and C fibres resulting in 
responsiveness to a much broader range of stimuli. Of particular importance is the ability of 
WDR neurones to code stimulus intensity and wind up, parallel to observations in humans 
(Price 2013). WDR neurones integrate and modulate signals before they are relayed to higher 
centres  and  indeed  the  coding  output  of  these  spinal  neurones  is  comparable  to 
psychophysical reports by humans (Dubner et al. 1989; LaMotte et al. 1991; Simone et al. 
1991;  Dougherty and Willis  1992;  Sikandar  et al. 2013).  That is  to say, that the  stimulus 
response curves of WDR neurones are remarkably similar to human reporting’s (Dubner et al. 
1989; Price 2013). A recent study by Sikandar and colleagues clearly demonstrated using LV 
WDR  neurone  recordings  along  with  human  quantitative  sensory  testing  (QST)  and 
electroencephalography  (EEG),  that  the  response  characteristics  of  these  DH  neurones 
parallels responses in humans (Sikandar et al. 2013). Turning to the animal models of chronic 
pain WDR neurones have once again been shown (figure 1-6) to exhibit changes that parallel 
the human responses; in models of hypersensitivity, these neurones increase their firing just 
as human pain reporting’s increase (LaMotte et al. 1991; Simone et al. 1991; Dougherty and 
Willis 1992).  
An additional advantage of studying WDR neurones comes from the fact that these neurones 
have  been  shown  to  model  numerous  drug  responses.  For  example,  pregabalin  and 
gabapentin are effective treatments in many chronic pain disorders, which can quite clearly 
be demonstrated using recordings from LV WDR neurones that these compounds are able to 
reduce  neuronal  activity  in  a  comparable  fashion  (Dworkin  et  al.  2003).  Whilst  the 
compounds shows efficacy in models of altered nociceptive processing such as SNL and MIA, 
no such effects can be seen in naïve animals (Suzuki et al. 2005; Bee and Dickenson 2008; 
Rahman  et  al.  2009).  The  same  is  true  in  case  of  tapentadol,  whereby  it  has  been 65 
 
demonstrated  that  it  reduces  evoked  activity  in  DH  neurones  post  SNL  in  parallel  to  its 
efficacy in chronic pain patients (Prommer 2010; Bee et al. 2011).  As such it is clear that WDR 
neurones are a useful point of study in order to predict clinical efficacy and reduction in pain 
intensity. 
 
Figure  1-6  Responses  to  increasing  intensities  of  laser  stimuli.  There  is  considerable  overlap  between 
responses of WDR cells and human perception.  (Sikandar et al. 2013). 
 
1.3.2.  Overcoming the subjective nature of assessing human experimental pain 
The  assessment  of  chronic  pain  in  experimental  human  models  and  the  clinic  is  equally 
compromised by the subjective nature of the disorder, the limited number of tools that are 
available, and the time consuming nature of application. Assessment attempts are often made 
in the form of standardised questionnaires, which are used to aid diagnosis. Since pain is such 
a  subjective  experience  it  difficult  to  capture  and  quantify  even  with  such  methods.  Pain 
ratings in questionnaires  vary depending on  the  individual and  the  biological  aspects  are 
inextricably intertwined with the social and psychological, which makes analysis complicated. 
It  has  been  shown  that  a  number  of  individual  and  cultural  factors  such  as  age,  gender, 
upbringing, personality, can all influence a patient’s response to pain (Frederiksen et al. 1978; 
Chapman 2004). This lack of linear relationship between the underlying cause of the pain and 66 
 
the patient reports hinder the possibility to extrapolate the potential mechanisms and thus 
could  limit  the  usefulness  of  these  questionnaires.  The  wide  variety  of  different 
questionnaires used also makes comparison between studies difficult. Furthermore, as stated, 
these provide very different outcome measures than those produced in preclinical the studies, 
making is very difficult to draw comparisons.  
However, that is not to say that such methods provide redundant information – verbal pain 
descriptors provide important information about the patient phenotype and have been shown 
to identify up to 90% of cases of neuropathic pain (Haanpää et al. 2011). They are quick and 
easy  to  use,  providing  immediate  information.  The  painDETECT  questionnaire  has  been 
validated for  repeat  testing and assesses  measures  that begin  to  approach the  preclinical 
studies  (i.e.  examining  different  modalities)  (Freynhagen  et  al.  2006).  Furthermore, 
questionnaires can also assess the emotional aspects of chronic pain, which may be seen as 
equally as important to the patient and thus it should also be monitored as to how a treatment 
affects co-morbidities such as sleep disturbance, anxiety and depression (Rehm et al. 2010).  
In order to address the issue of subjectivity there are a number of objective techniques that 
have been investigated and hold some potential to be adopted for use in experimental and 
clinical  examination.  These  range  from  fMRI  and  diffusion  tensor  imaging  to 
magnetoencephalography and EEG. fMRI has been particularly useful in the elucidation of 
areas of the brain involved in central sensitisation observed in both preclinical pain models 
and patients, in addition to quantifying pharmacological manipulation (Iannetti et al. 2005; 
Zambreanu et al. 2005; Lee et al. 2008; Gwilym et al. 2009). Whilst this has driven a lot of 
interest in fMRI in the past few years, including many successful studies it must be noted that 
this  technique  does  not  directly  sample  neural  activity,  but  rather  the  consequential 
haemodynamic  changes.  It  is  also  restrictive  in  terms  of  providing  information  that  has 
limitations of both the spatial and temporal domains. As Tracey and Mantyh emphasise, it is 
imperative to understand the temporal integration within spatially defined areas (Tracey and 
Mantyh 2007). In addition to this, since the ‘pain matrix’ is not in fact a unique signature of 
pain and the same patterns of activation can be evoked by other sensory modalities it could 
be influenced by other sensory or factors (Legrain et al. 2011). The procedure is also costly 
and time consuming, which further hinders uptake into the clinic.  
In order to address the poor temporal resolution of fMRI, EEG may be used alongside. EEG, 
although lacking spatial resolution, can provide much better information regarding temporal 
events. EEG measures ongoing electrical brain activity, which is a reflection of the summation 67 
 
of  low  frequency  neuronal  activity  -  i.e.  postsynaptic  potentials  -  in  cortical  neurones 
(Speckmann  1999).  A  number  of  sensory,  motor,  or  cognitive  stimuli  (or  events)  can  be 
recorded using EEG and are known as event related potentials. Stimulus elicited changes in 
the  EEG  waveforms,  and  may  be  phase  locked  or  non  phase  locked  to  the  specific  event 
(Iannetti 2010). The largest wave is known as the negative-positive complex (N2-P2), and is 
detected mostly at the scalp vertex. A smaller preceding wave is known as N1 and is detected 
around the temporocentral region on the contralateral side to stimulation. Taken together it is 
believed that N1, N2 and P2 reflect activity that is generated in the primary and secondary 
somatosensory cortices as well as the insula and anterior cingulated cortex, in response to 
sensory stimuli (Garcia-Larrea et al. 2003).  With regards to pain, the magnitude of the wave 
appears to be positively correlated with perceived intensity of the stimuli (Garcí-Larrea et al. 
1997;  Timmermann  et  al.  2001).  They  can  therefore  be  used  to  assess  the  functional 
significance of brain processing in response to specific nociceptive stimuli.  
However, as with fMRI, EEG is very time consuming and provides limited information as to 
the  underlying  mechanisms.  Greater  uptake  has  instead  been  seen  with  since  the  recent 
introduction of a standardised form of QST designed by the German Research Network on 
Neuropathic Pain (DFNS) (Rolke et al. 2006; Rolke et al. 2006). The detailed protocol will be 
described  in  chapter  2,  and  despite  not  being  purely  objective  the  technique  has  many 
benefits;  not  least  the  minimal  costs  and  quick  nature  of  the  tests.  QST  enables  the 
examination of sensory processing, across a number of modalities, under both normal and 
pathological conditions. A standardised protocol was introduced in 2006, which has allowed 
the collection of large amounts of data from both healthy human volunteers and patients – all 
of which is directly comparable.  
The QST battery involves a comprehensive list of validated short form tests across relevant 
somatosensory  modalities  (Rolke  et  al.  2006;  Rolke  et  al.  2006).  These  tests  range  from 
mechanical  and  thermal  detection  thresholds,  to  pain  thresholds  and  symptoms  of 
hyperalgesia and allodynia. Whilst assessment of mechanical detection threshold (MDT) using 
von Frey filaments, or vibration detection using a tuning fork, indicate the function of Aβ 
fibres, determining the mechanical pain threshold (MPT) using pinpricks assesses Aδ fibre 
function (Hansson et al. 2007). Abnormalities such as hyperalgesia or allodynia picked up in 
the stimulus/ response function (S/R function) may also indicate changes in Aβ or Aδ fibres, 
and could denote the presence of central sensitisation. Assessment of thermal detection and 
pain  thresholds  indicate  the  function  of  Aδ  and  C  fibres,  and  thermal  hypersensitivity  is 68 
 
believed to be a useful marker of peripheral sensitisation. Finally, pressure pain thresholds 
(PPT) are testing using an algometer and may be used to gauge the function of muscle Aδ and 
C fibres. Overall, these symptom profiles give a good indication of the potential underlying 
pathology. Importantly, these evoked measures can be compared more easily with preclinical 
studies; for example numerical pain ratings and thresholds can easily compared with animal 
behaviour  and  electrophysiological  data.    This  allows  for  preclinical  studies  to  be  run  in 
tandem to collect complimentary data sets. 
The QST protocol examines small and large fibres, assessing both gain and loss of function. 
These functions are explored in cutaneous, and to some extent, deep pain. Furthermore, the 
tests measure symptoms associated with peripheral and central mechanisms and therefore 
may aid a more accurate diagnosis than simply asking the patient to rate their pain, and base 
treatment on this rating and disease state. Different symptoms are believed to be the result of 
differing  underlying  pathological  mechanisms  –  therefore  a  thorough  analysis  of  these 
sensory  profiles  allows  identification  of  relevant  components,  reflecting  the  underlying 
aetiologies and guides diagnosis of chronic pain conditions.   
For patients in particular, this could allow the determination of particular subgroups with 
similar somatosensory phenotypes within chronic pain. The patterns of symptoms emerging 
amongst groups of patients are likely to reflect particular underlying mechanisms. Indeed, it 
has already been shown that within neuropathic pain patients, 5 subgroups can be defined, 
based on their symptom profiles (Baron et al. 2012). This suggests that members of each 
group  may  have  similar  underlying  mechanisms  and  thus  may  benefit  from  the  same 
treatments. Most likely a mix of these groups will have previously been included in clinical 
trials and therefore it is not unsurprising that many drugs have failed to show any efficacy 
across  a  range  of  mechanisms  not  necessarily  suitable  for  the  particular  compounds.  By 
incorporating  experimental  human  models  into  preclinical  studies,  evoking  known 
mechanisms, we can begin to attribute particular symptoms to particular causes. This not 
only aids diagnosis, but also management of chronic pain - facilitating the move towards the 
concept of a mechanism based approach to treatment.  
However, even QST is limited in the scope of phenotypes measured (Rolke et al. 2006). QST 
relies on accurate reports from the subject or patient, which will always produce a reasonable 
amount  of  variation.  As  such  there  would  be  great  benefit  to  the  introduction  of  more 
objective assessment. Yet, despite its high clinical relevance, an exclusively objective measure 
of pain does not yet exist. Rather, as it stands currently QST is one of the best tools available 69 
 
to  fully  characterise  and  compile  detailed  sensory  profiles  of  patients,  and  its  uptake  in 
preclinical models will increase its usefulness. Using the same tools in the clinic and in early 
studies  is  particularly  important  for  translation.  If  QST  is  used  to  characterise  preclinical 
models, with known mechanisms we can begin to understand what the patient profiles mean 
with regards to the underlying pathology and potential responsiveness of subgroups to novel 
analgesics. Furthermore, using animal models in addition to QST allows the study of detailed 
molecular  underpinnings.  This  thesis  will  explore  the  use  of  characterising  translational 
models  of chronic  pain  in animals  and humans  in order to  bridge  the  gap between basic 
research and the clinic. 70 
 
1.4.   Thesis aims 
This thesis aims to characterise possible translational models of chronic pain using analogous 
standardised procedures in animals and humans to allow a comparison of results. The models 
include: capsaicin cream, UVB and UVB heat rekindling.  By using both animals and humans, 
this thesis aims to overcome potential species differences and align the preclinical models 
that  are  used.  Furthermore,  the  use  if  human  subjects  enables  the  exploitation  of  verbal 
capacity and a thorough investigation of the exact location, intensity and quality of the pain.  
Full characterisation of the models will involve the use of an objective outcome measures in 
animals:  in  vivo  electrophysiology.  The  use  of  such  measures  helps  overcome  the  issues 
discussed around subjective behavioural measures. The concordance in outcome measures 
between  animal  and  human  studies  aims  to  assess  the  ability  to  evoke  the  same 
changes/signs/symptoms in animals and humans, suggestive of the induction of overlapping 
mechanisms.  Furthermore, by using QST as the outcome measure in humans this thesis aims 
to create full sensory profiles of the above models, in order to draw comparison with patient 
profiles.  
This  thesis  also  aims  to  investigate  a  novel  translational  pain  mediator:  CXCL5.  The 
consequence  of  intraplantar  injection  of  CXCL5,  a  chemokine  believed  to  be  involved  in 
sensitisation post UVB irradiation, will be assessed in animals.  
Finally, this thesis aims to assess the ability to modulate translation models using the same 
drugs, and using a mechanism based approach to treatment. The ability of ADO to prevent 
capsaicin induced hypersensitivity will be investigated in both animals and humans, whilst a 
more in depth study of the mechanism will involve the use of CPA in animals.  71 
 
2.  Materials and Methods 
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All experimental procedures were approved by the UK Home Office and were performed in 
accordance with the guidelines provided by the International Association for the Study of Pain 
for the  care  and use of Laboratory animals. Human studies were  approved by  The  Kings 
College Research Ethics Committee and all participants gave written informed consent before 
commencing the study. 
 
2.1.    Animals 
Male Sprague-Dawley rats were obtained from the UCL Central Biological Unit. The rats were 
housed in cages under a 12-hour light/dark cycle with readily available food and water. The 
weight of the rats used in these experiments was consistently between 220 and 250g.  
 
2.2.   In vivo Electrophysiology 
2.2.1.  Animal set up 
The following protocol has been well established and is detailed in full by Urch and Dickenson 
(Urch and Dickenson 2003). 
Rats were anaesthetised in an induction box using 4% isoflurane (carried in 66% N2O and 
33% O2). Once the rat was fully unconscious and checked for absence of reflexes (by pinching 
the toes of the hindpaw) a tracheotomy was performed. This procedure involved exposing the 
trachea and making a small incision with a scalpel horizontally across.  A polyethene cannula 
was then inserted around 80-100mm into the trachea and fastened in place using 3-0 silk 
thread. Isoflurane was delivered through this cannula for the full duration of the experiment. 
Once this procedure was completed, the rat was placed in a stereotaxic frame and secured 
using ear bars. The anaesthesia was then dropped to 2-3% to perform a laminectomy.  Within 
the stereotaxic frame the rat was placed onto a homeothermic heat mat, controlled using a 
rectal temperature probe, to maintain core temperature at 37C. 
An incision was made into the skin along length of vertebra, to expose connective tissue and 
muscle. Connective tissue was removed and the bottom of the rib cage was identified – where 
the lower ribs meet is the approximate position of the T12 region. Above this, two incisions 73 
 
were made either side of the vertebral column to enable clamping and stabilisation of the cord 
to facilitate the laminectomy. 
Muscle  and  vertebrae were  removed  from  around  L1-L3  using  rangeurs  in  order  to  fully 
expose the L4-5 segments of the spinal cord; where recordings from WDR cells were made 
and drugs can also may be applied. Watchmaker forceps were used to remove the dura from 
the cord to improve recordings. Below this region two further incisions either side of the 
column  were  made,  once  again  to  enable  clamping  and  stabilisation,  as  well  as  to  aid 
positioning of the cord for optimum recording. It was important that the cord was straight 
and no movement occurred with respiration. Further to this the isoflurane was dropped to 
1.75-2%  for  the  remaining  duration  of  the  experiment.  This  was  raised  to  5%  upon 
completion of the experiment in order to overdose the rat before ensuring death via cervical 
dislocation of the neck. 
 
2.2.2.  Electrophysiological recording 
Recordings were made from single WDR neurones located in the deep dorsal horn (DDH) of 
the spinal cord (500μm ventral to the surface of the spinal cord). The recordings were made 
using  a  parylene  coated  tungsten  electrode  (125μm  in  diameter)  and  the  system  was 
grounded through both the animal and the frame. Thus the final recording of the input from 
the electrode was that from the neurone minus the signal from the animal, in order to reduce 
interference.  The  electrode  was  secured  into  a  head  stage  attached  to  a  3-axis  manual 
micromanipulator.  Recordings  were  obtained  using  an  AC  recording  system  (NeuroLog 
System,  Digitimer,  UK)  and  were  amplified  and  filtered,  before  being  displayed  on  an 
oscilloscope, as well as heard through a sound amplifier. 
In order to identify an individual neurone, the ipsilateral plantar surface of the rat’s hindpaw 
and toes were tapped. Spikes must be clearly distinguished from background noise and of a 
uniform  shape  and  amplitude.    It  was  sometimes  necessary  to  distinguish  the  cell  from 
neighbouring ones by  slightly adjusting the  electrode  up  or down. Once a  cell was  easily 
differentiated  and  counted,  the  response  to  different  stimuli  were  recorded.  Data  was 
captured using Spike 2 software on a Pentinum computer, which is coupled to a CED 1401 
interface. Responses were recorded to natural stimuli (mechanical and thermal) – including 
brush, von Frey filaments of graded forces (2g, 8g, 15g, 26g, 60g) and different temperatures 74 
 
of water (35C, 40C, 45C, 48C). These stimuli were applied to the receptive field for 10 
seconds.  
 
Figure  2-1  Example  responses  of  a  single  WDR  neurone.  Stimulus  histogram  showing  WDR  neuronal 
responses to a variety of graded natural stimuli. Mechanical stimuli include dynamic brush and vF filaments and 
thermal stimuli are water jets. 
 
2.2.3.  Transcutaneous electrical stimulation 
In order to induce wind up, two fine stimulating needles were inserted under the skin within 
the cells receptive field. Single electrical pulses were then delivered at graded mA intervals 
(beginning at 0) in order to find the threshold of A and C fibres.  These were identified by the 
presence of an action potential in the correct latency band of each fibre; i.e. evoked potentials 
from C fibre stimulation must lie within the latency range of 90-300ms. A train of 16 stimuli 
were  then  delivered  (2ms  wide  pulse  at  0.5Hz)  at  3  times  the  C  fibre  threshold.  A  post 
stimulus time histogram was constructed in order to classify the responses evoked from the 
A  (0-20ms),  A  (20-90ms)  and  C  (90-300ms)  fibres,  in  addition  to  calculating  the  post-
discharge (PD) – this is the activity which occurs after C fibre latency, around 300-800ms. 
This separation of fibres relies on assuming the conduction distance is approximately 10cm. A 
predicted ‘no wind up’ response (e.g. a lack of change in the evoked responses over the 16 
stimuli) was calculated by multiplying the number of action potentials elicited by the first 
single  stimulation  by  16  (number  of  action  potentials  after  the  first  stimulus  x  16).  This 
hypothetical number is termed input.  The wind up was then calculated by using the formula: 
Wind up = total number of action potentials after 16 stimuli – input 75 
 
This paradigm was repeated 3 times, every 20 minutes, within the space of one hour, in order 
to confirm a stable baseline response of the cell. Depending on the experiment, this may have 
been further repeated after the application of a drug or sensitising chemical stimuli. 
 
Figure 2-2 In vivo electrophysiology set up. A laminectomy was performed to expose L4-5 segments of the 
spinal cord and recordings were taken from LV neurones of the DH using a tungsten electrode. Natural and 
electrical stimuli were applied to the RF on the hindpaw. Action potentials were visualised on an oscilloscope 
and captured using spike 2 software (Asante 2009). 
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Figure 2-3 Schematic of neurolog recording system. The recording electrode was inserted into the spinal 
cord  and  input  enters  the  recording  system  via  the  headstage.  Grounding  was  achieved  through  a  lead 
connecting  to  the  stereotaxic  frame.  The  reference  lead  recorded  interference/  basal  electrical  activity  and 
subtracted this from the signal, which was then amplified and filtered before being fed into the audio speaker 
and oscilloscope. These visual and audio representations of the action potentials allowed for isolation of single 
unit  WDR  neurones. Action potentials with an amplitude above a set  threshold  were fed into the CED1401 
interface and were  quantified by the computer. Electrical stimuli were delivered into the receptive field using 
two  stimulating  electrodes  and  a  post-stimulus  time  histogram  was  generated  depending  on  the  latency  of 
evoked potentials. Natural stimuli were also displayed on a rate histogram and the number of action potentials 
evoked in 10 seconds were quantified. 
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2.3.    Subjects 
Healthy  volunteers  between  18  and  59  years  old  with  no  history  of  chronic  pain  were 
recruited for the studies detailed in this thesis. All subjects were in good health at the time of 
study, and were advised to avoid painkillers, caffeine and alcohol up to 12 hours prior to the 
study, since these substances may interfere with the results. Additionally, all female subjects 
confirmed  they  were  not  pregnant  at  the  time  of  the  study.  Any  volunteers  with  skin 
conditions or inflammation such as eczema or dermatitis were excluded from taking part in 
any study. Once subjects had been selected to take part in any study, they were familiarised 
with the sensory testing procedure detailed below, so they knew what to expect during the 
study. 
 
2.4.   Human Quantitative Sensory Testing 
Subjects were sat comfortably in a temperature controlled, quiet room with no external visual 
disturbances. After obtaining written informed consent and explaining the protocol, seven 
tests, measuring 13 different parameters were then undertaken as described by Rolke and 
colleagues (Rolke et al. 2006; Rolke et al. 2006). The same testing equipment was used for all 
studies. Before beginning each study, the subject was familiarised with each of the tests on an 
independent area. 
 
2.4.1.   Mechanical detection threshold (MDT): 
A  standardised  set  of  vF  filaments  (Optihair2-Set,  Marstock  nervtest,  Germany.  0.5mm 
diameter rounded tip to avoid nociceptor activation to low force vF), ranging between 0.25 
and 512mN were used to assess the average MDT. The subject sat with their eyes closed and 
their hand, or arm, placed comfortably in front of them. The hairs were carefully applied to 
the point of bending, over a small area, one at a time using the ‘up-down’/ ‘method of limits’. 
Beginning with 16mN the subject was asked to report if they felt any touch sensation. If so the 
force was then decreased until the subject reported they were no longer able to feel anything. 
Increasing forces then were then applied until the subject reported they were able to feel the 
vF. Overall 5 series of ascending and descending stimulus intensities were applied and the 
geometric mean was calculated to work out the MDT. This threshold is most likely mediated 
by A fibres (Hansson et al. 2007). 78 
 
2.4.2.  Mechanical pain thresholds (MPT): 
A  standardised  set  of  custom-made  pinprick  stimulators  (Pinprick,  MRC  Systems  GmbH, 
Heidelberg,  Germany.  0.2mm  diameter)  ranging  between  8mN  and  512mN  were  used  to 
assess the average MPT. The subject once again closed their eyes with their hand, or arm, 
placed comfortably in front of them. The pinpricks were carefully applied perpendicularly at a 
standard force, using the ‘up-down’/ method of limits. Each pinprick was applied for one 
second  over  a  small  area.  The  test  began  with  8mN  and  increasing  pinprick  forces  were 
applied until the subject reported that the sensation changed from ‘blunt’ to ‘sharp’. Once the 
subject reported the pinprick to be ‘sharp’, the force was decreased until the subject reported 
the sensation felt ‘blunt’. This process was repeated 10 times and the geometric mean was 
calculated to work out the MPT. The threshold is most likely mediated on the whole by A, 
with a contribution from C fibres (Hansson et al. 2007; Iannetti et al. 2013). 
 
2.4.3.  Stimulus-response-functions (S/R functions) - mechanical pain sensitivity for 
pinprick stimuli and DMA for stroking light touch: 
The seven pinprick stimuli, ranging from 8mN-512mN, were used along with a cotton wisp 
(3mN), a cotton wool tip fixed to an elastic strip (100mN) and a standardised brush (Somedic, 
Sweden. 200-400mN). Unlike the determination of thresholds, this allowed for the detection 
of hyper and hypoalgesia to supra-threshold stimuli. The different stimuli were applied 5 
times each in a specific order, as determined by the DFNS protocol. For each stimulus the 
subject was required to give a rating from 0-100, where 0 = no pain, and 100 = worst pain 
imaginable. The tactile stimuli were integrated with the pinpricks, and were applied with a 
single stroke across a 1-2cm length of skin. These functions are mediated by A, A, and C 
fibres (Hansson et al. 2007). 
 
2.4.4.  Wind-up ratio (WUR): 
The  256mN  pinprick  stimulator  was  used  to  assess  the  WUR,  which  is  a  measure  of  the 
perceptual correlate of temporal summation to repetitive stimuli. The subject was once again 
asked to close their eyes and place their hand, or arm comfortably in front of them. A train of 
10 stimuli was applied at the same force at over an area of 1cm2. The stimuli were delivered at 
a rate of 1/s. The subject was asked to give a rating from 0-100 for the first and last of the 79 
 
train of stimuli. This test was repeated 5 times over different areas within the same region of 
the body. The WUR was then calculated from the average pain rating of the final stimuli in the 
train, divided by the average rating of the initial single stimuli. 
 
2.4.5.  Vibration detection threshold (VDT): 
A Rydel-Seiffer tuning fork (64hZ, 8/8 scale) was used to assess the VDT. The tuning fork was 
placed over the nearest bony prominence to the test area and the subject was asked to report 
when they felt the vibration stop. The threshold was determined by averaging 3 trials. VDT is 
mediated by A fibres (Hansson et al. 2007).  
 
2.4.6.  Pressure pain threshold (PPT): 
An algometer pressure gauge device (FDN200, Wagner Instruments USA) with a rubber probe 
area of 1cm2 was used to assess the PPT. The probe was applied to the hand, or arm, at an 
increasing ramp of 50 kPa/s, until the subject reported the sensation was painful (up to a 
maximum force of 2000 kPa). The threshold was determined by averaging 3 trials. PPT is also 
mediated by A fibres (Hansson et al. 2007). 
 
2.4.7.  Thermal detection, thermal pain thresholds and paradoxical heat sensations: 
The TSA thermal sensory testing device (TSA 2001-II; Medoc Ltd, Ramat Yishai, Israel) was 
used to assess both thermal detection and pain thresholds. The subject is instructed to sit 
with  their  hand,  or  arm,  in  front  of  them  and  a  thermode  (area  =  between5x5  mm  and 
16x16mm largest is 30x30mm) was fixed in place using a Velcro band. The subject was not 
able to see the computer screen for the duration of the tests, but was instructed when the test 
would  begin.  Thresholds  were  recorded  using  the  medoc  TSA  system  (WinTSA  5.3 
NeuroSensory  Analyzer).  All  thresholds  were  obtained  using  a  ramped  stimulus  (1C/s), 
which was cut off as soon as the subject clicked a mouse. Testing began at 32C and the 
temperatures were cut of at 0C and 52C to avoid injury. 
The subject was first asked to click the mouse as soon as they perceived a cooling sensation 
(CDT) i.e. the first time they felt the temperature decrease. This was followed by detection of a 
warming sensation (WDT) i.e. the first time they felt the temperature increase. Each of these 80 
 
detection thresholds were repeated 3 times, with an inter-stimulus interval of 10s, and an 
average value was calculated. A normal detection threshold is within 1-2C from baseline 
(32C),  and  whilst  CDT  is  believed  to  be  mediated  by  A  fibres,  WDT  is  predominantly 
mediated by C fibres (Arendt-Nielsen and Chen 2003; Rolke et al. 2006; Hansson et al. 2007).  
Next, paradoxical heat sensations were measured using a thermal sensory limen procedure 
for alternating cold and warm stimuli. The subject was instructed to click the mouse as soon 
as they perceived a cooling or warming sensation, in addition to also verbally reporting which 
sensation they felt.  
Finally the cold pain, and heat pain thresholds were measured (CPT and HPT, respectively). 
Subjects were informed that they would feel a cooling, cold and finally a cold pain sensation 
and that they must click the mouse as soon as they felt the device become painfully cold. 
Similarly, to measure HPT they were instructed that they would feel a warming, warm and 
finally a heat pain sensation and that they must click the mouse as soon as they felt the device 
become  painfully  hot.  Once  again,  these  pain  thresholds  were  measured  3  times  and  an 
average was taken. CPT is mediated by both A and C fibres and is highly variable, on the 
other hand HPT is always around 45C and mediated on the whole by C fibres with a small A 
fibre contribution (Arendt-Nielsen and Chen 2003; Rolke et al. 2006; Hansson et al. 2007). 
In  the  original  DFNS  description  of  the  QST  battery  the  thermal  tests  preceded  the 
mechanical. However, in this thesis the protocol was reversed since it has been shown that by 
applying heat first a slight sensitisation may be induced, significantly increasing mechanical 
pain sensitivity (Gröne et al. 2012). 
 
2.4.8.  Data evaluations and z-transformation 
Data was first assessed for normality using the Kolmogorov-Smirnov. Any data that did not 
pass  this  test  was  log-transformed  and  re-tested.  It  is  generally  accepted  that  most 
psychophysical measures will not be normally distributed, with the exception of heat and 
CPTs,  and  VDTs.  Negative  QST  scores  (CDT),  were  be  multiplied  by  -1,  before  they  were 
logged.  Additionally,  a  small  constant  of  +0.1  was  added  to  all  numerical  ratings  before 
logging, to avoid a loss of zero values (Magerl et al. 1998; Rolke et al. 2006). In order to 
compare the data collected from the surrogate models to the baseline responses across all 81 
 
QST  parameters,  Z-scores  were  then  calculated  using  the  following  formula:  
Z-score = (XSingle Subject– MeanControls)/SDControls 
Where  X  =  the  value  for  any  parameter  of  a  given  individual  subject.  When  presented 
graphically, the algebraic sign of the Z-score value was adjusted so that Z-scores above ‘0’ 
indicate a gain of function, while those that are below represent a loss. Post-model scores can 
be compared to baseline controls using the 95% confidence intervals: 
95% CI = MeanControls 1.96SDControls 
 
2.5.   Chronic Pain Models 
2.5.1.  In vivo Electrophysiology – Capsaicin  
Topical  capsaicin  cream  was  used  in  order  to  induce  sensitisation  of  the  pain  pathway, 
altering both peripheral and central processing mechanisms. Capsaicin was applied only once 
a cell had been characterised, using the above protocol involving mechanical, thermal and 
electrical stimuli, and stable responses have been achieved. Following this between 0.1-0.2 ml 
of 1% capsaicin (Pharmasol & Pharmaserve NW, UK) was applied onto the receptive field 
(depending on it’s size) using a 1.0ml syringe. Once the receptive field was covered, the area 
was covered with parafilm to ensure there was no loss of cream during the 30 minutes it was 
applied for. 
The  capsaicin  cream formulation  also contains purified water, sorbitol solution, isopropyl 
myristate, cetyl alcohol, white soft paraffin, glyceryl stearate, PEG-100 stearate and benzyl 
alcohol. The vehicle was not studied since this has been previously been shown to have no 
effect on sensory measures and thus, in line with the NC3Rs, these experiments were not 
repeated (Simone and Ochoa 1991; Altman et al. 1994; Magerl et al. 2001). 
30 minutes post application the cream was carefully removed using an alcohol wipe. Since 
mechanical  pressure  could  affect  the  degree  of  sensitisation  induced,  this  procedure  was 
conducted  as  gently  as  possible  and  in  the  same  manner  each  time,  in  order  to  reduce 
variability. Subsequently the natural (mechanical and thermal) and electrical responses were 
then re-tested at 30, 60 and 90 minutes post application. 82 
 
If  the  experiments  were  aimed  at  modulating  the  effects  of  capsaicin,  the  drug  was 
administered prior to capsaicin application. The method of drug administration is detailed in 
section 2.6. 
 
2.5.2.  In vivo Electrophysiology – UVB 
UVB is a stimulus believed to cause an entirely peripheral sensitisation of the pain pathway. 
Rats were first anaesthetised in an induction box using 4% isoflurane (carried in 66% N2O 
and 33% O2). Once the rat was fully unconscious and checked for absence of reflexes they 
were placed on-to a heat mat and fully covered with UV resistant material. After exposing the 
plantar surface of the right hindpaw, the UVB light source (Dermfix 1000MX UV-B Lamp fitted 
with a 9 Watt fluorescent UVB tube, λ max = 311nm) was placed at a set distance from the 
paw, ensuring the correct dose is delivered. The irradiance of the lamp was determined using 
a calibrated photometer (Solartech Inc Solarmeter 6.2 UVB Meter, Merlin Lazer). This reading 
was used to determine the length of time required to deliver a set dose of 1000mJ/cm2. The 
dose used in these studies was chosen on the basis of previous studies, which have found this 
to have the greatest effect without resulting in any signs of skin damage such as blistering 
(Bishop  et  al.  2007).  Post  irradiation  the  rats  were  placed  in  a  temperature  controlled 
recovery  box  until  the  effects  of  the  anaesthetic  had  completely  reversed.  In  vivo 
electrophysiology was performed 24-30 hours post UVB. 
 
2.5.3.   In vivo Electrophysiology – UVB Rekindling 
UVB irradiation was carried out as described above in 2.5.2, however only the upper half of 
the hindpaw was exposed to the light source, rather than the entire paw. 24-30 hours later in 
vivo electrophysiology was performed. Once a cell had been isolated and characterised with 3 
stable  baselines  the  rekindling  procedure  was  initiated.  A  heat  source  of  a  constant 
temperature of 40C was then applied to the irradiated area for an initial 5 minutes. A second 
identical rekindling was then performed after an interval of 15 minutes. Subsequently the 
natural (mechanical and thermal) and electrical responses were re-tested at 30, 60, 90, 120 
and 150 minutes post rekindling. 
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2.5.4.  QST – Capsaicin 
Administration of capsaicin cream to volunteers was similar to the protocol described for the 
animals. Once full sensory testing had been completed, 0.5ml of 1% capsaicin cream was 
applied to the test area (16x16mm) marked on to the skin. This was then covered with a 
transparent film dressing (Tegaderm Film, 3M Health Care) ensuring no cream was lost or 
removed during the 30 minutes it was applied for. Once again, care was taken when removing 
the cream to ensure it was in a gentle and uniform manner, in order to minimise any effects 
on the level of sensitisation induced. 
 
2.5.5.  QST – UVB 
Volunteers were irradiated in a similar protocol as described for the animals. However, the 
dosing  was  calculated  on  an  individual  basis  depending  largely  on  skin  type.  An  initial 
screening was conducted on each subject to determine their minimal erthymal dose (MED); 
this is defined as the time required to produce a uniform reddening of the area at 24 hours 
post  irradiation.  3  times  the  MED  was  then  used  for  the  final  experiment  to  irradiate  a 
16x16mm area - the surrounding area must was covered with a UV resistant material to 
ensure a uniform burn. 
 
2.5.6.  QST – UVB Rekindling 
24-30 hours post UVB irradiation subjects returned for the heat rekindling procedure and full 
QST profiling. The procedure was carried out using the TSA thermal sensory testing device 
(TSA 2001-II; Medoc Ltd, Ramat Yishai, Israel), as used for the thermal testing in the QST 
protocol. The thermode (16x16mm) was placed directly over the UVB burn and held in place 
with a Velcro strap. The rekindling procedure carried out was the same as that described for 
the animals – the thermode was kept at 40C for 5 minutes, followed by a 15 minute interval 
and a subsequent second rekindling identical to the first.  
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2.6.   Drug Administration 
2.6.1.  In vivo Electrophysiology  - ADO/ CPA 
50 L of adenosine (ADO) (26g) or N6-cyclopentyladenosine (CPA) (5g) in a saline solution 
was injected into the receptive field of the cell (adjacent to the testing area) using a Hamilton 
syringe.  In  the  paradigm  exploring  the  ability  of  the  drugs  to  prevent  capsaicin  induced 
sensitisation the injection was given 10 minutes before the application of capsaicin over the 
receptive field.  
 
2.6.2.  QST - ADO 
A  1ml  syringe  was  used  to  inject  26g/50L  ADO  in  a  saline  solution  into  the  test  area 
(5x5mm).  Successful  injection  was  confirmed  by  the  appearance  of  a  bleb.  As  with  the 
animals, 10 minutes post injection capsaicin is applied over the treated area (5x5mm). 
 
2.7.   Statistical Analysis 
All statistical analysis was performed using SPSS software (IBM SPSS Statistics v21). Data was 
assessed for normality using the Kolmogorov-Smirnov test to determine further methods of 
analysis. Detailed statistical analysis is found in each individual chapter. 85 
 
2.8.   Control Experiments  
All  compounds  used  in  this  thesis  were  in  solution  with  0.9%  saline  (ADO/CPA/CXCL5). 
Therefore we first tested the effect of intraplantar/ intradermal saline on WDR cell responses 
and human QST.   
2.8.1.  Control methods 
In  vivo electrophysiological  recordings  were  performed as previously described to  obtain 
baseline responses. Once stable responses had been characterised for each  individual cell, 
50L saline was injected using a Hamilton syringe, into the receptive field of the cell, distal 
from  the  point  at  which  natural  stimuli  were  applied.  The  train  of  electrical  and  natural 
stimuli was repeated at every 30 minutes, up to 4 hours post injection. The maximum change 
was calculated once results had been collected. 
Full QST was performed as described in chapter two to obtain baseline responses. The area 
was  then cleaned with an alcohol wipe  before  intradermal  injection of 50L 0.9%  saline. 
Thresholds and ratings we retested at every 30 minutes, up to 180 minutes post application. 
The maximum change in subject responses was calculated. 
2.8.2.  Intraplantar injection of saline has no effect on LV WDR cell responses 
Natural  and  electrical  evoked  responses  of  WDR  cells  were  recorded  both  pre  and  post 
intraplantar saline. There was no difference in responses to any of the stimuli tested, thus 
suggesting that any effects in the following chapters can be attributed to the drug rather than 
vehicle. 
2.8.3.  Intradermal  injection  of  saline  has  no  effect  on  human  psychophysical 
responses.  
Mechanical  and  thermal  thresholds,  in  addition  to  NRS  ratings  were  tested  pre  and  post 
intradermal saline. There was no effect on any of the measures, thus suggesting that as with 
the animals, any effects in the following chapters may be attributed to the drugs tested. 
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Figure 2-4 Natural and electrical WDR cells responses are unchanged by intraplantar saline. Using the 
protocol described in chapter 2.2 in vivo single unit recordings of responses of LV WDR cells to natural and 
electrical stimuli. Natural stimuli (mechanical and thermal) were applied for 10s and included brush, von Frey 
filaments of graded forces and different temperatures of water. Transcutaneous electrical stimulation was used 
to measure the input and wind up, in addition to calculating the responses driven by different fibre types.  These 
responses were unchanged up to 90 minutes post intraplantar administration of saline into the receptive field. 
Such measures are taken as a control for drugs administered via intraplantar injection (as in chapter 4 and 6). 87 
 
 
Figure  2-5  Psychophysical  human responses are  unchanged  by intradermal  saline. Using  the  protocol 
described in chapter 2.3 standardised QST was undertaken to determine the subject’s mechanical pain threshold 
(MPT) and heat pain threshold (HPT), in addition to obtaining numerical ratings (NRS) to graded mechanical and 
thermal stimuli.  These responses were unchanged up to 90 minutes post intradermal injection of saline. Such 
measures are taken as a control for drugs injected intradermally (as in chapter 4).   88 
 
3.  Capsaicin Cream 89 
 
3.1.   Introduction 
One approach in establishing experimental pain models is to mimic the events that produce 
pain in patients. This is most often undertaken in laboratory animals. One example of such is 
the pioneering work from the Mantyh lab in creating a model of bone cancer pain in rodents 
that has considerable face validity in mirroring the pathology in human patients (Bloom et al. 
2011;  Mantyh  2013).  However,  one  important,  and  highly  criticised,  limitation  of  these 
models is the possible confound of species differences. Furthermore, it is difficult to fully 
explore the human condition, since sensory phenotypes and profiles cannot be identified from 
patients with concomitant therapies and analgesics. 
Therefore,  a  second  key  approach  is  to  implement  models  where  the  same  protocols  are 
undertaken in animals, as well as in otherwise healthy volunteers, in order to approach this 
possible species issue and explore possible human sensory phenotypes. Understandably it is 
usually not feasible, or ethical, to attempt to recreate the actual pathology occurring in pain 
patients. Instead one can attempt to mimic the signs and symptoms exhibited by chronic pain 
patients with the aim of modelling as closely as possible the mechanisms in healthy humans of 
the relevant underlying pathophysiologies in patients. Pivotal mechanisms of chronic pain 
include  peripheral  and  central  sensitisation,  which  can  indeed  be  mimicked  in  healthy 
volunteers  using  a  number  of  surrogate  models,  such  as  with  the  use  of  capsaicin.  This 
chapter explores the use of electrophysiology and QST in order to objectively characterise the 
use of topical capsaicin cream as a translational model of chronic pain. 
Capsaicin is the chemical found in chilli peppers and is responsible for the hot and spicy 
flavour upon consumption. The molecule is able to depolarise nociceptors and increases their 
cytosolic free Ca2+ concentration. This action is exerted through the TRPV1 receptor, which is 
expressed  on  small  sensory  neurones,  including  peptidergic  and  non-peptidergic  C  fibres 
(Michael and Priestley 1999; Kobayashi et al. 2005). In addition to immunohistochemistry 
studies, capsaicin has been shown to selectively activate C fibres and the ablation of TRPV1 
positive fibres has been found to result in a reduction in C fibre, but not A fibre related activity 
(Culp et al. 1989; Brenneis et al. 2013). Thus it would appear that the majority of TRPV1 
receptors in the periphery are expressed on nociceptive C fibres. Activation of the receptor 
with capsaicin results in a flare and burning pain, which can further leads to the development 
of  hypersensitivity  to  mechanical  and  thermal  stimuli;  a  phenomenon  which  has  been 
extensively explored with regards to the relevance of these symptoms in chronic pain. 90 
 
3.1.1.  Capsaicin has been widely explored as a surrogate model of hypersensitivity 
The use of capsaicin as a surrogate pain model in human subjects has been explored since the 
1960’s (Jancsó 1960). It was first introduced by Jansco and colleagues and it is now well 
described that administration of capsaicin through various means can lead to the hallmarks of 
chronic pain, such as hyperalgesia and allodynia (O'Neill et al. 2012). The model has been 
extensively used in healthy volunteers to understand the peripheral and central mechanisms 
that  underpin  such  symptoms,  in  addition  to  screening  novel  analgesics.  It  can  be 
administered intradermally, topically, or in combination with a heat source (heat/capsaicin 
model);  it  is  well  established  that  both  intradermal  and  the  heat/capsaicin  model  induce 
robust central sensitisation – a key mechanism believed to be involved in chronic pain (Modir 
and Wallace ; LaMotte et al. 1991; Petersen and Rowbotham 1999; Baron et al. 2013). For a 
full review on the use of heat/capsaicin and intradermal capsaicin as surrogate models, see 
O’Neill et al (O'Neill et al. 2012). 
On the other hand, topical application alone has not been as thoroughly investigated, although 
it is also believed to lead to both peripheral and central modifications of the pain pathway. 
This model has mainly be used in humans, whereby the previous studies have on the whole 
followed a uniform paradigm consisting of topical application of 0.1-1% capsaicin to the skin 
for  30  minutes  before  sensory  testing  is  conducted.  A  variety  of  endpoints  have  been 
examined although many studies focus on the changes in the secondary area (see table 3-1 for 
full details)(Carpenter and Lynn 1981; Kenins 1982; Culp et al. 1989; Koltzenburg et al. 1992; 
LaMotte et al. 1992; Kilo et al. 1994; Liu et al. 1998; Mohammadian et al. 1998). Overall, the 
general  consensus  is  that  topical  capsaicin  evokes  an  initial  C  fibre  discharge  and 
subsequently leads to the development of thermal and mechanical hypersensitivity, with both 
pinprick and brush hypersensitivity extending into the non-treated, secondary area (Kenins 
1982; Koltzenburg et al. 1992; LaMotte et al. 1992; Kilo et al. 1994). Although one study has 
confirmed the activation of C fibres, and another the development of secondary mechanical 
hypersensitivity in rodents, there have been few investigations conducted in animals (Kenins 
1982;  Moylan  Governo  et  al.  2006).  Furthermore,  as  stated,  very  few  studies  have  fully 
characterised the primary area of injury, where there is likely to be a mix of peripheral and 
central changes. Since no area of desensitisation is created with the use of low dose topical 
capsaicin, as  with the  intradermal  injection, it  is  possible  to  fully explore  the  effects of a 
peripheral sensitisation leading to central modifications in the primary area of injury and 
therefore, it can also be used to study drugs that modulate both the peripheral and central 
components.  Examination  of this primary area may be relevant as there are likely to  be 91 
 
painful patient conditions that encompass both phenomenon. Indeed, this could be the case 
for patients suffering from OA, post-surgical pain or even fibromyalgia (Gwilym et al. 2009; 
Baron et al. 2013).  
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Table 3-1 Studies of topical capsaicin cream. Sensory changes evoked in previous studies exploring topical capsaicin in animals and humans. 
Study  Capsaicin  Treated Area  Time Frame  Thermal 
Hyper-
sensitivity 
Mechanical 
Hyper-
sensitivity 
Other Observations 
Carpenter et al, 1981  1% capsaicin solution 
painted topically on to 
slightly abraded skin 
Forearm (area 6 to 
28cm2) 
Retesting 10 minutes post 
application, capsaicin reapplied 
every 2 hours until 7 applications  
   
Kenins et al, 1982  1% capsaicin solution  Rat: Hind leg (square 
area 1cm2) 
30 minute application, followed 
by multiple applications to cause 
desensitisation 
Not Tested  Not Tested  Topical capsaicin evokes polymodal C 
fibre discharge and alters activation 
thresholds (initially decreased, followed 
by an increase post desensitisation) 
Culp et al, 1989  Up to 6% capsaicin solution 
soaked gauze pad 
Forearm or palm 
(area 1.6x2.5cm2) 
30 minute application    A fibre block does not abolish 
mechanical hypersensitivity 
LaMotte et al, 1992  1% capsaicin applied 
topically to the skin inside a 
dam with a cotton-tipped 
applicator 
Around the peroneal 
nerve 
Retesting 15-60 minutes post 
application 
  Topical capsaicin evokes C fibre 
discharge 
Koltzenberg et al, 
1992 
1% capsaicin solution in a 
plaster 
Volar forearm/ hairy 
skin of hand dorsum 
30 minute application  Not Tested   Reduction in PPT, DMA, block of large 
myelinated fibres abolishes 
hypersensitivity 
Kilo et al, 1994  1% capsaicin soaked filter 
paper under an occlusion 
dressing 
Forearm (square area 
1.5cm2) 
30 minute application   Not Tested  Pressure pain hypersensitivity 
Liu et al, 1998  1% capsaicin soaked 
cellulose adhesive patch 
Volar forearm 
(square area 4cm) 
30 minute application  Not Tested  Not Tested  DMA and pinprick hyperalgesia in 
secondary area 
Mohammadian et al, 
1998 
1% capsaicin cream  Volar forearm 
(square area 16cm2) 
15 minute application  Not Tested  Not Tested  DMA and pinprick hyperalgesia in 
secondary area 
Moyalan Governo et 
al, 2006 
0.1% capsaicin cream  Rat: Left hindpaw  Retesting after 30 minutes, 
capsaicin cream is left on 
throughout the experiment 
Not Tested  Not Tested  Secondary mechanical hypersensitivity, 
BOLD signal intensity is increased in the 
thalamus and PAG 
Bishop et al,  
2009 
1% capsaicin soaked filter 
paper under an occlusion 
dressing 
Volar forearm 
(square area 
10.24cm2) 
30 minutes application    Pinprick hyperalgesia in secondary area 93 
 
Further  advantages  of  using  the  topical  cream  model  include  avoiding  confounding  the 
experiment with an intradermal injection, which may itself result in pain and irritation of the 
skin. Additionally, anxiety could potentially be associated with the use of needles, and since 
the cream is less invasive it also overcomes this hurdle. On the other hand, if necessary, it 
enables the use of an intradermal injection to administer peripherally acting drugs, as two 
injections in close proximity would be a further confound to any study and would require 
extensive  controls  within  the  experiment.  Given  the  wide  use  of  capsaicin  to  explore  the 
secondary consequences of central sensitisation, it is of value to further explore the changes 
in the primary area, in addition to the use of the topical model in rodents.  
Here, objective in vivo electrophysiology is used to characterise the model in rodents, since 
many  animal  studies  rely  on  behaviour  and  outcome  measures  based  on  nociceptive 
thresholds  (Chapman  et  al.  1985;  Sikandar  et  al.  2013).  To  fully  explore  the  signs  and 
symptoms of chronic pain like models, it is important to assess both sub and supra threshold 
stimuli and recording from spinal WDR neurones enables exploration of the full range coding 
to  stimuli  of  varying  intensities  and  modalities.  Importantly,  it  enables  the  study  of 
suprathreshold stimuli which may be relevant to the higher intensities of pain described by 
patients. 
 
3.1.2.  Application of topical capsaicin cream induces peripheral sensitisation 
Since  capsaicin  activates  TRPV1  an  obvious  consequence  of  this  is  the  development  of  a 
peripheral sensitisation of both the receptor itself, and a more general increase in excitability 
of the fibres on which it is located. Indeed, activation of TRPV1 by capsaicin is to sensitise the 
receptors/fibre through a number of intracellular pathways, leading to decreased activation 
thresholds and an increased frequency in action potential discharge when confronted with 
supra-threshold stimuli. Activation of TRPV1 resulting in this sensitisation of ion channels is 
likely  to  be  relevant  to  certain  pathological  conditions  since  a  number  of  endogenous 
inflammatory mediators are also able to result in this phenomenon. Indeed, the pivotal role of 
TRPV1 in the development of such states is demonstrated by the phenotype of TRPV1-/- mice, 
who are unable to develop thermal hypersensitivity post inflammation (Caterina et al. 2000; 
Davis et al. 2000).  94 
 
Numerous studies have explored the mechanisms underpinning this peripheral sensitisation 
of TRPV1, whereby the mediators act through second messenger cascades to increase the 
excitability of the afferents (Kanai et al. 2007). This sensitisation is usually associated with 
inflammation,  as  numerous  innate  and  adaptive  immune  cells  including  mast  cells, 
macrophages, neutrophils and T lymphocytes release/induce the release of mediators such as 
BK, histamine, NGF, PGs, protons, and numerous cytokines (including: IL1β, IL-6, CCL2).  All of 
which may result in activation of a number of intracellular signalling cascades that result in 
phosphorylation and upregulation of ion channels such as TRPV1. 
During a  state of tissue  injury or ischemia protons  are able  to  both directly activate and 
potentiate activity of TRPV1, as these hydrogen ions act at an extracellular site to increase the 
potential of channel opening (Jordt et al. 2000). On the other hand, mediators such as PGs, 
including PGE2 and PGI2, act at EP1 or IP receptors, respectively, which are coupled to Gs. 
They have  been  demonstrated to  interact with TRPV1 through PKA  dependent pathways, 
resulting in lowering of the temperature activation threshold to as low as 35°C (Smith et al. 
2000; Moriyama et al. 2005). BK, ATP and endothelin act at Gq coupled receptors - B1/B2, 
P2Y2 and ETA, respectively. This is believed to activate the DAG-PKC pathway (Moriyama et 
al. 2003; Vellani et al. 2004) and therefore once again resulting in phosphorylation of TRPV1. 
PKCε has been implicated in phosphorylation of TRPV1 at serine residues 502 and 800 as 
cells containing the mutations S502A or S800A are unable to sensitise (Numazaki et al. 2002; 
Kawamata  et  al.  2008).  Finally,  the  influx  of  Ca2+  through  TRPV1  and  the  release  from 
intracellular stores can result in the activation of CaMKII. 
TRPV1 actions may also be potentiated by increasing the surface expression of receptors; 
either through an increase in transport or in number of receptors produced and inserted into 
the  membrane.  In  inflammatory  conditions,  such  as  OA,  NGF  is  released  and  contributes 
towards increased pain through actions at TrkA receptors, which are expressed on specific 
sensory neurons such as C and Aδ fibres. TrkA induced activation of PI3 kinase/ Src kinase 
causes  phosphorylation  of  the  Y200  residue,  which  leads  to  an  in  increased  membrane 
expression of TRPV1 (Zhang et al. 2005). Additionally, Xue et al have showed that NGF can 
increase  transcription  of  TRPV1,  whilst  Ji  and  colleagues  found  that  it  could  also  induce 
translation via p38 MAPK activation (Ji et al. 2002; Xue et al. 2007). Therefore suggesting that 
NGF  released  in  conditions,  such  as  OA,  may  lead  to  an  upregulation  and  potentiation  of 
TRPV1. Furthermore, after nerve injury it has also been found that TRPV1 is upregulated on 95 
 
uninjured C-fibres, which may also contribute to the symptoms experienced by patients (Ma 
et al. 2005). 
Overall these studies highlight that peripheral sensitisation of TRPV1 receptors, which results 
in lowering of the activation temperature and manifests as heat hypersensitivity, may occur in 
a number of inflammatory, and possibly neuropathic, conditions. Thus the capsaicin model 
induces  clinically  meaningful  changes.  The  resulting  thermal  hypersensitivity  does  indeed 
appear to develop in pathological states; for example, it is suggested that patients with OA and 
up to 25% of patients with a post-traumatic nerve lesion suffer from heat hyperalgesia (Baron 
et al. 2010; Soni et al. 2013). Furthermore, the burning pain experienced by certain subgroups 
of patients with neuropathic pain may be underpinned by sensitisation and activity of TRPV1 
containing afferents (McMahon and Wood 2006; Biggs et al. 2008; Baron et al. 2012). 
It is important to note that the intracellular signalling pathways that may be activated through 
the accumulation of Ca2+ inside the neurone are also able to phosphorylate other ion channels, 
such as Nav channels (Nassar et al. 2004). This may lower the activation threshold of the 
afferent fibres and increase overall excitability. Therefore a peripheral sensitisation caused by 
the activation of TRPV1 may not only lead to a thermal hypersensitivity through changing the 
properties of the receptor itself, but it may also alter how these TRPV1 expressing afferents 
respond to all stimuli.  
 
3.1.3.    Ongoing activity from capsaicin alters central processing 
Although  capsaicin  certainly  does  lead  to  a  strong  peripheral  sensitisation,  this  cannot 
account  for  all  the  sensory  changes  evoked  by  the  model,  such  as  the  development  of 
secondary  hyperalgesia  and  allodynia  mentioned  in  the  human  studies.  Whilst  Lewis  had 
originally postulated that  an  axonal  reflex causing a  release of neuropeptides  to  the  area 
surrounding injury was responsible for the sensory changes, Hardy suggested it was more 
likely the result of a sensitisation of central neurones (Lewis 1942; Hardy et al. 1950). Indeed, 
LaMotte and colleagues were able to show that intradermal injection of capsaicin resulted in a 
hyperexcitability of second order neurones (LaMotte et al. 1991; Simone et al. 1991). Further 
unravelling of the mystery of these changes in the untreated area post capsaicin has mainly 
been through the use of intradermal administration, and the heat/ capsaicin model - although 
the  handful  of  studies  regarding  topical  capsaicin  application  previously  mentioned  also 96 
 
assessed sensory changes in the secondary area. These studies quite clearly conclude that 
certain changes  are due to  central mechanisms  (LaMotte et al. 1991;  Simone et al. 1991; 
Ziegler et al. 1999; Iannetti et al. 2005; O'Neill et al. 2012). 
It  is  now  well  established  that  following  a  barrage  of  peripheral  input  post  intradermal 
capsaicin, an increase in mechanical sensitivity is observed in the surrounding secondary area 
(LaMotte et al. 1991; Willis W.D 1997). The ongoing peripheral activity from the treated area 
is  believed  to  sensitise  spinal  neurones  through  a  number  of  homo-  and  heterosynaptic 
mechanisms.  In  a  state  of  central  hyperexcitability  enhanced  neurotransmission  through 
activation of the NMDA and NK1 receptors leads to complex intracellular events involving 
phosphorylation, receptor trafficking and transcriptional changes (Latremoliere and Woolf 
2009).  Consequently,  there  is  an  increase  in  membrane  excitability,  increased  synaptic 
strength and a reduction in spinal cord inhibition. As such the thresholds of spinal neurones 
are lowered and activation kinetics are altered. Thus it is accepted that ongoing activity into 
the  spinal cord is  a  core  driver for the  development  of central sensitisation  (Baron  et al. 
2013). 
A reduction in this drive has also been noted to be able to decrease the area of secondary 
hyperalgesia usually observed post capsaicin (Dirks et al. 2000; O'Neill et al. 2012). Therefore 
it appears that the key to developing a stable central sensitisation/ secondary hyperalgesia in 
experimental  models  is  simply  an  ongoing  peripheral  drive  of  adequate  strength,  most 
notably from C-fibres (McMahon et al. 1993; Baron et al. 2013). Proof that this input and 
subsequent sensory changes are of central origin has come from the fact that the symptoms of 
pinprick hyperalgesia and allodynia are dependent on non TRPV1 expressing A and A fibres 
and that they may be modulated by centrally acting drugs, which have no effect in the naïve 
state  (Ziegler  et  al.  1999;  Magerl  et  al.  2001;  Iannetti  et  al.  2005;  Iannetti  et  al.  2005). 
Furthermore,  fMRI  has  revealed  altered  brain  processing  and  a  role  for  the  brainstem  in 
capsaicin induced central sensitisation (Iannetti et al. 2005; Lee et al. 2008). 
Intradermal  capsaicin  is  not  only  associated  with  the  signs  and  symptoms  of  central 
sensitisation, but it is also known to be underpinned by the induction of numerous pivotal 
molecular mechanisms for altering spinal cord processing (for a full review see O’Neill et al. 
2012).  Given  that  the  previous  studies  with  topical  capsaicin  also  found  secondary 
hypersensitivity it is likely that this model also induces such changes. These are thought to be 
particularly  important  with  regards  to  chronic  pain  disorders  and  thus  there  is  clinical 97 
 
relevance of this model (Baron et al. 2013). As previously described, here the activation of 
fibres  by  capsaicin  itself  results  in  an  ongoing  drive  into  the  DH,  which  alters  central 
processing. However, it has been further suggested that in chronic pain states a peripheral 
sensitisation of TRPV1 could allow activation of the receptor at body temperature and thus 
result in an ongoing pain, and the model may therefore have more clinical relevance that 
initially anticipated (McMahon and Wood 2006). Although this is yet to be proven, whatever 
the cause of the ongoing peripheral input in patients, the resulting alteration in the properties 
of central neurones is likely to be involved in many chronic pain conditions and thus is an 
important area of study. 
 
3.1.4.  Capsaicin cream application causes primary mechanical hypersensitivity 
The presence of pinprick and brush hypersensitivity in the primary area of insult may also be 
reflective  of  central  rather  than  peripheral  sensitisation  –  although  this  is  a  contentious 
matter,  and  perhaps  benefits  from  a  discussion  of  a  current  topic  in  pain  research  –  the 
existence of modality specific subsets of neurones in the periphery. 
Since  many  C  fibres  are  believed  to  be  polymodal,  it  is  widely  accepted  that  distinction 
between modalities is made at either a spinal or supra spinal level. However, recent evidence 
has begun to reveal the possibility of modality specific subpopulations of peripheral afferents. 
Whilst  it  was  clear  that  the  original  theory  of  modality  specific  labelled  lines  was  too 
simplistic, a modified hypothesis dubbed ‘population coding’ encompasses the idea of both 
modality specific afferents, and cross talk among them at higher levels (Ma 2012). A number 
of pivotal studies (described in table 3-2) suggest distinct functions for TRPV1+ and IB4+ 
sensory neurones, respectively (Cavanaugh et al. 2009; Mishra and Hoon 2011; Brenneis et al. 
2013; Zhang et al. 2013). It appears that whilst TRPV1 expressing afferents are required for 
sensing  of  noxious  heat  and  pressure,  IB4+  afferents  lend  themselves  to  both 
mechnosensation  and noxious mechanical  sensing.  Furthermore, TRPV1+ afferents appear 
essential for the development of heat, cold and mechanical hypersensitivity post inflammation 
or nerve injury (Brenneis et al. 2013). 
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Figure 3-1 Modality specific peripheral afferents. Recent studies have suggested that afferent fibres can be 
subdivided  by  function,  depending  on  whether  they  express  TRPV1  or  IB4.  Whilst  ablation  of  peptidergic 
TRPV1+ fibres results in a loss of noxious heat sensation, ablation of IB4+ afferents results in a selective loss of 
mechano/ noxious mechanical sensation. 
Study  TRPV1+ Peptidergic Afferent Function 
Cavanaugh, 2009  IT capsaicin ablates TRPV1 expressing fibres, near complete loss of response 
to noxious heat, no change in noxious mechanical or cold 
Mishra, 2011  Pharmacological ablation of TRPV1+ neurones from embryo, reduction in 
noxious heat and cold responses  
Zhang, 2013  Pharmacological ablation of TRPV1+ neurones, LI and LV neurones lose 
responsiveness to noxious heat 
Brenneis, 2013  TRPV1 silencing, reductions in C fibre, but not A fibre mediated action 
potentials, deficits in heat and mechanical pressure, no difference in pinprick 
or light touch, abolishes heat, mechanical and cold hypersensitivity post 
inflammation, abolishes tactile and cold allodynia post nerve injury  
Table 3-2 Studies exploring the possibility of modality specific subpopulations of afferent fibres.  Both 
genetic  and  pharmacological  ablation  techniques  have  been  used  to  help  elucidate  the  distinct  functions  of 
TRPV1 and IB4+ afferents. 
 
Study  IB4+ Non-peptidergic Afferent Function 
Cavanaugh, 2009  Genetic ablation of Mrgprd+, selective reduction in noxious mechanical 
sensitivity 
Zhang, 2013  Ablation of Mrgprd+ neurones, LI NS neurones had reduced responses to 
noxious mechanical stimuli, proportion of mechanosensitive WDR neurones 
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Given  that  capsaicin  activates  TRPV1+  fibres  it  may  be  assumed  that  a  direct  peripheral 
sensitisation of these fibres discussed above would therefore result in a hypersensitivity to 
thermal and pressure stimuli if both these modalities are transmitted by TRPV1 afferents 
alone. Since none of the studies found that ablation of TRPV1 expressing fibres had any effect 
on touch or pinprick sensitivity, it is unlikely that TRPV1 is co-expressed with the molecular 
transducers of these stimuli and therefore could be directly sensitised by capsaicin as other 
ion channels may be. Induction of a mechanical pinprick, or dynamic brush sensitisation must 
therefore  result  from  central  changes.  Additionally,  ablation  of  the  TRPV1  expressing 
population was only found to reduce C fibre mediated action potentials, rather than A fibre 
mediated activity, which is believed to be responsible for mechanical hypersensitivity post 
capsaicin (Ziegler et al. 1999; Brenneis et al. 2013). However, since ablation of these fibres 
prevents the development of hypersensitivity to inflammation it can be inferred that ongoing 
input from these TRPV1 expressing fibres, for example due to topical application of capsaicin, 
is required development of this mechanical hypersensitivity. Indeed the requirement of this 
peripheral  drive  for  development  of  certain  types  of  hypersensitivity  is  well  established 
(McMahon et al. 1993; Baron et al. 2013). This theory certainly suggests that the development 
of  DMA  and  pinprick  hypersensitivity  post  capsaicin  are  on  the  whole  reflective  of  the 
engagement of central, rather than a peripheral mechanisms.  
Despite numerous studies using capsaicin, the primary area of treatment is yet to be fully 
characterised. Additionally, the translational arm in animals as well as humans, exploring the 
central neuronal consequences of temporary topical capsaicin cream application has not been 
examined. In humans, the full QST profile in the primary treated area is also yet to be studied. 
Here, this chapter explores the true translational nature of the use of capsaicin cream as a 
surrogate  model  in  animals  and  humans.  In  particular,  focusing  on  use  of  paradigms 
encompassing the same time points and measured end points. Furthermore, this chapter uses 
objective measures of spinal neuronal activity in rats and full QST in humans in order to fully 
characterise primary area of treatment of this model. 100 
 
3.2.   Methods 
3.2.1.  In vivo electrophysiology: 
Adult male Sprague-Dawley rats, between 220-250g, were obtained from the UCL Biological 
Services Unit. All procedures were approved by the UK Home Office and were performed in 
accordance with the guidelines provided by the International Association for the Study of 
Pain. 
In  vivo electrophysiological  recordings  were  performed as previously described to  obtain 
baseline responses. Once stable responses had been characterised for each individual cell, 0.1-
0.2ml of a 1% capsaicin cream was applied to the receptive field of the cell on the hindpaw for 
30 minutes. Capsaicin was then removed, taking care not to further stimulate the treated area. 
The train of electrical and natural stimuli was repeated at 30, 50, 70 and 90 minutes post 
application of capsaicin and the maximum change was then calculated. 
 
3.2.2.  Human Quantitative Sensory Testing: 
Experiments were conducted in 10 healthy human volunteers aged between 19-59 years old. 
Individuals were familiarised with the experimental protocol beforehand and gave written, 
informed consent. The study was approved by The Kings College Research Ethics Committee. 
All subjects were free from pain and medical conditions which may otherwise interfere with 
the results of the study. They were advised they must avoid pain medication such as non-
steroidal anti-inflammatory drugs (NSAIDs) and caffeine in the 24 hours prior to the study. 
Baseline thresholds were obtained at marked sites (16x16mm) on the ventral forearms for 
MPT and HPT as previously described. In addition to MPT, subjects were asked for numerical 
ratings for the 32mN and 256mN pinprick devices; and in addition to HPT, subjects were 
asked for numerical ratings to 35C and 45C. For 6 of the subjects full QST was performed as 
described in chapter two. The area was then cleaned with an alcohol wipe before topical 
application of 0.5ml 1% capsaicin cream. A transparent film dressing was placed over the area 
to ensure no capsaicin was accidentally removed during the 30 minutes it was applied. The 
test and control arms were alternated. Capsaicin was then carefully removed after 30 minutes 
before re-testing took place. Thresholds and NRS ratings we retested at 30, 50, 70 and 90 
minutes post application. The maximum change in subject responses was calculated. 101 
 
3.2.3.  Statistical analysis: 
All analysis was undertaken using SPSS software (IBM SPSS Statistics v21). Data was assessed 
for normality using the Kolmogorov-Smirnov test to determine further methods of analysis. 
Electrophysiological data was analysed using either a paired or unpaired t-test, or a 2 way 
ANOVA accordingly. Psychophysical data, with the exceptions of HPT and CPT, were logged 
and re-tested for normality. A paired t-test or 2 way ANOVA was then carried out. HPT and 
CPT were found to be normal without logging, and thus the raw data was used for analysis 
with a paired t-test. All graphs were plotted to show the mean  SEM. 102 
 
3.3.   Results  
3.3.1.   In vivo electrophysiology 
Objective electrophysiological recordings of LV WDR cells to a range of natural and electrical 
applied stimuli were examined pre and post application of topical capsaicin cream to the 
hindpaw. The results highlighted a clear hypersensitivity to thermal stimuli post capsaicin, in 
comparison  to  baseline  responses  in  the  same  animals.  A  negligible  effect  was  noted 
regarding  mechanical  stimuli.  These  changes  seen  in  the  primary  area  of  treatment  post 
capsaicin are akin to the results observed previously in human psychophysical experiments 
(Culp  et  al.  1989;  LaMotte  et  al.  1992;  Bishop  et  al.  2009),  however  this  is  the  first  full 
characterisation  of  the  model  in  animals.  This  effect  primarily  found  regarding  thermal 
responses is most likely due to the well-known ability of capsaicin to sensitise TRPV1. 
3.3.1.1.  Topical  capsaicin  application  significantly  enhances  dynamic  brush  evoked 
baseline WDR cell responses in naïve animals. 
Post capsaicin dynamic brush responses were significantly increased above baseline from 
326.0  25.77 to 680.4  47.52 action potentials/ 10s (figure 3-2; p= <0.000) in the primary 
treated  area.  Both  pre  and  post  capsaicin,  coding  to  the  increasing  forces  of  mechanical 
stimuli is observed. There was no overall significant difference in the evoked responses to 
innocuous or noxious vF post capsaicin, however there is a clear increase in the number of 
action potentials/ 10s to 8g from 149.7  21.96 to 335.1  27.3 (figure 3-2).  
3.3.1.2.  Topical  capsaicin  cream  significantly  enhances  both  innocuous  and  noxious 
thermally evoked WDR cell responses in comparison to baseline responses. 
Once again, there is a clear coding of WDR cell responses to increasing thermal stimuli, both 
pre and application of topical capsaicin. A facilitation of neuronal responses was observed in 
response to all temperatures tested post capsaicin cream (figure 3-3; p= <0.001). The greatest 
increase was seen at 35C, where an 827% increase in the firing was observed (p= 0.002). 
Firing to supra threshold stimuli (45C and 48C) were also significantly enhanced by 106.9% 
and 45.6%, respectively (p= 0.000, 0.022). Overall, there appeared to be a parallel shift in the 
stimulus-response  curves,  indicative  of  a  peripheral  sensitisation  and  reduced  C  fibre 
threshold. 103 
 
 
Figure 3-2 Effects of capsaicin on mechanically evoked baseline WDR cell responses. a) Using the protocol 
described in chapter 3.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
mechanical  stimuli,  including  brush  and  graded  vF,  applied  to  the  receptive  field  for  10s.  There  is  a  clear 
facilitation of mean dynamic brush responses from 326 to 680.4 action potentials/ 10s (p< 0.000). b) Responses 
to  vF  on  the  other  hand  were  unaffected,  although  neuronal  responses  to  innocuous  8g  appear  enhanced. 
(Overall 2-way ANOVA p= 0.27). n= 10 
   
Figure 3-3 Effects of capsaicin cream application on thermally evoked WDR cell responses. a) Using the 
protocol described in chapter 3.2 in vivo single unit recordings of LV WDR cells responses were recorded to a 
range  of  thermal  stimuli,  applied  to  the  receptive  field  for  10s.  Post  capsaicin,  evoked  responses  to  both 
innocuous and noxious temperatures were elevated when compared to pre-treatment baselines (Overall 2-way 
ANOVA p= 0.001; 35°C p= 0.002, 45°C p< 0.000, 48°C p= 0.022). n= 10 
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3.3.1.3.  Topical  capsaicin  cream  significantly  increases  A  fibre  responses  recorded 
from WDR cells when compared to baseline responses. 
Whilst no significant difference was observed between post capsaicin responses and baselines 
with regards to electrically evoked input, wind up, A fibres and PD, in contrast responses in 
the A fibre range were significantly facilitated from 178.5  22.83 to 193.5  32.63 action 
potentials/ 10s (figure 3-4; p=0.004), and responses in the C fibre range were reduced by 
25.9% (p=0.02). Such changes are likely driven by a simultaneous central facilitation of A 
input  and  peripheral  C  fibre  desensitisation.  Furthermore,  although  not  found  to  be 
significant, wind up also appears reduced post capsaicin. Since this measure is quantified by 
calculating the difference between the overall response observed and the baseline response to 
the first stimulus it is  directly effected by a  change in input. Examination of the wind-up 
graphs reveals that the small increase in the initial responses in the capsaicin group was 
responsible for the apparent reduction of wind-up. In fact, the neuronal responses started 
from a level close to that normally elicited when wind-up is produced. 
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Figure 3-4 Effects of capsaicin on electrically evoked WDR cell responses. Using the protocol described in 
chapter 2.2 and 3.2 in vivo single unit recordings of LV WDR cells responses were recorded to electrical stimuli.  
Transcutaneous electrical stimulation was used to measure the input and wind up, in addition to calculating the 
responses driven by different fibre types – depending on the latency.  Post capsaicin treatment a) there was no 
significant effect on electrically evoked Aβ mediated transmission nor post-discharge, however responses within 
the Aδ fibre range were significantly enhanced (p= 0.004) and responses within the C fibre range were reduced 
(p= 0.02); b) electrically induced input appears to be enhanced, although this was not found the be significant; c) 
overall wind up was also unaffected. n= 10   106 
 
3.3.2.  Human Quantitative Sensory Testing 
Using  a  standardised  QST  procedure,  human  subjects  were  also  found  to  exhibit  sensory 
changes indicative of hypersensitivity post capsaicin treatment, including both mechanical 
and thermal hypersensitivity.  
3.3.2.1.  Topical capsaicin significantly reduces MPT and increases numerical ratings to 
innocuous and noxious punctate stimuli.  
Unlike  the  rodent  studies,  in  humans  responses  to  pinprick  were  measured  (whereas  vF 
stimuli are used in the animals), here post capsaicin treatment there was a significant drop in 
the average 50% pain threshold to pinprick stimulation from 128.2   23.2 to 36.0  13.1 
(figure  3-5;  p= 0.003)  within  the  primary treated area.  This  is  likely underpinned by the 
facilitation  of  Aδ  fibres  observed  in  the  animal  model.  Furthermore,  numerical  ratings  to 
dynamic brush were significantly increased (figure 3-5; p= <0.000). Ratings to both sub and 
supra-threshold mechanical stimuli were also elevated, although this was not found to be 
statistically  significant.  There  was  also  no  difference  found  in  perceptual  wind  up  post 
capsaicin. 
3.3.2.2.  Topical capsaicin induces a thermal hypersensitivity 
 Average HPT was significantly reduced in the primary treated area from 45.29  0.73°C to 
34.45  0.48°C (figure 3-6; p= <0.000). Furthermore, ratings to both sub and supra-threshold 
temperatures were significantly increased post capsaicin treatment (p< 0.000). Conversely, 
CPT was reduced highlighting a cold hypoalgesia (figure 3-6; p= 0.003).  107 
 
 
Figure  3-5  Effects  of  topical  capsaicin  on  psychophysical  MPT  and  NRS  ratings.  Using  the  protocol 
described in chapter 3.2 standardised QST was undertaken to determine the subject’s mechanical pain threshold 
(MPT), in addition to obtaining numerical ratings (NRS) to graded mechanical stimuli. a) Average MPT was 
significantly lower in the primary area post capsaicin treatment in comparison to pre-treatment baselines (p= 
0.003). b) NRS rating to dynamic brush significantly increased (p< 0.000). Ratings to both 32mN and 256mN 
appear increased, although this was not significant (p= 0.084) n= 9 
Figure 3-6 Effects of topical capsaicin on psychophysical HPT, NRS ratings and CPT. Using the protocol 
described  in  chapter  3.2  standardised  QST  was  undertaken  to  determine  the  subject’s  heat  and  cold  pain 
thresholds (HPT/CPT), in addition to obtaining numerical ratings (NRS) to graded thermal stimuli. a) Average 
HPT was significantly reduced in the primary area (p< 0.00). b) NRS ratings to previously innocuous and noxious 
temperatures  are  significantly  increased  (p<  0.000;  35C  <  0.000,  45C  p<  0.000).  c)  CPT  was  significantly 
decreased (p= 0.003). n= 8 108 
 
3.3.2.3.  Sensory  profiles  post  topical  capsaicin  illustrate  a  unique  combination  of 
hyper- and hyposensitivities 
Full  sensory  profiling  using  a  standardised,  comprehensive  QST  procedure  confirmed  a 
sensitisation in the primary  area across a number of modalities including: HPT, MPT and 
mechanical pain sensitivity (figure 3-7). Conversely, there is a clear cold hyposensitivity. This 
is the first study to fully characterise the primary treated area post topical capsaicin and thus 
provides a novel profile indicative of a peripheral and central sensitisation, which may be 
compared to clinical patient profiles in order to assess the potential relevance of the model. 
a)     
Figure  3-7  Somatosensory  changes  produced  by  application  of  topical  capsaicin.  Using  the  protocol 
described in chapter 2.4 full QST profiling was undertaken. a) A variety of parameters were tested both pre and 
post capsaicin treatment, the magnitude of the changes are expressed here as Z-scores which highlight specific 
gains or loss in function. Hypersensitivity to heat, pinprick and dynamic mechanical stimuli are demonstrated 
here by the gain of function in heat pain threshold (HPT), mechanical pain threshold (MPT), and mechanical pain 
sensitivity (MPS). On the other hand, there is a hyposensitivity to cool and painful cold, highlighted by the loss in 
function of cold detection threshold (CDT), cold pain threshold (CPT) and thermal sensory limen (TSL) 
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3.3.3.  Capsaicin induced somatosensory changes in rats and humans show 
considerable overlap 
a) 
Stimulus 
Hypersensitivity 
Animal  Human 
Brush   
Subthreshold Mechanical   
Suprathereshold Mechanical  No change  
Subthreshold Thermal   
Suprathreshold Thermal   
Input   
Wind up  No change  No change 
Fibre count  Reduction in C fibre, 
increase in A 
Not tested 
 
Table 3-3 Comparison of animal and human characterisation. a) There is a remarkable similarity in the 
sensory changes post capsaicin across species, highlighting the translational nature of this model. Both animals 
and humans show heightened responses to brush, subthreshold mechanical stimuli and thermal stimuli, whilst 
wind  up  is  unchanged.  The  only  difference  noted  between  species  is  regarding  suprathreshold  mechanical 
stimuli, whereby human pain ratings were increased, whilst there was no changed observed in WDR cell evoked 
responses. Fibre count was only assessed in the animal model, this term refers to a change in the number of 
action potentials elicited from each fibre type; there was a clear reduction in action potentials elicited by C fibres, 
whilst there was an increase in A mediated activity. Since capsaicin may also desensitise fibres, this reduction in 
C  fibre  count  was  not unexpected,  whilst  an  increase  in  A  fibre  count  is  likely  to underpin  the  observed 
mechanical hypersensitivity in animals and humans.  
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3.3.3.1.  Lowered HPT in human volunteers post capsaicin corresponds to the number 
of action potentials evoked in WDR cells 
When comparing the animal and human data in terms of the neuronal activity produced by 
the temperatures which correspond to the HPTs, before and after capsaicin, a remarkable 
correspondence  can  be  observed  (figure  3-8).  It  can  be  seen  that  the  number  of  action 
potentials evoked by 45.3C (the average human HPT under normal conditions) was 681, 
which is very similar to the 642 action potentials that would be evoked by 34.5C the reduced 
human HPT post capsaicin (prior to the treatment, this would only evoke around 72 action 
potentials). 
 
Figure 3-8 Overlap in animal and human data.  Comparing changes in thermally evoked neuronal activity to 
the shift it human HPT, post capsaicin treatment, reveals a remarkable similarity: a) Pre capsaicin the average 
human HPT was 45.3C, which corresponds to 681 action potentials/ 10s, post topical capsaicin application this 
dropped to 34.5 C, which corresponds to 642 action potentials/ 10s. 111 
 
3.4.   Discussion 
Using objective in vivo electrophysiological single unit recordings from LV WDR cells, and 
human QST, this study assessed the sensory changes evoked by topical capsaicin cream in the 
primary  area  of  treatment.  Increased  responses  to  thermal  stimuli  post  topical  capsaicin 
application were clearly demonstrated in both animals and humans. This sensory abnormality 
indicates the induction of a peripheral sensitisation, as hypothesised. Tests also revealed the 
presence of a primary brush hypersensitivity, which was once again observed in both animals 
and humans. Heighted responses to pinprick stimuli were observed in humans, which are 
thought to be an A mediated function; indeed in the rodents A responses were facilitated. 
Although overall mechanical  coding in the rodents  did not  change, 8g vF responses  were 
clearly  increased  and  this  force  represents  a  possible  drop  in  threshold  since  this  is  the 
minimum force that elicits behaviour in naïve animals. This is most likely reflective of the 
engagement  of  central,  rather  than peripheral  mechanisms.  Overall there  is  a  remarkable 
similarity in the sensory changes post capsaicin across species, highlighting the translational 
nature of the model. Furthermore this study reinforces the relevance of using WDR cells in 
order to predict the outcome of human behavioural pain reports.  
 
3.4.1.  Topical capsaicin cream produces a consistent primary thermal hypersensitivity 
in animals and humans 
This is the first study to objectively quantify the change in response to thermal stimuli in the 
primary area of capsaicin treatment. As expected, the human HPT is dramatically reduced 
post capsaicin treatment, whilst numerical ratings to 35C and 45C are increased. In parallel 
to this shift in stimulus-response function, the rodent counterpart also revealed evidence of a 
strong  thermal  hypersensitivity.  LV  WDR  cells  show  a  large  increase  in  firing  across 
temperatures, once again ranging from sub-threshold 35C to supra-threshold stimuli 45C 
and 48C. The translational nature of this model is further highlighted by the fact that the 
number  of  action  potentials  corresponding  to  the  human  thresholds  before  and  after 
capsaicin are remarkably similar. That is to say, the threshold temperature in humans before 
capsaicin  evoked  a  certain  number  of  action  potentials,  which  was  roughly  equal  to  the 
number of action potentials elicited by the lowered threshold post capsaicin. Consequently, 
thermal sensitisation in humans appears to almost identically alter coding in spinal neurones. 112 
 
This  phenomenon  has  been  observed  in  previous  human  studies  of  topical  capsaicin 
application (Carpenter and Lynn 1981; Culp et al. 1989; LaMotte et al. 1992; Bishop et al. 
2009). A study of the responses of C-fibre units in humans pre and post topical capsaicin 
revealed that the activation threshold for such dropped from around 45C to 35C, which 
corresponded exactly to the perceptual thresholds noted in the study in addition to with the 
drop in HPT observed in human subjects here (LaMotte et al. 1992). Whilst the threshold and 
responses  of  C  fibres  units  were  altered  for  thermal  stimuli,  this  was  not  the  case  for 
mechanical stimuli despite the presence of mechanical hypersensitivity (LaMotte et al. 1992). 
This  provides  sound  objective  data  supporting  the  hypothesis  that  capsaicin  application 
results in primary heat hypersensitivity.  
As noted, this symptom is most likely a reflection of a peripheral sensitisation, since capsaicin 
is able to sensitise TRPV1 and lower the activation threshold, which would explain the drop in 
HPT  and  increased  firing  across  temperatures  (Moriyama  et  al.  2005).    Indeed,  since 
peripheral recordings have demonstrated that afferent C fibres show reduced thresholds and 
increased activity to thermal stimuli this confirming there is at least a peripheral component 
to this phenomenon (LaMotte et al. 1992). Taken together, the results here and the previous 
studies confirm that topical capsaicin is able to induce a robust peripheral sensitisation in 
both animals and humans, which may be useful for exploring drug modulation of thermal 
hypersensitivity.  Furthermore,  it  is  interesting  to  note  that  this  phenomenon  can  still  be 
picked up even when not recording peripherally, but from DH neurones. In the future it would 
be interesting to examine if topical TRPV1 antagonists or NSAIDs were able to alter these 
measures since this would directly address whether this is truly a peripheral phenomenon.  
 
3.4.2.  Brush hypersensitivity is apparent in the primary treated area post topical 
capsaicin of both animals and humans 
Once again, in both animals and humans, evidence was found for the induction of dynamic 
brush evoked hypersensitivity in the primary treated area. Whilst humans reported a novel 
pain sensation evoked by dynamic brush, LV WDR cells showed enhanced firing to this same 
stimuli  post  capsaicin  treatment.  In  agreement  with  the  observations  made  here,  earlier 
studies of topical capsaicin cream have been found to induce primary and secondary dynamic 
brush  evoked  allodynia  in  humans,  although  this  finding  is  previously  unreported  in  the 113 
 
animal model (LaMotte et al. 1992; Bishop et al. 2009). This finding further highlights the 
translational nature of the model, evoking signs of brush hypersensitivity across species.  
Dynamic brush responses are more commonly assessed in the secondary rather than primary 
area (Koltzenburg et al. 1992; Andersen et al. 1995; Liu et al. 1998; Mohammadian et al. 
1998). Similar to the changes noted here in the primary area, Andersen and colleagues noted 
that a subset of volunteers develop pain (allodynia) to brush stimuli in the secondary area 
post topical capsaicin, whilst others report an unpleasant sensation (Andersen et al. 1995).  
Brush evoked allodynia is believed to be a symptom indicative of central changes, resulting 
from plasticity in the spinal cord, allowing synaptic reorganisation, and the ability of A fibres 
to transmit nociceptive signals (Andersen et al. 1995; Latremoliere and Woolf 2009). Since 
capsaicin evoked allodynia does not develop in the absence of A fibres, this would suggest 
that such mechanisms are imperative (Treede and Cole 1993). Furthermore, pharmacological 
evidence involving manipulation of mechanisms involved in central sensitisation using drugs 
such as ketamine, alfentanil and remifentanil (whose actions include spinal mechanisms) are 
able to reduce brush hypersensitivity, thus suggesting the engagement of central mechanisms 
(Park  et  al.  1995;  Sethna  et  al.  1998;  Petersen  et  al.  2001).  Additionally,  brush 
hypersensitivity  is  not  sensitive  to  topical  NSAID  treatment,  unlike  other  peripherally 
mediated symptoms, once again suggesting a role for central modifications (Kilo et al. 1995; 
Bishop et al. 2009). It is possible that similar mechanisms may be involved in both primary 
and secondary brush hypersensitivity. Bishop and colleagues noted that the primary brush 
evoked  allodynia  spread  into  the  secondary  area,  suggesting  that  they  may  indeed  be 
mediated  on  the  whole  by  the  same  (central)  mechanisms  (Bishop  et  al.  2009).  Further 
studies using an A fibre block and central drug modulation are required to fully elucidate the 
mechanisms behind the changes in the primary area. 
In light of recent discoveries regarding modality specific subsets of primary afferents, it seems 
unlikely that peripheral sensitisation would result in hypersensitivity to dynamic brush. Since 
it has been suggested that light touch is not affected by TRPV1 expressing fibres, it may be 
inferred that they do not play a large role in conveying this sensation. Therefore, a peripheral 
sensitisation of these fibres may not affect dynamic brush responses.  Taken together with 
previous  evidence  of  central  mechanisms  for  brush  hypersensitivity,  the  presence  of  this 
symptom in the capsaicin model could therefore suggest that central sensitisation is indeed 
induced.  114 
 
Given WDR cells respond to dynamic brush under normal conditions, a sensitisation of the 
WDR cell directly recorded from could indeed lead to a facilitation of brush evoked responses. 
However, since the changes observed here are in the primary area it is difficult to fully rule 
out peripheral mechanisms. It is believed that mechanical hypersensitivity in the capsaicin 
treated area  does  indeed have  a  peripheral  component, since  the  symptom is  not  always 
abolished by blocking A fibre conduction (Culp et al. 1989). It is also suggested that certain 
subgroups  of  C  fibre  afferents  may  respond  to  low  threshold  inputs,  which  could  be 
hypothesised  to  also  become  sensitised  to  brush  stimuli  post  capsaicin,  whilst  non-brush 
responsive  C  fibres  have  been  found  to  develop  a  small  sensitivity  post  topical  capsaicin 
(LaMotte  et  al.  1992;  Olausson  et  al.  2002;  Löken  et  al.  2009).  These  studies  implicate  a 
potential peripheral component of brush hypersensitivity, which cannot be fully ruled out.  
 
3.4.3.  Sensory changes post topical capsaicin cream application are suggestive of 
peripheral and central sensitisation 
The results discussed so far, including the development of thermal and brush hypersensitivity 
suggest that there are most likely a number of peripheral and central mechanisms that are 
engaged  post  topical  capsaicin  application.  However,  the  inferences  made  based  on  the 
potential underpinnings of the brush hypersensitivity are inconclusive and further evidence is 
required to support the notion of capsaicin induced central sensitisation. 
Ongoing  activity  into  the  DH  is  a  key  driver  of  central  sensitisation.  Although  it  was  not 
assessed  here,  it  is  widely  reported  that  both  intradermal  and  topical  capsaicin  result  in 
ongoing  activity,  highlighted  in  human  psychophysical  reporting’s  and  recordings  from 
afferent  fibres  (Kenins  1982;  LaMotte  et  al.  1991;  LaMotte  et  al.  1992).  Furthermore,  an 
increase in basal cFos levels (a surrogate marker of increased input into the spinal cord) has 
also been associated with intradermal capsaicin (Mitsikostas et al. 1998). Ongoing activity of 
primary afferents that converge in the DH can modulate NMDA receptor function, as seen in 
wind-up of spinal neurones and heterosynaptic central sensitisation (Dickenson and Sullivan 
1987; Haley et al. 1990; Lewin et al. 1994). As such, many models of altered pain processing 
or chronic pain states are sensitive to a blockade of this receptor (Woolf and Thompson 1991; 
Stubhaug  et  al.  1997).  Indeed  capsaicin  evoked  mechanical  allodynia  is  sensitive  to  such 
modulation,  including  ketamine,  MK-801,  protein  kinase  inhibitors  and  gabapentin,  thus 115 
 
suggesting the engagement of central mechanisms(Sluka and Willis 1997; Mitsikostas et al. 
1998; Sethna et al. 1998; Dirks et al. 2002).  
Further evidence for the presence of central sensitisation in the topical model, comes from the 
responses of WDR cells to electrical stimulation. A potentiation in the range of A fibres to 
electrical  stimulations  was  identified post  capsaicin (which could underlie the  changes  in 
pinprick  sensitivity  observed  in  human  subjects).  Given  that  central  sensitisation  may  be 
associated  with  the  recruitment  of  increasing  numbers  of  afferent  fibres  it  could  be 
hypothesised  that  this  would  be  reflected  in  the  selective  increase  in  neuronal  firing  to 
stimulation of these fibres. Furthermore, it has recently been shown that in the MIA model of 
knee OA, which has a clear central component since there is no injury in the primary area 
tested, there is also a potentiation of electrically evoked responses in the A fibre range from 
the paw which may be taken as a sign of central changes (Burnham 2012; Thakur 2012).  A 
non-significant increase in A has also been found after carrageenan inflammation, which is 
believed  to  evoke  central  changes  (Rahman  et  al.  2004).  Given  that  models  with  proven 
central modifications also show this facilitation of A fibre responses, it can be concluded that 
this may be a sign of engagement of such mechanisms post topical capsaicin, and in addition 
may help explain the drop in human MPT. 
Turning to the C fibres, it was observed that the fibre count here was reduced post capsaicin 
treatment. This is most likely a consequence of the fact that capsaicin is also able to cause 
temporary  desensitisation  of  afferents.  Desensitization  is  a  dose-dependent  phenomenon, 
whereby repeated application of low dose or a single high dose of injected or topical capsaicin 
can  lead  to  levels  of  immediate  desensitization  (LaMotte  et al.  1991;  Simone  et  al.  1998; 
Kennedy  et  al.  2010).  There  are  a  number  of  ways  in  which  capsaicin  can  result  in 
desensitization of TRPV1-positive afferents, from an acute rapid desensitization to long-term 
tachyphylaxis, and withdrawal of intraepidermal nerve fibres. Both types of desensitization 
occur in the area localized to the site of injection/ application; however, the time frame for 
each varies; the initial acute desensitization occurs almost immediately after agonist binding 
and is thus most relevant in this case, whereas tachyphylaxis and intraepidermal nerve fibre 
withdrawal occur over much longer periods up to 72 h after application (Simone et al. 1998; 
Touska  F  2011).  Rapid  desensitization  first  involves  capsaicin  binding  of  TRPV1,  one 
consequence  of  which  is  the  release  of  neuropeptides  from  the  C  fibre  terminals.  Once 
released, the terminals are depleted and the nerve may become desensitized (Maggi and Meli 116 
 
1988; Simone et al. 1998). Second, voltage-gated ion channels are inactivated, which also 
results  in  a  rapid,  short-lasting,  desensitization  as  further  action  potentials  cannot  be 
generated (Simone et al. 1998). This desensitization of fibres is believed to be a protective 
mechanism to inhibit excessive calcium influx, which leads to excitotoxic cell death. Since 
there was also heat hypersensitivity, as previously discussed, this provides further evidence 
for the peripheral sensitisation of C fibres. If the overall count was reduced, in order for heat 
hypersensitivity to manifest, it is likely that the remaining fibres must have been sensitised.  
It is also interesting to note that wind up is unchanged in both animals and humans. With 
regards to the animal data, it is clear that the initial input is much larger than in untreated 
animals. This is despite the apparent desensitisation in C fibres post capsaicin, previously 
discussed. Since wind up is dependent on C fibre input, a reduction in fibre count could have a 
knock  on  effect  with  regards  to  wind  up.  Therefore,  the  overall  increase  in  input  that  is 
observed could suggest once again that the remaining peripheral fibres are sensitised. Thus 
they are able to evoke greater activity and compensate for any desensitisation. This initial 
increase allows the WDR cells to reach a plateau more quickly than normal, representing what 
would have happened after further stimulation in untreated animals. Alternatively, it could be 
inferred that central sensitisation is present and that the increase in input is due to a lowering 
in threshold of the WDR neurone. A combination of peripheral and central sensitisation would 
also explain the results observed here. The  wind up ratio is also similar in humans, thus 
suggesting that the output of WDR neurones reflects human perception. 
 
3.4.4.  The discrepancy in mechanical hypersensitivity between animals and humans 
may be a result of the nature of the tests 
Although the majority of sensory changes post topical capsaicin were found to be analogous 
across  species,  there was  a  discrepancy  in  the  results  regarding  responses  to  mechanical 
stimuli. As reported in previous human studies, there was a drop in MPT post capsaicin in the 
primary treated area, however LV WDR cell responses to a range of increase vF stimuli were 
overall unchanged (Carpenter and Lynn 1981; Culp et al. 1989). However, it is important to 
note that there is  a  clear increase  in  responses  around sub  threshold stimuli  such as  8g, 
despite the overall ANOVA not being found to be significantly different from baseline. Given 
that this difference is seen around what is believed to be the normal withdrawal thresholds, it 
is possible that if only these stimuli were tested a significant change may have been found. 117 
 
Therefore  the  results  would  be  in  line  with  the  human  experiments  that  suggest  topical 
capsaicin may alter the mechanical threshold for pain. This finding highlights the importance 
of  testing  with  stimuli  around  threshold  and  in  future  studies,  a  15g  vF  should  be 
incorporated since this is commonly found to induce a withdrawal response. Previous studies 
have found a strong concordance in coding to mechanical stimuli in animals and humans, both 
pre and post sensitisation (LaMotte et al. 1991; Simone et al. 1991; Dawes et al. 2011).  
Furthermore,  although  human  mechanical  responses  are  tested  with  pinprick  devices, 
animals are tested with vF, which may not activate the exact same pattern of peripheral fibres. 
The responses to higher pinprick forces are mediated on the whole by A fibres (Iannetti et al. 
2013), and indeed an increase in A fibre mediated activity was recorded in the rodents, 
which could underlie the results observed in humans. On the other hand, evoked responses vF 
filaments could involve a higher proportion of C fibre units, some of which may be sensitised 
but  others  are  desensitised  and  thus  the  overall  effect  is  no  net  change.  Alternatively,  if 
mechanically  sensitive  C  fibres  do  not  express  TRPV1,  a  peripheral  sensitisation  or 
desensitisation of these fibres is unlikely (Cavanaugh et al. 2009). Future animal studies could 
include pinprick devices in order to ensure the same mechanisms are tested. 
 
3.4.5.  LV WDR cell recordings highlight changes that are reflective of human 
psychophysical reporting 
Despite the discrepancy observed regarding mechanical stimuli, there are many similarities in 
the  changes  produced  by  topical  capsaicin  in  animals  and  humans  apparent  from  the 
responses of LV WDR neurones and QST results. It is well known that responses of second 
order WDR cells correlate well with human psychophysical reporting’s (Dubner et al. 1989; 
Maixner et al. 1989). Indeed a recent study by Sikandar and colleagues found that reported 
pain intensities to both sub and supra threshold laser stimulation are highly correlated with 
the evoked firing of WDR cells, rather than NS cells (Sikandar et al. 2013). Whilst WDR cells 
continue  to  code  for suprathreshold stimuli,  NS cells reach a  ceiling and plateau and fire 
considerably less  than the  WDR cells. The study found that when  comparing human  NRS 
responses  and  WDR  cell  firing  there  was  no  significant  difference  between  the  two, 
highlighting the high translational nature of DH electrophysiology. The ability of second order 
spinal  neurones  to  encode  stimulus  intensity  may  therefore  be  related  to  the  perceptual 
outcome through the graded discharge frequency being relayed to higher centres.  118 
 
A second advantage of this use of electrophysiological recordings from second order spinal 
neurones  is  that  it  enables  the  study  of  a  range  of  stimuli  of  differing  intensities,  most 
importantly to those of a suprathreshold nature. Mechanisms involved in processing these 
high intensity stimuli may be important in the high levels of pain reported by patients. This is 
particularly important for screening of analgesics, since many may have modulatory effects 
only at the higher intensities. The results here, in addition to previous reports, highlight the 
important information that can be extrapolated from WDR cell recordings and translated to 
human sensory perception. 
 
3.4.6.  Topical capsaicin cream produces a cold hypoalgesia in healthy human subjects 
Few  studies  have  examined  the  consequences  of  topical  capsaicin  application  on  cold 
sensitivity,  although  perhaps  the  resultant  hypoalgesia  is  to  be  expected,  given  that  it  is 
known that cooling may alleviate other capsaicin induced hypersensitivities (Culp et al. 1989). 
Human  QST  results  here  clearly  demonstrate  a  dramatic  reduction  in  CPT  post  topical 
capsaicin  in  the  primary  area  of  injury.  These  findings  do  replicate  that  of  one  previous 
psychophysical  study,  where  it  was  found  that  average  CPT  dropped  from  25.1C  to  0C 
(Callsen et al. 2008). The authors suggest that given the phenomenon is localised to the site of 
injury, and does not spread into areas of secondary pinprick hyperalgesia, it is the result of a 
peripheral  change  (Callsen  et  al.  2008).  Capsaicin  has  also  been  shown  to  reduce  cold 
activated currents in cultured neurones, which would support the results observed in this 
study and the previous (Reid et al. 2002). The mechanisms underpinning this are still unclear, 
although  Callsen  and  colleagues  suggest  that  the  co-expression  of  TRPV1  and  TRMP8 
intracellular interactions may reduce the activity of the cold sensing receptor (Callsen et al. 
2008).  Further  investigation  of  this  symptom  will  be  necessary  to  elucidate  the  true 
mechanisms.  During  electrophysiological  recordings,  cold  responses  were  attempted, 
however reproducibility was poor and so it was not possible to quantify the responses to cold 
in the animal  studies. It  would be  interesting to  assess any changes  in cold sensitivity in 
animals if this technique could be refined. 
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3.4.7.  QST characterisation of the topical capsaicin model produces a novel 
somatosensory profile 
Full  sensory  characterisation  post  capsaicin  indicates  a  strong  heat  and  mechanical 
hypersensitivity,  in  addition  to  a  cold  hypoalgesia,  in  the  primary  treated  area.  The  true 
clinical  relevance  of  this  model  depends  on  the  occurrence  of  such  features  in  patients. 
Certain patients with neuropathy are reported to have burning pain, dynamic allodynia and 
mechanical hypersensitivity (Baron et al. 2012). In particular many patients with oxaliplatin-
induced  neuropathy  suffer  from  both  heat  and  mechanical  hypersensitivity  (Binder  et  al. 
2007). In addition, there also appears to be some overlap of symptoms being shared with 
inflammatory conditions such as OA (Farrell et al. 2000). However, it would be interesting to 
see if there are any subgroups of patients whose profiles match that observed with capsaicin. 
The closer the overlap in symptoms, the greater the indication that capsaicin may mimic some 
of the underlying mechanisms associated with these conditions, and thus allows them to be 
modelled pre clinically.   
Capsaicin induced primary heat and pinprick hypersensitivity are already well documented, 
although primary brush hypersensitivity and cold hypoalgesia are less frequently mentioned. 
The creation of a sensory profile from these evoked symptoms increases the relevance of this 
model for future studies, since it may be used to match the symptoms profile with those 
created from various abnormal pain states in order to assess which conditions the model 
most well reflects. The mechanisms underlying the thermal changes are well understood and 
thus  drugs  that  alter  the  transduction  of  heat  stimuli  could  be  screened  in  this  model. 
However,  further  exploration  of  the  mechanisms  underpinning  the  sensory  abnormalities 
such as brush and pinprick hypersensitivity in animals could help understand the true clinical 
usefulness of the model; indeed the use of drugs with peripheral or central actions will help to 
evaluate the contribution of each phenomenon with regards to mechanical hypersensitivity 
post capsaicin. 
 
3.4.8.  Sensitisation of TRPV1 may be relevant in chronic pain conditions 
Although the real contribution of activation/ sensitisation of TRPV1 in chronic pain states 
remains unclear, it is known that patients with gastro-esophageal reflux disease suffer from 
heat hypersensitivity and it has been shown that in cases of IBS and  inflammatory bowel 
disease patients have upregulated TRPV1 (Reddy et al. 2007; Akbar et al. 2010; Krarup et al. 120 
 
2011).  In  addition,  the  fact  that  chronic  cough  patients  (which  shares  many  overlapping 
mechanisms with chronic pain) are more sensitive to inhaled capsaicin, suggests that TRPV1 
sensitisation may be underlying some of their symptoms of hypersensitivity  (O'Neill et al. 
2013).  Furthermore, children carrying the TRPV1 SNP I585V (decreasing channel activity) 
appear to be at a lower risk of developing asthma related cough  (Cantero-Recasens et al. 
2010). Taken together, these findings suggest that an upregulation and sensitisation of TRPV1 
may be an important mechanism in states of hypersensitivity, and thus modulation of this 
receptor could hold potential as a therapeutic target for relief of symptoms in both chronic 
pain.  Additionally,  since  many  chronic  pain  states  may  arise  from  damage  to  peripheral 
tissues,  leading  to  ongoing  activity  and  central  sensitisation,  this  feature  of  the  capsaicin 
model may be of importance (Baron et al. 2013). The model may be used to test drugs that 
manipulate the ongoing pain and if successful at reducing this symptom and further signs of 
central  sensitisation,  it  may  indicate  their  potential  use  in  the  clinic.  Since  it  has  been 
hypothesised that ongoing burning pain may arise from TRPV1 activation, this model could be 
particularly relevant (McMahon and Wood 2006).  
However, it is important to note the specificity in induction of mechanisms, such as peripheral 
sensitisation of TRPV1, may limit the relevance to patients. Additionally, it is a short-term 
model whereby the changes reverse after a number of hours and therefore does not mimic 
any long-term modifications, which are likely to be involved in most chronic pain syndromes. 
Therefore, it is likely only relevant to the early developmental stages of many conditions.  
 
3.4.9.  Topical capsaicin is a reliable translational model of hypersensitivity 
Translational  models  are  useful  to  explore  both  pain  mechanisms  and  validate  new 
treatments, however since a number of mechanisms of capsaicin induced sensitisation are 
quite well described, the main use of the model in the future is most likely the use of assessing 
novel therapies. 
The study conducted here used relatively low n numbers, since it is important to keep the use 
of animals to the minimum required to show significance. However, in larger human studies it 
has been noted that there may be a variation in responses to the model, which may be a 
further limitation to the usefulness of this model (Klein et al. 2008). It is possible that TRPV1 
polymorphisms  may  explain  some  of  this  variation  and  such  genetic  factors  may  be  a 121 
 
potential source of variability in this model. Of note, this previous observation did not appear 
to affect the results in this study. 
 
3.5.   Concluding remarks 
Overall, this is the first study to fully characterise the primary area of injury, and compare the 
results in animals and humans in order to assess the translational impact of this model. A full 
sensory examination of the primary area post topical capsaicin cream in animals and humans 
revealed  the  presence  of  thermal  and  mechanical  hypersensitivity,  most  likely  due  to  a 
peripheral sensitisation of C fibre afferents, and a central sensitisation including a facilitation 
of A fibre responses. In addition, in humans a cold hypoalgesia was also noted. Overall this 
study found an analogous set of sensory abnormalities across species. Therefore, the use of 
topical capsaicin cream as a translational model of peripheral sensitisation, leading to central 
modifications, could be useful in assessing novel treatments for early stage chronic pain. With 
regard to the heat hypersensitivity, it is well known that this symptom is the consequence of 
TRPV1 sensitisation and thus this model is particularly suitable for assessing drug modulation 
of this well-defined mechanism. On the other hand, further pharmacological manipulations 
will help fully elucidate the mechanisms underpinning the dynamic brush hypersensitivity. 122 
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4.1.   Introduction 
Many  of  the  current  treatments  for  chronic  pain,  including  drugs  such  as  Pregabalin, 
Tramadol, Amitriptyline, target the pain pathway at spinal or supra spinal sites (Sindrup and 
Jensen 1999; Field et al. 2006). Not only must we assume they reach their destined site of 
action through crossing the blood brain barrier, but activity at central pain targets will also be 
accompanied  by  potential  undesirable  side  effects  through  interactions  with  other  CNS 
functions that utilise the neuropharmacological targets of these drugs. These can range from 
sedation,  dizziness  and  fatigue,  to  the  less  frequently  reported  memory  impairment, 
hallucinations and other subtle actions which are extremely difficult to gauge in nonhumans 
(Finnerup et al. 2010). Treatments targeting the periphery are less common, and other than 
topical formulations, are often given systemically so may in fact also be acting at a number of 
locations in the pain pathway and elsewhere.  Having said this, it must not be overlooked that 
the new 8% capsaicin patch has been reported to be effective in both HIV-related neuropathy 
and PHN (Simpson et al. 2008; Irving et al. 2012). Taking together the limited amount of 
peripherally acting treatments available (such as the lidocaine patch), and the recent success 
of 8% capsaicin, it could be concluded that the development of a wider range of such drugs 
could be useful (Argoff et al. 2004; Dworkin et al. 2007). Here, we examine the possibility of 
developing locally administered peripheral adenosine 1 receptor (A1R) agonists. Bearing in 
mind  that  different  treatments  are  needed  for  different  pain  mechanisms  (Dworkin  et  al. 
2003; Baron et al. 2010), we assessed the possible modulation by the A1R of TRPV1 function 
and the ability of A1R agonists to attenuate the specific feature of thermal hypersensitivity – 
thus focusing on a mechanism based approach to treatment.  
ADO is an endogenous nucleotide, which is ubiquitously expressed, and is involved in many 
physiological processes. It acts at the GPCRs  A1, A2A, A2B and A3, which dictate its actions 
accordingly.  Whilst  A1  and  A3  receptors  are  coupled  to  Gi/o  and  thus  are  inhibitory,  A2 
receptors are coupled to Gs/ Gq/11 and have excitatory actions (Sawynok and Liu 2003; Gao 
and Jacobson 2007). It is well known that levels of extracellular ADO are elevated after stress 
or injury to tissues; such as ischaemia, hypoxia or seizures and is involved in a number of 
processes through actions at these receptors. The half-life of ADO is short as it is rapidly taken 
up by erythrocytes and metabolised by adenosine deaminase, and thus it is believed that the 
actions are localised to the site at which it is released (Kowaluk 1998).  
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4.1.1.  A1 Receptors have antinociceptive properties 
The A1R is widely expressed, in the periphery and the CNS, including within the DH, cortex, 
cerebellum  and  hippocampus  (Gessi  et  al.  2011).    Actions  at  the  A1R  are  believed  to  be 
involved in both pain transmission and modulation. More specifically ADO is believed to exert 
an endogenous antinociceptive effect at this receptor, through its coupling to Gi/o (Dickenson 
et al. 2000; Fredholm 2010; Lima et al. 2010; Fredholm et al. 2011). In the periphery, it has 
been shown that A1Rs are expressed on a significant amount of small- medium nociceptive 
fibres (Lima et al. 2010). Whilst in the DH of the spinal cord it has been shown to be present 
both presynaptically on afferent fibres, and on specific sets of interneurons  (Schulte et al. 
2003). Pre-synaptic inhibitory effects may involve interaction with Q-, P- and N-type Ca2+ 
channels,  and  a  reduction  in  release  of  neurotransmitters  such  as  substance  P  and  CGRP 
(Dolphin et al. 1986; Fredholm 2010). However, it is believed that the majority of A1Rs in the 
DH are found post synaptically within the substantia gelatinosa (Geiger et al. 1984). Post-
synaptic inhibitory effects are likely to be through interaction with K+ channels, resulting in 
hyperpolarisation (Gessi et al. 2011). 
A1Rs have also been shown to be co-localised with TRPV1 on afferent fibres, where a study by 
Lima and colleagues found 79.55% of A1Rs positive neurons also expressed TRPV1, whilst 
95.6% of TRPV1 positive neurons also expressed the A1R  (figure 4-1) (Lima et al. 2010). 
Activation of the A1R has been reported to activate PLC, catalysing the breakdown of PIP2, 
which  may  be  required  for  function  of  TRPV1  and  therefore  ADO  may  have  an  indirect 
inhibitory effect on this receptor function through interference with a common downstream 
mechanism (Rohacs et al. 2008). 
 
 
 
 
 
Figure 4-1 Expression and co-localisation of the A1R and TRPV1 on rat primary afferent neurones. Anti-
A1R immunoreactivity in subpopulations of DRG neurons labelled using TRPV1 antibodies (Lima et al. 2010). 
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4.1.2.  Activation of the A1R in the spinal cord reduces acute and chronic pain 
The most well documented actions of ADO/ activation of the A1R are in the spinal cord, where 
its actions are known to be antinociceptive. Interestingly, it has been observed that ATP is 
elevated in DRG after nerve injury (which could be broken down into ADO, as the enzymes 
converting ATP into ADO are highly localised within the DH), suggesting a possible role for 
endogenous modulation of pain signals (Matsuka et al. 2008). Spinal infusion of ADO has been 
shown  to  produce  antinociceptive  effects  in  both  animal  and  human  models  of  acute, 
inflammatory  and  neuropathic  pain  (Kowaluk  1998;  Dickenson  et  al.  2000).  Reeve  and 
Dickenson showed that IT application of a selective A1R agonist CPA reduced wind up, as well 
as  decreasing both the first  and second phase  of the  formalin  test  (Reeve  and Dickenson 
1995).  Further  studies  in  rodent  models  of  nerve  injury  and  inflammation  revealed  an 
inhibitory effect on hypersensitivity to both noxious and innocuous stimuli (Sawynok and Liu 
2003;  Sawynok  2007).  For  example,  spinal  ADO  was  found  to  reduce  mechanical 
hypersensitivity  post  nerve  injury  (Lavand'homme  and  Eisenach  1999),  whilst  in  the  CCI 
model  of  neuropathy  it  was  shown  that  R-phenylisopropyl-adenosine  (R-PIA)  attenuated 
scratching behaviour and tactile hypersensitivity (Sjölund et al. 1996; Cui et al. 1997). 
Additionally,  IT  administration  of  ADO/  A1R  agonists  have  been  shown  to  have  both 
antihyperalgesic and antiallodynic actions in healthy volunteers (Lynch et al. 2003; Sawynok 
2007).  Rane  and  colleagues  demonstrated  that  IT  ADO  was  able  to  reduce  the  area  of 
secondary hyperalgesia induced by topical mustard oil, as well as attenuating the reduction in 
tactile pain threshold usually seen in this model (Rane et al. 1998). In concurrence, Eisenach 
and colleagues also found that the area of hyperalgesia and allodynia induced by capsaicin 
were reduced with pre-treatment of IT ADO (Eisenach et al. 2002). As these symptoms are 
generally attributed to central mechanisms, it can be inferred that ADO is able to suppress this 
short-term induction of central hyperexcitability.  
IT ADO is also able to attenuate both spontaneous and evoked pain, as well as areas of tactile 
hyperalgesia and allodynia, in patients with neuropathic pain (Karlsten and Gordh Jr 1995; 
Belfrage et al. 1999). Whilst Eisenach further confirmed ADO reduced the area of allodynia for 
up to 24 hours in neuropathic pain patients, it is interesting to note that this affect was not 
seen if given intravenously (Eisenach et al. 2003). Spontaneous pain is also inhibited by a 
spinal A1R agonist in a surgical model, and furthermore when give pre-emptively before (and 
during) surgery it was demonstrated to suppress post-operative pain (Gan and Habib 2007; 126 
 
Zahn et al. 2007). This suggests there is an important role of spinal ADO via activation of the 
A1R in antinociception. Not only is it associated with a reduction in common symptoms of 
chronic  pain  such  as  allodynia,  but  it  also  appears  to  be  involved  in  preventing  the 
development of certain alterations in pain processing. 
There is conflicting evidence regarding systemic infusion of ADO, which was originally shown 
to increase HPTs in healthy volunteers and attenuate ischaemic pain, as well as reduce the 
area of cutaneous burn induced secondary hyperalgesia (Segerdahl et al. 1994; Ekblom et al. 
1995; Rae et al. 1999) (Sjölund et al. 1999). Systemic infusion of ADO is also reported to 
reduce the area of allodynia in patients with neuropathic pain (Sjölund et al. 2001). However, 
it has also been found that systemic ADO had no effect on a human model of capsaicin induced 
central sensitisation (Dirks et al. 2001) and whilst some trials report that IV ADO delivered 
before surgery resulted in both pain relief and decreased need for opioids, others found it to 
have no effect (Gan and Habib 2007; Habib et al. 2008). Due to the short half-life of ADO it 
may be inferred that systemic or IV delivery could be insufficient to reach the target areas 
(including the DH or peripheral receptors) and thus the modest effects are not necessarily 
surprising.   
 
4.1.3.  Paradoxical actions of peripherally administered ADO and activation of the A1R 
The role of ADO in the periphery is also debated and the specific endogenous actions on the 
peripheral nociceptive system are unclear. Taiwo and Levine found that intradermal injection 
of ADO in rats of concentrations up to 1.5M led to a decrease in mechanical threshold for up 
to 20 minutes post injection (Taiwo and Levine 1990). In addition, Pappagallo and colleagues 
found  that  2M  ADO  delivered  intradermally,  not  only  caused  pain  on  injection  but  also 
resulted in an area of primary heat and mechanical hyperalgesia (Pappagallo et al. 1993). 
Sawynok also suggested that peripheral ADO is pronociceptive, though these actions could 
explained by activation of the A2R rather than the A1R.  Additionally, the ADO receptors are 
expressed  on  various  innate  immune  cells  and  activation  may  result  in  the  release  of 
proinflammatory cytokines and tissue destruction pathways, which could contribute to this 
pronocicpetive action (Haskó and Cronstein 2004). However, since the overriding action of 
ADO on the immune system is thought to be anti-inflammatory, it is unlikely that there is a 127 
 
substantial contribution of immune cell mediated sensitisation responsible for the observed 
hypersensitivity (Haskó et al. 2008).   
On  the  other  hand,  it  has  also  been  found  that  ADO  analogues  such  as  R-PIA  and  N-
ethylcarboxamide-adenosine, when co-administered peripherally with formalin, reduced pain 
related  behaviours  in  mice  (Karlsten  et  al.  1992).  This  study  went  on  to  show  that  the 
compounds had no effect on local blood flow upon injection, which therefore would suggest 
that the effects are in fact mediated via A1Rs located on the PAFs themselves (Karlsten et al. 
1992).  
Local injection of CPA reduces noxious thermal, but not mechanical, sensitivity, in mice. This 
effect  was  only  seen  on  the  ipsilateral  side  and  was  further  lost  in  A1R  KO  mice,  overall 
suggesting a local effect of A1R activation (Hurt and Zylka 2012). This observation of actions 
specific for the thermal modality is consistent with the theory of A1R and TRPV1 interaction. 
Additionally, peripheral ADO is thought to underlie pain relieving effects of acupuncture in 
both  humans  and  mice,  and  the  A1R  has  been  demonstrated  to  be  required  for  the 
antinociceptive  actions of acupuncture  in a  mouse model of chronic  pain  (Goldman  et al. 
2010).  
It is clear that the actions of ADO depend on site and respective receptor subtype and density. 
The expression ratio of A1 vs. A2Rs on peripheral fibres for example is unknown, however 
what is apparent is the high affinity of ADO for the A1R over the other subtypes. The reported 
EC50 of ADO for the A1R is as low as 70nM, whereas for the A2A and A2B it is 150nM and 
510nM, respectively (Fredholm et al. 1994; Sawynok and Liu 2003). This would suggest that 
at lower concentrations it is possible to target the A1R over excitatory A2 receptors.  
It is particularly interesting to further explore this role in the periphery as although positive 
results have been found using IT and systemic administration of ADO/ A1R agonists they were 
also associated with side effects such as back pain, headaches and reduced heart rate (Zylka 
2011).  If  there  is  an  overriding  antinociceptive  role  in  the  periphery,  it  could  have  the 
potential for exploitation as a local drug target. 
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4.1.4.  Peripheral inhibitory actions of ADO may rely on interactions with TRPV1 
More  recently it has been  demonstrated in animals that peripheral administration  of A1R 
agonists  decrease  inflammatory  peripheral  hypersensitivity  through  second  messenger 
cascades (Lima et al. 2010). Experiments from Zylka and colleagues have suggested that this 
may involve PLC, catalysing the breakdown of PIP2, which may be required for function of the 
heat sensing receptor TRPV1 (Rohacs et al. 2008; Sowa et al. 2010). Animal models have 
shown that direct application of PIP2 enhanced thermosensation, thermal hyperalgesia and 
also capsaicin currents (Stein et al. 2006; Sowa et al. 2010).  This suggests that the peripheral 
antinociceptive actions of ADO could be attributed to the secondary interaction with other 
receptors and ion channels. 
 
4.1.5.  Clinical implications and pain relieving prospects of ADO? 
Despite  the  evidence  for  the  pain  reducing  effects  of  ADO  it  is  currently  not  used  as  a 
treatment for patients. There are a  number  of reasons  for this, including the  undesirable 
cardiovascular  side  effects  if  ADO  is  given  intravenously.  Additionally,  little  is  known 
regarding  the  effect  ADO  has  on  spontaneous  pain,  which  is  a  critical  symptom  in  many 
chronic pain conditions. This study investigates the use of ADO as a prophylactic treatment, 
given  pre-emptively before  the  induction  of  the  model,  in order to assess whether it can 
prevent the development of certain chronic pain symptoms. Although this is not necessarily 
possible in the clinic, it may be useful to explore the benefits of early treatment, which may 
prevent the progression of chronic pain conditions – in particular it may prevent/ slow the 
development of central sensitisation. Since ongoing peripheral activity is often the driver for 
central sensitisation, a reduction of such activity may indeed prevent its development. Finally, 
the  peripheral  actions  of  ADO  currently  remain  unclear  in  humans.  Therefore  further 
investigation  of both the  peripheral  effects of ADO and the  possible  ability to  reduce  the 
consequences  of  an  ongoing  painful  stimulus  (capsaicin)  are  required.  A  clear  benefit  of 
peripheral  injections  is  the  reduction  in  cardiovascular  and  central  side  effects,  however 
conducting studies with not only ADO but also partial A1 agonists would also be useful as it 
has been suggested they also have limited side effects.  
Here, this chapter aims to further elaborate on the mechanism of action of ADO through the 
use  of  an  intradermal  injection.  It  is  hypothesised  that  intradermal  ADO  should  decrease 129 
 
baseline responses to thermal stimuli in both rodents and healthy volunteers, possibly due to 
an indirect interaction with TRPV1. Furthermore, the chapter explores the effect of ADO on 
the response to topically applied capsaicin cream, which also acts at the TRPV1 receptor. To 
investigate the contribution of the A1R experiments are repeated using a specific and more 
stable agonist, CPA, in the animal studies. 130 
 
4.2.   Methods 
4.2.1.  In vivo electrophysiology: 
Adult male Sprague-Dawley rats, between 220-250g, were obtained from the UCL Biological 
Services Unit. All procedures were approved by the UK Home Office and were performed in 
accordance with the guidelines provided by the International Association for the Study of 
Pain. 
In  vivo electrophysiological  recordings  were  performed as previously described to  obtain 
baseline responses. Once stable responses had been characterised for each individual cell, 
26g/50L solution of ADO in 0.9% saline was injected using a Hamilton syringe, into the 
receptive field of the cell, distal from the point at which natural stimuli were applied. (Nb. 
Control experiments found that intraplantar injection of saline alone causes no significant 
changes monitored over a time period of 4 hours post injection, see chapter 2). The train of 
electrical and natural stimuli was repeated at 10, 25, 40, 55 and 70 minutes post injection. The 
maximum change was calculated once results had been collected. 
From this initial experiment it was found that the maximal effects of ADO occurred around 
10-25 minutes post injection, thus in the second experiment ADO was injected 10 minutes 
before application of 1% capsaicin cream for 30 minutes. (Nb. Control experiments found that 
intraplantar injection of saline alone had no effect on capsaicin induced hypersensitivity, data 
not shown). Capsaicin was applied as described in chapter 3. Electrical and natural stimuli 
were then tested at 30, 50, 70 and 90 minutes post capsaicin and once again the maximum 
change was calculated.  
The same protocol was followed for CPA. 5g /50L CPA in 0.9% saline was injected into the 
receptive field, distal to the area of testing. Post intraplantar injection the train of electrical 
and natural stimuli was repeated at 10, 30, 50, 70 and 90 minutes post injection. The maximal 
effects of CPA occurred around 30-50 minutes post injection, thus in the second experiment 
CPA  was  injected  30  minutes  before  application  of  1%  capsaicin  cream  for  30  minutes. 
Electrical and natural stimuli were then tested at 30, 50, 70 and 90 minutes post capsaicin and 
the maximum change was calculated.  
 131 
 
4.2.2.  Human Quantitative Sensory Testing: 
Experiments were conducted in 8 healthy human volunteers aged between 19-33 years old. 
Individuals were familiarised with the experimental protocol before hand and gave written, 
informed consent. The study was approved by The Kings College Research Ethics Committee. 
All subjects were free from pain and medical conditions which may otherwise interfere with 
the results of the study. They were advised they must avoid pain medication such as NSAIDs 
and caffeine in the 24 hours prior to the study. This was particularly important, as caffeine is 
an antagonist at the A1R. 
Baseline thresholds were obtained at marked sites (5x5mm) on the ventral forearms for MPT 
and HPT, as  previously described. In  addition  to  MPT, subjects were  asked for numerical 
ratings for the 32mN and 256mN pinprick devices; and in addition to HPT, subjects were 
asked for numerical ratings to 35C and 45C. The area was then cleaned for injection of 
26g/ 50L ADO in 0.9% saline; the test arm was alternated between subjects. (Nb. Control 
experiments found that intradermal injection of saline alone causes no significant changes 
monitored  over  a  time  period  of  180  minutes  post  injection,  see  chapter  2).    Successful 
intradermal injections were confirmed by the presence of a bleb beneath the skin. Thresholds 
and NRS ratings we retested at 10 and 25 minutes post injection. 
Secondly, to examine the effects of pre-treatment with ADO on capsaicin induced sensitisation 
an injection of ADO or vehicle (0.9% saline) was given 10 minutes before topical application 
of  1%  capsaicin  cream.  Vehicle  and  treatment  arms  were  alternated.  Threshold  and  NRS 
ratings were then retested 30 minutes post capsaicin. 
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Figure 4-2 Schematic to summarise the experimental protocols conducted in this chapter. Dark blue text 
describes  the  protocols  undertaken  in  animals  and  humans  evaluating  the  effects  of  ADO.  Light  blue  text 
describes the protocols investigating CPA in animals. 
 
4.2.3.  Statistical analysis: 
All analysis was undertaken using SPSS software (IBM SPSS Statistics v21). Data was assessed 
for normality using the Kolmogorov-Smirnov test to determine further methods of analysis. 
Electrophysiological data was analysed using either a paired or unpaired t-test, or a 2 way 
ANOVA accordingly. Psychophysical data, with the exception of HPT, was logged and re-tested 
for normality. A paired t-test or 2 way ANOVA was then carried out. HPT was found to be 
normal without logging, and thus the raw data was used for analysis with a paired t-test. All 
graphs were plotted to show the mean  SEM. 
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4.3.   Results 
4.3.1.   ADO In vivo electrophysiology 
Using objective electrophysiological recordings, LV WDR cell responses to thermal stimuli 
were  found  to  be  significantly  reduced  post  intraplantar  ADO  in  comparison  to  baseline 
responses.  Only  a  small  effect  was  noted  regarding  mechanical  stimuli,  and  electrical 
responses were unchanged. This selective effect primarily on thermal responses is suggestive 
of the expected reduction in activity of TRPV1+ fibres and a possible indirect modulation of 
TRPV1 itself. 
4.3.1.1.  Intraplantar  injection  of  ADO  leads  to  small  but  significant  reductions  in 
mechanically evoked baseline WDR cell responses in naïve animals 
Post ADO dynamic brush responses were lower than baseline, although this was not found to 
be significant (figure 4-3). There was also little change in the number of action potentials to 
innocuous or noxious vF, however the decrease was found to be significant for 2g and 26g. At 
2g there was a decrease from 27.7  3.7 to 14.9  4.7 action potentials/ 10s, and the response 
to 26g decreased from 556.6  80.2 to 440.3  102.5 action potentials/ 10s (figure 4-3; p= 
0.025, 0.009). 
 
Figure  4-3  Effects  of  ADO  on  mechanically  evoked  baseline  WDR  cell  responses.  Using  the  protocol 
described in chapter 4.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
mechanical  stimuli,  including  brush  and  graded  vF,  applied  to  the  receptive  field  for  10s,  before  and  after 
intraplantar ADO. a) The mean response to dynamic brush was reduced from 262.1 to 132.6 action potentials/ 
10s, although this was not shown to be statistically significant (p= 0.069). b) On the other hand, innocuous 2g vF 
responses, were significantly reduced, as well as noxious 26g responses (Overall 2-way ANOVA p= 0.025; 2g p= 
0.025, 26g p= 0.009). n= 7 134 
 
4.3.1.2.  Intraplantar injection of ADO significantly reduces thermally evoked baseline 
WDR cell responses in naïve animals. 
Decreased firing of WDR cells was observed to all temperatures tested post intraplantar ADO, 
from warm to highly noxious, in comparison to baseline responses (figure 4-4; p= 0.009). The 
most significant reduction was seen at 45C, just above behavioural threshold, from 598.7  
78.9 to 285.0  96.5 action potentials/ 10s (p= 0.01). Since TRPV1 is activated at around 42C 
this may be the result of A1R-TRPV1 indirect interactions. 
 
Figure 4-4 Effects of ADO on thermally evoked baseline WDR cell responses. Using the protocol described 
in chapter 4.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of thermal 
stimuli applied to the receptive field for 10s, before and after intraplantar ADO. a) Both innocuous and noxious 
thermal responses were significantly decreased post intraplantar injection of ADO (Overall 2-way ANOVA p= 
0.009; 35C p= 0.026, 45C p= 0.01, 48C p= 0.015). n = 7 
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4.3.1.3.  Intraplantar injection of ADO has no effect on electrically evoked baseline WDR 
cell responses in naïve animals 
Overall, no significant difference was observed between post ADO and baseline responses to 
electrical stimuli (figure 4-5). The number of action potentials elicited from each fibre type 
was unchanged, suggesting that the decrease in responses to natural stimuli is due to an 
interaction with specific transducers, rather than an overall effect on the excitability of the 
fibres. Input and wind-up appear reduced, although this was not found to be significant. 
 
 
Figure  4-5  Effects  of  intraplantar  ADO  on  baseline  electrical  WDR  cell  responses.  Using  the  protocol 
described in chapter 2.2 and 4.2 in vivo single unit recordings of LV WDR cells responses were recorded to 
electrical  stimuli  both  pre  and  post  intraplantar  ADO.    Transcutaneous  electrical  stimulation  was  used  to 
measure  the  input  and  wind  up,  in  addition  to  calculating  the  responses  driven  by  different  fibre  types  – 
depending on the latency. a) There was no significant effect on electrically evoked A, A, and C fibre mediated 
transmission, nor post-discharge; b) electrically induced input or wind up. n= 7. 
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4.3.2.   ADO/CAP – In vivo electrophysiology 
Overall, pre-treatment with ADO was found to have only a small effect on capsaicin induced 
hypersensitivity  to  thermally  evoked  stimuli.  However,  there  was  a  clear  reduction  in 
capsaicin induced brush hypersensitivity. The results suggest that ADO can partially prevent 
capsaicin induced sensitisation. 
4.3.2.1.  Pre-treatment with intraplantar ADO inhibits capsaicin induced sensitisation 
of innocuous dynamic brush WDR cell responses in naïve animals 
1%  capsaicin  cream  results  in  an  increased  firing  of  WDR  cells  to  dynamic  brush.  Pre-
treatment  with  ADO  inhibits  this  sensitisation,  as  responses  post  ADO/CAP  are  not 
significantly different from baseline (figure 4-6). Additionally, when compared to cells treated 
with CAP alone, responses of ADO/CAP cells are significantly reduced from 680.4  47.52 to 
360.3  121.2 action potentials/ 10s (figure 4-6; p=0.033). 
4.3.2.2.  Pre-treatment  with  intraplantar  ADO  partially  attenuates  capsaicin  induced 
sensitisation of thermal neuronal responses in naïve animals 
1%  capsaicin  cream  results  in  a  strong  sensitisation  to  thermal  stimuli  highlighted  by  a 
significant enhancement of evoked responses post CAP treatment. Pre-treatment with ADO 
does not fully inhibit this sensitisation, as responses of ADO/CAP cells are still significantly 
enhanced from baseline, with the exception of responses to 48C which appear no different 
from baseline (figure 4-7; p= 0.049). However, when compared to cells treated only with CAP, 
overall there is no significant difference. This suggests a partial effect of ADO on capsaicin 
induced thermal hypersensitivity. 137 
 
 
Figure  4-6  Effects  of  pre-treatment  with  ADO  on  capsaicin  induced  sensitisation  of  dynamic  brush 
evoked  baseline  WDR  cell  responses.    Using  the  protocol  described  in  chapter  4.2  in  vivo  single  unit 
recordings of LV WDR cells responses were recorded to brush applied to the receptive field for 10s, before and 
after pre-treatment with ADO and capsaicin application. a) Brush responses are no longer significantly increased 
when  intraplantar  injection  of  ADO  is  given  10  minutes  before  application  of  topical  capsaicin  cream. 
Furthermore, there is a significant difference between the group of cells pre-treated with ADO and those with 
capsaicin alone (unpaired t-test p= 0.033) capsaicin n= 10, ADO/CAP n= 7. 
 
Figure 4-7 Effects of pre-treatment with ADO on capsaicin induced sensitisation of thermally evoked 
baseline neuronal responses. Using the protocol described in chapter 4.2 in vivo single unit recordings of LV 
WDR cells responses were recorded to thermal stimuli applied to the receptive field for 10s, before and after 
pre-treatment with ADO and capsaicin application. Previously, with capsaicin alone, sensitisation was seen at 
35C,  45C  and  48C.    a)  Innocuous  and  noxious  thermal  responses  (35  and  45C)  are  increased  despite 
prophylactic  intraplantar  injection  of  ADO  given  10  minutes  before  application  of  topical  capsaicin  cream, 
although 48C appears unchanged from baseline (Overall 2-way ANOVA p= 0.049; 45C p= 0.026.) n=7. However, 
there is no significant difference between the group of cells pre-treated with ADO and those with capsaicin alone.  138 
 
4.3.2.3.  Pre-treatment with intraplantar ADO inhibits capsaicin induced enhancement 
of A fibre mediated responses and reduction of C fibre mediated transmission in naïve 
animals 
In the previous chapter it was found that 1% capsaicin cream results in a potentiation of A 
fibre  mediated  responses  through  central  changes,  alongside  a  reduction  in  responses 
mediated in the C fibre range which could be due to peripheral desensitisation. Neither of 
these differences were seen when cells were pre-treated with ADO (figure 4-8). Since all the 
results  suggest  the  main  effect  of  ADO  is  due  to  an  indirect  interaction  with  TRPV1,  the 
respective enhancement and reduction are likely to also be TRPV1 related phenomenon. A 
modulation of events downstream from TRPV1 by ADO can explain the ability of the purine to 
inhibit these changes. Alternatively, A1R induced hyperpolarisation could be counteracting 
activation of TRPV1. Furthermore, although capsaicin alone results in an increase in input, 
when pre-treated with ADO the input is significantly decreased, as is wind up, suggesting a 
possible effect on overall excitability of peripheral fibres (figure 4-8; p= 0.013, 0.005). 
 
Figure 4-8 Effects of pre-treatment with ADO on electrical neuronal responses post capsaicin. Using the 
protocol described in chapter 2.2 and 4.2 in vivo single unit recordings of LV WDR cells responses were recorded 
to electrical stimuli. a) There was no significant difference between baseline and ADO/CAP treated neurones 
with regards to electrically evoked A, A, and C fibre mediated transmission, nor post-discharge, suggesting 
that capsaicin induced facilitation of A fibres and reduction of C fibre transmission were inhibited. b) Both input 
and electrically induced wind up were significantly decreased when compared to baseline responses (p = 0.013 
and 0.005). n= 6 
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4.3.3.  ADO – Human Quantitative Sensory Testing 
Using a standardised procedure, human subjects were also found to have increased HPTs post 
ADO,  with  minimal  effect  on  mechanical  responses.  This  is  in  line  with  the  animal  data 
previously  reported, consistent  with the  theory of a  preferential  activation  of the  A1R on 
TRPV1+ fibres and a possible indirect interaction of ADO and TRPV1.  
4.3.3.1.  Intradermal ADO has no effect on MPT or numerical ratings to innocuous and 
noxious punctate stimuli 
Post intradermal ADO there was no significant difference found in either average MPT, or in 
ratings to innocuous or noxious pinprick in the treated area, suggesting ADO has no effect or 
normal innocuous or noxious mechanosensation (figure 4-9). 
 
Figure  4-9  Effects  of  intradermal ADO  on psychophysical  MPT and punctate mechanical NRS ratings. 
Using  the  protocol  described  in  chapter  4.2  standardised  QST  was  undertaken  to  determine  the  subject’s 
mechanical pain threshold (MPT), in addition to obtaining numerical ratings (NRS) to graded mechanical stimuli 
both pre and post intraplantar ADO. a) Average MPT was unaffected by ADO, and b) NRS ratings to 32mN and 
256mN were also unchanged post ADO administration. n= 8 
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4.3.3.2.  Intradermal ADO significantly increases HPT 
Average HPT was increased in the treated area from 44.9  2.1 C to 46.9  2.1 C, and this 
trend was the case across all subjects (figure 4-10; p≤ 0.0001). Although numerical ratings to 
35C  and  45C  appear  reduced,  this  was  not  found  to  be  significant  (figure  4-10).  These 
results are similar to those found in the animals, and are once again suggestive of downstream 
interactions with the TRPV1 receptor. 
 
Figure  4-10  Effects  of  intradermal  ADO  on  psychophysical  HPT  and  NRS  ratings.  Using  the  protocol 
described in chapter 4.2 standardised QST was undertaken to determine the subject’s heat pain threshold (HPT), 
in addition to obtaining numerical ratings (NRS) to graded thermal stimuli, both pre and post intradermal ADO. 
a) HPT was significantly increased post ADO (p ≤ 0.0001); b) which can be seen consistently in all single subject 
HPTs. c) NRS ratings to 35C and 45C were unaffected, although there was a trend towards a decrease in ratings 
to 45C (p= 0.072). n = 8 
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4.3.4.   ADO/ CAP – Human Quantitative Sensory Testing 
Since  ADO  mainly  effects  thermal  stimuli,  the  ability  to  prevent  capsaicin  induced 
hypersensitivity  was  examined  using  HPTs  and  numerical  ratings  to  thermal  stimuli.  The 
results  suggest  that  pre-treatment  with  ADO  is  able  to  partially  inhibit  capsaicin induced 
sensitisation of thermal stimuli. 
4.3.4.1.  Intradermal ADO partially inhibits capsaicin induced reduction in HPT 
1% capsaicin cream significantly reduces average HPTs from 42.3  4.0C to 37.5  4.9C. This 
reduction is inhibited by pre-treatment with ADO, where average HPT was only reduced from 
42.4  1.6C to 39.1  2.4C (figure 4-11). However, although the HPT post CAP treatment 
alone  is  lower  than  when  subjects  received  ADO  pretreatment,  this  was  not  found  to  be 
statisically significant, suggestive of only a partial inhibition of TRPV1 function. NRS ratings 
revealed a similar picture, since they were not significantly different from baseline control, 
nor capsaicin treated cells (figure 4-11). Overall it would appear that pre-treatment with ADO 
is able to paritally reduce CAP induced thermal hypersensitivty. 
 
Figure 4-11 Effects of ADO pre-treatment on capsaicin induced sensitisation of psychophysical HPT and 
NRS ratings. Using the protocol described in chapter 4.2 standardised QST was undertaken to determine the 
subject’s  heat  and  cold  pain  thresholds  (HPT),  in  addition  to  obtaining  numerical  ratings  (NRS)  to  graded 
thermal stimuli. a) Average HPT post ADO/CAP was reduced by 3.3C, which was not found to be significantly 
different from baseline (p=0.089). However, no significant difference was found between average HPT post CAP 
treatment, and average HPT post ADO/CAP. b) NRS post ADO/CAP ratings were not significantly different from 
baseline, however neither were ratings significantly different from post CAP NRS.  142 
 
4.3.5.  CPA – In vivo electrophysiology 
Pre-treatment with ADO was unable to fully inhibit capsaicin induced sensitisation in animals, 
or humans. This is most likely due to the short half life  (~30s) and possibly non specific 
actions through activation of all receptor subtypes. The A1R is the major inhibitory subtype of  
ADO receptor, and has previously been shown to have antinociceptive properties. Therefore, 
by targeting this receptor spefically  it is possible to further investigate the inhibitory actions 
of  the  A1R  in  the  periphery  and  its  interaction  with  TRPV1.  Overall,  CPA  had  a  more 
pronounced  effect  on  evoked  responses  than  ADO,  which  once  again  were  stronger  for 
thermal stimuli.  
4.3.5.1.  Intraplantar  injection  of  CPA  significantly  reduces  innocuous  and  noxious 
mechanically evoked baseline neuronal responses in naïve animals 
Intraplantar CPA reduced WDR cell responses to dynamic brush from 387.9  84.8 to 227.0  
151.0  action  potentials/  10s,  although  this  was  not  found  to  be  significant  (figure  4-12). 
However, responses to both innocuous and noxious vF were reduced at 8g and 26g (figure 4-
12).  
 
Figure  4-12  Effects  of  CPA  on  mechanically  evoked  baseline  neuronal  responses.  Using  the  protocol 
described in chapter 4.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
mechanical  stimuli,  including  brush  and  graded  vF,  applied  to  the  receptive  field  for  10s,  before  and  after 
intraplantar CPA. a) There was no significant effect of CPA on dynamic brush responses; although b) a reduction 
in mechanical responses was observed (Overall 2 way p= 0.005); both innocuous 8g (p= 0.008) and noxious 26g 
(p= 0.003) were significantly reduced. n = 6 
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4.3.5.2.  Intraplantar injection of CPA significantly reduces thermally evoked baseline 
neuronal responses in naïve animals 
There is a clear reduction in firing to noxious temperatures post CPA treatment, although 
coding is unaffected (figure 4-13). A decrease in firing can be observed to both 45C and 48C 
post CPA, from 875.1  142.5 to 309.3  120.8, and 1232.6  162.2 to 545.6  105.7 action 
potentials/ 10s, respectively (figure 4-13; p= 0,003, 0.001). This is strongly suggestive of the 
hypothesised interaction with TRPV1+ fibres, or modulating function of the receptor itself. 
 
Figure 4-13 Effects of CPA on thermally evoked baseline neuronal responses. Using the protocol described 
in chapter 4.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of thermal 
stimuli applied to the receptive field for 10s, before and after intraplantar CPA. a) CPA significantly decreased 
firing to both 45 and 48C (Overall ANOVA p= 0.001; p= 0.003 and 0.001, respectively.) n=6 
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4.3.5.3.  Intraplantar  injection  of  CPA  has  minimal  effects  on  electrically  evoked 
baseline neuronal responses in naïve animals 
Overall, there was no significant effect of CPA on the number of action potentials elicited from 
A or C fibres, or post discharge (figure 4-14). Additionally, there was no effect on input or 
wind-up. This suggests that although the A1R may interact with TRPV1 to reduced thermal 
responses,  since  overall  excitability  of  the  neurones  is  unaffected.  However,  A  fibres 
mediated transmission was increased from 197.4  119.3 to 230.6  119.5 (figure 4-14; p= 
0.032). 
 
Figure  4-14  Effects  of  intraplantar  CPA  on  baseline  electrical  neuronal  responses.  Using  the  protocol 
described in chapter 2.2 and 4.2 in vivo single unit recordings of LV WDR cells responses were recorded to 
electrical stimuli both pre and post intraplantar CPA.  a) There was no significant effect on electrically evoked A 
and C fibre mediated transmission, nor post-discharge, although A mediated transmission was significantly 
increased (p= 0.032) b) There was no effect on electrically induced input or wind up. n = 5 
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4.3.6.   CPA/CAP – In vivo electrophysiology 
Overall, in contrast to previous results with ADO, pre-treatment with CPA was found to inhibit 
both CAP induced sensitisation to dynamic brush, and thermal hypersensitivity. This strongly 
suggests that the positive effects of ADO in reducing thermal responses in naïve animals, and 
partially reversing capsaicin induced sensitisation, is due to activation of the A1R. 
4.3.6.1.  Pre-treatment with intraplantar CPA inhibits capsaicin induced sensitisation of 
innocuous mechanical neuronal responses in naïve animals 
As previously mentioned, 1% capsaicin cream results in a clear increase in firing of WDR cells 
to dynamic brush. Pre-treatment with CPA is able to completely inhibit this sensitisation, as 
responses  post  CPA/CAP  are  not  significantly  different  from  baseline  (figure  4-15). 
Additionally, when compared to cells treated with CAP alone, responses of CPA/CAP cells are 
significantly reduced from 680.4  47.52 to 242.0  56.1 action potentials/ 10s (figure 4-15, 
p= 0.000). This suggests that CPA is able to completely prevent the development of capsaicin 
induced hypersensitivity. 
 
Figure 4-15 Effects of pre-treatment with CPA on capsaicin induced sensitisation of mechanically evoked 
baseline neuronal responses. Using the protocol described in chapter 4.2 in vivo single unit recordings of LV 
WDR  cells  responses  were  recorded  to  brush  applied  to  the  receptive  field  for  10s,  before  and  after  pre-
treatment with CPA and capsaicin application. a) There is no significant difference between the baseline control 
and CPA/CPA treated cells, however the latter group are significantly different from those treated with capsaicin 
alone (p= 0.000). n=6 146 
 
4.3.6.2.  Pre-treatment with intraplantar CPA inhibits capsaicin induced sensitisation of 
thermal neuronal responses in naïve animals 
CPA produces a very similar pattern of effects to ADO when administered before capsaicin, 
however the inhibition is much more pronounced with the use of a specific and stable agonist. 
There is only a small degree of sensitisation still apparent with CPA pre-treatment, which is 
not  significantly  different  from  the  baseline  controls  (figure  4-16).  Additionally,  when 
compared  to  the  group  of  cells  treated  with  capsaicin  alone,  there  is  a  clear  significant 
difference, suggesting that activation of the A1R by CPA is able to prevent the development of 
thermal hypersensitivity (figure 4-16; p= 0.013).  
 
Figure 4-16 Effects of pre-treatment with CPA on capsaicin induced sensitisation of thermally evoked 
baseline neuronal responses. Using the protocol described in chapter 4.2 in vivo single unit recordings of LV 
WDR cells responses were recorded to thermal stimuli applied to the receptive field for 10s, before and after 
pre-treatment with CPA and capsaicin application. Capsaicin treatment leads to a sensitisation of responses to 
intraplantar injection of CPA is given 10 minutes before application of topical capsaicin cream. Furthermore, 
there is a significant difference between the group of cells pre-treated with CPA and those with capsaicin alone. 
(Overall ANOVA p= 0.013; p= 0.008 and p= 0.014, respectively.) n=6 
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4.3.6.3.  Pre-treatment with intraplantar CPA inhibits capsaicin induced enhancement 
of A fibre mediated responses and reduction of C fibre mediated transmission in naïve 
animals 
In the previous chapter it was found that 1% capsaicin cream results in a potentiation of A 
fibre mediated responses through likely central changes, alongside a reduction in responses 
mediated  in  the  C  fibre  range  which  could  be  due  to  peripheral  desensitisation.  As  was 
observed with ADO pre-treatment, neither of these differences were seen when cells were 
pre-treated with CPA (figure 4-17). This suggests that capsaicin induced facilitation of Aδ 
fibres and reduction of C fibre transmission were inhibited by CPA. Furthermore, although 
capsaicin alone results in a non-significant increase in input, when pre-treated with CPA there 
are no signs of an enhanced input (figure 4-17). 
 
Figure 4-17 Effects of pre-treatment with CPA on electrical neuronal responses post capsaicin. . Using the 
protocol described in chapter 2.2 and 4.2 in vivo single unit recordings of LV WDR cells responses were recorded 
to  electrical  stimuli.  a)  There  was  no  significant  difference  between  baseline  control  and  CPA/CAP  treated 
neurones with regards to electrically evoked A, A, and C fibre mediated transmission, nor post-discharge, 
whilst a comparison between the groups treated with CAP and CPA/CAP show a significant difference in A fibre 
mediated transmission. b) Furthermore, there was no difference with regards to input and electrically induced 
wind up between baseline control and CPA/CAP treatment, or between the CAP treated group and CPA/CAP 
treatment. n= 6 148 
 
4.4.   Discussion 
The data in this chapter supports the theory that the A1R on peripheral fibres is a viable drug 
target. In this study WDR cell responses were measured post intraplantar administration of 
ADO; after a combination of ADO pre-treatment followed by capsaicin; post intraplantar CPA; 
and after a combination of CPA pre-treatment followed by capsaicin. Additionally, QST was 
undertaken  on  healthy human  volunteers post  ADO and after a  combination  of ADO pre-
treatment followed by capsaicin. The key findings were that ADO reduces thermally evoked 
responses in animals, and increases HPTs in human volunteers. ADO therefore appears to 
produce  similar  changes  across  species  with  regards  to  acute  nociception.  Furthermore, 
despite  being  unable  to  fully  inhibit  capsaicin  induced  thermal  hypersensitivity,  brush 
sensitivity was reduced, suggesting a partial inhibitory effect of ADO pre-treatment. Finally, 
CPA was able to reduce both thermally evoked responses in naïve rats, and also attenuate 
capsaicin induced sensitisation of brush and thermal responses. These results are consistent 
with the hypothesis that activation of peripheral A1Rs would be able to modulate capsaicin 
induced thermal hypersensitivity. As such this receptor may be a useful drug target for future 
peripheral therapies. 
 
4.4.1.  Intraplantar administration of ADO reduces thermally evoked responses of WDR 
cells and increases HPTs of healthy human volunteers 
This is the first study to examine the effects of peripherally administered ADO where the 
outcome was measured using objective, quantitative, in vivo electrophysiology or QST. ADO 
led to clear reduction in WDR cell responses to thermal stimuli, which appears to be strongest 
at around 45C. Conversely, the effect on mechanically and electrically evoked responses of 
WDR cells was found to be minor. In line with these observations, the effects of intradermal 
ADO on healthy human volunteers confirmed an increase in HPT, with modest differences in 
responses to mechanical stimuli pre/ post ADO. There are relatively few studies that have 
been conducted in either animals or humans to investigate the local peripheral actions of 
ADO.  However,  of  those  that  do  exist,  few  have  previously  reported  this  antinociceptive 
property. In fact, the results of this study are in stark contrast to previous behavioural studies 
which have suggested that administration of ADO could result in an area of primary heat and 
mechanical hypersensitivity (Taiwo and Levine 1990; Pappagallo et al. 1993).  149 
 
When ADO is injected into the skin it may act at peripheral receptors expressed on neurones, 
or resident immune cells. The subsequent physiological response will thus depend not only on 
which of these cells ADO acts on, but also the subtype of receptor activated. Activation of the 
A1 or A3 receptors will lead to a reduction of intracellular cAMP, whilst either A2A or A2B 
activation mediates the opposite biological effect (Fredholm et al. 2011). Upon binding to 
receptors on peripheral small- medium nociceptive fibres, interactions with K+ and Q-, P-, or 
N-type Ca2+ channels may lead to an inhibition or excitation. In the case of A1 or A3 receptor 
activation,  the  lowered  levels  or  cAMP  reduce  activity  of  Ca2+  channels  and  decrease 
neurotransmitter release, and/ or cause an increased conductance of K+ channels leading to 
hyperpolarisation. Therefore, binding to the A1 or A3 receptors on peripheral afferents could 
explain the reduction in WDR cell responses to thermal stimuli and elevated human HPTs. 
Given the reported high expression of the A1R on TRPV1+ fibres, it is unsurprising that the 
overriding effects are on thermal responses. On the other hand, activation of the A2 receptors 
on peripheral afferents could explain the reported hypersensitivity in previous studies. When 
using ADO it is important to select an appropriate dose, which appears to produce selective 
A1R activation. Responses also depend on the subtype/ density of receptors, which could be 
affected by the precise location of the injection and therefore could be a further factor that 
explains the differences between the studies.  
A1R receptor activation has also been suggested to have an indirect modulatory effect on 
TRPV1 itself, through downstream signalling. In vitro experiments have revealed that ADO 
can inhibit TRPV1 mediated Ca2+ entry to HEK293 cells (Puntambekar et al. 2004). Whilst in 
vivo it has been hypothesised that activation of the A1R results in a breakdown of PIP2, which 
may be required for optimum function of TRPV1, and as such there may be a subsequent 
reduction in function of the receptor (Sowa et al. 2010). This reported breakdown of PIP2 
could explain the lower levels of firing to thermal stimuli and increased HPTs observed here. 
Indeed, Sowa and colleagues recently demonstrated that PIP2 is required for normal sensing 
of noxious heat, as administration enhanced thermosensation for up to two hours (Sowa et al. 
2010). Given that the experiments here found the actions exerted by ADO were mainly linked 
to thermal, rather than mechanical, thresholds and responses, it seems plausible that they 
could  be  explained  by  this  interaction  between  TRPV1  and  the  A1R  through  potential 
modulation of PIP2 levels. 150 
 
Turning  to  the  immune  system,  the  interaction  between  ADO  and immune  cells  is  highly 
complex and there is still much to be understood. The actions of ADO once again depend on 
activation of different receptor subtypes, in addition to the varied functionality of intracellular 
signalling pathways within different immune cells. It has been proposed that activation of the 
A2BR  mediates  mast  cell  deregulation  in  humans,  and  may  lead  to  a  release  of  pro-
inflammatory cytokines such as IL-4 (Ryzhov et al. 2006; Haskó et al. 2008). On the other 
hand, the A2AR is known to be expressed on macrophages, and activation may result in an 
increased production of the anti-inflammatory cytokine IL-10 and a reduction in levels of 
TNF-. In  addition,  the  A2AR is  expressed on  neutrophils  and regulates  the  production  of 
cytokines such as TNF-, CCL3, CCL4, CXCL2 and CCL20  (McColl et al. 2006). Thus, there 
appear to be varied polar roles for ADO within the immune system. However, it has been 
suggested that overall it appears that the actions of ADO are on the whole regulatory, offering 
a protective role involving a reduction in inflammation (Haskó and Cronstein 2004; Haskó et 
al. 2008).  The present data show ADO can be antinociceptive under conditions even where 
inflammation is minimal. 
Although  there  are  no  previous  studies  which  have  found  this  antinociceptive  effect  of 
peripherally administered ADO, when Ekblom and colleagues explored the effect of systemic 
infusion  of  ADO  on  healthy  human  volunteers  they  did  report  an  increase  in  HPT  post 
treatment (Ekblom et al. 1995). Since it is not known exactly where systemic infusions will 
act,  it  is  impossible  to  say  whether  this  could  be  due  to  a  peripheral  mechanism,  as 
demonstrated here. However, a peripheral action is certainly one possibility and this study 
confirms that regardless of the method of administration ADO is able to reduce HPTs. These 
observations are most likely explained due to the increased expression of the A1R on TRPV1+ 
fibres, or through an indirect interaction with TRPV1 itself, involving a combination of the 
mechanisms discussed above. 
 
4.4.2.  Intraplantar administration of ADO has a negligible effect on mechanical and 
electrical evoked responses  
Post  ADO WDR cell  responses  to  dynamic brush, sub  and supra nociceptive  threshold vF 
appear slightly reduced. Furthermore, human MPT is raised, although this was not found to be 
significant. Whilst these changes appear in both animals and humans, it is important to note 
that they are modest in comparison to the changes previously discussed with regard to heat 151 
 
responses. Indeed, similar observations using CPA have been made, where it is clear that 
there is a stronger effect on thermal responses rather than mechanical (Gong et al. 2010; Hurt 
and Zylka 2012). However, regardless of how minor the reduction in activity seen across 
modalities  is  this  nevertheless  suggests  that  ADO  may  have  an  inhibitory  effect  across 
modalities on peripheral neurons.  
Assuming that the molecular transducer of heat, TRPV1, is expressed on a high proportion of 
peripheral nociceptive neurones, if the reduction in activity of WDR cell responses to thermal 
stimuli was due to a generalised dampening of neuronal activity, this effect would most likely 
be seen to a similar extent across modalities. Since the effect is clearly strongest for thermal 
stimuli, the main effect of ADO is most likely explained through a more specific interaction 
with specific channels such as TRPV1. Furthermore, given ADO has no effect on responses to 
electrically evoked stimuli, it is unlikely that there is an overall decrease in afferent activity. 
On the other hand, the overriding inhibition of thermal responses could be the result of a 
preferential expression or activation of the A1R on fibres that respond to thermal, rather than 
mechanical,  stimuli.  Given  that  most  peripheral  afferents  are  traditionally  thought  of  as 
polymodal  this  theory  may seem unlikely. However, as  discussed in chapter 3, recently a 
number of cases have begun to be put forwards for modality specific subgroups of afferent 
fibres. Ablation of TRPV1 expressing neurones results in a reduction in C fibre, but not A-fibre 
mediated activity, in addition to deficits in heat and mechanical pressure, but not pinprick or 
light touch perception (Cavanaugh et al. 2009; Brenneis et al. 2013). Since it has been shown 
that 95.6% of TRPV1 positive fibres also express the A1R this could suggest that the A1R is 
largely  expressed  on  these  thermo-pressure-specific  neurones  and  therefore  can  cause  a 
generalised inhibition of these fibres, through interaction with specific ion channels (Lima et 
al. 2010).  This could explain the heightened drop in thermal responses over mechanical. 
Further  investigation  of  modality  specific  fibre  populations  could  therefore  be  useful  to 
explore and validate this finding.  
Additionally, since the A1R is also expressed on non-TRPV1 positive fibres (which may be 
responsive to noxious mechanical stimuli), it may simply have less of an effect on these fibres 
due  to  a  possible  reduced  density  of  receptors.  It  has  been  shown  that  95.6%  of  TRPV1 
expressing fibres also express the A1R (Lima et al. 2010), however it may be the case that 
expression of the A1R is lower on the non-TRPV1 expressing fibres, which would certainly 
explain the preferential effect on thermal, rather than mechanical stimuli. Furthermore, since 152 
 
the  molecular  transducer  of  mechanical  stimuli  is  unknown,  it  cannot  be  predicted  as  to 
whether any downstream consequences of A1R activation could interfere with this receptor.  
 
4.4.3.  Pre-treatment with ADO reduces capsaicin induced brush hypersensitivity 
Transient  application  of  topical  capsaicin  cream  is  able  to  sensitise  WDR  cell  evoked 
responses to dynamic brush. As discussed in chapter 3, it is not fully understood whether this 
is due to an underlying peripheral or central sensitisation, although the latter is more likely. It 
is  clear  here  that  pre-treatment  with  ADO  was  able  to  significantly  reduce  this  capsaicin 
induced brush sensitisation.  
Firstly, as discussed above, intraplantar ADO in naïve animals appears to have a subtle effect 
on peripheral neuronal activity. The subset of neurones that are modulated by ADO could 
include  peripheral  neurones  that  respond  to  dynamic  brush  and  are  themselves  directly 
sensitised by capsaicin, such as low threshold C fibres, which may express TRPV1. Through 
binding to inhibitory receptors on these neurones, such as the A1 or A3 receptors, ADO could 
lead to a reduction in overall activity of the neurones and thus directly reduced their ability to 
be sensitised. Since ADO can reduce WDR cell brush responses in naïve animals, it is possible 
that pre-treatment reduces baseline responses, and capsaicin is then still able cause some 
sensitisation but simply to a lesser extent.  
However, the inhibitory effects of ADO on peripheral neurones could also directly counteract 
mechanisms of capsaicin-induced sensitisation. When capsaicin binds to TRPV1, Ca2+ enters 
the  neurone  and  a  number  of  intracellular  kinases  are  activated.  These  in  turn  may 
phosphorylate  receptors,  targeting  them  to  the  membrane  and  reducing  their  activation 
threshold.  The  candidate  receptor  for  the  transduction  of  dynamic  brush  responses  is 
unknown. However, it is possible that it could be sensitised in this way.  Furthermore, in the 
same way it has been hypothesised that the A1R is able to modulate TRPV1, perhaps it is able 
to interact with and modulate this unidentified receptor. If this transducer requires PIP2 for 
signalling, the breakdown of this molecule by activation of the A1R could reduce activity of the 
receptor.  This  reduction  in  activity  could  also  reduce  its  ability  to  become  sensitised  by 
capsaicin. 
As  previously  discussed,  ADO  is  also  able  to  interact  with  the  immune  system  to  reduce 
inflammatory responses. Capsaicin cream application causes a clear reddening of the skin 153 
 
when applied to human volunteers. This indicates a level of extravasation, which may allow 
immune cells to filtrate out into the tissues. It is therefore possible that ADO could mediate 
any proceeding inflammatory responses that may play a part in sensitising PAFs. Given that 
the  regulatory  actions  of  ADO  are  believed  to  be  through  the  A2A  and  A2B  receptors,  this 
mechanism is quite distinct from the others discussed.  
Finally, since the A1R may interact with TRPV1 function, pre-treatment may reduce ongoing 
activity caused by capsaicin application (Kenins 1982; LaMotte et al. 1992). Ongoing activity 
into the DH post capsaicin is thought to drive central sensitisation, which may in turn result in 
brush hypersensitivity. It has been shown that in vitro ADO is able to mediate Ca2+ entry into 
HEK293 cells expressing receptors for ADO and TRPV1, suggesting ADO does indeed reduce 
activity of the channel (Puntambekar et al. 2004). Furthermore, inward capsaicin currents in 
DRG neurones were inhibited, suggesting ADO is able to reduce the activity of neurones post 
capsaicin application (Puntambekar et al. 2004). Therefore, it is plausible that this reduction 
on  TRPV1  activity  could  also  prevent  the  development  of  central  sensitisation,  and 
subsequent development of symptoms such as brush hypersensitivity. 
Since there is a lack of evidence regarding the peripheral actions of ADO on either chronic 
pain  models,  or  in  patients,  inferences  can  only  be  made  from  alternative  methods  of 
administration.  Several  studies  have  also  found  that  IT/IV  ADO  is  able  to  reduce  both 
secondary hyperalgesia and brush evoked allodynia, associated with human surrogate models 
such as topical mustard oil, and also in patients with neuropathic pain – confirming this anti-
allodynic property of ADO, as observed here (Rae et al. 1999; Eisenach et al. 2002; Lynch et al. 
2003). As ADO is not being administered peripherally in these studies it is not possible to 
gauge  whether ADO is acting against central or peripheral mechanisms. Whilst this effect 
could  be  driven  through  interactions  with  ion  channels  on  peripheral  fibres  as  discussed 
above, it is important to note they could also be due to actions at ADO receptors in the spinal 
cord,  which  are  well  known  to  be  antinociceptive.  Further  studies  of  peripherally 
administered ADO/ A1R agonists are required to investigate the mechanism underlying the 
effects observed here. 
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4.4.4.  Pre-treatment with ADO inhibits capsaicin induced electrical changes 
In naïve animals, capsaicin cream causes an enhancement of A fibre responses, at the same 
time as a parallel decrease in C fibre mediated transmission. As discussed in the previous 
chapter, a potentiation of A fibre responses is often seen in models associated with central 
changes,  and  may  indeed  be  attributed  to  a  centrally  mediated  mechanisms  induced  by 
ongoing activity as a result of sustained TRPV1 activation. Since this is not observed with ADO 
pre-treatment, this supports the theory that ADO is able to partially reduce TRPV1 mediated 
ongoing activity, enough to prevent the development of certain central changes to the pain 
system. Furthermore, the inhibition of capsaicin induced C fibre desensitisation also suggests 
that excessive TRPV1 activity is prevented by pre-treating with ADO. Since desensitisation of 
C fibres is usually associated with excessive Ca2+ entry, resulting in temporary desensitisation 
of fibres and/ or excitotoxicity, these results suggest that ADO inhibits these high levels of 
TRPV1 activity. Indeed, both the induction of central sensitisation, through ongoing afferent 
activity,  and  peripheral  desensitisation/excitotoxicity  are  related  to  high  levels  of  TRPV1 
activity. Thus it may be inferred that ADO is able to partially inhibit the actions of capsaicin, at 
least  to  a  level  where  central  changes  such  as  an  enhancement  of  A  fibre  mediated 
transmission are no longer observed, in addition to reducing excessive Ca2+ entry related 
desensitisation.  
 
4.4.5.  ADO partially attenuates capsaicin induced thermal hypersensitivity 
Despite the ability to inhibit capsaicin induced brush sensitisation, ADO was not able to fully 
prevent the development of thermal hypersensitivity.  As previously discussed, it is likely that 
the reduction in thermal evoked WDR cell activity observed when ADO is administrated is due 
to the interactions between the A1R and TRPV1, which would suggest that ADO would be able 
to interfere with the actions of capsaicin. However, since capsaicin is a very strong stimulus, 
and the actions of ADO are relatively short in duration it is feasible ADO would not be able to 
fully inhibit these actions. Additionally, responses to heat are large and induced sensitisation 
enhances these further, therefore a weak effect of ADO is not enough to reduce this. Indeed, 
given the rather short half-life of ADO, and non-specific actions, it is not entirely surprising 
that this was the case. 
Since  thermal  hypersensitivity  was  still  induced,  despite  pre-treatment  with  ADO,  this 
suggests that a level of TRPV1 activity remained: enough to result in peripheral sensitisation. 155 
 
That is to say, whilst high levels of TRPV1 activity may be required for the development of 
central  sensitisation  and  peripheral  desensitisation,  lower  levels  may  induce  peripheral 
sensitisation.  Although  the  activation  of  the  A1R  and  possible  downstream  interactions 
between the A1R and TRPV1 may be enough to prevent any central changes, a low level of 
activity still remains and leads to the development of peripheral hypersensitivity.  
With regards to the results discussed above in relation to the inhibition of brush sensitisation, 
this may rule out a few of the explanations offered. If engagement of TRPV1 is at a level 
whereby thermal hypersensitivity is induced, it is likely that other peripheral receptors would 
also be sensitised during this process. This suggests that if brush induced hypersensitivity 
was a result of sensitisation of peripheral receptors it would not have been reduced by pre-
treatment  with  ADO.  Furthermore,  it  has  been  shown  that  it  is  possible  for  activation  of 
receptors to cause peripheral sensitisation, but not necessarily lead to central changes, such 
as with the use of UVB (Bishop et al. 2010). If a stimulus is not strong enough to result in an 
ongoing activity into the DH, there is nothing to drive the central sensitisation. Therefore, 
given that thermal hypersensitivity is still present, it seems most likely that the dampening of 
peripheral activity by ADO is not enough to fully inhibit peripheral sensitisation, but perhaps 
does lower the level of activity to below the threshold required to cause central changes. This 
would suggest not only that ADO is able to prevent capsaicin induced brush hypersensitivity 
but that this symptom is driven by a central mechanism.  
 
4.4.6.  ADO as a possible pain therapy 
Several studies have already assessed the possibility of ADO as a chronic pain therapy and 
indeed IT ADO has been shown to alleviate symptoms of neuropathic pain (Belfrage et al. 
1999).  However,  this  is  a  rather  inconvenient  mode  of  administration  and  due  to  the 
undesirable cardiac side effects a systemic therapy is not likely to be possible either. Indeed, a 
peripheral therapy seems the most plausible option. 
Furthermore, methotrexate (which is used in the treatment of  RA patients) is believed to 
exert  some  of  its  actions  through  an  ADO  mediated  modulation  of  the  immune  system. 
Methotrexate  inhibits  the  enzyme  5-aminoimidazole-4-carboxamide  ribonucleotide 
transformylase.  By  reducing  the  activity  of  this  enzyme,  there  is  an  accumulation  of  5-
aminoimidazole-4-carboxamide  ribonucleotide,  which  is  a  competitive  inhibitor  of  AMP 156 
 
deaminase. The in turn leads to an enhanced release of ADO, which is believed to decrease 
pain associated with RA (Haskó et al. 2008). This suggests that there may be some possible 
positive effects of ADO with regards to reducing chronic pain. 
However, due to the rather weak and non-specific actions of ADO, and the inability to fully 
reduce capsaicin induced sensitisation observed here, it may be concluded that peripheral 
ADO itself would not make a successful chronic pain therapy. Furthermore, since the half-life 
is so short the duration of action would be very limited, unless given with a complimentary 
therapy to suppress the breakdown. 
Nonetheless, the pain relieving effects of ADO have been explored with regards to alternative 
therapies and it has been shown that an exercise induced increase ADO can decreases CRPS 
related pain. Furthermore, this effect was enhanced by suppressing breakdown of ADO and by 
blocking  the  A1R  (Martins  et  al.  2013).  Since  the  short  half-life  of  ADO  renders  the 
development of such a treatment unlikely, exploring these possibilities could be one way to 
exploit the antinociceptive effects of ADO. Additionally, this intrinsic ability to reduce pain 
should be taken into account by chronic pain patients who consume high levels of caffeine. 
Since  caffeine is  a  competitive  antagonist  of  ADO  receptors it is  possible  that it could be 
counteracting the body’s own attempts to dampen the pain. 
 
4.4.7.  Intraplantar administration of CPA reduces thermally evoked responses of WDR 
cells 
As previously mentioned, intraplantar/ intradermal injection of ADO clearly reduced WDR 
cell firing to thermal stimuli and increased HPTs, in rats and humans, respectively. This action 
is most likely explained through the actions of ADO at the inhibitory A1 or A3 receptors. In 
order to further elaborate on these mechanisms underpinning the aforementioned decrease 
in thermally evoked responses, this study also investigated the specific role of the A1R. CPA, 
which  binds  preferentially  to  the  A1R,  was  administered  via  intraplantar  injection  to  the 
receptive field of WDR cells. Once again there was a clear reduction in firing of WDR cells to 
thermal stimuli ranging from 35C to 48C. This strongly suggests that the weaker reduction 
in firing of WDR cells, and increased HPTs, seen post administration of ADO is due to actions 
at the A1 receptor.  157 
 
Several  other groups  have  also noted this  specific  effect of CPA in  reducing responses  to 
thermal  stimuli.    Gong  et  al  found  that  intraperitoneal  CPA  increased  paw  withdrawal 
latencies, whilst  mechanical  thresholds were unchanged  (Gong et al. 2010).  Additionally, 
local  peripheral  injection  of  CPA  has  been  shown  to  reduce  noxious  thermal,  but  not 
mechanical, sensitivity (Sowa et al. 2010; Hurt and Zylka 2012). This effect was localised, and 
furthermore  lost  in  A1R  KO  mice.  These  studies  suggest  the  effect  is  indeed  due  to  local 
actions  at  the  A1R  (Sowa  et  al.  2010).  The  authors  suggest  that  this  is  due  to  a  specific 
interaction of the A1R with TRPV1. Given that the actions of CPA, like ADO, appear stronger 
against thermal stimuli this seems like a reasonable explanation. Although, it cannot be ruled 
out that it may also be due to a hyperpolarisation of neurones, which express both the A1R 
and  TRPV1.  This  study  confirms  that  a  peripherally  administered  agonist  of  the  A1R  can 
dampen  thermal  responses,  though  the  exact  downstream  mechanisms  are  still  yet  to  be 
proven. 
CPA appears to have a stronger effect than ADO, which is most likely due to the stability, and 
preference to bind to the A1 receptor. ADO can bind to all ADO receptors, and it is therefore 
unlikely that at any one time all the A1 receptors will be saturated. This sub-optimal binding, 
leaving some A1Rs left open, along with those that are activated being counteracted by A2Rs, 
may explain the modest results observed with ADO. Whereas CPA acts specifically on the A1R 
and therefore there is likely to be a higher saturation of these inhibitory receptors with no 
opposing actions from A2R activation.  
 
4.4.8.  CPA reduces mechanically evoked responses 
Overall CPA was able to reduce mechanically evoked responses of WDR cells, whilst having 
only a small effect on electrically evoked responses. In fact, rather paradoxically given the 
reduction in mechanical responses, A mediated transmission appeared enhanced post CPA. 
Given how minor this increase was, it is possible that it may not be biologically significant, or 
indeed  an  anomalous  result.  On  the  other  hand,  electrically  induced  input  and  C  fibre 
mediated activity were reduced by CPA administration, although these were not found to be 
statistically significant. Previous studies have also observed the ability of CPA to decrease C 
fibre,  but  not  A  fibre  mediated  activity,  as  was  observed  here  (Gong  et  al.  2010).  These 
reductions  in  mechanically  evoked  responses,  and  electrically  induced  input  could  be 158 
 
explained  a  general  inhibitory  effect  that  activation  of  the  A1R  may  exert  on  peripheral 
neurones, or a specific effect on mechano-transducers. 
As discussed this may involve interactions with voltage gated ion channels, such as Q-, P- and 
N-type  Ca2+  and  K+  channels.  That  is  to  say,  activation  of  the  A1R  could  lead  to  a 
hyperpolarisation  of  afferent  fibres.  Given  that  both  ADO  and  CPA  have  relatively  minor 
effects on electrically evoked responses, it seems unlikely that there is on the whole due to 
indirect interactions with transducers themselves. Since this effect on mechanically evoked 
responses  has  not  been  found  before  it  is  difficult  to  fully  ascertain  the  underpinning 
mechanisms. As previously mentioned, Gong and colleagues found that CPA in naïve animals 
reduced thermal, but not MPTs (Gong et al. 2010). Therefore, there are three possibilities that 
we may consider to explain the results observed here. 
Firstly, it is possible that these actions are at A1Rs expressed on afferent fibres other than 
those responding to thermal stimuli. Indeed, only 79.55% of A1R expressing fibres co-express 
TRPV1,  therefore  the  remaining  20.45%  are  not  TRPV1  positive.  This  small  percentage 
expressed on non-TRPV1 expressing fibres could be mechano-sensitive afferents, such as A 
fibres, and therefore and an overall reduction in excitability of these fibres, or an interaction 
with mechano-transducers on these fibres, would explain the results observed here. Given 
that fewer A1Rs are expressed on these fibres, it is unsurprising the effect is less than on 
thermal responses and perhaps may go unnoticed in some studies. A second possibility is that 
they are expressed on a population of non-TRPV1 expressing C fibres, which are mechano-
sensitive  and  also  express  the  A1R  (i.e.  non-peptidergic  C  fibres).  Once  again,  an  overall 
reduction in excitability of these fibres, or an interaction with mechano-transducers on these 
fibres would explain the results here. Thirdly, there may be some TRPV1 and A1R positive C 
fibres, which also respond to mechanical stimuli (C-MH fibres) and a reduction in activity of 
mechano-transducers on these fibres is at the route of these observations. However, this final 
explanation raises some doubt over the modality specific theory discussed. Indeed, this is yet 
to be fully accepted, and we cannot rule this out as an explanation. It would be interesting to 
investigate the actions of CPA after ablation of TRPV1 positive neurones to help understand 
these results observed here. 
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4.4.9.  CPA is able to reduce capsaicin induced sensitisation of brush and thermal 
stimuli 
Pre-treatment with intraplantar CPA was  clearly able  to  inhibit usual levels  of brush and 
thermal  hypersensitivity  associated  with  1%  capsaicin  application.  Since  thermal 
hypersensitivity is usually attributed to TRPV1 this decrease is most likely explained by the 
actions on TRPV1+ fibres or the proposed interaction of the A1R and TRPV1 as discussed 
above.  Lima  and  colleagues  have  also  noted  that  peripheral  A1R  activation  decreases 
inflammatory peripheral hypersensitivity (Lima et al. 2010). Whist Stein and colleagues have 
demonstrated that polylysine (an agent which sequesters PIP2) has an inhibitory effect on 
TRPV1, and Liu et al found that replenishing PIP2 can aid recovery after desensitisation (Liu 
et  al.  2005;  Stein  et  al.  2006).  More  recently  it  has  also  been  demonstrated  that  PIP2  is 
required for both normal sensing of noxious heat and for the development of sensitisation 
(Sowa et al. 2010).  In addition to enhancing thermosensation for up to two hours, PIP2 also 
increased thermal hypersensitivity and mechanical allodynia. Therefore it can be inferred that 
PIP2 is required for function of TRPV1 and a breakdown through activation of the A1R is the 
most likely explanation for the results observed in this study.  
As  previously  discussed  with  regards  to  ADO,  continuous  activation  of  TRPV1  results  in 
ongoing activity into the spinal cord, which is likely to cause central changes that lead to 
enhanced brush sensitivity or allodynia. A reduction of TRPV1 activity would therefore also 
explain the ability of CPA to inhibit capsaicin induced brush hypersensitivity, attenuate A 
facilitation and C fibre desensitisation. 
Additional studies have also found that inosine is able to reduce pain-related behaviours, due 
to  possible  actions  at  the  A1R.    Nascimento  and  colleagues  demonstrated  that  inosine 
decreases  responses  in  the  late  stage  of  the  formalin  test,  in  addition  to  CFA  induced 
mechanical allodynia, and PSNL induced mechanical and cold allodynia  (Nascimento et al. 
2010). These effects were blocked by an A1R selective antagonist (Nascimento et al. 2010). 
Thus suggesting that inosine has antinociceptive and antiallodynic properties, related to the 
involvement of ADO A1R. Supporting the theory proposed here that the A1R may be able to 
modulate such hypersensitivity. However, as inosine was given systemically in these studies, 
central actions cannot be ruled out. 
This analgesic effect of A1R agonists has also been observed in other models of chronic pain, 
including the formalin model and DPN (Balasubramanyan and Sharma 2008; Liu et al. 2013). 160 
 
These models induce very different mechanisms, however A1R agonists were effective across 
both. This may be explained by the fact that the A1R is widely expressed throughout the pain 
pathway and its inhibitory actions do not require any specific chronic pain related changes, 
unlike many therapies that act against mechanisms which require the presence of chronic 
pain induced plasticity. Taken together, the results of this study and previous work, suggest 
that  A1R  agonists  may  be  a  useful  therapy  effective  across  a  number  of  symptoms/  pain 
conditions.  Whilst  previous  studies  have  validated  the  effects  of  systemic  A1R  activation 
against signs and symptoms of chronic pain, this study confirms a peripheral action. 
The results presented here in this study also highlight the use of objective measures, such as 
in vivo electrophysiology, as useful pharmacodynamic endpoints to aid drug development. 
Not only do the recordings of WDR cells produce a clear picture of sensitisation across a range 
of innocuous and noxious stimuli in response to certain models, such as capsaicin, but they 
also allow the study of how drugs act across modalities and varying intensities. Behavioural 
studies,  including  those  with  ADO  or  CPA,  have  often  used  threshold  measurements  and 
produced conflicting results, whereas here we are able to examine how the drug may effect 
sub  and  suprathreshold  stimuli.  Importantly,  since  capsaicin  is  a  highly  suprathreshold 
stimulus,  this  study  the  extension  of  the  role  of  ADO/  CPA  modulation  into  these 
suprathreshold levels of pain related activity that is likely to be relevant to patients. 
 
4.4.10.  Potential chronic pain therapies: the A1R receptor and beyond 
This study has highlighted the antinociceptive effect of activating the A1R – an action which is 
likely to be relevant in animals and humans. Given the positive effects seen here attenuating 
capsaicin induced sensitisation, and the results of previous studies, it can be concluded that 
this  is  a  promising  drug  target.  In  particular  this  could  be  explored  as  a  peripherally 
administered therapy. Indeed, Giorgi et al have recently noted the potential of A1R ligands 
with regard to both efficacy and preferable side effect profiles – in particular for those given 
by topical administration (Giorgi and Nieri 2013).  
Notably, it was observed here that CPA appears to be able to reduce signs of ongoing activity 
and prevent centrally induced symptoms, such as brush hypersensitivity and increase in A 
fibre mediated activity. This confirms the importance of peripheral activity, leading to central 
changes  (Baron  et  al.  2013).  Furthermore,  it  highlights  the  possibility  of  developing 161 
 
peripheral  therapies  that  may  be  given  with  the  aim  of  preventing  pain  from  becoming 
‘central’. Indeed such therapies may be able to prevent both the induction and maintenance of 
certain pathological changes in chronic pain states.  
Another possible therapy, although it was not explored in this chapter, is targeting the A3R. 
Since the A3R actions are similar to that of the A1R this receptor may also be a useful potential 
drug target. Chen and colleagues have investigated A3R pharmacology and demonstrated that 
several agonists of this receptor were able to reduce CCI induced mechanical hypersensitivity 
(Chen et al. 2012).  The actions were found to be as effective as gabapentin or amitriptyline, 
which are both widely used chronic pain therapies (Chen et al. 2012). The expression of A3R 
on  peripheral  fibres  has  not  yet  been  explored,  but  given  the  positive  results  observed 
regarding systemic therapy it could be useful to explore the peripheral effects of A3R agonists. 
Other than adenosine receptors, studies have also explored alternative indirect modulation of 
TRPV1 function and the effect on chronic pain models. Fischer and colleagues have recently 
demonstrated  that  disruption  of  A  kinase  anchoring  protein  79  prevents  sensitisation  of 
TRPV1 and the subsequent thermal hyperalgesia in the pre-clinical carageenan and formalin 
models (Fischer et al. 2013). These indirect  modulations are particularly useful given the 
potential role the receptor plays in chronic pain, but direct antagonists often interfere with 
thermoregulation.  Thus, it could be interesting to investigate this further in the translational 
model of capsaicin to explore the potential in humans. 
 
4.5.   Concluding remarks 
Overall this chapter has examined the effects of ADO and CPA on acute pain, in addition to 
exploring the possibility of preventing capsaicin induced hypersensitivity.  Both ADO and CPA 
were able to reduce acute thermal responses, which may be explained through an indirect 
interaction with TRPV1, or an overall hyperpolarisation of PAFs. Modest effects were also 
observed regarding reductions in mechanical stimuli, the mechanism of which is not yet clear. 
Finally, CPA was able to prevent capsaicin induced sensitisation to both brush and thermal 
stimuli, highlighting the potential of A1R agonists in chronic pain therapy. 162 
 
 
Figure  4-18  Activation  of  the  A1R  attenuates capsaicin  induced  peripheral  and  central  sensitisation. 
Topical capsaicin leads to the development of both thermal and  brush hypersensitivity, however  peripheral 
administration of CPA was able to attenuate the development of both of these symptoms. Activity of TRPV1+ 
afferents is most likely reduced through interaction with voltage gated ion channels, or an indirect modulation of 
the TRPV1 receptor. Subsequently, capsaicin was unable to activate TRPV1 at the levels required to drive either 
peripheral or central changes. As such the A1R holds potential as a future drug target. 163 
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5.1.   Introduction 
Ideally, surrogate pain models will mimic the signs and symptoms exhibited by chronic pain 
patients with the aim of modelling as closely as possible the mechanisms in healthy humans of 
the relevant underlying pathophysiologies in patients. We have gained much insight from the 
use of models initiated by administration of an exogenous agent such as topical capsaicin 
application  (as  described  in  the  previous  chapters),  which  in  its  acute  phase  induces  a 
powerful peripheral and central sensitization of pain-signalling circuits. The power of this 
approach is that it, by definition, studies a particular mechanism. However, the weakness is 
that it is frequently unknown how important a particular mechanism is in a given pain state. 
The continuous development and improvement of surrogate models is crucial in furthering 
our knowledge, in particular with regards to pharmacological interventions that modulate 
specific key targets brought into play in the model. The closer the mechanisms induced in the 
models  become  to  the  patient  reality,  the  higher  the  likelihood  that  they  will  allow  the 
identification of drug interventions which succeed all the way through to the clinic. Obviously, 
this  excludes  models,  for  ethical  reasons,  where  there  is  actual  marked  tissue  or  nerve 
damage. This chapter explores the use of electrophysiology in rats and QST in humans in 
order to further characterise the UVB model of inflammatory pain. 
It has long been known that exposure to ultra violet (UV) light evokes sensory changes to the 
skin. In 1942 Lewis wrote that in this model he had observed a reddening and swelling of the 
treated area, resulting in ‘nerve endings in a state of hyperexcitability’ which he then described 
as a ‘hyperalgesic state’ (Lewis 1942).  In more recent years, it has been further established 
that UV light in the UVB range (290-320nm) is absorbed by the epidermis, and results in an 
inflammation characterised by the classical features of erythma, hyperalgesia and allodynia - 
to both mechanical and thermal stimuli (Hoffmann and Schmelz 1999; Benrath et al. 2001; 
Harrison et al. 2004; Bishop et al. 2007). 
 
5.1.1.  UVB irradiation leads to a local inflammatory response 
When UVB is absorbed by epidermal cells such as keratinocytes and fibroblasts, the resulting 
apoptosis and DNA damage leads to the release of a number of neuropeptides, free radicals 
and inflammatory mediators (Hruza and Pentland 1993; Saadé et al. 2000; Clydesdale et al. 
2001;  Matsumura  and  Ananthaswamy  2004;  Angst  et  al.  2008;  Dawes  et  al.  2011).  The 165 
 
sensitisation  of  nocieptors  by  these  released  molecules  occurs  through  a  number  of 
intracellular signalling cascades, as discussed in chapter 1. In addition, their release may also 
recruit  immune  cells,  such  macrophages,  neutrophils,  lymphocytes  and  mast  cells,  which 
work a long side the resident innate cells, further releasing inflammatory mediators such as 
cytokines and chemokines that act to maintain and enhance the sensitisation of peripheral 
nociceptors, therefore resulting in a long lasting hypersensitivity of peripheral transduction 
(figure  5-1).  The  model  has  been  used  to  probe  the  upregulation  of  such  mediators,  to 
compare across rodents and humans with the aim of the identification of potential candidate 
molecules in inflammatory pain states. In many cases, a skin biopsy was taken (or blood/ CSF) 
and cytokine levels were measured (table 5-1). 
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Figure 5-1 UVB induced recruitment of immune cells and peripheral sensitisation. Studies have 
highlighted  the  recruitment  of  neutrophils  and  macrophages  as  a  result  of  UVB  irradiation.  These  adaptive 
immune cells act in synchrony with resident cells to release numerous inflammatory mediators, which are able 
to sensitise peripheral receptors through intracellular mechanisms.   167 
 
Mediators  Change in 
expression post  
UVB? 
Associated with chronic pain? 
CXCL5   Unknown, associated with a number of other preclinical 
models  
IL-24   Unknown 
CXCL2   Unknown 
IL-6   Potential role in peripheral inflammation 
CCL7   Unknown 
IL-10   Reduced in peripheral neuropathy 
IL-1B   Increased in peripheral neuropathy 
TNF-A  X  Increased in CRPS, peripheral neuropathy 
NGF  X  Increased in interstitial cystitis/painful bladder syndrome, 
chronic prostatitis/chronic pelvic pain syndrome, OA and 
DPN 
IL-8  X  Increased in PHN 
 
Table 5-1 A selection of inflammatory mediators associated with UVB and/ or chronic pain. Dawes and 
colleagues found that changes in expression of 90 mediators could be observed post UVB irradiation. IL-1 was 
upregulated post UVB, whilst IL-10 was found to be downregulated. Both of these mediators have already been 
recognised as having a potential role in chronic pain and thus highlight the clinical relevance of this model. 
However, there are also a number of novel mediators identified by this study. TNF-, NGF and IL-8 are examples 
of previously indentified mediators believed to play a role in chronic pain, however these were unchanged post 
UVB. (Sommer et al. 1998; Kotani et al. 2004; Marchand et al. 2005; Üçeyler et al. 2007; Uceyler and Sommer 
2007; Backonja et al. 2008; Kumar and Mahal 2012; Dawes 2013).  
With regards to the data in table 5-1 it will be interesting to investigate the role of these 
cytokines in chronic pain, to understand the full relevance of this  model to patients. It is 
important  to  note,  that  even  if  the  mediators  are  not  involved  specifically  in  any  pain 
conditions  the  model  may  still  hold  clinical  relevance.  The  downstream  mechanisms  of 
inflammatory  mediators  may  indeed  have  some  overlap  with  those  that  are  involved  in 
chronic pain states. 168 
 
5.1.2.  Peripheral sensitisation is the predominant mechanism of UVB irradiation  
Through  a  number  of  pivotal  studies,  using  extensive  psychophysical  and  behavioural 
characterisation, Bishop and colleagues concluded that the inflammatory process occurring in 
the UVB treated area led to a predominant peripheral sensitisation, that accounts for all the 
sensory  changes  recorded  (Bishop  et  al.  2007;  Bishop  et  al.  2009;  Bishop  et  al.  2010). 
Assessing not only the phenotypic changes induced by UVB - namely the reduced thresholds 
restricted to the primary area of insult - but also the respective pharmacological sensitivity of 
the  model,  in  both  rats  and  humans,  the  group  made  a  strong  case.  The  UVB  induced 
physiological  changes  were  found  to  be  dose  dependent  and  peak  around  24-48  hours 
(Hoffmann and Schmelz 1999; Bishop et al. 2007). Most notably, in the human studies, Bishop 
and colleagues extensively compared UVB to the capsaicin and thermal burn models; showing 
that although the latter two evoke pinprick hyperalgesia and allodynia in the secondary area, 
neither of these manifestations of central changes could be found post UVB, supporting the 
notion this is on the whole a peripheral model. 
The majority of animal data do not support the presence of notable central changes, with only 
one study finding a significant mechanical hypersensitivity in the secondary area (Davies et al. 
2011). One key driver of central sensitisation, that appears to be absent in the UVB model, is 
spontaneous or ongoing pain; the degree of spontaneous activity is believed to correlate with 
the level of hypersensitivity (Chu et al. 2004; Baron et al. 2013).  Overall the studies in tables 
5-2 and 5-3 report  no signs of spontaneous pain-like  behaviour. Furthermore, recordings 
from peripheral afferents highlighted no change in spontaneous activity, which is present in 
other inflammatory models associated with hypersensitivity and central changes, such as OA, 
CFA and carageenan (Andrew and Greenspan 1999; Hamilton et al. 2001; Chu et al. 2004; 
Schuelert  and  McDougall  2009).    In  addition,  there  were  no  reports  of  UVB  inducing  an 
increase in basal c-fos levels (otherwise seen with CFA), which is another marker suggestive 
of ongoing noxious input linked to central changes (Ma and Woolf 1996). Since peripheral 
recordings  also  highlighted  heat  insensitive  C  fibres  increasing  their  response  to 
suprathreshold mechanical stimuli, and heat-sensitive C fibres increasing activity to thermal 
stimuli, all together this suggests a peripheral mechanism for the observed hypersensitivity 
(Bishop et al. 2010). 
However, this proposal of a of an overriding peripheral sensitisation has been opposed by 
Gustorff,  Sycha  and  colleagues  (2013)  who  presented  evidence  of  additional  changes, 169 
 
including large areas of secondary pin prick hyperalgesia. The details of all animal and human 
studies are recorded in tables 5-2 to 5-5. Interestingly, this model is one of the few which has 
been explored further in humans, and it is only in these human studies that clear evidence of 
secondary changes, and thus a central sensitisation, are present. Though it must be noted that 
the studies in which this is the case, have a much larger area of irradiation – which may lead 
to small amounts of spontaneous activity, which could drive central sensitisation. However, in 
the large majority of studies with relatively restricted UVB irradiation, the changes seem to be 
confined to the periphery. It may simply be that the way the UVB model is implemented and 
tested can lead to almost pure peripheral change or peripheral and central change. However, 
there is enough evidence to show that this model may be used to study the consequences of a 
strong peripheral sensitisation. 
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Table 5-2 Studies of UVB in animals. Sensory changes evoked in previous studies exploring UVB irradiation in animals.
Study  UVB Dose  Treated Area  Time Frame  Evoked Observations  Site of Changes 
Spontaneous 
Activity 
Histological Changes 
Saadé et al. 
2000 
Up to 300mJ/ cm2  Back 
3-6 and 48-96 
hours 
Dose dependent thermal 
hypersensitivity 
Secondary area   
Upregulation of IL-1, TNF- and 
NGF 
Davies et al. 
2005 
(UV) 
52.65mJ/cm2 
Hindpaw 
(circular area 
8mm in 
diameter) 
Maximal changes 
seen at 24-48 
hours 
Hypersensitivity to thermal 
and mechanical stimuli, 
including both heat and cold 
Primary 
irradiated area 
only 
   
Bishop et al. 
2007 
Up to 
1000mJ/cm2 
Hindpaw 
Maximal changes 
seen at 24-48 
hours 
Dose dependent thermal and 
mechanical hypersensitivity 
in hairy and glaborous skin 
Primary 
irradiated area 
only 
No signs of 
spontaneous pain 
behaviours 
No increase in basal c-fos. 
Increased c-fos expression in 
response to 45C 
Bishop et al. 
2010 
1000mJ/cm2  Hindpaw  48 hours 
Hypersensitivity to thermal 
and mechanical stimuli 
Restricted to the 
primary site of 
irradiation 
No difference in the 
degree of 
spontaneous 
activity in primary 
afferents 
 
Dawes et al. 
2011 
1000mJ/cm2  Hindpaw  40 hours 
Hypersensitivity to thermal 
and mechanical stimuli 
Primary 
irradiated area 
only 
 
Upregulation of numerous 
inflammatory mediators (including 
CXCL5, IL-24, CXCL2, CCL4 and IL-
6) 
Davies et al. 
2011 
 
1000mJ/cm2  Hindpaw 
24 hours-72 
hours 
Hypersensitivity to vF and 
brush 
Secondary area 
No signs of 
spontaneous pain 
behaviours 
 171 
 
Table 5-3 Studies of UVB in humans. Sensory changes evoked in previous studies exploring UVB irradiation humans
Study  Treated Area  Time Frame 
Thermal 
Hypersensitivity 
Mechanical 
Hypersensitivity 
Site 
Spontaneous 
Activity 
Hoffmann and 
Schmelz.1999 
Thigh (circular area 1.5cm in 
diameter) 
Maximal changes 
at 24-48 hours 
  Primary irradiated area only   
Koppert. 1999  Ventral forearm (circular area 
1.5cm in diameter) 
24 hours   
(Impact stimuli) 
Primary irradiated area only  No spontaneous 
pain was reported 
Benrath et al. 
2001 
Forearm (circular area 5cm in 
diameter) 
Maximal changes 
at 24-48 hours 
 
(Pressure pain) 
Primary irradiated area only   
Sycha et al. 2003  Proximal upper leg  20 hours    Primary irradiated area only   
Gustorff et al. 
2004a 
Lateral side of upper leg 
(circular area 5cm in diameter) 
20-30 hours    Thermal hypersensitivity observed in the primary 
area, pinprick hyperalgesia observed in the secondary 
area. 
 
Gustorff et al. 
2004b 
Lateral side of upper leg 
(circular area 5cm in diameter) 
20-30 hours    Thermal hypersensitivity observed in the primary 
area, pinprick hyperalgesia observed in the secondary 
area. 
 
Harrison et al. 
2004 
Buttock (6.25cm2)  Maximal changes 
at 24 hours 
  Primary irradiated area only  No spontaneous 
pain was reported 
Sycha et al. 2005  Ventral side of upper leg 
(circular area 5cm in diameter) 
24 hours    Thermal hypersensitivity observed in the primary 
area, pinprick hyperalgesia observed in the secondary 
area 
 
Chizh et al. 2007  Ventral side of upper leg 
(circular area 2cm in diameter) 
24 hours    Thermal hypersensitivity was tested only in the 
primary area 
 
Bishop et al. 
2009 
Volar forearm (2cm2)  Maximal changes 
at 24 hours 
  Restricted to the primary site of irradiation  No reports of 
spontaneous 
ongoing pain 
Dawes et al. 
2011 
Volar forearm (1cm2)  40 hours    Primary irradiated area only   
Gustorff et al. 
2011 
Ventral side of upper leg 
(circular area 4.2cm in 
diameter) 
24 hours  
(Heat and cold 
hypersensitivity)
 Thermal hypersensitivitiy and dynamic mechanical 
allodynia were observed in the primary area, pinprick 
hyperalgesia was observed in the secondary area. 
 
Ortner etal. 
2012 
Ventral side of upper leg 
(diameter 4.2cm) 
24 hours  
(Heat and cold 
hypersensitivity)
 Heat, cold and pinprick hypersensitivity in the treated 
area. Surrounding area of mechanical pinprick 
hyperalgesia and DMA. 
No spontaneous 
pain was reported 172 
 
5.1.3.  The UVB model is sensitive to peripheral NSAIDs and opioids 
Pharmacological  evidence  from  both  animal  and  human  studies  indicate  an  overriding 
peripheral mechanism in this model. Since the majority of changes evoked by UVB can be 
reversed by peripheral administration of both NSAIDs, as well as a TRPV1 antagonist, this 
suggests there is a strong peripheral component. Whilst NSAIDs block the production of local 
sensitising mediators such as PGs, opioids may act on the afferent terminals themselves to 
inhibit activity. Inflammatory processes can lead to up-regulation of peripheral OR’s, and the 
efficacy of opioids in the UVB model suggest that this may occur following irradiation (Stein et 
al. 2001) although the well-established central analgesic actions of these drugs cannot be 
excluded. Since morphine binds preferentially to the OR – which has been shown to affect 
predominantly thermal, rather than mechanical responses (Cavanaugh et al. 2011) – it is no 
surprise that the thermal hypersensitivity induced by UVB irradiation is more responsive to 
morphine  administration,  and  it  does  not  indicate  that  the  mechanical  hypersensitivity  is 
centrally mediated. TRPV1 has been  shown  in  numerous studies to  play a  pivotal role in 
primary hypersensitivity (O'Neill et al. 2012), thus by blocking this receptor and finding an 
increase  in  HPTs  and  tolerance,  it  is  clear  that  TRPV1  is  involved  in  the  inflammatory 
sensitisation induced by UVB.  
 
5.1.4.  Centrally targeted interventions fail to alleviate UVB induced hypersensitivity 
Ongoing activity of primary afferents that converge in the DH can modulate NMDA receptor 
function,  as  seen  in  wind-up  of  spinal  neurones  and  heterosynaptic  central  sensitisation 
(Dickenson and Sullivan 1987; Haley et al. 1990; Lewin et al. 1994). Thus many models of 
altered pain processing or chronic pain states are sensitive to a blockade of this receptor 
(Woolf and Thompson 1991; Stubhaug et al. 1997). Since Bishop and colleagues found the 
changes  induced  by  UVB  could  not  be  reversed  by  the  NMDA  antagonist  MK-801,  it  is 
therefore unlikely that any of these central mechanisms underpin the model. Furthermore, 
gabapentin is effective across numerous models of central sensitisation, whilst showing no 
effect in naïve animals and healthy individuals, and is thus state-dependent; requiring the 
upregulation of the 2 subunit of voltage gated calcium channels and other conditions such 
as a shift in descending controls and intense peripheral drives (Iannetti et al. 2005; Field et al. 
2006;  Bee  and  Dickenson  2008).  Once  again  the  UVB  model  has  also  been  shown  to  be 173 
 
resistant to this treatment (Gustorff et al. 2004), suggesting the central changes required for 
this state dependency are not present post UVB irradiation. 
Taken  together,  the  evidence  strongly  suggests  that  hypersensitivity  resulting  from  UVB 
irradiation is a predominantly peripheral phenomenon. Whilst some behavioural studies have 
concluded  there  are  signs  of  central  components,  the  majority  of  pharmacological  and 
quantitative  electrophysiological  data  show  little  confirmation  of  this.  UVB  is  therefore  a 
suitable  model  for  assessing  mechanisms  involved  in  peripheral  sensitisation  and 
investigating peripherally acting analgesics. 
Study  Pharmacological Intervention 
Saadé et al. 2000 
IL-10 and IL-13 (anti-inflammatory cytokines) reduce UVB induced thermal 
hypersensitivity, and attenuate pro-inflammatory cytokine levels (such as NGF). 
Davies et al. 2005   
Bishop et al. 2007 
Systemic and topical ibuprofen reduced thermal and mechanical 
hypersensitivity. Systemic and peripherally acting opioids reduced thermal and 
mechanical hypersensitivity. NGF block also reduces thermal and mechanical 
hypersensitivity, with a greater effect on thermal. 
Bishop et al. 2010 
The NMDA blocker MK-801 had no effect on mechanical hypersensitivity. 
Neonatal capsaicin treatment attenuated the development of UVB induced 
thermal and mechanical hyperalgesia. 
Dawes et al. 2011 
Intraplantar CXCL5 causes mechanical hypersensitivity. NSAID piroxicam 
attenuated CXCL5 increase post UVB. CXCL5 neutralising Ab reduces UVB 
induced mechanical hypersensitivity. 
Davies et al. 2011   
 
Table 5-4 Pharmacological sensitivity of the UVB model in animals. Hypersensitivity resulting from UVB 
irradiation is sensitive to NSAIDs and anti-inflammatory cytokines, but not the NMDA antagonist MK-801. 
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Study  Pharmacological Intervention 
Hoffmann and 
Schmelz.1999 
 
Koppert et al. 1999  Peripheral and systemic morphine reduced thermal hypersensitivity, with 
no effect on mechanical hypersensitivity. 
Benrath et al. 2001   
Sycha et al.2003  Ibuprofen reduced thermal hypersensitivity. 
Gustorff et al. 2004a   
Gustorff et al. 2004b  A systemic opioid (Remifentanil) reduced thermal hypersensitivity and 
decreased the area of secondary pin prick hypersensitivity. Gabapentin 
had no effect on either of the sensory changes induced by UVB. 
Harrison et al. 2004   
Sycha et al. 2005  Oral cox-2 inhibitor (Rofecoxib) reduced thermal hypersensitivity and 
had a modest effect on decreasing the area of secondary pinprick 
hypersensitivity. 
Chizh et al, 2007  A TRPV1 antagonist (SB-705498) increased heat pain thresholds, and 
tolerance. 
Bishop et al. 2009   
Dawes et al. 2011   
Gustorff et al. 2011  Pretreatment with 5% lidocaine decreased cold hypersensitivity, the area 
of pinprick hyperalgesia and secondary mechanical hyperalgesia. 
Ortner et al, 2012  Tramadol had a modest effect on primary pinprick hypersensitivity and 
DMA, it did not reduce the area of secondary hyperalgesia or heat/ cold 
hypersensitivity in the primary area. 
 
Table 5-5 Pharmacological sensitivity of the UVB model in humans. Hypersensitivity resulting from UVB 
irradiation is sensitive to NSAIDs, lidocaine, systemic opioids and the TRPV1 antagonist SB-705498. On the other 
hand there was little effect of gabapentin or tramadol. 
Overall,  there  are  several  features  of  this  model  which  make  it  attractive.  Firstly,  it  is 
reasonably straightforward to standardise – unlike responses to topical algogens, which are 
notoriously variable. Secondly, it can be used to cleanly study peripheral sensitisation, in the 
absence of secondary changes. Thirdly, the multiple lines of evidence discussed show that the 
model can be implemented in both humans and rodents and that mechanisms are very similar 
in both. Finally, it does in fact have face validity in that sunburn can be a clinically relevant 
source of pain. Here we aim to further characterise the UVB model in animals and humans, 175 
 
using in vivo electrophysiology to assess evoked responses of WDR cells, a long side QST. The 
same time point was assessed in both animals and humans, and wherever possible similar 
stimuli were used. 
 
5.1.5.  CXCL5 contributes to UVB induced sensitisation 
Many of the  mechanisms underpinning peripheral  sensitisation  of afferent fibres are well 
established, and many of the mediators are mentioned in table 5-1 above, though those which 
drive  UVB  induced  changes  are  not  definitively  established.  However,  a  recent  study 
identified a novel key mediator of UVB induced pain, the chemokine CXCL5  (Dawes et al. 
2011).  CXCL5  is  also  known  as  epithelial-derived  neurtophil-activating  peptide-78  or 
lipopolysaccharide induced CXC chemokine in humans and rodents, respectively. 
Chemokines are a family of chemotactic cytokines. They are an important part of the immune 
response,  mediating  the  trafficking  and  activation  of  numerous  leukocytes  at  the  site  of 
inflammation, thus bridging the gap between the innate and adaptive responses. There are 
over 50 chemokines, many of which have overlapping functions, which they exert through G 
protein  coupled  receptors.  ELR+  chemokines  (possessing  a  glutamic  acid-leucine-arginine 
motif), such as CXCL5, are believed to act at CXCR1 and CXCR2 (Smith et al. 2008; Lüttichau 
2010). With regards to CXCL5 in particular, the majority of actions are likely to be through 
CXCR2  (Lüttichau  2010).  CXCL5  is  a  potent  chemoattractant  as  CXCR2  is  expressed  on 
neutrophils, monocytes and endothelial cells (Charo and Ransohoff 2006). CXCR2 is coupled 
to Gi/o and thus activates multiple signalling pathways, including MAPK/ERK, PI3K/AKT and 
PLC, which may result in protein translation and gene expression; in endothelial cells this 
increases the expression of numerous inflammatory mediators (Chandrasekar et al. 2003).  
Antagonism of the receptor has already shown efficacy in a number of chronic pain models 
such as carageenan, CFA and collagen induced arthritis (Cunha et al. 2008; Manjavachi et al. 
2010). 
Dawes et al found that CXCL5 was highly upregulated at the peak of UVB inflammation in both 
rats and humans (Dawes et al. 2011). There were strong correlations between expression of 
many mediators in rodents and humans but this mediator topped the list in both species. 
Subsequently,  using  intraplantar  injection  they  found  it  could  mimic  the  mechanical 
hypersensitivity  seen  post  UVB;  however,  there  was  no  difference  in  the  latency  of 176 
 
withdrawal  to  a  radiant  heat  source,  thus  suggesting  that  CXCL5  does  not  mediate  UVB 
induced thermal hypersensitivity. The study also highlighted a pivotal mechanism for CXCL5, 
through the recruitment of macrophages, which was previously unexplored. Furthermore, by 
blocking  CXCL5  with  the  use  of  a  neutralising  antibody,  a  reduction  was  seen  in  both 
infiltration  of  macrophages,  and  the  associated  mechanical  hypersensitivity.  Therefore 
suggesting that through the recruitment of immune cells such as macrophages and the further 
release  of  inflammatory  mediators,  CXCL5  is  able  to  lead  to  the  observed  mechanical 
hypersensitivity post UVB.  
Despite the existence of many studies exploring UVB induced changes, the central neuronal 
consequences and correlates of a peripheral hypersensitivity have not been examined. Thus, 
the question of what happens at spinal levels in the face of pure peripheral enhanced drives 
remains open. Here, this chapter aims to investigate spinal neuronal activity in this model and 
further characterise and explore this role of CXCL5 in the mediation of hypersensitivity. 177 
 
5.2.   Methods 
5.2.1.  UVB irradiation - rats: 
Adult male Sprague-Dawley rats, between 210-240g, were obtained from the UCL Biological 
Services Unit. All procedures were approved by the UK Home Office, and were performed in 
accordance with the guidelines provided by the International Association for the Study of 
Pain. 
Rats were anaesthetised in an induction box using 4% isoflurane (carried in 66% N2O and 
33% O2). Once the rat was fully unconscious and was checked for absence of reflexes (by 
pinching the toes of the hindpaw) they were placed on-to a heat mat and fully covered with 
UV resistant material. The plantar surface of the right hindpaw was then exposed, and placed 
at  a  set  distance  of  2cm  away  from  the  UVB  light  source,  ensuring  only  this  area  was 
irradiated. All experiments were conducted using a Dermfix 1000MX UV-B Lamp fitted with a 
9 Watt fluorescent UVB tube, λ max = 311nm. The irradiance of the lamp was determined 
using a calibrated photometer (Solartech Inc Solarmeter 6.2 UVB Meter, Merlin Lazer). This 
reading  was  used  to  determine  the  length  of  time  required  to  deliver  a  set  dose  of 
1000mJ/cm2. The dose was chosen on the basis of previous studies, which have found this to 
have  the  greatest  effect  without  resulting  in  any  signs  of  skin  damage  such  as  blistering 
(Bishop  et  al.  2007).  Post  irradiation  the  rats  were  placed  in  a  temperature  controlled 
recovery box until the effects of the anaesthetic were completely reversed.  
 
5.2.2.  In vivo electrophysiology: 
24-30 hours post UVB irradiation, rats were anaesthetised and in vivo electrophysiological 
recordings were performed as previously described, to obtain baseline responses to electrical 
and natural stimuli. Once stable responses of an individual WDR cell had been characterised, 
further cells  from the  same  animal  were sampled to  obtain  a  thorough population  study. 
Additional cells were contributed by Dr Shafaq Sikandar as part of a collaborative study. 
 
5.2.3.  Receptive field mapping: 
Receptive fields on the plantar hindpaw were mapped for each cell with an 8g vF, using the 
methods detailed in (Suzuki et al. 2000). The stimulus was applied repeatedly around the area 178 
 
of  baseline  testing  until  firing  was  depleted  below  0.5Hz.  Applications  were  made  at  30s 
intervals to ensure no wind up was elicited from the testing sequence. The observed receptive 
field was marked onto a standard diagram of the hindpaw and subsequently digitalised using 
a  Canon  MP610  scanner.  The  size  of  each  receptive  field  was  determined  using  ImageJ 
software and calculated as a percentage of the total area of the hindpaw. 
 
Figure 5-2 Receptive field mapping. Receptive fields of single DH LV WDR neurones were mapped using an 8g 
vF. The exact size was measured using ImageJ software. 
 
5.2.4.  UVB irradiation - humans: 
Experiments were conducted in 10 healthy human volunteers aged between 22-32 years old. 
Individuals were familiarised with the experimental protocol before hand and gave written, 
informed consent. The study was approved by The Kings College Research Ethics Committee. 
All subjects were free from pain and medical conditions which may otherwise interfere with 
the results of the study. They were advised they must avoid pain medication such as NSAIDs 
and caffeine in the 24 hours prior to the study. This was particularly important as NSAIDs 
have been shown to be effective against the sensory changes elicited by UVB. 
Volunteers were irradiated in a similar protocol as described for the animals. However, the 
dosing  was  calculated  on  an  individual  basis  depending  largely  on  skin  type.  An  initial 
screening was conducted on each subject to determine their MED; this is defined as the time 
required to produce a uniform reddening of the area at 24 hours post irradiation. 3 times the 
MED was then used for the final experiment to irradiate an area of 16x16mm on the volar 179 
 
forearm, the surrounding area was covered with a UV resistant material to ensure uniform 
burn. 
 
5.2.5.  Mapping area of secondary hyperalgesia: 
In  line  with  the  animal  experiments,  subjects  were  then  tested  at  24-30  hours  post  UVB 
irradiation. Initially, the  edges  of the  primary burn  site  were marked on  the  skin and an 
acetate template was used to mark a spider probe map at 1cm increments along eight spokes 
(oriented at 45 intervals) radiating out from the primary area (shown below). Once marked 
on the skin subjects were assessed for the development of both pinprick hyperalgesia and 
dynamic brush evoked allodynia. Pinprick hyperalgesia was mapped using a 256mN probe 
(Pinprick,  MRC  Systems  GmbH,  Heidelberg,  Germany.  0.2mm  diameter)  -  an  example 
stimulation  was  given  on  the  contralateral  arm  in  order  for  the  subject  to  familiarise 
themselves with the sensation. Beginning at 8cm from the centre of the map the stimulation 
was repeated at 1cm intervals a long each spoke towards the treated area, and the subject was 
requested to report when this sensation changed. This was usually described as a sharper, or 
more intense pricking sensation. The stimulus was only applied once to each point, for around 
1s. The point at which this change was reported was marked on a standard spider probe map 
diagram. Adjacent spokes were connected to create 8 triangles, for which the individual areas 
could be calculated (area of each triangle = 1/2(length a x length b) sin45); the summation of 
these, minus the primary area (256mm2), gave the total area of secondary hyperalgesia.  
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Figure  5-3  Mapping  the  area  of  secondary  hyperalgesia.  A  spider  probe  map  consists  of  8  radial  paths 
projecting out from the primary treated area. The area of treatment was 256mm2 in the middle of the map and 
mechanical stimulation began 8cm from the edge of the burn and continued towards the centre at 1cm intervals 
until the subject reported a change in sensation. 
 
5.2.6.  Human Quantitative Sensory Testing: 
Once it was determined if the burn had elicited any secondary changes, full QST profiling was 
performed as  previously described (Chapter  2.4) on  the  primary irradiated site, and as a 
control  on  the  contralateral  ventral  forearm.  In  addition  to  the  standard  QST  protocol, 
subjects were asked for numerical ratings (0-100) to 35C, 40C and 45C. 
 
5.2.7.  Administration of CXCL5: 
To  assess  the  effects  of  CXCL5,  a  previously  identified  mediator  of  UVB  inflammation,  in 
rodents  we  used  an  intraplantar  injection  of  3g  dissolved  in  0.9%  saline  (Nb.  Control 
experiments found that intraplantar injection of saline alone causes no significant changes 181 
 
monitored over a time period of 4 hours post injection). This experiment was only carried out 
in rodents, and not human subjects. 
Once a stable cell had been identified and characterised, with at least 3 rounds of baseline 
testing, a Hamilton syringe was used to inject the solution into the receptive field of the cell, 
distal from the point at which natural stimuli were applied.  The train of electrical and natural 
stimuli was repeated 30 minutes post injection, and subsequently every 30 minutes up to 4 
hours post injection. 
 
5.2.8.  Statistical analysis: 
All analysis was undertaken using SPSS software (IBM SPSS Statistics v21). Data was assessed 
for normality using the Kolmogorov-Smirnov test to determine further methods of analysis. 
Electrophysiological data was analysed using either an unpaired t-test or a 2 way ANOVA 
accordingly. Psychophysical data, with the exceptions of HPT and CPT, was logged and re-
tested for normality. A paired t-test or 2 way ANOVA was then carried out. HPT and CPT were 
found to be normal without logging, and thus the raw data was used for analysis with a paired 
t-test. All graphs were plotted to show the mean  SEM. 
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5.3.   Results 
5.3.1.   UVB – In vivo electrophysiology 
Using  objective  electrophysiological  recordings,  LV  WDR  cell  responses  to  applied  stimuli 
were found to be significantly enhanced when compared to responses observed in naïve rats 
to the same stimuli, across a range of natural and electrical stimuli. These changes are akin to 
both mechanical and thermal hypersensitivity observed in previous behaviour experiments, 
suggestive of an exclusive peripheral sensitisation. The UVB dose (1000mJ/cm2) and time 
point (24-30 hours post irradiation) were selected from previous studies (Bishop et al. 2007; 
Dawes et al. 2011) suggesting these resulted in the maximal hypersensitivity.  
5.3.1.1.  UVB  irradiation  significantly  enhances  both  innocuous  and  noxious 
mechanically evoked WDR cell responses in comparison to naïve animals 
24-30  hours  post  UVB  treatment,  evoked  responses  to  dynamic  brush  were  significantly 
enhanced from 331.1  36.6 to 667.6 37.7 action potentials/ 10s (figure 5-4; p= 0.000), 
whilst neuronal responses to low vF forces (8g and 15g) were larger but not significantly 
changed; thus suggesting that different mechanisms could be involved in the sensitisation of 
these  two  stimuli.  Responses  to  higher  vF  (26g  and  60g),  which  are  usually  considered 
noxious in behavioural experiments, were significantly increased by 49 and 54%, respectively 
(figure 5-4; p= 0.001, 0.000).  
5.3.1.2.  UVB irradiation significantly enhances both innocuous and noxious thermally 
evoked WDR cell responses in comparison to naïve animals 
Increased firing of WDR cells was observed in response to all temperatures tested post UVB 
treatment (figure 5-5; p< 0.000). Although this was not shown to be statistically significant at 
35C, there is still an obvious increase from 178  30.8 to 456  45.1 action potentials/10s. 
The greatest increase was seen just below behavioural threshold, at 40C, where an increase 
of 186% in the firing was observed (p= 0.011). Firing to supra threshold stimuli (45C and 
48C)  was  also  significantly  enhanced  by  115%  and  81%,  respectively  (p<  0.000,  0.000). 
Overall, there appeared to be a parallel shift in the stimulus-response curves, indicative of a 
peripheral sensitisation. 
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Figure  5-4  Effects  of  UVB  irradiation on mechanically  evoked  WDR  cell  responses.  Using  the  protocol 
described in chapter 5.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
mechanical stimuli, including brush and graded vF, applied to the receptive field for 10s, before and after UVB 
irradiation.  24-30  hours  post  treatment  both  a)  dynamic  brush  and  b)  noxious  vF  evoked  responses  were 
elevated when compared to naïve animal baselines (brush p=0.000; 26g p= 0.001; 60g p< 0.000). There is a clear 
coding of mechanical stimuli in naïve animals, which remains in UVB treated animals. n= 38 
 
Figure  5-5  Effects  of  UVB  irradiation  on  thermally  evoked  WDR  cell  responses.  Using  the  protocol 
described in chapter 5.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
thermal stimuli applied to the receptive field for 10s, before and after UVB irradiation. a) 24-30 hours post 
treatment evoked responses to both innocuous and noxious temperatures were elevated when compared to 
naïve animal baselines (Overall 2-way ANOVA p< 0.000; 40C p= 0.011, 45C p< 0.000, 48C p< 0.000). There is a 
clear coding of thermal stimuli in naïve animals, which remains post UVB.  n= 37 184 
 
5.3.1.3.  UVB irradiation significantly increases electrically evoked input responses of 
WDR cells in comparison to naïve animals 
Overall, no significant difference was observed between UVB treated and naïve animals, with 
regards to the number of action potentials elicited from each fibre type (figure 5-6). Although 
a small difference may be noted in C fibre and PD count – increasing from 405  35.7 to 473  
41.9  and  348    37.6  to  430    38.4,  respectively,  suggestive  of  a  small  degree  of  fibre 
sensitisation. WU also remained unchanged – the enhanced responses of the spinal neurones 
remained the same as in normal animals but superimposed upon a greater initial response 
(figure  5-6).  Conversely,  C-fibre  thresholds  were  significantly  lowered  and  input  was 
significantly enhanced by 125% (figure 5-6; p= 0.04, 0.01), which is likely due to a peripheral 
sensitisation reducing thresholds and enhancing pre-synaptic activity of the neurones. 
Figure  5-6  Effects  of  UVB  irradiation  on  electrically  evoked  WDR  cell  responses.  Using  the  protocol 
described in chapter 2.2 and 5.2 in vivo single unit recordings of LV WDR cells responses were recorded to 
electrical stimuli pre and post UVB irradiation.  Transcutaneous electrical stimulation was used to measure the 
input and wind up, in addition to calculating the responses driven by different fibre types – depending on the 
latency. 24-30 hours post treatment a) C-fibre thresholds were significantly lower in UVB treated animals (p= 
0.04); b) there were no significant effects on electrically evoked A, A, and C fibre mediated transmission, nor 
post-discharge; c) electrically induced input was significantly increased (p= 0.01), d) however wind up remained 
statistically unchanged (graph shows a small sample of example cells) . n= 26 185 
 
5.3.1.4.  UVB irradiation has no effect on receptive field size of WDR cells in comparison 
to naïve animals 
8g  vF  receptive  field  size  of  LV  WDR  cells  in  UVB  treated  animals  was  not  found  to  be 
significantly different from the average receptive field size observed in naïve animals (figure 
5-7). This is consistent with the evoked responses, which were suggestive of a peripheral, 
rather than central sensitisation. 
 
Figure 5-7 Effects of UVB irradiation on receptive field size of WDR cells. Using the protocol described in 
chapter 5.2 the receptive field was mapped using an 8g vF filament. 24-30 hours post treatment a) there was no 
significant effect on the size of receptive field in comparison to naïve animals. n= 16 186 
 
5.3.2.  UVB – Human Quantitative Sensory Testing 
Using  a  standardised  QST  procedure,  human  subjects  were  also  found  to  exhibit  sensory 
changes post UVB treatment, such as mechanical and thermal hypersensitivity, once again 
indicative of a peripheral sensitisation. 
5.3.2.1.  UVB irradiation significantly reduces MPT and increases numerical ratings to 
innocuous and noxious punctate stimuli 
At  the  same  time-point  as  the  rodent  studies,  24-30  hours  post  treatment,  there  was  a 
significant drop in the average 50% pain threshold to pinprick stimulation from 103.9mN  
16mN to 14.9mN  3.7mN within the irradiated area (figure 5-8; p< 0.000). Ratings to both 
sub and supra-threshold mechanical stimuli were increased, whilst perceptual WU remained 
unchanged (figure 5-8; p< 0.000). 
Figure  5-8  Effects  of  UVB  irradiation  on  psychophysical  MPT  and  mechanical  NRS  ratings.  Using  the 
protocol described in chapter 5.2 standardised QST was undertaken to determine the subject’s mechanical pain 
threshold (MPT), in addition to obtaining numerical ratings (NRS) to graded mechanical stimuli and measuring 
the wind up ratio (WUR) to repetitive mechanical stimulation. a) Average MPT was significantly lower in UVB 
treated  skin  in  comparison  to  pre-irradiation  baselines  (p<  0.000).  b)  NRS  rating  to  dynamic  brush  was 
unchanged, whereas ratings to 32mN and 256mN were significantly increased (Overall 2 WAY ANOVA p< 0.000; 
32mN p< 0.000, 256mN p= 0.004). c) Wind up was unaffected. n= 10 187 
 
5.3.2.2.  UVB irradiation causes a significant primary thermal hypersensitivity 
Average HPT was also significantly reduced in the treated area from 45  0.89 C to 37.4  0.5 
C (figure 5-9; p< 0.000). In line with the rodent data, ratings to both sub and supra-threshold 
temperatures  were  significantly  enhanced  (figure  5-9;  p,  0.000).  Interestingly,  a  cold 
hypersensitivity was also observed, as average CPT was raised from 10.1  3.5 C to 18.5  2.8 
C (figure 5-9; p= 0.022). 
 
Figure 5-9 Effects of UVB irradiation on psychophysical HPT, thermal NRS ratings and CPT. Using the 
protocol described in chapter 5.2 standardised QST was undertaken to determine the subject’s heat and cold 
pain  thresholds  (HPT/CPT),  in  addition  to  obtaining  numerical  ratings  (NRS)  to  graded  thermal  stimuli.  a) 
Average  HPT  was  significantly  reduced  in  UVB  treated  skin  in  comparison  to  pre-irradiation  baselines  (p< 
0.000). b) NRS ratings to previously innocuous and noxious temperatures were significantly increased (Overall 2 
WAY ANOVA p< 0.000; 35C p= 0.006, 40C p< 0.000, 45C p= 0.038). c) CPT was also significantly elevated (p= 
0.022). n= 10 188 
 
5.3.2.3.  UVB irradiation causes negligible secondary changes 
The area of secondary hyperalgesia was assessed prior to testing of sensory changes in the 
primary, using a 256mN probe. A relatively small area surrounding the burn was reported by 
all  subjects  as  being  more  sensitive  (figure  5-10).  Although  secondary  hyperalgesia  is 
generally  attributed  to  central  facilitations,  an  area  of  this  size  is  more  likely  driven  by 
infiltration of inflammatory mediators outside the treated area.  
 
Figure 5-10 The area of secondary hyperalgesia induced by UVB irradiation. As described in chapter 5.2 the 
area of secondary hyperalgesia was mapped with a 256mN probe. a) 24-30 hours post UVB irradiation a small 
area (380.3 mm2) of secondary hyperalgesia was observed in 9/10 subjects. b) The area is negligible across all 
subjects. 189 
 
5.3.2.4.  Sensory profiles post UVB irradiation illustrate a non specific hypersensitivity. 
Full  sensory  profiling  using  a  standardised,  comprehensive  QST  procedure  confirmed  a 
generalised sensitisation in the primary burn area across a number of modalities including: 
CPT, HPT, MDT, MPT, MPS and PPT. Pinprick and thermal hypersensitivity are previously well 
documented, however cold and blunt pressure hypersensitivity are new findings (figure 5-
11). 
 
Figure 5-11 Somatosensory changes in UVB irradiated skin. Using the protocol described in chapter 2.4 full 
QST profiling was undertaken. A variety of parameters were tested both pre and post UVB, the magnitude of the 
changes are expressed here as Z-scores which highlight specific gains or loss in function. Hypersensitivity to 
cold, heat, pinprick and pressure are demonstrated here by the gain of function in CPT, HPT, MPT, MPS and PPT. 
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5.3.3.   UVB induced somatosensory changes in rats and humans show considerable 
overlap 
 
Table 5-6 Comparison of animal and human characterisation. a) There is a remarkable similarity in the 
sensory changes post UVB across species, highlighting the translational nature of this model. Both animals and 
humans show heightened responses to mechanical stimuli and thermal stimuli, whilst wind up is unchanged. 
Fibre  count  was  only  assessed  in  the  animal  model,  this  term  refers  to  a  change  in  the  number  of  action 
potentials elicited from each fibre type. UVB reduced the electrical c-fibre threshold used to elicit the fibre count. 
Additionally, there was no increase in WDR receptive field size to 8g vF, or an area of secondary hyperalgesia in 
human subjects. The only difference noted between species is regarding dynamic brush, whereby WDR evoked 
neuronal responses were increased, whilst there was no changed observed in human perception.  
   
Stimulus 
Hypersensitivity 
Animal  Human 
Brush   No change 
Subthreshold Mechanical   
Suprathereshold Mechanical   
Subthreshold Thermal   
Suprathreshold Thermal   
Input   
Wind up  No change  No change 
Fibre count  Reduction in C fibre 
threshold 
Not tested 
Receptive field/ Area of secondary 
hyperalgesia 
No change  No change 191 
 
5.3.3.1.  Lowered HPT in human volunteers post UVB corresponds to the number of 
action potentials evoked in WDR cells 
When comparing the animal and human data in terms of the neuronal activity produced by 
temperatures  which  correspond  to  the  HPTs,  before  and  after  UVB,  a  remarkable 
correspondence can be observed (figure 5-12). Thus, it was seen that the number of action 
potentials evoked by 45C, the average human HPT under normal conditions was 641, very 
similar to the 614 action potentials that would be evoked by 37.4C, the reduced human HPT 
post UVB. 
 
Figure 5-12 Overlap in animal and human data. Comparing changes in thermally evoked neuronal activity to 
the shift it human HPT, post UVB irradiation, reveals a remarkable similarity a) Pre UVB average human HPT was 
45C, which corresponds to 641 action potentials/ 10s, 24 hours post UVB irradiation this dropped to 37.44 C, 
which corresponds to 614 action potentials/ 10s. 192 
 
5.3.4.  CXCL5 – In vivo electrophysiology 
Using  objective  electrophysiological  recordings,  LV  WDR  cell  responses  were  found  to  be 
significantly  enhanced  post  intraplantar  administration  of  3g  CXCL5,  when  compared  to 
baseline responses across a range of natural and electrical stimuli. These data mimicked the 
changes  seen  post  UVB  treatment,  as  a  clear  mechanical  and  thermal  hypersensitivity  of 
comparable magnitude was elicited. These results support the notion that CXCL5 may be a 
key mediator of UVB induced sensitisation. 
5.3.4.1.  Intraplantar  injection  of  CXCL5  significantly  enhances  both  innocuous  and 
noxious mechanically evoked WDR cell responses in comparison to baseline responses 
Dynamic brush responses were significantly elevated from 331.1 36.6 to 632.6 76.7 action 
potentials/  10s  post  CXCL5  administration  (figure  5-13;  p=  0.002).  Responses  to  both 
innocuous  and  noxious  vF  were  also  significantly  increased  from  baseline,  suggesting  a 
widespread sensitisation of neurones encoding both modalities (figure 5-13; p= 0.002). 
 
Figure 5-13  Effects  of 3g intraplantar CXCL5 on mechanically evoked neuronal responses. Using the 
protocol described in chapter 5.2 in vivo single unit recordings of LV WDR cells responses were recorded to a 
range of mechanical stimuli, including brush and graded vF, applied to the receptive field for 10s, before and 
after intraplantar CXLC5. a) Dynamic brush responses were significantly enhanced post CXCL5 (p ≤ 0.001). b) 
Innocuous and noxious punctate mechanically evoked responses were also significantly increased (Overall 2 
WAY ANOVA p= 0.002; 2g p= 0.031, 8g p= 0.001, 15g p= 0.003, 26g p= 0.002, 60g p= 0.012). n = 10 193 
 
5.3.4.2.  Intraplantar  injection  of  CXCL5  significantly  enhances  thermally  evoked 
baseline neuronal responses in naïve animals 
There was an increase in firing to all temperatures assessed post CXCL5 treatment (figure 5-
14; p≤ 0.001). The greatest change was seen at 40C, where there was an increase in number 
of action potentials/10s of 235% (p≤ 0.001). As with UVB this is suggestive of sensitisation of 
peripheral neurones.  
 
Figure 5-14 Effects of 3μg intraplantar CXCL5 on thermally evoked neuronal responses. Using the protocol 
described in chapter 5.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
thermal stimuli applied to the receptive field for 10s, pre and post intraplantar CXCL5. a) Innocuous and noxious 
thermally evoked responses were significantly increased post CXCL5 (Overall 2 WAY ANOVA p≤ 0.001; 35C p= 
0.001, 40C p≤ 0.001, 45 p≤ 0.001, 48C p= 0.002). n = 10 194 
 
5.3.4.3.  Intraplantar injection of CXCL5 potentiates electrically evoked input in naïve 
animals 
Overall there was no significant effect of CXCL5 on the number of action potentials elicited 
from  each  fibre  type,  though  a  small  increase  can  be  noted  in  both  the  C  fibre  and  post 
discharge  count  –  from 405.6    35.9 to  488.8   74.8 and 348.9   37.6 to  460.9   112.8, 
respectively (figure 5-15). However, input was increased from 268.4  48.6 to 705.6  152.9, 
strongly suggesting a sensitisation of peripheral, or central neurones (figure 5-5; p= 0.005). 
 
Figure 5-15 Effects of intraplantar CXCL5 on baseline electrical neuronal responses. Using the protocol 
described in chapter 2.2 and 5.2 in vivo single unit recordings of LV WDR cells responses were recorded to 
electrical stimuli pre and post intraplantar CXCL5.  Transcutaneous electrical stimulation was used to measure 
the input and wind up, in addition to calculating the responses driven by different fibre types – depending on the 
latency. a) There were no significant effect on electrically evoked Aβ ,Aδ, and C fibre mediated transmission, nor 
post-discharge. b) Electrically induced wind up was unaffected, although input was significantly increased (p= 
0.005). n = 10 195 
 
5.3.4.4.  Intraplantar injection of CXCL5 in naïve animals mimics UVB irradiation 
When compared with the  previous results  from UVB irradiated rats, the  sensory changes 
induced  via  intraplanter  CXCL5,  are  very  similar  (figure  5-16).  The  magnitude  is  also 
comparable, supporting the theory that CXCL5 is important in UVB induced sensitisation. 
 
Figure 5-16 Sensitisation of WDR cell responses post CXCL5 to a) brush; b) von Frey and; c) thermal stimuli 
are comparable in magnitude to those evoked by UVB. Using the protocol described in chapter 5.2 in vivo single 
unit recordings of LV WDR cells responses were recorded to a range of mechanical and thermal stimuli, including 
brush and graded vF and water jets, applied to the receptive field for 10s. These were compared for control 
animals with no treatment, and post UVB/ intraplantar CXCL5. 196 
 
5.4.   Discussion 
This  is  the  first  study  to  examine  the  central,  spinal,  neuronal  consequences  of  UVB 
irradiation. In this study WDR cell responses were measured 24-30 hours post UVB and after 
intraplantar  administration  of  CXCL5.  Additionally,  full  QST  was  undertaken  on  healthy 
human  volunteers  24-30  hours  post  UVB.  The  key  findings  were  that  UVB  is  a  reliable 
translational model of hypersensitivity, producing similar changes in animals and humans. 
The  model  induces  a  strong  peripheral  sensitisation,  with  little  apparent  contribution  of 
central mechanisms. Finally, CXCL5 is able to mimic the sensory changes seen post UVB, and 
this reinforces the idea that this is a strong candidate as a key mediator of UVB induced 
inflammatory hypersensitivity and may have relevance in chronic pain states. 
 
5.4.1.  UVB irradiation produces a consistent mechanical and thermal hypersensitivity 
in animals and humans, which can be measured from WDR cells, and with QST 
UVB consistently led to a strong mechanical and thermal hypersensitivity in both animals and 
humans  24-30  hours  post  irradiation.  This  is  the  first  full  characterisation  of  WDR  cells 
responses post UVB using in vivo electrophysiology. Evoked activity of spinal WDR neurones 
was enhanced to dynamic brush and a range of mechanical forces and temperatures. QST 
revealed a drop in both MPT and HPT, in addition to increased numerical pain ratings to both 
sub and supra threshold stimuli. Thus confirming, using objective assessment measures, the 
induction  of thermal  and mechanical  hypersensitivity as  previously  shown  in behavioural 
studies (Benrath et al. 2001; Harrison et al. 2004; Davies et al. 2005; Bishop et al. 2007; 
Bishop  et  al.  2009;  Bishop  et  al.  2010).  Furthermore,  the  results  validate  the  ability  to 
measure hypersensitivity (associated with inflammation) from activity evoked in WDR cells 
under anaesthesia. This enhanced responsivity has also been shown in alternative models of 
inflammation such as CFA, thus suggesting WDR cells in the spinal cord, the primary relay site 
of  somatosensory  information,  are  useful  for  studying  the  consequences  and  further 
characterisation of such models (Marchand et al. 2011).  
Also in agreement with previous behavioural reports, the  evoked  changes  in the  primary 
irradiated  area  are  similar  in  both  species  (Bishop  et  al.  2007;  Bishop  et  al.  2009). 
Interestingly, there is a strong observational parallel between the animal and human thermal 
responses.  Pre  UVB  the  average  human  HPT  was  45C,  which  corresponds  to  641  action 197 
 
potentials/ 10s, 24 hours post UVB irradiation this dropped to 37.44 C, which corresponds to 
614  action  potentials/  10s;  that  is  to  say,  the  number  of  action  potentials/10s  which 
correspond to the threshold is very similar both at baseline and post UVB treatment. This was 
also  found  in  the  previous  studies  detailed  in  this  thesis  and  is  particularly  important  in 
support  of the  value  of animal  models. Identification  of a  possible designated ‘number of 
action potentials’ which corresponds to human pain thresholds would be a valuable tool for 
future research and would enhance translation of knowledge from animals studies to humans. 
This may help bridge the gap between the species and allow better predictions to be made 
from pre clinical animal data. 
The  only  discrepancy  between  the  animal  and  human  data  lies  in  the  dynamic  brush 
responses. There was a marked increase in WDR cell activity in response to dynamic brush 
post UVB, whereas reports of brush eliciting pain in human subjects were modest. Conversely, 
previous studies in humans have suggested there is an element of brush-evoked allodynia in 
both the primary and secondary areas (Bishop et al. 2009; Gustorff et al. 2011; Ortner et al. 
2012). However, of note, these studies use a larger area of irradiation, which may result in 
small amounts of subthreshold spontaneous activity that could drive some central changes. It 
is  clear  in  this  study  from  the  subject  reports  that  there  is  a  negligible  brush  evoked 
hypersensitivity, in comparison to models such as capsaicin cream (Bishop et al. 2009).  
It is possible that the increasing response of WDR cells to dynamic brush does not necessarily 
equate to a perceptual pain in volunteers (or rats). It is important to note that WDR cells, by 
their very nature, are characterised by a response to dynamic brush in naïve animals, since 
they  receive  tactile  input  from  both  A  and  low  threshold  C  fibres  (Andrew  2010).  This 
suggests  that there must be  mechanisms in higher centres which allows this  signal  to be 
‘filtered out’. While many A afferents travel in the dorsal column, bypassing the spinal cord, 
to convey the sensation of touch, the A input (and low threshold C fibres) to WDR cells may 
in fact have very little contribution towards normal tactile sensations (Kandel et al. 2000). 
This process allowing the selection of which inputs are eventually perceived is not necessarily 
altered  even  with  these  enhanced  responses  post  UVB.  Therefore,  even  if  there  was  a 
peripheral sensitisation, progressive tactile hypersensitivity, or even small central changes 
occurring,  these  may  not  result  in  the  perception  of  a  painful  sensation.  It  is  unknown 
whether low threshold C fibres express chemoreceptors, however should this be the case, it is 
certainly  possible  that  they  may  be  sensitised  by  UVB.  While  brush  stimuli  may  become 198 
 
painful  in  patients  with  neuropathies  whereby  function  of  sensory  nerves  are  altered  by 
disease or a lesion, leading to changes in the processing of the tactile input to WDR cells, may 
result  in  allodynia  this  does  not  necessarily  occur  here.  In  the  case  of  a  peripheral 
sensitisation of low threshold C fibres, perceptual changes may not develop in the absence of 
any central modifications. Given that any alterations  in  sensitivity to brush stimuli  in the 
human subjects are not sufficiently large to alter perception, it may be the same in rats that 
this increase in WDR cell activity does not necessarily equate to a sensation of ‘pain’.  
A second possibility that cannot be excluded is the engagement of different mechanisms in 
rats and humans. This could include the development of centrally mediated brush allodynia, 
or a progressive tactile hypersensitivity, in the animals but not humans. One key difference 
between the animal and human studies is that while the humans are unlikely to have further 
strong stimuli come into contact with their burn during the 24 hours between irradiation and 
tests, the animals continue to walk around during this time.  Furthermore, irradiating the 
whole  hindpaw  is  proportionally  speaking  a  much  larger  area,  which  could  lead  to  some 
spontaneous pain. These differences could lead to a level of afferent input strong enough to 
evoke some central changes. However, since there is no association with any increase in basal 
c-fos, in addition to no other signs of central sensitisation in this study, this explanation seems 
unlikely (Bishop et al. 2007).  On the other hand, progressive tactile hypersensitivity has been 
associated  with  inflammation  and  thus  may  be  one  possible  explanation  (Ma  and  Woolf 
1996).  The  phenomenon  is  underpinned  by  phenotypic  changes  in  the  primary  afferents, 
rather than requiring central changes. Further behavioural studies, or recordings from PAFs 
may help further understand this discrepancy. 
Overall using objective characterisation methods, UVB appeared to be a reliable translational 
model of inflammatory hypersensitivity, evoking similar phenotypic changes in both animals 
and humans, which can be measured using electrophysiology and QST. 
 
5.4.2.  UVB induced hypersensitivity is the result of a predominant peripheral 
sensitisation 
In this study, there was no change in the size of receptive field of WDR cells, and only a very 
modest area of secondary pinprick hyperalgesia was seen in human subjects. Wind-up was 
not altered in either species and post-discharge, a measure of enhanced evoked activity in 199 
 
spinal neurones as a consequence of wind-up, was also unaltered. Enlarged receptive fields 
and increased post discharge of neural activity are key measures of central sensitisation as a 
result of spinal cord plasticity, which may share overlapping mechanisms. The absence of 
such here implies the lack of central changes in the UVB model.  
An expansion of receptive field of second order spinal neurones indicates the recruitment of 
additional peripheral fibres, and may result from a number of possible mechanisms. It has 
been proposed that WDR cell receptive fields are composed of an inner excitatory, ‘firing 
zone’ and a surrounding low probability ‘firing fringe’ (Woolf and King 1989). Input from the 
firing  fringe  under  normal  conditions  generates  sub  threshold  excitatory  postsynaptic 
potentials  (EPSPs),  from  which  an  action  potential  cannot  be  generated  in  the  WDR  cell. 
However, when the cord is in a state of sensitisation, and thus activation thresholds are lower, 
this input is able to activate the second order neurone. Mechanisms that underpin this include 
engagement and recruitment of NMDA receptors due to enhanced activity into the spinal cord, 
in addition to being compounded by a loss of inhibitory GABAergic controls, and/or a loss of 
descending inhibition. Since  enhanced receptive  fields are sensitive to  an NMDA receptor 
block,  and  removal  of  descending  controls  can  generate  novel  receptive  fields  it  can  be 
assumed these central mechanisms are involved (Schaible et al. 1991; Ren et al. 1992).  
The mechanisms discussed above are likely to also be involved in secondary hyperalgesia, 
whereby the damaged primary area results in ongoing input into the spinal cord, unblocking 
NMDA receptors and lowering the activation threshold of spinal neurones. Activation of A 
fibres in the surrounding area then results in an increased activity in the spinal cord, which is 
perceived by the subjects as more painful than before. Since secondary punctate hyperalgesia 
can be induced in patients lacking A fibres, and a complete block of A fibres abolishes this 
symptom, it can be concluded that A fibres are the key mediators of this modality (Treede 
and Cole 1993; Ziegler et al. 1999). 
SNL and CFA are two very different forms of peripheral injury, involving damage to nerves 
and  damage  to  tissue,  respectively,  which  may  therefore  produce  modifications  to  pain 
signalling through different mechanisms; though both are associated with central changes. In 
both models signs of spontaneous or ongoing pain are present, which are further associated 
with comparable expanded RFs (Suzuki et al. 2000; Chu et al. 2004). Suzuki et al mapped RFs 
with  a  9g  vF  and  found  a  clear  increase  in  RF  size  post  SNL  surgery,  in  agreement  with 
previous studies using CCI and chronic inflammation  (Ren et al. 1992; Grubb et al. 1993; 200 
 
Cumberbatch et al. 1998; Suzuki et al. 2000). The expansion in receptive field can be blocked 
by  the  NMDA  receptor  antagonist  MK-801,  suggesting  that  such  central  mechanisms  are 
indeed involved in this phenomenon (Ren et al. 1992). Since hypersensitivity observed in the 
UVB model was previously shown to be unaltered by MK-801, and in this study there is no 
increase in receptive field size, it can be concluded this pivotal mechanism of heterosynaptic 
central sensitisation is unlikely to be present in the model (Bishop et al. 2010). 
The lack of considerable areas of pinprick hyperalgesia seen in the human studies here also 
indicates peripheral, but not central, sensitisation mediating evoked hypersensitivities. Post 
UVB there was a modest area around the burn that subjects reported as more being painful 
than normal skin; given the size (380.3mm2) it is not impossible to postulate that this is the 
consequence of a spread of inflammatory mediators outside the site of injury itself; although a 
weak  engagement  of  central  sensitisation  cannot  be  fully  discounted.  In  recent  studies 
Gurstoff and colleagues continue to find large areas of pinprick hyperalgesia (Gustorff et al. 
2013; Rössler et al. 2013), which were not replicated here. 
Despite the evidence against any central changes in both animals and humans found in this 
study, further research is required to settle this ongoing debate. Since QST still largely relies 
on  subjective  reports,  a  more  quantitative  measure  is  needed.  Capsaicin  induced  central 
sensitisation has been found to be associated with activity in the brainstem, including the 
mesencephalic pontine reticular formation (Lee et al. 2008). Human imaging of the spinal 
cord, at present, is restricted.  This central activity was found to be correlated to specifically to 
the state of central sensitisation, rather than an increased stimulus intensity. Therefore, a 
similar experiment using fMRI to examine the activity post UVB could be a useful tool in 
resolving this debate. Further pharmacological manipulation of targets implicated in central 
sensitisation may also be useful. 
As  previously  noted,  there  were  also  negligible  reports  of  dynamic  brush  evoked  pain  in 
human  volunteers.  Brush  evoked  allodynia  is  a  symptom  once  again  indicative  of  central 
changes,  resulting  from  plasticity  in  the  spinal  cord,  allowing  synaptic  plasticity,  and  the 
ability of A fibres to transmit nociceptive signals. These mechanisms therefore differ from 
those involved in secondary pinprick hyperalgesia and expanding receptive fields. In contrast 
to UVB, both capsaicin cream and thermal burn models have been found to induce primary 
and secondary dynamic brush evoked allodynia (Bishop et al. 2009). Both of these models are 201 
 
associated with central changes and therefore this is not an unexpected finding. The absence 
of this in the UVB model suggests that such changes are not present. 
 
5.4.3.  UVB produces hypersensitivity to certain electrically evoked responses 
In addition to the hypersensitivity observed in response to natural stimuli there is also a clear 
reduction  in  C  fibre  activation  threshold  and  an  increase  in  electrically  induced  input, 
indicating  hypersensitivity  to  electrically  evoked  activity  which  will  bypass  peripheral 
receptor transduction. The recordings are taken from second order neurones, and the pattern 
of changes  observed are  highly suggestive of changes  due to  sensitisation  of the  primary 
afferent, and not the secondary neurone itself. Reduced C –fibre thresholds and increased 
input were the only changes seen in the neuronal responses, with no blanket changes and 
importantly, no changes seen in wind-up or post-discharges which result from post-synaptic 
mechanisms. However, a recent paper by Weinkauf and colleagues examined the effect of UVB 
on electrical stimuli in humans and also found evidence of a sensitisation to this modality 
(Weinkauf et al. 2013). The results shown are similar to the findings presented here, in that 
both  the  electrical  pain  threshold  and  the  ratings  to  suprathreshold  electrical  stimuli 
increased by 70% (Weinkauf et al. 2013). The authors suggest that as this hypersensitivity is 
correlated  well  with  the  thermal,  but  not  mechanical,  hypersensitivity,  which  implicates 
axonal hyperexcitability. It is possible that the mediators which sensitise peripheral receptors 
such as TRPV1, also sensitise ion channels such as voltage gated sodium channels, through 
downstream intracellular mechanisms. This axonal sensitisation could certainly explain the 
increase in input seen here, and would be in line with the theory of an overriding peripheral 
sensitisation. 
Electrically evoked responses were not potentiated in the range of any of the fibres, nor was 
there any change in wind up. Given that central sensitisation may be associated with the 
recruitment of increasing numbers of afferent fibres it could be hypothesised that this would 
be reflected in these fibre counts. It has recently been shown that in the MIA model of OA, 
which has a clear central component, there is a potentiation of electrically evoked responses 
in the A fibre range which may be taken as a sign of central changes (Burnham 2012; Thakur 
2012).    A  non  significant  increase  in  A  response  has  also  been  found  after  carrageenan 202 
 
inflammation, though there is little further evidence of such changes in other models and thus 
is difficult to draw firm conclusions from the evidence available (Rahman et al. 2004). 
With regards to electrically induced wind up, it is well known that this phenomenon relies on 
the recruitment of NMDA receptors (Dickenson and Sullivan 1987; D'Mello et al. 2011). This 
mechanism is shared with central sensitisation, which has also been shown to require this 
receptor (Woolf and Thompson 1991).  Thus, if central sensitisation is induced by a particular 
model, engaging the NMDA receptor and inducing a state of hyperexcitability in spinal cord 
neurones, it may be expected that their ability to wind up is reduced as the receptor is already 
close to capacity. That is to say, since they both rely on the same receptor, it may not be 
possible for the two to occur in tandem. Given that no change in wind up was observed here, 
this may also suggest the lack of central sensitisation. 
 
5.4.4.  UVB produces a cold hypersensitivity in human volunteers 
As found in a recently published study, here a cold hypersensitivity was also noted during the 
human QST sessions. CPT was elevated post UVB from 10.0 3.5C to 18.5 2.8C. This was a 
previously  unreported  phenomenon  associated  with  UVB  inflammation.  Gustorff  and 
colleagues reported similar values, with CPT rising from 15.3 2C to 19.1 1.7C. Little is 
known  about  mechanism  underpinning  cold  hypersensitivity,  although  TRPM8  has  been 
implicated in this since KO mice have impaired development of cold hypersensitivity (Colburn 
et al. 2007; Dhaka et al. 2007). Given that the data so far indicates an overriding peripheral 
sensitisation,  it  may  therefore  be  inferred  there  is  a  peripheral  component  to  cold 
hypersensitivity. This could include the sensitisation of cold receptors, such as TRMP8 or 
TRPA1, or of ion channels on the axons of the afferent fibres.  
Since  at  least  two  studies  have  now  confirmed  the  development  of  cold  hypersensitivity 
associated  with  UVB,  it  can  be  inferred  that  this  may  be  a  useful  model  to  assess  the 
mechanisms associated with this symptom, and the respective pharmacological sensitivity. 
Cold hypersensitivity is a symptom associated with conditions such as oxaliplatin-induced 
neuropathy and has so far been difficult to model in humans (Binder et al. 2007). This finding 
is therefore important for future studies wishing to assess cold hypersensitivity. 
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5.4.5.  UVB QST profile  
Full sensory characterisation post UVB indicates a general hypersensitivity across modalities 
in the primary irradiated area. A non-specific hypersensitivity such as this is shared with 
conditions  including  complex  regional  pain  syndrome,  and  chemotherapy  induced 
neuropathic pain (Binder et al. 2007; Gierthmühlen et al. 2012). Therefore suggesting UVB 
may mimic some of the underlying mechanisms associated with these conditions, and thus 
allows them to be modelled pre clinically.   
Pinprick and heat hypersensitivity are already well documented, but sensitisation to cold and 
blunt pressure represent new findings. These have been replicated by a recent publication, 
released after the completion of the study described here (Gustorff et al. 2013). These findings 
increase the relevance of this model for future studies, since both of these symptoms are 
associated with various abnormal pain states. A study of 1236 patients with varying pain 
origins found that heightened sensitivity to blunt pressure occurred in 36% patients, and cold 
hyperalgesia  in  19%  (Maier  et  al.  2010).  Consequently,  further  characterisation  of  these 
sensory abnormalities in animals could aid the understanding of their respective underlying 
mechanisms. Additionally, drugs that alter the transduction of cold or blunt pressure stimuli 
could be screened in this model to evaluate the contribution of relevant transducers in UVB-
induced sensitisation. 
 
5.4.6.  CXCL5 produces a consistent mechanical and thermal hypersensitivity in 
animals  
The mechanisms underpinning UVB are not yet fully established, however it is generally well 
accepted that inflammation induced sensitisation is responsible for sensory changes observed 
in the primary burn area (Møiniche et al. 1993; Saadé et al. 2000; Marchand et al. 2005; 
Bishop et al. 2010). However, the exact inflammatory mediators involved in this process are 
still under investigation. Since CXCL5 is upregulated in both rats and humans post UVB it was 
hypothesised  that  it  may  contribute  towards  nociceptor  sensitisation.  Here,  intraplantar 
injection of CXCL5 led to a clear mechanical and thermal hypersensitivity. This is in partial 
agreement with behavioural data, which suggests that CXCL5 mediates mechanical, but not 
thermal,  hypersensitivity  (Dawes  et  al.  2011).  Additionally,  an  increase  in  input  also 
highlights  a  previously  unreported  electrical  hypersensitivity.  These  results  suggest  that 204 
 
CXCL5 is able to result in the sensitisation of primary afferent neurones, including peripheral 
receptors and ion channels in the axon.  
The discrepancy between the previous behavioural data and electrophysiology could be due 
to a number of reasons. Thermal hypersensitivity is tested in behaviour using the latency of 
withdrawal to a radiant heat source, which would only demonstrate a difference in reflex 
action to this temperature. Although there was a trend towards a  reduction in latency of 
withdrawal with 3g CXCL5, this was not found to be significant; it could simply be that this 
test is not sensitive enough to pick up the changes. The measure is of a reflex withdrawal, 
which occurs usually in less than 15 seconds and thus may be difficult to pick up significant, 
yet subtle differences. Since the temperature of the paw after 10-12 seconds exposure to the 
radiant heat source is unlikely to be very high, it is probable that the temperatures being 
assessed correspond to the lower temperatures examined with electrophysiology, where the 
difference is not as highly significant. Thus, if suprathreshold temperatures were assessed 
with  behaviour  a  difference  may  have  been  found.  This  emphasises  the  importance  of 
electrophysiology and the ability to assess a range of stimuli from sub to supra threshold 
(Sikandar and Dickenson 2013).  
However, since other chemokines, which may act through similar mechanisms to CXCL5, have 
been shown to result in thermal hypersensitivity and even direct sensitisation of TRPV1 it 
seems most likely that the results seen here reflect a true thermal hypersensitivity (Zhang et 
al.  2005;  Dansereau  et  al.  2008).  Assessment  of  intradermal  administration  of  CXCL5  in 
humans would be useful to further investigate the role of CXCL5 in thermal and mechanical 
hypersensitivity. 
 
5.4.7.  Chemokines such as CXCL5 are important in the development of altered pain 
states  
CXCL5  is  associated  with  infiltration  of  both  neutrophils  and  macrophages  (Dawes  et  al. 
2011). Therefore it is plausible that a release of inflammatory mediators from these immune 
cells results in sensitisation of the peripheral neurones. Additionally, chemokines have been 
shown to directly interact with neurones, via sensitisation of TRPV1 on peripheral afferents, 
as  well  as  inhibition  the  OR  (Zhang  et  al.  2005;  Zhang  and  Oppenheim  2005).  This 
interaction  between  the  nervous  and  immune  system  is  likely  to  be  involved  not  just  in 205 
 
inflammatory  pain,  as  evidence  suggests  it  may  also  play  a  role  in  neuropathic  pain 
(Marchand  et  al.  2005;  Uceyler  and  Sommer  2007).  Therefore,  chemokines  and  their 
receptors may be potential drug targets. 
CXCL5 is  already known  to  be  upregulated  in the  joints of arthritic patients, although its 
associations with other chronic pain conditions are yet to be revealed (Grespan et al. 2008). 
Since  this  study  has  highlighted  the  ability  of  the  chemokine  to  induce  a  strong 
hypersensitivity, it is possible it will be found to be associated with other inflammatory pain 
conditions. Should this be the case, these basic mechanistic studies may have identified a new 
drug target for inflammatory pain. Blocking CXCL5 with a neutralising Ab does indeed reduce 
UVB induced hypersensitivity, though due to the high levels of redundancy in the roles of 
most chemokines, it is more logical to target the receptor; in this case CXCR2. This receptor 
also binds CXCL1 and CXCL8 and thus blocking the receptor would mediate the action of all 
three  inflammatory  chemokines.  In  fact,  antagonism  of  CXCR2  reduces  hypersensitivity 
associated with both carrageenan and CFA, indicating the importance of this receptor in the 
development  of  inflammatory  induced  sensitisation  (Cunha  et  al.  2008;  Manjavachi  et  al. 
2010). 
 
5.4.8.  CXCL5 evokes similar sensory changes to UVB 
Using in vivo electrophysiology we measured evoked responses of spinal neurones to a range 
of natural and electrical stimuli post UVB and post intraplantar CXCL5. The changes seen in 
both conditions  show  a  considerable  similarity across all modalities, i.e. a  potentiation  of 
thermally-evoked and mechanically evoked activity with little effect on electrically-evoked 
responses. The only discrepancy is seen around the lower, behaviourally innocuous vF. It is 
feasible that this may be due to the dose of CXCL5 used in our study, as it is  higher than 
naturally  upregulated  levels  post  UVB.  Therefore  this  may  induce  a  stronger  immune 
response with subsequent hypersensitivity. The similarities in changes to evoked measures 
post  UVB  and  CXCL5  suggest  an  analogous  underlying  biological  mechanism.  Thus  this 
electrophysiological  evidence  supports  the  theory  that  CXCL5  is  a  key  mediator  of  UVB 
induced inflammation. 
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5.5.   Concluding remarks 
Overall using objective characterisation methods, UVB appeared to be a reliable translational 
model of peripheral sensitisation, evoking similar phenotypic changes in both animals and 
humans, which can be measured using electrophysiology and QST. Furthermore, in animals 
CXCL5 produces a remarkably similar set of alterations, confirming its place on the list of 
strong candidate molecules for mediating UVB induced hypersensitivity. 
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6.  UVB Rekindling 208 
 
6.1.   Introduction 
The previous chapters of this thesis have focused on the development and characterisation of 
possible reliable, translational models of chronic pain. As previously mentioned, although it is 
one of the most widely recognised and frequently used, the capsaicin cream model has a 
number of drawbacks with regards to its true clinical relevance. On the other hand the newer 
model  of  UVB  irradiation  could  begin  to  closer  reflect  clinically  meaningful  mechanisms. 
However, it was concluded in the last chapter that this model is mainly underpinned by a 
peripheral sensitisation, and whilst this is useful for exploring these mechanisms alone, most 
patients who suffer from chronic pain will most likely have numerous overlapping peripheral 
and central mechanisms contributing to their symptom profiles (Baron 2006; Gwilym et al. 
2009; Latremoliere and Woolf 2009; Thakur et al. 2012). 
Central sensitisation differs substantially from peripheral sensitisation, both in terms of the 
location and molecular mechanisms that underpin the phenomenon and in its manifestation. 
As such, a model encompassing both peripheral and central changes is likely to best reflect 
certain  underlying  aetiologies  relevant  to  patients.  Therefore,  the  continuation  in 
development of translational models is required to further bridge the gap between preclinical 
and clinical research - ensuring that models continue to approach more and more relevant 
mechanisms  and  in  the  hope  of  eventually  creating  particular  models  that  closely  reflect 
specific individual chronic pain conditions. This chapter explores the use of electrophysiology 
and QST in order to establish and characterise UVB rekindling as a translational model of 
inflammatory pain. 
Given that UVB irritation produces such clear somatosensory changes, which are not only 
apparent in both rodents and humans, but also may reflect clinically relevant inflammatory 
mechanisms, it is logical to build on and further explore the potential of this model. It is well 
established  that  models  of  peripheral  sensitisation  and  ongoing  activity,  may  lead  to  a 
subsequent central sensitisation given adequate levels of stimulation (Latremoliere and Woolf 
2009; Baron et al. 2013). However, it has been discussed in the previous chapter that UVB is 
unlikely to  produce  a  large  enough peripheral  drive on  its own  to  establish, or maintain, 
central changes. Coupled with a second stimulus on the other hand, it may be possible to 
induce  a  state  of  central  sensitisation.    In  fact,  other  models  have  already  explored  the 
possibility of combining a heat rekindling method in order to enhance central sensitisation. 209 
 
6.1.1.  Heat rekindling enhances capsaicin cream induced central sensitisation leading 
to robust secondary mechanical hyperalgesia 
The central aspects of the pain pathway can be sensitised through a range of different forms 
of functional, chemical, and structural plasticity. The hallmarks of such central sensitisation 
include  mechanical  hyperalgesia  and  allodynia/  mechanical  and  brush  evoked 
hypersensitivity  in  the  secondary  area  –  i.e.  an  area  adjacent  to  that  which  received  the 
original treatment. This may also be thought of as an area outside the inner excitatory ‘firing 
zone’ of the neurones in the treated area. Stimuli to this zone are only able to evoke activity 
when  the  spinal  neurones  are  sensitized.  Any  model  that  induces  central  sensitisation  is 
therefore characterised by evoking clear signs of inducing hypersensitivity in this secondary 
area. As reported in the first chapter, the use of capsaicin cream alone is believed to result in a 
strong peripheral sensitisation, along with the induction of a degree of central sensitisation 
(O'Neill et al. 2012). However, it is apparent that the symptoms generated by this model, 
including secondary mechanical hyperalgesia, are smaller than those seen with intradermal 
injection of capsaicin.  
The idea of strengthening these changes with heat rekindling was therefore pioneered by 
Petersen and Rowbotham. The colleagues found that by combining the chemical stimuli with a 
physical  stimuli  (45C  for  5  minutes,  0.075%  capsaicin  cream  for  30  minutes,  40C  heat 
rekindling for 5 minutes repeated 3 times with intervals of 40 minutes) it was possible to 
evoke a more stable secondary mechanical hyperalgesia for a longer duration (Petersen and 
Rowbotham 1999). Dirks et al confirmed the increased strength of this model was indeed due 
to the rekindling procedure (Dirks et al. 2003). Given that the changes induced by the model 
were shown to be responsive to systemic lidocaine, remifentanil, and oral gabapentin it can be 
concluded that it is sensitive to peripheral and central modulation (Dirks et al. 2000; Petersen 
et al. 2001; Dirks et al. 2002). Furthermore, highlighting that this is also a model suitable for 
the assessment of pharmacological interventions. 
 
6.1.2.  Preliminary investigation of UVB rekindling reveals enhancement of central 
changes 
Cookson  and  colleagues  adapted  the  rekindling  paradigm  described  by  Peterson  and 
Rowbotham,  to  explore  its  potential  use  in  combination  with  UVB  irradiation.  Given  the 
dispute as to whether UVB alone could result in central changes, it was suggested that this 210 
 
might  provide  a  more  reliable  model  of  inflammatory  pain  involving  a  robust  central 
sensitisation. The model was established in human volunteers, whereby subjects received 
irradiation  at  3  x  their  individual  MED  and  24  hours  later  returned  for  the  rekindling 
procedure and sensory testing. The rekindling involved 3 rounds, each lasting for 5 minutes at 
a temperature of ≤45C, equally spaced by 40-minute intervals. The study concluded that this 
rekindling  procedure  enhanced  and  maintained  both  secondary  mechanical  pinprick 
hyperalgesia and brush evoked allodynia (Cookson 2005; Wang 2005). Therefore the studies 
suggest that combining an initial stimulus that  produces  inflammation  with a  subsequent 
noxious stimuli, can indeed evoke more robust alterations in central pain processing.  
Despite these positive results, the model has not been explored any further in human subjects, 
most  likely due to  the inconvenient timing of the  study, whereby the multiple  rekindling 
procedures were spaced by 40 minutes each. However, the model has since been tested in 
animals and initial data published appears to suggest it could be another useful translational 
model of chronic pain (Davies et al. 2011). More recently, Davies et al employed a similar 
rekindling procedure in rats to that originally described by Cookson, in order to behaviourally 
characterise this model. However, for the animals the paradigm involved a maximum of two 
rekindling procedures, separated by only 15 minutes (Davies et al. 2011). A clear benefit of 
rekindling, with regards to enhancing the signs of central sensitisation, was also observed in 
the animals; the study concluded that while a single rekindling procedure alone was able to 
enhance mechanical hypersensitivity in the secondary area, the effect was even stronger with 
two procedures as these animals then had the lowest withdrawal threshold to vF filaments 
(Davies et al. 2011). The effect was found to last up to 10 days in the group receiving 2 
rekindling procedures, a duration which exceeds most models currently used. Therefore it 
appears possible to induce long lasting signs of modifications of central processing in animals, 
through rekindling of the UVB irradiated area. 
When  originally  characterising  the  model  of  UVB  irradiation,  Bishop  and  colleagues 
extensively compared UVB to the capsaicin and thermal burn models; while the latter two 
evoke  pin  prick  hyperalgesia  and  allodynia  in  the  secondary  area,  neither  of  these 
manifestations of central changes were found post UVB (Bishop et al. 2009). On the other 
hand, both the animal and human studies of UVB rekindling mentioned above suggest that 
brush and mechanical hypersensitivity are present in the secondary area. The somatosensory 
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and the thermal burn, both of which are known to evoke central sensitisation. Taken together 
the initial studies by Cookson and Davies suggest that combining UVB irradiation with heat 
rekindling  in  animals  and  humans  results  in  robust  and  long  lasting  secondary  changes, 
reflective of altered central processing mechanisms. 
 
6.1.3.  The UVB rekindling model is sensitive to COX-2 inhibition and NMDA antagonism 
Pharmacological evidence from both animal and human studies indicate that both peripheral 
and central mechanisms are indeed involved in this model. Preliminary studies have found 
that the model of UVB rekindling is sensitive to both oral rofecoxib and intravenous ketamine. 
Whilst both of the compounds were able to reduce the area of secondary hyperalgesia in 
human subjects, ketamine had a patently stronger effect (Wang 2005). Given that ketamine is 
an  antagonist  of  the  NMDA  receptor,  which  is  involved  in  central  hyperexcitability,  this 
supports the theory that such mechanisms are engaged. It has also been shown in animals 
that systemic ibuprofen can reverse the secondary mechanical hypersensitivity induced by 
the model, which could be acting at peripheral or central sites (Davies et al. 2011). These 
studies indicate that the model is sensitive to both peripheral and central modulation, and 
thus such mechanisms must be induced by the rekindling procedure.  
Both heterosynaptic central sensitisation and wind up of spinal neurones are underpinned by 
ongoing activity of primary afferents that converge in the DH and modulate NMDA receptor 
function (Dickenson and Sullivan 1987; Haley et al. 1990; Lewin et al. 1994). Thus many 
models of altered pain processing or chronic pain states are sensitive to a blockade of this 
receptor (Woolf and Thompson 1991; Stubhaug et al. 1997). In the model of UVB irradiation it 
was observed that the NMDA antagonist MK-801 could not reverse the changes induced and it 
is therefore unlikely that any of these central mechanisms underpin the model (Bishop et al. 
2010),  in  keeping  with  the  observations  made  in  the  previous  chapter.  However,  since 
ketamine  is  able  to  reduce  secondary  mechanical  hyperalgesia  in  humans  after  UVB 
rekindling treatment, this would suggest that such mechanisms have indeed been induced in 
the model. Therefore, overall, the limited evidence available suggests that as hypothesised, 
somatosensory changes evoked by rekindling are most likely underpinned by sensitisation at 
both  levels  of  the  pain  pathway.  Further  objective  characterisation  of  the  model  and 
pharmacological interventions will aid understanding of the mechanisms involved. 212 
 
6.1.4.  Rekindling may lead to a barrage of activity into the CNS, driving excitability and 
altered central processing 
UVB  irradiation  leads  to  a  local  inflammatory  response,  and  subsequent  peripheral 
sensitisation.  It  has  been  concluded  that  this  alone  does  not  lead  to  any  spontaneous  or 
ongoing input into the spinal cord. On the other hand, in the model of topical capsaicin it has 
been suggested that rekindling is able to increase the ongoing input into the DH, which is 
necessary for induction and /or maintaining the state of central sensitisation. A reduction in 
this drive, has also been noted to be able to decrease the area of secondary hyperalgesia 
observed (Dirks et al. 2000; O'Neill et al. 2012). Thus the key to developing a stable central 
sensitisation/ secondary hyperalgesia in experimental models could simply be an ongoing 
peripheral drive of adequate strength, most notably from C-fibres (McMahon et al. 1993). It is 
likely  that  rekindling  the  pre-sensitised  nociceptive  endings  post-UVB  treatment  will  also 
result  in  an  ongoing  activity  into  the  second  order  neurones  of  the  spinal  cord.  These 
sensitised  primary  afferents  not  only  have  lowered  activation  thresholds,  but  may  also 
generate activity of a greater magnitude than those in untreated skin. In addition previously 
silent nociceptors may also have been recruited (Schmidt et al. 1995). Overall this may lead to 
a barrage of activity into the CNS, driving excitability and altered central processing (Baron et 
al. 2013). 
In exploring the transition from acute to chronic pain, Levine and colleagues have described a 
similar  phenomenon  known  as  ‘priming’.  Exposing  neurones  to  an  initial  inflammatory 
stimulus  such  as  TNF-,  prior  to  exposure  to  a  subsequent  pro-inflammatory  mediator 
(PGE2)  results  in  a  prolonged  mechanical  hyperalgesia  (Parada  et  al.  2003).  Changes  in 
nociceptor function as a result of the initial insult are believed to be the driving factor behind 
this observed increase in hypersensitivity. However, given that these studies focus on primary 
hypersensitivity it is difficult to draw any further comparisons. Additionally, administration of 
TNF at 24 or 48 hours before the second insult did not induce a prolonged hypersensitivity, 
and rather it appears that 72 hours are required to establish these ‘priming’ mechanisms 
(Bogen  et  al.  2012).  Given  the  time  frame  required  it  would  appear  this  phenomenon  is 
related to genomic changes and thus it seems unlikely that such mechanisms underpin the 
changes seen post rekindling.  
Simply  put,  an  afferent  barrage  of  C  fibre  activity  resulting  in  the  engagement  of  central 
mechanisms may underpin this model (LaMotte et al. 1991). This sensitisation as a result of 213 
 
an afferent peripheral drive is also relevant to patients, since by removing the ongoing activity 
when  replacing  a  damaged  joint  the  signs  and  symptoms  of  central  sensitisation  may 
disappear (Malfait and Schnitzer 2013). 
This chapter aims to validate the preliminary findings from the studies of UVB rekindling, in 
order to confirm this as a translational model of inflammatory pain involving modifications to 
the central pain pathway. The critical intent was to establish a paradigm suitable for use in 
animals and humans that is convenient to execute and robust in symptom induction, though 
investigation  of  spinal  neuronal  activity  in  animals,  and  full  QST  profiling  in  human 
volunteers.   214 
 
6.2.   Methods 
6.2.1.  UVB irradiation - rats: 
Adult male Sprague-Dawley rats, between 210-240g, were obtained from the UCL Biological 
Services Unit. All procedures were approved by the UK Home Office, and were performed in 
accordance with the guidelines provided by the International Association for the Study of 
Pain. 
Rats were anaesthetised in an induction box using 4% isoflurane (carried in 66% N2O and 
33% O2). Once the rat was fully unconscious and was checked for absence of reflexes (by 
pinching the toes of the hindpaw) they were placed on-to a heat mat and fully covered with 
UV resistant material. The upper half of the plantar surface of the right hindpaw was then 
exposed, and placed at a set distance of 2cm under the UVB light source, ensuring only this 
area was irradiated. All experiments were conducted using a Dermfix 1000MX UV-B Lamp 
fitted with a 9 Watt fluorescent UVB tube, λ max = 311nm. The irradiance of the lamp was 
determined using a calibrated photometer. This reading was used to determine the length of 
time required to deliver a set dose of 1000mJ/cm2. Post irradiation the rats were placed in a 
temperature  controlled  recovery  box  until  the  effects  of  the  anaesthetic  were  completely 
reversed.  
 
Figure  6-1  Method  of  Rodent  UVB  Irradiation.  In  order  to  test  the  effects  in  the  secondary  area  post 
rekindling, only the top half of the paw is irradiated. Therefore cells can be found with receptive fields outside 
the area of treatment. The bottom half of the hindpaw is covered with a UVB resistant material.  
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6.2.2.  In vivo electrophysiology and heat rekindling: 
24-30 hours post UVB irradiation, rats were anaesthetised and in vivo electrophysiological 
recordings were performed as previously described, to obtain baseline responses to electrical 
and natural stimuli. Cells were only used if they had receptive fields located on the lower half 
of the hindpaw in the untreated, secondary area. Once stable baselines were established the 
rekindling procedure was carried out. The treated area of the paw was exposed to a heat 
source kept at a constant temperature of 40C for 5 minutes. After 15 minutes, a second 
rekindling  procedure  was  carried  out,  once  again  using  a  heat  source  kept  at  a  constant 
temperature of 40C for 5 minutes. Following this, natural and electrical responses were re-
tested  every  30  minutes,  up  until  180  minutes  post  rekindling.  Additional  cells  were 
contributed by Dr Shafaq Sikandar as part of a collaborative study. 
 
       
 
 
 
Figure 6-2 Rekindling procedure. 24 hours post UVB baseline tests were conducted in the secondary area, 
away from the site of irradiation. Two separate rekindling procedures were undertaken on the irradiated area, 
separated by 15 minutes. 
 
6.2.3.  Receptive field mapping: 
Receptive fields on the plantar hindpaw were mapped for each cell with an 8g vF, using the 
methods detailed in (Suzuki et al. 2000). The stimulus was applied repeatedly around the area 
of  baseline  testing  until  firing  was  depleted  below  0.5Hz.  Applications  were  made  at  30s 
intervals to ensure no wind up was elicited from the testing sequence. Receptive fields were 216 
 
mapped  both  pre  and  post  heat  rekindling,  before  each  round  of  testing.  The  observed 
receptive  field  was  marked  onto  a  standard  diagram  of  the  hindpaw  and  subsequently 
digitalised using a Canon MP610 scanner. The size of each receptive field was determined 
using ImageJ software and calculated as a percentage of the total area of the hindpaw. 
 
6.2.4.  UVB irradiation - humans: 
Experiments were conducted in 10 healthy human volunteers aged between 22-32 years old. 
Individuals were familiarised with the experimental protocol beforehand and gave written, 
informed consent. The study was approved by The Kings College Research Ethics Committee. 
All subjects were free from pain and medical conditions which may otherwise interfere with 
the results of the study. They were advised they must avoid pain medication such as NSAIDs 
and caffeine in the 24 hours prior to the study. This was particularly important as NSAIDs 
have been shown to be effective against the sensory changes elicited by UVB. 
Volunteers were irradiated in a similar protocol as described for the animals. However, the 
dosing  was  calculated  on  an  individual  basis  depending  largely  on  skin  type.  An  initial 
screening was conducted on each subject to determine their MED; this is defined as the time 
required to produce a uniform reddening of the area at 24 hours post irradiation. 3 times the 
MED was then used for the final experiment to irradiate an area of 16x16mm on the volar 
forearm, the surrounding area was covered with a UV resistant material to ensure uniform 
burn. 
 
6.2.5.  Heat rekindling- humans: 
24-30 hours post UVB irradiation subjects returned for the heat rekindling procedure and full 
QST profiling. The procedure was carried out using the TSA thermal sensory testing device 
(TSA 2001-II; Medoc Ltd, Ramat Yishai, Israel), as used for the thermal testing in the QST 
protocol. The thermode (16x16mm) was placed directly over the UVB burn and held in place 
with a Velcro strap. The rekindling procedure carried out was the same as that described for 
the animals – the thermode was kept at 40C for 5 minutes, followed by a 15 minute interval 
and a subsequent second rekindling identical to the first.  217 
 
6.2.6.  Mapping area of secondary hyperalgesia: 
In  line  with  the  animal  experiments,  subjects  were  then  tested  immediately  after  the 
rekindling procedure, and every 30 minutes up to 180 minutes post rekindling. Prior to the 
rekindling the edges of the primary burn site had been marked on the skin and an acetate 
template  was  used  to  mark  a  spider  probe  map  at  1cm  increments  along  eight  spokes 
(oriented at 45 intervals) radiating out from the primary area. After the rekindling procedure 
had  been  carried  out  subjects  were  assessed  for  the  development  of  both  pinprick 
hyperalgesia and dynamic brush evoked allodynia. Pinprick hyperalgesia was mapped using a 
256mN probe (Pinprick, MRC Systems GmbH, Heidelberg, Germany. 0.2mm diameter) - an 
example stimulation was given on the contralateral arm in order for the subject to familiarise 
themselves with the sensation. Beginning at 8cm from the centre of the map the stimulation 
was repeated at 1cm intervals a long each spoke towards the treated area, and the subject was 
requested to report when this sensation changed. This was usually described as a sharper, or 
more intense pricking sensation. The stimulus was only applied once to each point, for around 
1s. The point at which this change was reported was marked on a standard spider probe map 
diagram. Adjacent spokes were connected to create 8 triangles, for which the individual areas 
could be calculated; the summation of these, minus the primary area (256mm2), gave the total 
area of secondary hyperalgesia.  
 
6.2.7.  Human Quantitative Sensory Testing: 
Once the area of secondary hyperalgesia had been mapped full QST profiling was performed 
as previously described (Chapter 2.4) within this area of secondary changes, and as a control 
on the contralateral ventral forearm. In addition to the standard QST protocol, subjects were 
asked for numerical  ratings (0-100) to  35C,  40C and 45C. This  was  repeated every 30 
minutes, up until 180 minutes post rekindling. 
 
6.2.8.  Statistical analysis: 
All analysis was undertaken using SPSS software (IBM SPSS Statistics v21). Data was assessed 
for normality using the Kolmogorov-Smirnov test to determine further methods of analysis. 
Electrophysiological data was analysed using either an unpaired t-test or a 2 way ANOVA 
accordingly. Psychophysical data, with the exceptions of HPT and CPT, was logged and re-218 
 
tested for normality. A paired t-test or 2 way ANOVA was then carried out. HPT and CPT were 
found to be normal without logging, and thus the raw data was used for analysis with a paired 
t-test. All graphs were plotted to show the mean  SEM. 
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6.3.   Results 
6.3.1.  UVB  Rekindling– In vivo electrophysiology 
Using objective electrophysiological recordings, LV WDR cell responses to a range of natural 
and electrical  applied stimuli  were found to be  significantly enhanced when  compared to 
baseline responses in the same animal pre-rekindling (control). The initial baseline responses 
measured (control) were found to be no different to those recorded from a group of naïve 
animals with no treatment. (Note. It was not assessed whether the distance from the UVB 
treated area made a  difference to the degree of sensitisation). These changes seen in the 
secondary  area  post  rekindling  are  akin  to  the  mechanical  hypersensitivity  observed  in 
previous  behavioural  experiments  (Davies  et  al.  2011).  The  UVB  dose  (1000mJ/cm2), 
rekindling  procedure  and  time  point  (24-30  hours  post  irradiation)  were  selected  from 
previous data (Bishop et al. 2007; Davies et al. 2011; Dawes et al. 2011), along with an initial 
pilot  study  which  suggested  these  set  parameters  resulted  in  the  maximal  secondary 
hypersensitivity. These changes are most likely indicative of central sensitisation.  
6.3.1.1.  UVB  rekindling  significantly  enhances  both  innocuous  and  noxious 
mechanically  evoked  WDR  cell  responses  in  the  secondary  area,  in  comparison  to 
baseline responses 
There is a patent coding of mechanical stimuli in both naïve, untreated animals and in the 
secondary area of treated animals pre-rekindling. The control responses recorded in UVB 
treated animals pre-rekindling are no different to those seen in naïve animals (figure 6-3). 
Since the UVB irradiation is confined to the upper half of the hindpaw, and testing takes place 
on cells with receptive fields confined to the lower half (secondary area), this suggests there is 
no, or very little, spread of inflammatory mediators from the primary irradiated zone. Post 
UVB rekindling coding is also seen to mechanical stimuli. These evoked responses to both 
innocuous  and  noxious  vF  were  significantly  increased  (figure  6-3;  p<  0.000).  Neuronal 
responses to both low vF forces (2g, 8g and 15g) and higher vF (26g and 60g - which are 
usually considered noxious in behavioural experiments) were enhanced (figure 6-3; p= 0.019, 
< 0.000, 0.003, 0.055, 0.005). 26g and 60g vF responses were increased by 20.3% and 19.6% 
respectively,  although  this  was  only  found  to  be  significant  for  60g  (figure  6-3;  p=0.055, 
0.005). Furthermore, dynamic brush responses in the secondary area were also significantly 
enhanced by 42.8% from 351.1  49.55 to 613.8  44.72 action potentials/ 10s (figure 6-3; p= 220 
 
0.002). All of these data are strongly suggestive of the engagement of central mechanisms, 
such as a facilitation of Aδ fibre responses, and unmasking of Aβ fibres. 
6.3.1.2.  UVB rekindling significantly enhances both innocuous and noxious thermally 
evoked WDR cell responses in comparison to baseline responses 
Once again, there is a clear coding of WDR cell responses to increasing thermal stimuli, both 
pre and post rekindling. The baseline responses in the secondary area before rekindling are 
no different from responses recorded in naïve animals. Interestingly, an increased firing of 
WDR cells was observed in response to all temperatures tested post UVB rekindling (figure 6-
4). The greatest increase was seen at 40C, where a 40.9% increase in the firing was observed 
(figure  6-4;  p=  0.006).  Firing  to  supra  threshold  stimuli  (45C  and  48C)  were  also 
significantly enhanced by 32.6% and 28%, respectively (figure 6-4; p= 0.004, <0.000). Overall, 
there appeared to be a parallel shift in the stimulus-response curves. 
 
Figure 6-3 Effects of UVB rekindling on mechanically evoked WDR cell responses. Using the protocol 
described in chapter 6.2 in vivo single unit recordings of LV WDR cells responses were recorded to a range of 
mechanical stimuli, including brush and graded vF, applied to the receptive field for 10s, before and after UVB 
rekindling. Naïve values refer to animals with no treatment, whereas control values refer to pre UVB rekindling. 
Post rekindling treatment a) dynamic brush (p= 0.002), b) innocuous and noxious vF evoked responses were 
elevated when compared baseline controls (Overall 2-way ANOVA p< 0.000; 2g p= 0.019, 8g p< 0.000, 15g p= 
0.003, 26g p= 0.055, 60g p= 0.005). n= 30. 221 
 
 
Figure  6-4  Effects  of  UVB  rekindling  treatment  on  thermally  evoked  WDR  cell  responses.  .  Using  the 
protocol described in chapter 6.2 in vivo single unit recordings of LV WDR cells responses were recorded to a 
range of thermal stimuli applied to the receptive field for 10s, before and after UVB rekindling. Naïve values refer 
to animals with no treatment, whereas control values refer to pre UVB rekindling. a) Post rekindling, evoked 
responses  to  both  innocuous  and  noxious  temperatures  were  elevated  when  compared  to  pre-rekindling 
baselines (Overall 2-way ANOVA p< 0.000; 35C p= 0.005, 40C p= 0.006, 45C p= 0.004, 48C p< 0.000). n= 29 
6.3.1.3.  UVB rekindling significantly increases electrically evoked input and A fibre 
responses recorded from WDR cells when compared to baseline responses 
Overall,  no  significant  difference  was  observed  between  UVB  rekindled  responses  and 
baselines with regards to the number of action potentials elicited from A and C fibres, as well 
as  PD  (figure  6-5).  Conversely,  electrically  evoked  input  was  significantly  increased  from 
364.6  56.3 to 761.8  88.6 action potentials/ 10s, and responses in the A fibre range were 
potentiated  by  19.3%  (figure  6-5;  p=  0.02,  0.008).  Furthermore,  WU  was  significantly 
reduced, suggesting the central neurones were already in a state of hyperexcitability and thus 
responses  were  unable  to  be  further  enhanced  (figure  6-5;  p=  0.035).  This  measure  is 
quantified  by  calculating  the  difference  between  the  overall  response  observed  and  the 
baseline response to the first stimulus. Examination of the wind-up graphs reveals that the 
large increase in the initial responses in the rekindled group was responsible for the apparent 
reduction of wind-up. In fact, the neuronal responses started from a level that normally only 
would  be  elicited  when  wind-up  is  produced,  strongly  suggestive  of  enhanced  central 
processing. 222 
 
 
Figure  6-5  Effects  of  UVB  rekindling  on  electrically  evoked  WDR  cell  responses.  .  Using  the  protocol 
described in chapter 2.2 and 6.2 in vivo single unit recordings of LV WDR cells responses were recorded to 
electrical stimuli pre and post UVB rekindling.  Transcutaneous electrical stimulation was used to measure the 
input and wind up, in addition to calculating the responses driven by different fibre types – depending on the 
latency. Naïve values refer to animals with no treatment, whereas control values refer to pre UVB rekindling.  
Post rekindle y treatment a) there was no significant effect on electrically evoked A mediated transmission nor 
post-discharge, however responses within the C fibre range appear to trend towards an increase (p= 0.08) and 
responses within the A fibre range were significantly enhanced (p= 0.008); b) electrically induced input was 
also significantly increased (p= 0.02), whilst on the other hand, wind up appears decreased (p= 0.035). n= 30. c) 
Sample WU n=16 223 
 
6.3.1.4.  UVB  rekindling  significantly  increases  receptive  field  size  of  WDR  cells  in 
comparison to pre-treatment controls 
Receptive field size was mapped using an 8g vF both before and after rekindling. As with 
humans, the mapping uses mechanical stimuli in order to avoid extra sensitisation that could 
occur with thermal stimuli. Furthermore, it is not frequently reported that patients suffer 
from extensive areas of thermal sensitisation outside of the area of injury. The receptive fields 
of LV WDR cells post rekindling treatment was found to be significantly larger, about 2-fold, 
than the average receptive field size measured in the same animals before the rekindling 
(figure 6-6; p=0.01). This is consistent with the evoked responses, which were also suggestive 
of a central sensitisation. 
 
Figure 6-6 Effects of UVB rekindling treatment on receptive field size of WDR cells. Using the protocol 
described in chapter 5.2 the receptive field was mapped using an 8g vF filament.  a) There was a significant 
increase in the size of receptive field in comparison to pre-treatment controls in the same animals (p= 0.01). n= 
16 224 
 
6.3.2.   UVB Rekindling – Human Quantitative Sensory Testing 
Using a standardised QST procedure, human subjects were also found to exhibit secondary 
sensory changes indicative of a central sensitisation post UVB rekindling treatment, including 
both mechanical and thermal hypersensitivity.  
6.3.2.1.  UVB rekindling significantly reduces MPT and increases numerical ratings to 
innocuous and noxious punctate stimuli 
Similar to the rodent studies, post rekindling treatment, there was a significant drop in the 
average 50% pain threshold to pinprick stimulation from 103.98mN  15.99mN to 9.75  
0.28mN within the secondary, non irradiated area (figure 6-7; p< 0.000). Ratings to both sub 
and supra-threshold mechanical stimuli were also increased, whilst perceptual WU remained 
unchanged (figure 6-7; p< 0.000).  
Figure 6-7 Effects of UVB rekindling on psychophysical MPT and mechanical NRS rating. Using the protocol 
described in chapter 6.2 standardised QST was undertaken to determine the subject’s mechanical pain threshold 
(MPT), in addition to obtaining numerical ratings (NRS) to graded mechanical stimuli and measuring the wind 
up ratio (WUR) to repetitive mechanical stimulation. a) Average MPT was significantly lower in the secondary 
area post rekindling treatment in comparison to pre-treatment baselines (p< 0.000). b) NRS rating to dynamic 
brush were present in the secondary area unlike in normal skin, although this was not found to be significant. 
Ratings to both 32mN and 256mN were significantly increased (Overall 2 WAY ANOVA p< 0.000; 32mN p< 
0.000, 256mN p= 0.004). c) Perceptual wind up was unaffected. n= 10 225 
 
6.3.2.2.  UVB rekindling induces a secondary thermal hypersensitivity 
Average HPT was also significantly reduced in the secondary area from 45.0  0.89C to 40.3  
1.1C (figure 6-8; p= 0.001). However, despite a trend in increased ratings to both sub and 
supra-threshold temperatures these were not found to be significant. Interestingly, a cold 
hypersensitivity was also observed, as average CPT was raised from 10.08  3.45C to 15.01  
3.18C (figure 6-8; p= 0.003). 
 
Figure 6-8 Effects  of UVB rekindling on psychophysical HPT, thermal  NRS ratings  and CPT. Using the 
protocol described in chapter 6.2 standardised QST was undertaken to determine the subject’s heat and cold 
pain  thresholds  (HPT/CPT),  in  addition  to  obtaining  numerical  ratings  (NRS)  to  graded  thermal  stimuli.  a) 
Average  HPT  was  significantly  reduced  in  the  secondary  area  in  comparison  to  pre-irradiation/rekindling 
baselines  (p=  0.001).  b)  NRS  ratings  to  previously  innocuous  and  noxious  temperatures  appear  increased, 
although this is not significant. c) CPT was also significantly elevated (p= 0.003). n= 10 226 
 
6.3.2.3.  UVB rekindling results in a considerable area of secondary hyperalgesia 
The  area  of  secondary  hyperalgesia  was  assessed  before  testing  the  secondary  area  for 
sensory changes, using a 256mN probe. A large area surrounding the burn was reported by all 
subjects as being more sensitive than the percept to the stimulus in untreated skin (figure 6-
9). Indicative of central sensitisation, underpinned by and expansion of receptive fields. 
 
Figure 6-9 The area of secondary hyperalgesia induced by UVB rekindling. As described in chapter 5.2 the 
area of secondary hyperalgesia was mapped with a 256mN probe. a) Post rekindling a large area (2317.48 mm2) 
of  secondary  hyperalgesia  was  observed  in  all  subjects.  b)  The  area  is  variable,  yet  considerable  across  all 
subjects. 
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6.3.2.4.  Sensory  profiles  post  UVB  rekindling  illustrate  a  largely  mechanical 
hypersensitivity 
Full  sensory  profiling  using  a  standardised,  comprehensive  QST  procedure  confirmed  a 
sensitisation in the secondary area across a number of modalities including: WDT, CPT, HPT, 
MDT, MPT, MPS and PPT.  However, the mechanical hypersensitivity is much stronger than 
the other modalities (figure 6-10). Previous studies have observed pinprick hypersensitivity, 
however heat, cold and blunt pressure hypersensitivity represent novel findings of this study. 
 
Figure 6-10 Somatosensory changes in UVB rekindled subjects. Using the protocol described in chapter 2.4 
full  QST  profiling  was  undertaken.  A  variety  of  parameters  were  tested  both  pre  and  post  UVB  rekindling 
treatment, the magnitude of the changes are expressed here as Z-scores which highlight specific gains or loss in 
function.  Hypersensitivity  to  warm,  cold,  heat,  pinprick  and  pressure  are  demonstrated  here  by  the  gain  of 
function in WDT, CPT, HPT, MPT, MPS and PPT.. 
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6.3.3.  UVB rekindling induced somatosensory changes in rats and humans show 
considerable overlap 
 
Table 6-1 Comparison of animal and human characterisation. a) There is a remarkable similarity in the 
sensory changes post UVB rekindling across species, highlighting the translational nature of this model. WDR 
receptive field size to 8g vF were increased post rekindling, and large areas of secondary hyperalgesia were 
noted  in  human  subjects.  Both  animals  and  humans  show  heightened  responses  to  mechanical  stimuli  and 
thermal stimuli in the secondary area. On the other hand responses to dynamic brush were not aligned as WDR 
evoked  neuronal  responses  were  increased,  whilst  the  increase  in  human  perception  was  not  found  to  be 
significant. Fibre count was only assessed in the animal model, this term refers to a change in the number of 
action potentials elicited from each fibre type. The increase in action potentials elicited from A fibres supports 
the theory that UVB rekindling results in central sensitisation, and may underpin the brush hypersensitivity 
observed in animals. 
 
Stimulus 
Secondary Hypersensitivity 
Animal  Human 
Brush   Non significant 
increase 
Subthreshold Mechanical   
Suprathereshold Mechanical   
Subthreshold Thermal   
Suprathreshold Thermal   
Input   
Wind up  Reduced  No change 
Fibre count  Increase in A  Not tested 
Receptive field/ Area of secondary hyperalgesia  2-fold increase  2317.48 mm2 229 
 
6.4.   Discussion 
In  this  novel  study  WDR  cell  responses  were  measured  and  full  QST  was  undertaken  on 
healthy human volunteers, post UVB rekindling. This is the first study to examine this model 
using these techniques and includes many previously unexplored end points. The key finding 
is  that  UVB  rekindling  is  a  reliable  translational  model  of  secondary  hypersensitivity, 
producing  similar  changes  reflective  of  maladaptive  central  modifications  in  animals  and 
humans.  In  addition  to  confirming  the  previously  reported  secondary  mechanical 
hypersensitivity, the novel observations made in this study include secondary thermal and 
cold  hypersensitivity,  in  addition  to  changes  in  electrical  responses  and  an  expansion  in 
receptive field size of WDR cells. 
 
6.4.1.  UVB rekindling produces a consistent secondary mechanical hypersensitivity in 
animals and humans, which can be measured from WDR cells, and with QST 
This is the first full characterisation study post UVB rekindling using in vivo electrophysiology 
and QST. Rekindling treatment consistently led to a strong mechanical hypersensitivity in the 
secondary untreated area of both animals and humans. Evoked activity of LV spinal WDR 
neurones was enhanced to both dynamic brush and a range of mechanical von Frey forces. In 
the same way, in human volunteers, QST revealed a drop in MPT and increased numerical 
pain  ratings  to  both  sub  and  supra  threshold  stimuli.  Thus  the  data  provides  objective 
assessment measures of the induction of secondary mechanical hypersensitivity, as reported 
in the initial behavioural studies (Cookson 2005; Wang 2005; Davies et al. 2011).  In line with 
the WDR cell recordings here, the behavioural study found that post rekindling treatment von 
Frey  withdrawal  thresholds  were  significantly  reduced  and  dynamic  brush  withdrawal 
responses were enhanced for up to 10 days (Davies et al. 2011). In agreement with the human 
QST the previous group also revealed large areas of pinprick hyperalgesia and touch allodynia 
(Cookson 2005). Overall, secondary mechanical hypersensitivities are clearly induced by the 
rekindling of UVB irradiated skin. 
Since the receptive field of the cells are distal from the treated area, and MPT/ numerical 
ratings were performed in the area of mapped secondary hyperalgesia distant from the initial 
stimulated area, it is unlikely these changes can be explained by a peripheral sensitisation as 
seen with UVB irradiation alone. Rather, this enhancement of responses in the untreated area 230 
 
is reflective of changes in the properties of central neurones. This is comparable with models 
such  as  intradermal  capsaicin  where  it  is  well  established  that  following  a  barrage  of 
peripheral  input,  an  increase  in  mechanical  sensitivity  is  observed  in  the  surrounding 
secondary area (LaMotte et al. 1991; Willis W.D 1997). The ongoing peripheral activity from 
the  treated  area  is  believed  to  sensitise  WDR  neurones  through  a  number  of  homo-  and 
heterosynaptic  mechanisms.  In  a  state  of  central  hyperexcitability  enhanced 
neurotransmission  through  activation  of  the  NMDA  and  NK1  receptors  leads  to  complex 
intracellular  events  involving  phosphorylation,  receptor  trafficking  and  transcriptional 
changes (Latremoliere and Woolf  2009). Consequently, there is  an  increase  in membrane 
excitability, increased synaptic strength and a reduction in spinal cord inhibition. As such the 
thresholds of spinal neurones are lowered and activation kinetics  are altered. Subsequent 
stimulation  of  peripheral  fibres  in  the  surrounding  untreated  may  then  evoke  action 
potentials  of  greater  amplitude  and  frequency  than  under  normal  conditions,  which  is 
perceived by the subjects as more painful than before. For a full review of these events see 
Latremoliere and Woolf, 2009. 
With regards to the model of UVB rekindling many of these mechanisms are likely to underpin 
the observed secondary hypersensitivity. It has been hypothesised that an area of secondary 
hyperalgesia may be the result of a barrage of input from afferents in the primary treated 
area, sensitising the second order neurones directly and these spinal cells may also synapse 
with  afferents  in  the  secondary  area  (LaMotte  et al.  1991).  However,  since  in  the  animal 
studies here WDR cells recorded from are selected on the basis that their baseline receptive 
field is outside of the area of UVB irradiation this rather simplistic model cannot fully explain 
the changes seen.  Rather, when the rekindling procedure is undertaken the ongoing activity 
initially results in a sensitisation of second order neurons with direct synaptic input, i.e. those 
with  receptive  fields  in  the  primary  irradiated  area.  Through  a  process  of  volume 
transmission of neuropeptides such as substance P the surrounding second order neurones 
may  also  become  sensitised  (Sandkühler  1996).  Secondly,  a  loss  of  inhibition  through 
interneurones  and  descending  inhibitory  controls  could  also  contribute  towards  this 
widespread sensitisation. Finally, it is possible that WDR cells recorded from have afferent 
fibres sitting within a low probability firing fringe which encompasses the primary rekindling 
zone. Whilst under normal conditions stimulation of these afferent fibres may not produce an 
action potential the rekindling procedure and subsequent central sensitization may result in a 
summation of EPSPs that does lead to the generation of action potentials and subsequent 231 
 
sensitisation of the WDR cell. Any combination of these mechanisms could contribute towards 
in the secondary changes observed in both the animals and humans. 
A  number  of  models  of  chronic  pain  also  report  similar  changes  in  animal  and  human 
experiments. The enhanced firing of LV WDR cells to both punctate mechanical stimulation 
and dynamic brush seen here are also observed within the untreated area after intraplantar 
injection of capsaicin (Simone et al. 1991; T. K. Baumann 1991; Willis W.D 1997). Whilst in 
humans  intradermal  capsaicin  is  known  to  result  in  a  large  area  of  secondary  pinprick 
hyperalgesia,  in  addition  to  the  less  frequently  reported  development  of  brush 
hypersensitivity (LaMotte et al. 1991; Park et al. 1995; Magerl et al. 1998).  Intra-articular 
injection  of  CFA  and  the  MIA  model  of  OA  are  also  known  to  evoke  similar 
electrophysiological  changes,  whereby  an  increase  in  the  magnitude  of  responses  of  DH 
neurones  to  mechanical  stimuli  applied  outside  the  initial  area  of  treatment  is  observed 
(Martindale et al. 2007; Rahman et al. 2009; Burnham 2012). These models are all confirmed 
to have central components and therefore given that they induce similar changes to those 
observed  here  post  rekindling,  it  can  be  inferred  they  may  evoke  overlapping  central 
mechanisms. 
This  synaptic  plasticity  involves  engagement  of  different  fibre  types,  which  lead  to  the 
development  of the  distinct  symptoms observed in this  study such as  static pinprick and 
dynamic brush hypersensitivity. Since pinprick hyperalgesia can be induced in the absence of 
A fibres, but a complete block of A fibres abolishes this symptom, it has been assumed that 
A fibres are the key mediators of hypersensitivity to this modality (Torebjörk et al. 1992; 
Treede and Cole 1993; Ziegler et al. 1999). On the other hand it is the large A fibres that are 
thought  to  conduct  brush  evoked  hypersensitivity.  As  mentioned,  the  development  of 
secondary pinprick hyperalgesia post capsaicin has been observed in a subject found to suffer 
from a large-fibre sensory neuropathy, however allodynia could not be evoked (Treede and 
Cole 1993). Therefore suggesting that A fibres mediated brush evoked allodynia. Enhanced 
responsiveness of DH neurones to this low threshold A inputs is believed to underlie the 
phenomenon (Simone et al. 1991). 
To assess contribution of central mechanisms and fibre types a number of methodologies 
could be employed. It is possible to inhibit A fibre conduction through a superficial radial 
nerve  block  and  if  pinprick  hyperalgesia  is  unable  to  develop  this  would  confirm  the 
dependency  of  this  symptoms  on  A  fibres.    Additionally,  as  previously  mentioned,  the 232 
 
induction of this enhanced responsiveness of spinal cord neurones is believed to be activity 
dependent, that is to say it triggered by the ongoing input into the spinal cord (McMahon et al. 
1993; Baron et al. 2013). Since secondary hyperalgesia resulting from intradermal capsaicin 
can be reduced by pretreatment with systemic or local lidocaine, it can be inferred that the 
induction of the symptom is indeed dependent on the peripheral drive (Dirks et al. 2000). It is 
likely that rekindling the UVB treated area also results in a strong peripheral drive that is able 
to alter spinal processing. To further investigate this hypothesis, it would be interesting to 
treat both animals and humans with lidocaine before the rekindling procedure is undertaken 
in  order  to  confirm  the  contribution  of  this  mechanism  to  the  induction  of  the  changes 
reported here. NK1 antagonists could also be used to assess the contribution of  substance P 
in the induction of this hypersensitivity. 
However,  the  most  important  finding  here  is  the  induction  of  secondary  mechanical 
hypersensitivity to pinprick and brush across species. In line with the preliminary results 
from Cookson and Davies previously discussed, the findings of this study also highlight the 
similarities in changes evoked by the model in both animals and humans (Davies et al. 2011). 
Notably, recordings from WDR cells correlate particularly well with human QST.  
Furthermore, these results validate the ability to measure secondary hypersensitivity from 
activity evoked in WDR cells under anaesthesia. As discussed, enhanced responses have also 
been  shown  in  alternative  models  engaging  central  mechanisms,  such  as  intradermal 
capsaicin, CFA and the MIA model of OA (Willis W.D 1997; Martindale et al. 2007; Rahman et 
al. 2009; Burnham 2012). Thus suggesting that WDR cells in the spinal cord, the primary relay 
site  of  somatosensory  information,  are  useful  for  studying  the  consequences  and  further 
characterisation of such models. 
 
6.4.2.  Thermal hypersensitivity is observed in the secondary area in animals and 
humans post UVB rekindling 
One of the most interesting and unexpected observations in this study was the presence of a 
small, yet significant, degree of thermal hypersensitivity in the secondary untreated area in 
both animals and humans. There is a general consensus that thermal hypersensitivity is the 
result of a peripheral sensitisation, and it is not present in areas of secondary hyperalgesia. In 
fact evidence  from most  studies investigating the  consequences of  central sensitisation  is 233 
 
controversial,  with  the  majority  suggesting  that  there  is  no  increase  in  behavioural  or 
electrophysiological responses to thermal stimuli (Lewis 1942; LaMotte et al. 1991; Serra et 
al. 1998; Sumikura et al. 2003). 
On the other hand, a generalised trend for increased firing of LV WDR cells across modalities, 
including thermal responses, is also seen in both the early and late phases of the MIA model of 
OA (Rahman et al. 2009; Burnham 2012). This model is believed to evoke mainly central 
changes since MIA is injected into the knee and testing may be conducted on the hindpaw, 
which is therefore not associated with any peripheral damage (Vonsy et al. 2009; Thakur et al. 
2012). However, since the enhanced central processing is driven by ongoing activity from a 
site  of  peripheral  inflammation  similarities  may  be  drawn  between  this  model  and  the 
rekindling paradigm. The heat hypersensitivity has also been observed in patients suffering 
from OA, and therefore suggests that secondary thermal hypersensitivity may exist in such 
conditions  (Kosek  and  Ordeberg  2000).  Serra  and  colleagues  also  firmly  believe  that 
hypersensitivity at least to suprathreshold stimuli may exist, reporting large areas of heat 
hyperalgesia post intradermal capsaicin (Serra et al. 1998). Whilst Chen and colleagues found 
that a novel model of chronic pain induced by melittin – a protein found in honeybee venom – 
is also able to induce a secondary thermal hypersensitivity (Chen and Chen 2000; Sumikura et 
al.  2003;  Sumikura  et  al.  2006).  Therefore,  although  the  topic  is  controversial  and  the 
evidence is limited it appears there is a reasonable argument for the development of this 
symptom within a site distal to the initial injury.  
This is the first reporting of this somatosensory phenomenon being associated with the UVB 
rekindling model, and therefore can only be compared with similar preclinical models. The 
model  to  best compare  these results to  is the early phase  of MIA  induced OA. This  early 
inflammatory phase is underpinned by peripheral sensitisation of the joint afferents, with a 
barrage of ongoing input into the DH leading to a referred hypersensitivity driven by central 
mechanisms  (Vonsy et al. 2009;  Thakur et al. 2012).  Therefore  it is  not  dissimilar to  the 
rekindling model, and is logical they may evoke similar changes. Confirming that in a state of 
hyperexcitability,  driven  by  ongoing  activating  from  an  area  of  peripheral  inflammation, 
secondary thermal hypersensitivity may result. 
Thinking back to the cellular mechanisms underpinning the central sensitisation involved in 
these  models,  it  does  not  seem  implausible  that  a  generalised  increase  in  activity  across 
modalities could be induced in either of these models. Heterosynaptic central sensitisation 234 
 
results in a number of cells that receive input distal from the area of injury in the spinal cord 
becoming hyperexcitable. In fact, since the WDR neurones recorded have polymodal inputs, it 
would be expected that any sensitisation of these cells would lead to an enhancement of both 
mechanical and thermal stimuli. Indeed, both types of responses were similarly enhanced, 
both below and above the pain threshold, suggestive of post-synaptic changes. 
It  is  possible  to  further  investigate  the  presence  of  this  symptom  and  the  supporting 
mechanisms through pharmacological interventions. If it is true that thermal hypersensitivity 
results  from  a  central  sensitisation  it  stands  to  reason  that  the  development  should  be 
inhibited with drugs targeting such central mechanisms. There are a number of approaches 
which  could  be  adopted  to  interfere  with  the  cellular  processes  underpinning  central 
sensitisation, but as discussed they could include the use of MK-801, or an NK-1 antagonists. 
Alternatively  spinal  PKA/C  inhibition  could  be  a  useful  indicator  of  the  mechanisms 
underpinning this phenomenon. Finally an assessment of the status descending controls could 
also be useful to both confirm the presence of this symptom and highlight the underlying 
cause. 
The hypersensitivity seen in the MIA model does in fact appears to be partially dependent on 
a shift in descending controls. By blocking the 5HT3 receptor, secondary noxious thermal 
hypersensitivity may be alleviated (Rahman et al. 2009). This possible increase in descending 
facilitation arises in the RVM and also appears to be active in the model of topical mustard oil. 
Whilst ON cells discharge in response to mustard oil application, OFF cells decrease their 
firing.  In  parallel  to  this  appears  the  development  of  secondary  heat  hypersensitivity 
characterised by an increase in paw withdrawal latency, which can be inhibited by blocking 
ON cell activity (Xu et al. 2007). These studies suggest that an increased facilitatory drive may 
be required for secondary thermal hypersensitivity. It would be interesting to explore the 
contribution of descending modulation in the model of UVB rekindling, however given that 
these models are both associated with an acute inflammation leading to central modifications 
it is possible similar mechanisms may also be engaged post rekindling.  
 
6.4.3.  UVB rekindling results in a secondary cold hypersensitivity in human volunteers 
There is a clear increase in CPTs measured in the secondary area post UVB rekindling. This 
phenomenon has previously been reported post UVB in the primary irradiated area, however 235 
 
this is the first study to find it present in the area of secondary hyperalgesia (Gustorff et al. 
2013). An increased withdrawal to acetone in both the early and late phase of MIA induced OA 
is also suggestive of a hypersensitivity to cooling stimuli (Vonsy et al. 2009; Burnham 2012). 
Furthermore,  this  phenomenon  has  also  been  observed  in  patients  with  OA  (Kosek  and 
Ordeberg 2000). This evidence corroborates the finding here that a cold hypersensitivity may 
develop in an area distal to the main site of inflammation. Given that it has also been observed 
in patients this is an important finding with high clinical applicability. 
The mechanisms for cold hypersensitivity are quite unclear and from the studies conducted in 
this thesis there appears to be a role for both peripheral and central sensitisation. However, 
as discussed at length in this chapter, since the symptom is observed in the secondary area in 
this case it is most likely of a central origin, involving the mechanisms previously mentioned. 
It is important to further explore this sensory occurrence  since cold hypersensitivity is a 
symptom not only associated with OA, but is also present in conditions such as oxaliplatin-
induced neuropathy (Kosek and Ordeberg 2000; Binder et al. 2007). The identification of a 
stable model of cold hypersensitivity in humans has been rather illusive and therefore this 
finding is important for future studies wishing to assess cold hypersensitivity. 
 
6.4.4.  UVB rekindling potentiates A fibre responses 
A potentiation of responses in the A fibre range was observed in LV WDR neurones post 
rekindling treatment. This finding would certainly help explain the increased responses of 
WDR cells to dynamic brush and subthreshold vF, as well as the increased NRS ratings to non-
painful mechanical stimuli post rekindling treatment. Indeed it is believed that an enhanced 
responsiveness  of  DH  neurones  to  low  threshold  inputs  contributes  to  dynamic  brush 
hypersensitivity/ allodynia (LaMotte et al. 1991; Torebjörk et al. 1992). Administration of 
GABA or glycine antagonists results in the recruitment of A fibre input and thus it is thought 
that  the  loss  of  inhibition  associated  with  central  sensitisation  results  in  this  enhanced 
responsiveness  to  large  fibres  (Baba  et  al.  2003).  This  recruitment  of  A  fibres  is  often 
thought of as a novel input to the nociceptive pathways, leading to A fibre mediated pain. 
However, since WDR cells have a small A fibre input under normal conditions it is difficult to 
interpret this finding with regards to chronic pain. It could be hypothesised that normally this 
low level of input from A fibres, which is considerably smaller than A and C fibre input, is 236 
 
somehow filtered out in higher centres and does not result in the conscious perception of 
pain.  However,  the  recruitment  of  more  fibres  and  a  greater  A  input  may  result  in  the 
surpassing of a ‘threshold’ in order for the messages to be perceived as painful.  
Inflammation  alone  may  result  in  a  release  of  neuropeptides  from  large  fibres  and  a 
subsequent  increase  in A  fibre input in the DH  (Ma  and Woolf 1996;  Baba  et al. 1999). 
Indeed after UVB irradiation there is a clear increase in brush evoked responses, as found in 
chapter 5. It therefore appears likely that this potentiation is initiated after UVB inflammation 
and  is  further  induced  and  maintained  by  the  rekindling  procedure.  This  treatment  most 
likely engages central mechanisms such as a reduction in spinal inhibition and thus enhanced 
A fibre input. As suggested, this recruitment of A fibre may lead to the generation of activity 
such that is passes a threshold and is no longer ‘filtered out’ by higher centres in the pain 
pathway.  Therefore  the  potentiated  responses  in  the  A  fibre  range  observed  here,  may 
explain the brush hypersensitivity/ allodynia that is also induced by the model. 
  
6.4.5.  Secondary electrical hypersensitivity is induced by UVB rekindling 
The  increased input observed post  rekindling is  most likely the  result  of the  lowering in 
threshold of the WDR cell recorded from. As discussed, through a number of mechanisms such 
as  volume  transmission  and  disinhibition  the  cells  that  are  recorded  from  may  become 
sensitised. This results in both a reduction in activation threshold and an increase in response 
to noxious stimuli. The electrical responses of WDR cells are the result of stimulation within 
the  receptive  field  to  3  times  the  C-fibre  threshold.  The  threshold  is  obtained  during 
baselining and most likely will drop post rekindling. However, since re-thresholding is not 
conducted during the experiment in order to compare the results to baseline responses and 
reduce confounds, it is likely that the newly sensitised cell will have a greater response than at 
baseline. Given that the receptive field of the cell is distal to the rekindling, it is unlikely that 
this increase in input is reflective of a peripheral sensitisation. 
 A  reduction  in  pain  threshold  to  intraneural  micro  stimulation  in  the  secondary  area  is 
observed post capsaicin injection (Torebjörk et al. 1992). Furthermore, comparing this model 
once again to the early phase of MIA induced OA, an increase in input is seen in the early and 
late  phase  (Burnham  2012).    Suggesting  that  inflammation  associated  with  spontaneous 
ongoing  activity  results  in  a  central  sensitisation  and  heightened  sensitivity  of  spinal 237 
 
neurones to electrical stimulation. Electrical stimulation bypasses the traditional transduction 
machinery  that  is  the  receptors  located  on  the  afferent  terminals.  Therefore  electrical 
hypersensitivity could result from a peripheral or central sensitisation, however as discussed, 
in this case it is most likely a reflection of an enhanced central processing. 
 
6.4.6.  Spinal WU is not enhanced post UVB rekindling, and human perceptual WUR 
remains unchanged 
The ability to wind up is a key distinguishing feature of WDR cells, primarily located in the 
deep DH. Under normal conditions repetitive stimulation of C fibres at a low frequency (0.3-2 
Hz) can result in the progressive potentiation of WDR cell responses. Wind up is believed to 
be a homosynpatic event, whereby a repetitive activation of the peptidergic C fibres results in 
the  release of substance  P  and CGRP onto  neurones synapsing with the  peripheral  fibres 
activated. These neuropeptides produce slow EPSPs that allow the removal of the Mg2+ block 
of NMDA receptors. Indeed by blocking this receptor the ability of a cell to wind up is lost 
(Dickenson and Sullivan 1987; D'Mello et al. 2011).  
Post  rekindling,  there  is  an  enhanced  input  which  results  in  a  decrease  in  WU,  although 
examination of the AUC reveals an overall enhancement of around 25%. Once again, this is 
most likely due to the increase in input. The overall total number of action potentials reached 
is the same both pre and post rekindling.  It stands to reason that any given cell must have a 
maximum capacity – that is to say, it reaches a maximum level of discharge and regardless of 
an increasing peripheral input and further recruitment of NMDA receptors it is unable to 
produce  a  greater  amount  of  action  potentials.  This  mechanism  is  shared  with  central 
sensitisation,  which  has  also  been  shown  to  require  this  receptor  (Woolf  and  Thompson 
1991).  Thus, if central sensitisation is induced by a particular model, engaging the NMDA 
receptor and inducing a state of hyperexcitability in spinal cord neurones, it may be expected 
that their ability to wind up is reduced as the receptor is already close to capacity. That is to 
say, since they both rely on the same receptor, it may not be possible for the two to occur in 
tandem.  Given  that  wind  up  was  reduced  post  rekindling,  this  may  also  suggest  the 
engagement of central sensitisation in the model. 
Perceptual wind up is the human correlate of a similar engagement of temporal summation. 
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rating  for  the  final  stimuli,  with  respect  to  the  first.  Dependence  on  C  fibres  and  NMDA 
receptors is also a feature of this psychophysical correlate of wind up (Price et al. 1994). 
However, unlike in the animal experiments, there was no change observed in perceptual wind 
up post rekindling. It is possible that overall, in a state of central hyperexcitability only some 
cells would reach capacity, while others are simply primed by unblocking of NMDA receptors 
are may in fact wind up more readily. The balance of these two opposing mechanisms may 
explain why overall there is no change in the human psychophysical correlate. 
 
6.4.7.  Expansion of receptive fields and notable areas of secondary pinprick 
hyperalgesia are apparent post UVB rekindling 
In this study there is a clear enlargement of receptive fields post rekindling treatment. The 
receptive field is a malleable feature of WDR cells due to the synaptic plasticity of the spinal 
cord. Under normal conditions, only a fraction of synaptic inputs terminating in the DH will 
contribute towards the generation of action potentials as many simply result in subthreshold 
EPSPs (Woolf and King 1989). These neurones sit within what has been described as a low-
probability firing fringe. However, in a state of central hyperexcitability increased synaptic 
efficacy  leads  to  recruitment  of  subthreshold  inputs.  Models  confirmed  to  induce  central 
sensitisation often report expanded receptive fields, such as mustard oil, SNL, CCI and chronic 
inflammation (Woolf and King 1990; Ren et al. 1992; Grubb et al. 1993; Cumberbatch et al. 
1998; Suzuki et al. 2000). Therefore the ability of previously subthreshold EPSPs to generate 
action potentials seen in this model is most likely reflective of altered central processing as 
described. 
In humans the development of a large area of secondary hyperalgesia is also reflective of 
changes in properties of central neurones. Ongoing input during the rekindling procedure 
most likely results in an increase in membrane excitability, increased synaptic strength and a 
reduction in spinal cord inhibition. As such the thresholds of spinal neurones are lowered and 
activation kinetics are altered. Subsequent stimulation of peripheral fibres in the surrounding 
untreated may then evoke action potentials of greater amplitude and frequency than under 
normal conditions, which is perceived by the subjects as more painful than before. Secondary 
hyperalgesia most likely reflects both the lowering of activation thresholds and recruitment of 
neurones that previously sat within the firing fringe, in addition to the increased activity of 
spinal neurones.  239 
 
Although an expansion of receptive fields and the development of secondary hyperalgesia are 
not  directly  comparable,  they  are  both  indirect  measures  of  the  induction  of  central 
sensitisation and corroborate the theory that this state has been evoked in both animals and 
humans.  Overall  suggesting  that  this  model  induces  a  robust  central  sensitisation  across 
species and may be useful for examining the relevant mechanisms involved, and testing new 
treatments for chronic pain. 
 
6.4.8.  UVBR QST Profile 
The QST profile of subjects undergoing UVB rekindling treatment highlights a generalised 
gain in function of the nociceptive system. As expected there is a clear hypersensitivity to 
mechanical  stimuli  such as  vF, pinprick and brush. Novel  findings include  the  heightened 
warm detection, cold and heat hypersensitivity and a sensitisation to pressure. Given that all 
testing  is  undertaken  within  the  area  of  mapped  secondary  hyperalgesia,  these  increased 
responses are most likely reflective of enhanced central processing as described above. 
These  changes  are  similar  to  those  seen  in  OA  patients  where  QST  has  revealed 
hypersensitivity to cold, warm, heat, and pressure pain. Furthermore, in agreement with this 
study despite the cold hypersensitivity there was no difference in cold detection thresholds in 
patients. All of the  abnormalities  were found to  return  to  normal after surgery (total hip 
replacement  or  osteotomy),  suggesting  that  in  this  group  of  patients  they  had  been 
maintained by an ongoing afferent input, and any changes in the spinal cord were reversible 
(Kosek and Ordeberg 2000).  The similarities between symptoms of OA patients and those 
observed in this model of UVB rekindling suggest that similar mechanisms may be involved. 
Indeed, it has already been raised that the most analogous preclinical model appears to be is 
the MIA model of OA. The advantage of the UVB rekindling model over MIA is simply that is 
can be induced over a period of 24 hours and it suitable for use in both animals and humans 
and therefore may have greater translational relevance. 
 
6.4.9.  Somatosensory changes observed post UVB rekindling are reflective of altered 
central processing 
In order to induce central sensitisation, a stimulus must be intense, repetitive and sustained. 
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circuitry, through increases in membrane excitability, synaptic efficacy, or reduced inhibition 
(Latremoliere and Woolf 2009). Neuronal and perceptual correlates of central sensitisation 
include  spontaneous  activity,  threshold  reduction,  increased  responses  to  suprathreshold 
stimuli and enlarged receptive fields. Overall, these experiments provide objective evidence of 
reduced  thresholds,  increased  responses  to  suprathreshold  stimuli  in  the  secondary 
untreated  area,  in  addition  to  enlarged  receptive  fields  and  large  areas  of  secondary 
hyperalgesia in animals and humans, respectively. Suggesting that the activation of sensitised 
afferents during UVB rekindling results in an input of an adequate intensity and frequency to 
induce changes in properties of central neurones and is thus a robust translational model of 
central sensitisation. 
As previously mentioned, a peripheral sensitisation results in an increase in afferent input 
and  thus  may  indirectly  lead  to  central  sensitisation.  In  this  model  the  pre-sensitised 
peripheral  afferents  create  barrage  of  input  into  CNS  upon  rekindling.  Under  normal 
conditions it is thought that in order to induce a state of central sensitisation a temperature of 
above 49C is required, however since PAFs are already sensitised, it appears that a stimuli of 
40C is able to generate action potentials of same frequency and amplitude as 49C – as was 
observed  in  chapter  5  (Latremoliere  and  Woolf  2009).  Processes  underlying  central 
sensitisation likely to be involved in this model include NMDA receptor activation as a result 
of direct ongoing activating into the spinal cord, or from the summation of EPSPs from the 
firing fringe such that an action potential is generated from outside of a given cells receptive 
field.  Further  heterosynaptic  mechanisms  likely  to  be  involved  in  this  secondary 
hypersensitivity  include  volume  transmission  of  neuropeptides  and  a  disinhibition  of 
interneuron’s and descending controls. Engagement of any number or combination of these 
mechanisms may lead to the changes observed post rekindling. 
To further examine the extent of central mechanisms engaged in this model a number of 
pharmacological  modulations  could  be  employed.  From  an  anaesthetic  block  at  site  of 
peripheral  injury,  to  an  NMDA  receptor  block  and  an  examination  of  the  contribution  of 
descending  controls.  If  the  underpinning  mechanisms  are  truly  of  central  origin,  an 
anaesthetic block at the site of peripheral injury would be unable to reduce the expansion of 
receptive fields, and unlike UVB irradiation alone, the model should show sensitivity to NMDA 
receptor antagonists such as MK-801 (Bishop et al. 2010). Furthermore, since it is well known 241 
 
that  changes  in  descending  controls  contribute  towards  changes  in  properties  of  central 
neurones it would be interesting to investigate what role, if any, they play in this model. 
Central sensitisation is a cardinal feature of chronic pain and contributes to a number of 
conditions,  including  both  neuropathic  and  inflammatory  pain,  migraine  and  IBS 
(Latremoliere and Woolf 2009). It is therefore essential to be able to model this phenomenon 
effectively, to understand the mechanisms for induction and maintenance and to assess the 
pharmacological sensitivity. It is important to note that central sensitisation is made up of two 
distinct  phases,  and  whilst  the  early  phase  is  phosphorylation-dependent  (changes  in 
receptor and ion channel properties), the latter is transcription-dependent (synthesis of new 
proteins) (Woolf and Salter 2000). It is believed that the latter is more relevant to patients, 
and thus it will be important to assess the contribution of both to fully understand the true 
clinical meaningfulness of the model.  
 
6.5.   Concluding remarks 
Overall using objective characterisation methods, UVB rekindling appeared to be a reliable 
translational  model  of  secondary  hypersensitivity,  evoking  similar  phenotypic  changes  in 
both animals and humans, which can be measured using electrophysiology and QST. 242 
 
 
Figure 6-11 The UVB Rekindling Model. It is believed that UVB irradiation leads to a peripheral sensitisation, 
which increases afferent activity into the DH and thus the hyperexcitability can be recorded from WDR neurones 
(left  panel).  When  recording  from  WDR  neurones  with  receptive  fields  outside  of  the  treated  area,  heat 
rekindling increases evoked responses. This is indicative of the development of central sensitisation, involving 
release of neuropeptides such as substance P and recruitment of the NMDA receptor (right panel). 243 
 
7.  General Discussion 
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7.1.   Translational models induce similar signs and symptoms in animals 
and humans 
This thesis aimed to characterise translational models of chronic pain, in order to bridge the 
gap between basic science and the clinic, and to address the disparity between the animal and 
human preclinical models that are in current use. Furthermore, the studies were conducted 
using  similar  outcome  measures  in  order  to  draw  comparisons  between  the  animal  and 
human  data,  whilst  exploiting  the  advantages  of  each.  The  development  of  translational 
models is imperative since such models can be used not only in basic mechanistic studies, but 
also in pharmacological studies to assess analgesic efficacy (Arendt-Nielsen and Yarnitsky 
2009). 
All of the models explored in this thesis were able to induce signs and symptoms of chronic 
pain  in  both  animals  and  humans.  Table  7.1  below  summarises  the  changes  that  were 
observed across species in all 3 models. Overall in each of the studies it became clear that the 
models were able to induce analogous changes in the animal and human subjects, suggestive 
of the induction of comparable underlying mechanisms. Thus, highlighting their potential as 
surrogate translational models. 
The  topical  capsaicin  model  had  previously  been  used  on  the  whole  in  human  subjects 
(Carpenter and Lynn 1981; Koltzenburg et al. 1992; LaMotte et al. 1992); therefore this thesis 
assessed  the  translational  implications  in  animals.  Using  DH  single  unit  in  vivo 
electrophysiology and QST it is clear that within the primary area of treatment, capsaicin is 
able  to  induce  a  strong  thermal  and  mechanical  hypersensitivity  across  species.  Pinprick 
hyperalgesia in human subjects was complemented by a facilitation of A fibre responses in 
animals.  These  results  are  suggestive  of  peripheral  sensitisation  of  TRPV1/  C  fibres,  in 
addition to central modifications most likely driven by the afferent barrage of activity during 
the application of topical capsaicin. 
Conversely, the model of UVB irradiation had previously been explored in both animals and 
humans. However, these studies did not include a full objective characterisation (Gustorff et 
al. 2004; Bishop et al. 2007). Therefore, this thesis provided the first objective evidence of 
primary  mechanical  and  thermal  hypersensitivity  in  animals.  The  lack  of  receptive  field 
expansion and negligible area of secondary hyperalgesia in human subjects provide further 
proof of this model inducing dominant peripheral changes. 245 
 
Finally,  very  little  data  previously  existed  with  regards  to  the  model  of  UVB  rekindling 
(Cookson 2005; Davies et al. 2011). This thesis provided the first fully translational study to 
reveal the pattern of secondary hypersensitivity in animals and humans.  Hypersensitivity 
was  apparent  to  both  thermal  and  mechanical  stimuli.  Brush  evoked  allodynia  was 
complimented by the facilitation of A fibre responses in animals. Finally, the large expansion 
in receptive fields and area of secondary hyperalgesia in humans confirmed these changes 
were most likely underpinned by secondary changes. 
 
 
Table  7-1  Comparison  of  the  symptoms  induced  by  the  translational  models  
 
Patients  suffering  from  chronic  pain  exhibit  a  myriad  of  different  symptoms.  The  models 
explored in this thesis are able induce a range of these sensory changes that are observed in 
patients,  as  highlighted  in  table  7-2.  In  the  model  of  topical  capsaicin  symptoms  such  as 
pinprick hyperalgesia and DMA were found in the primary area. These symptoms were also 
observed in the secondary area post UVBR. These are both clinically relevant phenomenon 
Stimulus 
Capsaicin Induced 
Hypersensitivity 
UVB Induced 
Hypersensitivity 
UVBR Induced Secondary 
Hypersensitivity 
Animal  Human  Animal  Human  Animal  Human 
Brush     No change   Non 
significant 
increase 
Subthreshold 
Mechanical 
     
Suprathereshold 
Mechanical 
No change      
Subthreshold Thermal       
Suprathreshold Thermal       
Input       
Wind up  No change  No change  No change  No change  Reduced  No change 
Fibre count  Reduction 
in C fibre, 
increase in 
A 
Not tested  Reduction 
in C fibre 
threshold 
Not tested  Increase in 
Ab 
Not tested 
Receptive field/ Area of 
secondary hyperalgesia 
Not tested  Not tested  No change  No change  2-fold 
increase 
2317.48 
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since DMA occurs in up to 49% of patients with PHN and pinprick hyperalgesia is a symptom 
suffered by 36% and 30% of PHN and PNI patients, respectively (Maier et al. 2010). Both the 
UVB model and UVBR induced a cold hypersensitivity, which is also experienced by patients 
suffering from OA and oxaliplatin-induced neuropathy (Kosek and Ordeberg 2000; Binder et 
al. 2007). Additionally, all of the models produced a primary heat hypersensitivity, which is 
found in patients with OA and around 20% of neuropathic pain patients (Maier et al. 2010; 
Soni et al. 2013). Overall, suggesting that these models are able produce a number of positive 
sensory symptoms that may be applicable to the clinical conditions. 
Topical capsaicin also resulted in a reduced C fibre count, indicative of fibre desensitisation. 
This was not reflected in most of the animal or human evoked responses, with the exception 
of the CPT in humans. CPT was significantly lower post topical capsaicin, when compared to 
baseline responses. This symptom is observed in patients with central pain, PHN and PNI 
(Maier  et  al.  2010).  Therefore  suggesting  that  this  sensory  loss  may  also  be  relevant  to 
patients. 
As  apparent  from  table  7-2,  aside  from  a  cold  hypoalgesia,  one  limitation  of  the  models 
explored in this thesis is that they do not induce a profound sensory loss. Rather, each of the 
models  produced  strong  positive  symptoms  in  the  primary  (capsaicin  and  UVB)  and 
secondary areas  (UVBR). This is important to note since negative symptoms indicative of 
sensory loss are common in many chronic many patients (Rice et al. 2009; Maier et al. 2010). 
Negative  symptoms  are  often  associated  with  non-nociceptive  parameters,  and  may  be  a 
result of damage to peripheral or central neurones (Maier et al. 2010). Therefore, for ethical 
reasons  it  is  likely  that  such  symptoms  could  not  be  modelled  in  healthy  volunteers.  
However, it is important to note that such damage may be difficult to treat and as such there 
would only be a limited use of exploring these symptoms further in models. Additionally, one 
interesting  possibility  is  that  peripheral  and  central  hyperexcitability  is  actually  a 
compensation for a sensory loss associated with neuropathic pain conditions. Therefore, even 
though  the  models  do  not  induce  negative  symptoms,  they  may  still  engage  relevant 
mechanisms. 
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Symptom  Model 
Spontaneous pain (shooting)  - 
Spontaneous pain (ongoing)  - 
Heat allodynia  Capsaicin, UVB and UVBR 
Cold allodynia  UVB and UVBR 
Static mechanical allodynia  Capsaicin, UVB and UVB 
Dynamic mechanical allodynia  Capsaicin and UVBR 
Punctate mechanical hyperalgesia  Capsaicin, UVB and UVBR 
Sensory loss  Capsaicin (cold hypoalgesia) 
 
Table 7-2 Symptoms induced by experimental models in this thesis. The symptoms listed in the left hand 
column are experience by chronic pain patients, the right hand column highlights which model can be used to 
mimic each symptom. 
In addition to negative symptoms indicating a sensory loss, many chronic pain patients also 
report spontaneous or ongoing pain (Baron et al. 2009; Rice et al. 2009). A clear limitation of 
these studies is the inability to explore this symptom. This is partially due to the methods 
used in this thesis, since spontaneous pain is not easily assessed with either of the techniques 
described.  However,  models  such  as  UVB  are  not  believed  to  be  associated  with  any 
spontaneous pain (Bishop et al. 2010; Davies et al. 2011). Since we are unable to effectively 
model this symptom in translational studies it has been suggested this is better investigated 
in  patients  (Schmelz  2009).  However,  such  data  may  still  be  supplemented  by  ongoing 
research into examining mechanisms and modulation of spontaneous pain in animals using 
tests  such as  the  CPP  (King et al. 2009).  Induction  of CPP by manipulations  that are not 
otherwise rewarding provides evidence of ongoing pain in neuropathic animals. 
  
7.1.1.  Clinical relevance of the mechanisms induced by translational models 
The potential underlying mechanisms involved in each of the pain models have been inferred 
from  the  complimentary  animal  and  human  data.  For  example,  each  modality  in  the  QST 
battery relates to the function of different fibre types (Arendt-Nielsen and Yarnitsky 2009), 248 
 
whilst electrophysiological changes in fibre counts and receptive fields are useful to assess 
central changes. Collectively, this information allowed assumptions to be made with regards 
to the peripheral versus central components for each model. Each symptom may be the result 
of a number of underlying mechanisms, and therefore it is often more useful to look at the 
expression  pattern  of  pain-related  sensory  abnormalities  in  addition  to  the  sensory 
phenotypes  in  order  to  gather  hints  as  to  the  overall  underlying  pathophysiological 
dysfunctions  (von Hehn  et  al.  2012).  Given  that  the  models  explored  produce  symptoms 
observed  in  chronic  pain  patients,  it  may  be  assumed  that  these  are  reflective  of 
pathophysiological  mechanisms  involved  in  chronic  pain.  Therefore,  such  translational 
models can be used to gain a better understanding of the mechanisms that may be involved in 
chronic pain. 
The mechanisms involved in each of the models are discussed in each chapter, however, to 
briefly summarise: the sensory changes evoked by capsaicin in animals and humans were 
reflective of both a peripheral and central sensitisation, including mechanical hypersensitivity 
accompanied by a facilitation of responses in the A fibre range. UVB appeared to be a strictly 
peripheral  model,  resulting  in  no  secondary  changes  or  receptive  field  expansion.  On  the 
other  hand  the  UVBR  model  showed  clear  signs  of  engaging  both  peripheral  and  central 
mechanisms,  including  secondary  brush  hypersensitivity  and  a  facilitation  of  A  fibre 
responses. 
To  fully  understand  the  mechanisms  at  play  it  is  also  useful  to  be  able  to  compare  and 
contrast between the models explored in this thesis, in particular with regards to the model of 
UVB versus UVBR. There is much debate as to whether the original model of UVB irradiation 
in animals led to the development of a purely peripheral sensitisation, or whether it also 
engaged central mechanisms (Bishop et al. 2010; Gustorff et al. 2013). The somatosensory 
changes  observed here, in both animals  and humans, are certainly suggestive of a  strong 
peripheral sensitisation, without the induction of central sensitisation. On the other hand, 
UVBR  resulted  in  large  areas  of  secondary  hyperalgesia  and  expansion  of  WDR  neurone 
receptive  fields,  suggestive  of  the  development  of  central  sensitisation.  Furthermore,  the 
development of secondary brush hypersensitivity/ DMA accompanied by a facilitation of A 
fibre  responses  also  suggests  central  changes  are  present.  Given  such  changes  are  not 
observed in the model of UVB alone, this provides more support to the theory it is mainly 
driven by peripheral changes.  249 
 
Another interesting comparison is that of the CAP model vs. UVBR, both which appear to have 
elements of peripheral and central sensitisation contributing to the changes observed. It was 
noted that UVBR treated WDR cells lost the ability to wind up further, which was attributed to 
the prior induction of a strong central sensitisation. Since wind up and central sensitisation 
share overlapping mechanisms, it is possible that due to the induction of central sensitisation 
wind  up  cannot  occur  any  further,  since  all  NMDA  receptors  may  already  be  activated. 
Similarly, it has been found that it is more difficult to induce LTP in SNL rats, compared to 
naives (Rygh et al. 2000). This may be explained in analogous manner whereby the prior 
central  sensitisation  engages  mechanisms  similar  to  LTP  and  thus  further  induction  of 
excitability is not possible. On the other hand, turning to the model of topical capsaicin cream, 
there is no change in wind up with regards to WDR cells or human percept. Therefore this 
could  suggest  that  although  central  changes  may  have  been  induced,  the  degree  of 
sensitisation is less and therefore wind up can still occur. 
As  previously  mentioned,  the  model  of  capsaicin  cream  allows  the  study  a  particular 
mechanism (TRPV1 activation and sensitisation). However, the weakness of this model is that 
it is unknown how important this particular mechanism is in any given pain state. The newer 
model  of  UVB  irradiation  could  begin  to  closer  reflect  clinically  meaningful  mechanisms, 
however since it was concluded that this model was  mainly underpinned by a peripheral 
sensitisation  this  model  may  also  have  its  limitations.  Whilst  it  is  useful  for  exploring 
peripheral mechanisms alone, most patients who suffer from chronic pain will most likely 
have  numerous  overlapping  peripheral  and  central  mechanisms  contributing  to  their 
symptom profiles (Baron 2006; Gwilym et al. 2009; Latremoliere and Woolf 2009; Thakur et 
al. 2012). Therefore, it may be concluded that the UVBR model induces the most clinically 
relevant changes. The experiments in this thesis highlighted a clear primary hypersensitivity 
from UVB, followed by rekindling induced enlargement of WDR cell receptive fields, and large 
areas of secondary hyperalgesia in humans. UVBR therefore exhibits signs of engagement of a 
number of clinically relevant phenomena, such as peripheral inflammation driving a central 
sensitisation (Baron et al. 2013).  
Previous studies have shown that the common inflammatory mediators expressed post UVB 
irradiation in humans and rats not only highlight the translational nature of the model, but 
also  the  clinical  relevance.  The  correlation  in  gene  expression  in  rats  and  humans  is 
suggestive similar underlying biological (Dawes et al. 2011). This infiltration of immune cells 250 
 
and release of mediators may be applicable to other persistent pain states in humans. Pain in 
OA can arise from damage in the peripheral tissues and is driven by peripheral inflammatory 
mediators  (Malfait  and  Schnitzer  2013).  Although  many  of  these  mediators  are  currently 
unidentified, it is possible that there may be some overlap with the mechanisms induced here. 
Most  notably,  CXCR2-chemokines  are  believed  to  be  upregulated  in  arthritic  knee  joints 
(Grespan et al. 2008). This peripheral component of the disease is highlighted by the fact that 
local anaesthetics can reduce OA related pain. 
Central sensitisation is also believed to be present in OA, in addition to a number of other 
chronic pain conditions such as fibromyalgia, neuropathic pain (including PHN and PNI) and 
post-surgical pain (Woolf 2011; Baron et al. 2013). OA patients develop symptoms such as 
mechanical, heat and cold hypersensitivity distant from the site of injury, which are explained 
through central modifications (Gwilym et al. 2009; Lee et al. 2011). Studies further suggest 
that these centrally mediated symptoms may be linked to a peripheral ongoing input, since a 
block of afferent activity with lidocaine can abolish symptoms such as allodynia (Gracely et al. 
1992). Furthermore, in OA a total joint replacement often eliminates the pain, suggesting that 
it was driven by the ongoing afferent activity as a result of peripheral inflammation, reducing 
activation thresholds (Woolf 2011; Malfait and Schnitzer 2013). Similarly, the central changes 
involved in the UVBR model are driven by ongoing activity produced during the rekindling. 
Inflammation  caused  by  UVB  irradiation  reduces  the  threshold  of  afferent  fibres,  thus 
allowing ongoing activation of nociceptors by a 40C stimulus. On the other hand, the fact that 
some patients do not respond to local anaesthetics, or joint replacement suggests the central 
pain may become independent of the peripheral drive, and thus limits the use of UVBR in 
modelling such conditions (Lim et al. 2006; Malfait and Schnitzer 2013).  
Models  that  induce  only  a  peripheral  or  central  sensitisation,  are  useful  for  investigating 
peripherally and centrally acting drugs, respectively (Chizh et al. 2007). However, a model 
including both peripheral and central components can be used to detect efficacy of a wider 
range of analgesics. It is well known that the UVB model responds to anti-inflammatory drugs, 
and preliminary work suggests the model of UVBR responds to centrally acting mediators 
(Wang 2005; Bishop et al. 2007; Bishop et al. 2009).  Therefore the UVBR model is likely to be 
useful in assessing analgesic efficacy of novel analgesics acting at numerous sites in the pain 
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It is therefore possible that these models (in particular UVBR) can be used as proof of concept 
studies, conducted prior to larger clinical trials. Thus, the work described in this thesis has 
direct relevance and utility within drug discovery. Such a technique appears to have been 
successful when applied in retrospective studies, whereby drugs have been tested in models 
after approval for patients. Pregabalin is known to reduce pain in PHN patients, many of 
whom  suffer  from  pinprick  hyperalgesia  (Dworkin  et  al.  2003;  Maier  et  al.  2010). 
Furthermore, in patients with HIV-related neuropathy post-hoc analysis showed efficacy of 
pregabalin in a subgroup of patients with pinprick hyperalgesia (Simpson et al. 2010). It has 
since  been  shown  that  pregabalin  can  reduce  pinprick  hyperalgesia  induced  in  human 
subjects  by  electrical  stimulation  (Chizh  et  al.  2007).  Furthermore,  a  similar  compound 
(gabapentin) is able to reduce capsaicin induced pinprick hyperalgesia and the activation in 
the  brainstem  thought  to  be  associated  with  central  sensitisation  (Iannetti  et  al.  2005). 
Therefore  pregabalin  and  gabapentin  are  able  to  reduce  signs  of  central  sensitisation  in 
experimental models, such as pinprick hyperalgesia, which further translates to efficacy in the 
clinic. Current trials are also in process to evaluate the efficacy of tapentadol in the models of 
capsaicin and menthol. It is predicted that Tapentadol will also be able to reduce signs and 
symptoms of central sensitisation (such as areas of pinprick mechanical hyperalgesia and 
allodynia),  in  addition  to  reducing  pain  intensity  scores  (Baron  2013).  Pioneering 
experiments  such  as  these  that  are  run  alongside  clinical  trials  will  provide  important 
information as to the ability of these models to predict trial outcomes (Baron 2013).    
 
7.1.2.  Limitations to preclinical translational models 
It  is  important  to  note  that  surrogate  models  induced  in  humans  produce  short-term, 
reversible changes. As such, there are likely to be mechanisms involved in chronic pain that 
are not induced by these models. That is to say, since chronic pain often develops over the 
course of many months or years in patients, certain mechanisms may depend on this long 
term  set  up.  These  experimental  models  are  unlikely  to  model  the  full  complex  clinical 
conditions experienced by patients (Arendt-Nielsen et al. 2007; von Hehn et al. 2012).  
One example is the role of trophic factors such as NGF (Schmelz 2009). Neurotrophic factors 
are  known  to  regulate  long  term  processes  such  as  survival,  growth  and  differentiated 
function. NGF is seen to be upregulated in conditions such as OA and DPN, and anti-NGF 
molecules are able to reduce OA related pain (Lane et al. 2010; Kumar and Mahal 2012). 252 
 
Preclinical studies have revealed that NGF effects gene expression of ion channels such as 
TRPV1, ASIC3 and Nav 1.8, resulting in sensitisation of peripheral neurones (von Hehn et al. 
2012). Furthermore, NGF believed to be able to alter the distribution of A fibres, enabling 
greater proportions to respond to nociceptive stimuli (Stucky et al. 1999). These afferent 
fibres also showed heightened responses to mechanical stimuli (Stucky et al. 1999). Taken 
together, evidence suggests a potential role of NGF in contributing to chronic pain, which is 
particularly important to note; firstly as such changes may indeed require longer time periods 
of induction and secondly because NGF was not shown to be upregulated by UVB irradiation. 
Therefore these changes are unlikely to be captured by the models in this thesis.  
Additionally, it is believed that after nerve injury, Aβ fibres are able to undergo phenotypic 
changes, such as an increased expression of neuropeptides (Nitzan-Luques et al. 2011). Thus 
they may acquire the capacity to trigger or maintain central sensitisation. PNI has also been 
noted to induce changes in dendritic spines of DH neurons, mediated by the G protein Rac1, 
suggestive of physical changes in spinal cord circuitry (Tan et al. 2011). It is clear that the 
human experimental models discussed in this thesis cannot replicate such mechanisms. Thus, 
it is imperative to study the underpinnings of long-term modifications in animal models, and 
examine the possible consequences in patients.  
As previously mentioned,  spontaneous pain has not been associated with the UVB model. 
However, the  mechanisms underpinning this  symptom are of great clinical importance. A 
number of candidate molecules have been put forward as mediators of spontaneous pain, 
including  Na+,  K+  and  hyperpolarisation-activated  cyclic  nucleotide-gated  (HCN)  channels 
(von Hehn et al. 2012). Modifications to these ion channels due to inflammation or nerve 
injury  may  indeed  lead  to  ectopic  activity  of  peripheral  fibres.  Ongoing  activity  could  be 
generated by non-inactivating Nav1.3- and Nav1.6-mediated currents, or by down regulation 
of K+ channels such as Kv1.2, 1.4 or 2.2 (Herzog et al. 2001; Kim et al. 2002; Dib-Hajj et al. 
2010). HCN antagonists are able to alleviate both ectopic discharge in primary afferents and 
signs of spontaneous pain in nerve injured animals (Chaplan et al. 2003; Lee et al. 2005). 
Taken together these findings strongly suggest a role for these channels in the generation of 
spontaneous pain sensations. Given that spontaneous activity does not appear in the models 
described,  it  may  be  inferred  that  these  mechanisms  are  not  captured,  highlighting  an 
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7.2.   Novel therapies for chronic pain explored in this thesis 
This  thesis  provided  the  first  preclinical  assessment  of  the  effect ADO/  CPA  on  capsaicin 
induced  central  sensitisation.  Most  importantly,  it  included  studies  in  both  animals  and 
humans  that  also  involved  supra  threshold  stimuli.  Despite  the  ability  of  ADO  to  reduce 
thermally evoked responses in WDR cells and human HPT, it was unable to fully prevent the 
development of capsaicin induced hypersensitivity. However, the A1R agonist CPA was able to 
reduce  signs  of  both  peripheral  and  central  sensitisation  (i.e.  thermal  and  brush  evoked 
hypersensitivity) in rodents. Previous studies have also found that agonists of the A1R are able 
to reduce inflammatory pain (Lima et al. 2010), in addition to noting analgesic effects models 
such  as  formalin  and  DPN  (Balasubramanyan  and  Sharma  2008;  Liu  et  al.  2013).    This 
suggests that the A1R is a viable drug target, and using activation of this receptor as a pre-
emptive  treatment  may  be  able  to  reduce  peripheral  sensitisation  and  inhibit  the 
development of subsequent central modifications. 
An additional target explored in this thesis is the chemokine CXCL5. This chemokine has been 
shown to be upregulated in both animals and humans post UVB exposure (Dawes et al. 2011). 
Experiments here found that injection of intraplantar CXCL5 resulted in heighted responses of 
WDR  cells  to  both  thermal  and  mechanical  stimuli.  Although  this  chemokine  is  yet  to  be 
explored in patients, it has also been found to be associated with a number of other preclinical 
models  (Dawes  2013).  Therefore  an  antagonist  of  its  receptor,  CXCR2,  could  also  hold 
potential  for  future  drug  therapies,  in particular  for  inflammatory  conditions,  such  as  OA 
(Grespan et al. 2008; Dawes et al. 2011).  Indeed, preclinical data suggests that antagonism of 
this receptor is able to attenuate pain-related hypersensitivity in a number of experimental 
models, including the collagen-induced arthritis model, carrageenan, and CFA (Cunha et al. 
2008). 
Most importantly both of these potential targets are in the periphery. There are two main 
advantages of developing such treatment. Firstly, analgesics acting outside of the CNS should 
not induce side effects such as sedation, dizziness and fatigue, of which may be debilitating to 
patients  requiring  these  drugs  (Finnerup  et  al.  2010).  Secondly,  given  that  central 
sensitisation mechanisms are often inextricably linked to ongoing peripheral afferent activity, 
using  a  treatment  that  may  inhibit  this  activity  could  prevent  the  development  or 
maintenance of central modifications (Baron et al. 2013). The earlier the treatment is given, 
the higher the likelihood of interfering with disease progression. 254 
 
7.3.   Use of in vivo single unit DH recordings and QST 
This thesis also aimed to address the issues surrounding subjective measures of pain, through 
the use of objective in vivo electrophysiological recordings from LV WDR cells in animals. 
Relying on behavioural studies poses a number of difficulties with regards to pain research, in 
addition to the subjective nature of the tests. Most notably, whether reflex measures truly 
equate to the human pain sensation and the absence of suprathreshold measurements (Mogil 
2009;  Bennett  2010).  All  the  studies  undertaken  in  this  thesis  highlight  the  strong 
concordance between the rodent WDR cell activity and human psychophysical responses both 
pre and post the induction of the surrogate models, as has been observed in previous work. 
Indeed it has been noted that both the coding properties of WDR neurones, and the ability to 
wind up, correlate closely with human perceptions (Maixner et al. 1986; Dubner et al. 1989; 
Sikandar et al. 2013). 
Single unit recordings of spinal neurones allow the assessment of responses to both natural 
and  electrical  stimuli,  in  addition  to  their  modulation,  allowing  full  characterisation  of 
preclinical pain models. LV WDR neurones are of particular interest in the study of chronic 
pain since they are under regulation of both local networks and descending controls (D'Mello 
and  Dickenson  2008).  Additionally,  one  key  advantage  of  DH  electrophysiology  is  that 
responses to supra threshold stimuli, and their modulation, can be examined - which are 
likely to relate to the high pain levels which patients report (Sikandar and Dickenson 2013). 
When examining thermal threshold measurements, it was observed that the action potentials 
evoked correlate with human changes in threshold. That is to say, if the baseline threshold in 
humans  evokes  a  responses ‘X’ number of action  potentials in animals, after induction  of 
hypersensitivity the new human threshold now also evokes ‘X’ number of action potentials in 
the animals. This highlights not only the strong overlap between animal and human studies, 
but also the usefulness of using electrophysiology in chronic pain studies, in agreement with 
previous findings (Price 2013; Sikandar and Dickenson 2013). Therefore, it can be concluded 
that  objective  recordings  of  WDR  cells  are  a  useful  measure  that  reflect  the  human  pain 
sensation. 
This thesis also explored the potential of WDR responses as a potential endpoint with regards 
to drug efficacy. Single unit recordings also allow the study of how drugs act across modalities 
and  varying  intensities.  This  thesis  attempted  to  use  a  mechanism  based  approach  to 255 
 
treatment, with the use of ADO and CPA pre-treatment in order to inhibit capsaicin induced 
sensitisation. It has been suggested that activation of the A1R is able to indirectly reduce the 
activity of TRPV1, therefore it was hypothesised the ADO and CPA may be able to inhibit the 
effects  of  capsaicin  through  this  downstream  interaction  (Rohacs  et  al.  2008;  Sowa  et  al. 
2010).  Behavioural  studies,  including  those  with  ADO  or  CPA,  have  often  used  threshold 
measurements and produced conflicting results, whereas here we are able to examine how 
the  drug  may  effect  sub  and  suprathreshold  stimuli  across  modalities.  Importantly,  since 
capsaicin  is  a  highly  suprathreshold  stimulus,  this  study  extends  the  role  of  ADO/  CPA 
modulation  into  these  suprathreshold  levels  of  pain  related  activity  that  are  likely  to  be 
relevant to patients. It was found that the enhanced responses of WDR neurones produced by 
topical  capsaicin  could  be  partially  attenuated  by  ADO,  and  fully  inhibited  by  CPA.  This 
confirms the  use of WDR cell recordings as  a  suitable  measure  of analgesic efficacy.  It  is 
important to note that studies of analgesic efficacy without this objective measure could be 
misled by threshold measuring behaviour.  
One interesting observation from the results of this thesis is the possibility that recordings of 
LV WDR neurones provide a more sensitive and accurate measure of pain, as a predictor of 
human  perception.  For  example,  previous  behavioural  studies  using  A1R  agonists  have 
reported an overriding effect on thermal stimuli  (Gong et al. 2010). However, the studies 
conducted  in  this  thesis  also  reported  minor  effects  on  mechanical  stimuli.  A  small,  non-
significant, increase in human MPT was also observed. Thus suggesting that small changes 
picked up using the sensitivity of single unit recordings of WDR cells may indeed correlate 
with human behavioural responses. Studies in this thesis also found that intraplantar CXCL5 
resulted in a  thermal  hypersensitivity,  whereas  previous behavioural  reports  suggested it 
exclusively led to mechanical hypersensitivity (Dawes et al. 2011). It would be interesting to 
explore the changes in sensitivity in humans after intradermal CXCL5 to assess whether the 
electrophysiology or behaviour reflects most accurately the human perception. 
The use of QST in human subjects provided a comparable data set to that produced in the 
animals, importantly including tests across modalities to sub and suprathreshold stimuli. QST 
enables  the  examination  and  quantification  of  alterations  in  function  of  the  nociceptive 
system, resulting in a broader understanding of surrogate models, which compliments the 
data obtained from animal studies. The wide range of tests allows examination of a gain or 
loss  of  function  in  large  myelinated  fibres,  thin  myelinated  and  unmyelinated  fibres. 256 
 
Advantages  of  QST  include  the  controlled  nature  of  the  stimulus  intensity,  duration  and 
modality,  which  can  be  compared  over  time  (Arendt-Nielsen  and  Yarnitsky  2009). 
Additionally, standardisation of the procedure, allows comparison between studies. Finally, 
QST enables the creation of sensory profiles for each of the models to help understand the 
clinical relevance of the models, and to compare preclinical and clinical studies. 
As with the electrophysiological recordings, it was found that QST was sensitive to changes 
induced by the surrogate models at both sub and suprathreshold levels. Since optimum pain 
diagnosis and treatment should be mechanism based, a selection of QST tests were used in 
assessing  the  modulation  of  capsaicin  induced  sensitisation  (Woolf  et  al.  1998).  In  this 
experiment QST was also able to highlight the analgesic effect of ADO. This suggests that QST 
is suitable for use in testing the efficacy of chronic pain drugs, in both preclinical and clinical 
settings. By using the same tests addressing the same underlying mechanisms, in animals and 
humans, it may be possible to increase the potential to predict efficacy of drugs in given 
patient populations (Arendt-Nielsen and Yarnitsky 2009). Importantly, since QST is cheap, 
reasonably fast and provides reproducible results it could be used in proof of concept studies 
before drugs enter large clinical trials (Arendt-Nielsen and Yarnitsky 2009). 
It  is  important  to  note  that  there  are  of  course  limitations  to  both  of  these  techniques 
discussed. Notably, neither technique is able to  easily distinguish between peripheral and 
central  mechanisms  of  altered  pain  processing.    Assumptions  may  be  made  using  the 
complete  data  sets  from  both  animals  and  humans,  however  firm  conclusion  require 
pharmacological manipulation of the models. A further disadvantage of the methodologies 
used in this thesis is the difficulty in assessing spontaneous/ ongoing pain. With regards to in 
vivo  electrophysiological  recordings  of  single  units,  when  selecting  a  WDR  neurone  to 
characterise it is inevitable that based the criteria used, those with spontaneous activity will 
be discarded. This is due to the simple fact that it is inherently difficult to produce stable, 
reproducible baseline recordings when a cell exhibits inconsistent spontaneous firing. This is 
not to say that it is impossible to study ongoing activity with the technique, as it has been used 
to demonstrate increased activity post SNL  (Chapman et al. 1998). However, even in this 
instance it is not possible to tell the source or modality of the ongoing activity. With regards to 
QST, any spontaneous activity could also have a negative effect on subjects reported outcomes 
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Regarding QST, this method relies on subject cooperation and understanding, which could 
limit its usefulness in subjects who fail to comply with or comprehend the instructions given 
(Krumova et al. 2012). Furthermore, thresholds can be variable across subjects and therefore 
it may be difficult to detect small abnormalities in the models (Hansson et al. 2007). This is 
highlighted by the normative data provided by the DFNS where the value for female HPT on 
the  hand  is  42.61C    3.  33,  whilst  CPT  is  16.16C  7.08,  which  may  indeed  make 
interpretation  of  data  difficult  for  small  studies  or  moderate  effects  (Rolke  et  al.  2006). 
Finally, this method is limited in the examination of any models addressing deep somatic pain. 
However,  all  psychophysical  methods  are  faced  with  these  limitations  and  as  it  has been 
shown in this thesis, they do not necessarily affect all studies. 
QST can only be performed on a small area of body, which is suitable for models such as these 
where the area of interest is well defined. However, this does limit the use in patients where a 
small test site may not be fully representative of the affected area (Hansson et al. 2007). This 
may present a challenge when comparing model profiles to those of patients. As such it may 
be recommended to perform in the QST in several areas on patients (Krumova et al. 2012). 
Additionally,  as  previously  noted  the  DFNS  protocol  used  in  this  thesis  does  not  assess 
spontaneous pain, which is a major symptom suffered by many patients. Once again, this 
could be a potential hurdle for translation of preclinical models to patients. To overcome both 
of these limitations, QST data sets could be supplemented with questionnaires, to provide 
additional  complementary  information.  Questionnaires  such  as  the  fully  validated 
painDETECT would provide data to help fully determine the phenotype of both models and 
patients as it captures useful pain descriptors and qualities of pain, giving a good overview of 
the ‘whole picture’ (Baron et al. 2012). It has been suggested that these alone and could be 
used  to  subgroup  patients,  and  thus  would  nicely  complement  QST  (Baron  et  al.  2012). 
Questionnaires are quick and cheap to implement, although it important to note these are 
purely subjective and negative symptoms are difficult to analyse, thus they could not fully 
replace QST. 
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7.4.   A mechanism based approach to treatment 
It has long been noted that there is a need to shift focus from clinical trials based on change in 
pain scores and classifying patients by the underlying aetiology, to viewing chronic pain as a 
manifestation  of  pathological  neural  plasticity  that  may  result  in  a  number  of  different 
symptom profiles (Jensen and Baron 2003; Baron et al. 2012; von Hehn et al. 2012). Using a 
disease-based classification results in heterogeneous groups of patients in which drugs will 
inevitably  struggle  to  show  an  overall  positive  outcome.  Distinct  pathophysiological 
mechanisms produce specific sensory abnormalities, whilst individual phenotypes are made 
up  of  a  number  of  contributing  factors,  such  as  the  genotype  and  environmental  factors 
including diet and life style (von Hehn et al. 2012). Indeed chronic pain patients have diverse 
genetic and environmental backgrounds in addition to varying degrees of inflammation or 
nerve damage, all of which will contribute to the complex combination of pathophysiological 
mechanisms, which in turn manifest as the individual pain phenotype (von Hehn et al. 2012). 
Thus, it is unsurprising that a group of patients with the same aetiology will not necessarily 
present with the same signs and symptoms. Since we are unable to test for the presence of 
specific mechanisms in patients, the symptom profiles can be used as a surrogate marker. 
Classifying patients by their symptom profiles should reduce heterogeneity and provide clues 
as to the underlying mechanisms. Therefore serving as a guidance as to which drugs would be 
most suitable for use in each subgroup. 
It  has been  suggested  that identification  of the pattern  of symptoms  present in a  patient 
should  be  a  useful  approach  for  identifying  those  who  are  more  likely  to  respond  to  a 
particular  treatment.  As  previously  discussed,  this  is  due  to  the  fact  that  the  pattern  of 
expression  of  pain-related  sensory  abnormalities  and  the  individual  sensory  phenotype 
reveals clues of the underlying mechanisms involved (von Hehn et al. 2012). Given that a 
specific  symptom,  such  as  burning  pain,  may  be  generated  by  a  number  of  different 
underlying mechanisms (peripheral sensitisation – such as a reduced threshold of TRPV1, 
gain of function mutations in Nav1.7, or ectopic activity due to alteration in HCN channels), it 
is the overall profile of sensory symptoms and signs that will predict underlying mechanisms 
(von Hehn et al. 2012). Such profiles can be created by using QST as described in this thesis, in 
addition to validated questionnaires. Profiles of the preclinical models in this thesis are able 
to bridge the gap between research and the clinic, since they can help elucidate particular 259 
 
mechanisms  associated  with  the  symptom  profiles  in  addition  to  testing  pharmacological 
sensitivities.  
Classifying patients by their symptoms has already revealed a number of distinct subgroups 
in patient populations, characterised by their unique sensory profiles (Dworkin et al. 2007; 
Baron et al. 2009; Maier et al. 2010). Such studies have confirmed that there are no specific 
pain profiles associated with particular aetiologies, but rather clusters of different sensory 
profiles within each category (Freeman et al. 2013). Furthermore, similar symptoms profiles 
are  present  in  the  different  aetiologies,  suggesting  that  patients  can  be  classified  into 
subgroups based on symptoms, independent of the initiating disease  (Freeman et al. 2013). 
By  using  the  painDETECT  questionnaire,  Baron  and  colleagues  revealed  5  subgroups  of 
patients with neuropathic pain (PHN, DPN, painful radiculopathy) (Baron et al. 2009). On the 
other hand, using QST 12 subgroups of patients have been identified (Maier et al. 2010). Since 
the pattern of symptoms may be indicative of underlying mechanisms, it may be concluded 
that these subgroups of patients most likely have similar underlying pathophysiologies and 
therefore would benefit from the same treatment. Introducing this classification of patients 
will help guide future clinical trials. 
These  groups,  characterised  by  their  pattern  of  symptoms,  can  also  be  compared  to  the 
preclinical models, in order to improve translation of knowledge. This relies on preclinical 
models assessing the same outcome measures in animals and humans as in patients, such as 
the work presented in this thesis. When preclinical targets are taken forward into clinical 
development, drugs with preclinical efficacy reducing a specific group of symptoms should be 
tested in the equivalent patient population. 
However,  despite  more  than  a  decade  of  academic  discussion,  it  would  appear  that  the 
majority of clinical trials are still grouping patients by disease and using outcome measures of 
overall reduction in pain scores (table 7-3)  (Woolf et al. 1998; Jensen and Baron 2003; Baron 
et al. 2012). Not only is this more difficult for drugs to show efficacy in whole cohorts, but it is 
also difficult to use the preclinical data to guide the trial design. The models explored in this 
thesis produce specific symptoms and mechanisms, which could be used to screen suitable 
analgesics. If a drug is found to reduce a particular sign or symptom in the model, this could 
help guide selection of the group of patients it can be trialled in. However, this is not possible 
if  clinical  trials  still  used  disease  based  classification  and  do  not  assess  the  different 
symptoms.  260 
 
 
Table 7-3 Examples of recent clinical trials. A selection of recent clinical trials highlights the difficulty in 
getting  academic  work  reflected  in  practice.  Despite  being  raised  over  a  decade  ago,  very  few trials  aim to 
classify their patients by symptoms or test separate modalities. 
The  work  in  this  thesis  should  help  bring  together  preclinical  and  clinical  studies  and 
encourage the use of subgrouping in order to move towards a mechanism based approach to 
treatment.  In  this  thesis  it  has  been  shown  that  models  can  be  used  to  induce  a  specific 
symptom of chronic pain, such as capsaicin induced thermal hypersensitivity. This symptom 
is attributed to a peripheral sensitisation of C fibres, and most likely TRPV1 modulation. Using 
a mechanism based approach to treatment, whereby the A1R is believed to interfere with 
TRPV1 function, it was shown that it is possible to prevent this symptom. Therefore it may be 
Analgesic  Clinical Trial Criteria    Pain Specific Outcome Measures 
Quetenza 
  
  
PHN   
 
Percent change from baseline in the  
"average pain for the past 24 hours" 
HIV-Related Neuropathy   
 
Percent Change in the "Average Pain for  
the Past 24 Hours" 
DPN   
 
 
Change in the average daily pain scor,  
Question 5 of the Brief Pain Inventory- 
Diabetic Neuropathy (BPI-DN) 
Tapentadol 
  
  
  
Chronic Lower Back Pain   
 
 
Change in the Average Pain Intensity  
Score, painDETECT, Neuropathic Pain  
Symptom Inventory 
OA   
 
Change in the Average Pain Intensity  
Score 
DPN   
 
Change in the Average Pain Intensity  
Score 
Neuropathic Pain (thermal or 
mechanical hyperalgesia) 
 
 
Thermal thresholds, MPT, MPS, DMA,  
WUR 
CNV2197944 
  
PHN   
 
Pain Intensity Numerical Rating Scale,  
Neuropathic Pain Symptom Inventory 
DPN   
 
Pain Intensity Numerical Rating Scale,  
Neuropathic Pain Symptom Inventory 
MK-6096  DPN    Change in pain score 
KW21052  DPN    Numerical pain rating scale (NRS) 
NXN-462   PHN   
 
Change from baseline to the last week of  
treatment in daily pain scores  261 
 
predicted that A1R agonists would have efficacy in subgroups of patients who appear to have 
a strong peripheral component of their pain. 
There is already evidence that using drugs in subgroups may be effective. Although there are 
no  larger  studies  that  have  used  this  method  of  phenotyping  and  subgrouping,  positive 
retrospective data does exist (Baron et al. 2012). Using sensory tests it has been shown that 
patients  who  suffer  from  mechanical  allodynia  appear  to  respond  better  to  lidocaine 
treatment, than in those who do not exhibit this symptom (Attal et al. 2004). Additionally, a 
high baseline HPT and loss of peripheral terminals, correlates with the response to systemic 
opioids (Edwards et al. 2006). A study of clonidine in DPN patients also found they could 
predict responses using topical capsaicin cream. It was found that those who had increased 
responses  to  capsaicin  pre-treatment  (i.e.  indicative  of  peripheral  afferent  sensitisation) 
responded better to topical clonidine and their pain was significantly reduced (Campbell et al. 
2012). Furthermore, as previously mentioned, one important post-hoc analysis of pregabalin 
in HIV-related neuropathy revealed that despite an overall negative result, by subgrouping 
the patients it was found that those with pinprick hyperalgesia responded positively to the 
drug (Simpson et al. 2010). A pooled post hoc analysis of pregabalin trials based on cluster 
analysis also showed that patients in 3 particular subgroups responded better to the drug 
(Freeman  et  al.  2013).  Thus  overall  suggesting  that  subgrouping  patients,  based  on  their 
symptom profiles may allow prediction of response to different analgesics.  
Since the technique is not yet adapted in the clinic, for now a post hoc analysis may be a more 
realistic option to pursue. Furthermore, it is important to note it is difficult to truly predict 
responders, since the symptoms only indicate the mechanisms (Attal et al. 2011). However, by 
using  surrogate  models  to  explore  the  mechanisms  underlying  different  symptoms  and 
confirming their pharmacological sensitivity will help the design of subsequent clinical trials, 
if this method of profiling and subgrouping is taken up. The tapentadol study in table 7-3 
highlights a possible move in this direction, since the outcome measures of the trial include 
various QST measures. 
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Figure  7-1  Distinct  pathophysiologies  underling  chronic  pain  phenotypes  dictate  treatment 
requirements.  A  number  of  factors  contribute  to  individual  pain  phenoptypes;  this  includes  the  aetiology, 
genotype,  and  environmental  factors.  Together  these  lead  to  the  engagement  of  a  number  of  chronic  pain 
mechanisms  and  distinct  pain  profiles.  It  is  imperative  that  patients  are  subgrouped  to  define  their  pain 
phenotype in order to identify the most suitable treatment options. (von Hehn et al. 2012) 
 
7.5.   Future studies 
This  thesis has provided objective and quantitative  characterisation  of three translational 
models of chronic pain. Overall, it would appear that the most clinically relevant and useful 
model to take forward is that of UVB rekindling. This model consists of an initial inflammatory 
phase,  which  has  been  well  characterised,  followed  by  the  induction  of  secondary 
hypersensitivity. It is believed that these secondary changes are the result of engagement of 
mechanisms of central sensitisation. To fully understand the complex underpinnings of the 
sensory changes observed it would be useful to undertake some further studies involving 
pharmacological  manipulation.  It  is  well  known  that  central  sensitisation  involves  the 
activation of NMDA receptors, and thus modulation with antagonists such as ketamine and 
MK-801  would  help  confirm  the  engagement  of  such  mechanisms  (Bishop  et  al.  2010). 
Furthermore, central changes can also involve a shift in descending modulation. One example 
of such is an increase in descending facilitation from the brainstem, which has been shown to 
promote  spinal  neuronal  hyperexcitability  and  behavioural  mechanical  hypersensitivity  in 
chronic  pain  states  (Porreca  et  al.  2002;  Suzuki  et  al.  2002;  Rahman  et  al.  2009).  Under 
normal  conditions  there  is  little  effect  of  blocking  the  5HT3  receptor  with  low  doses  of 
ondansetron. However, after the induction of models such as SNL and OA even low doses are 
able to reduce signs of mechanical hypersensitivity (Suzuki et al. 2004; Rahman et al. 2009).  263 
 
Therefore, it would also be useful to assess the ability of ondansetron to modulate the changes 
observed post rekindling. 
Inhibitory controls can also be measured in humans, through conditioned pain modulation 
(CPM). CPM, or diffuse noxious inhibitory controls (DNIC) in animals, is the idea that a pain at 
one site may be able to inhibit another at a distant site. DNIC involves feedback loops similar 
to  the  descending  controls,  most  likely  reliant  on  input  from  LI/III  projection  neurones 
(Suzuki et al. 2002). An endogenous control loop involving supraspinal structures such as the 
caudal medulla and medullary reticular function then facilitate the descending modulation 
(Bouhassira et al. 1992; Le Bars et al. 1992). Given that lesions to the PAG and RVM do not 
alter DNIC, it is possible that it may involve reducing the descending inhibitory controls from 
the LC (Le Bars et al. 1992). A similar phenomenon is observed in humans and may be tested 
by  administration  of  two  simultaneous  painful  stimuli  (Pud  et  al.  2009)((Yarnitsky  et  al. 
2010). Working to  the principle  of a  mechanism based approach to treatment, it may be 
assumed that individuals exhibiting an inefficiency of CPM would respond better to drugs that 
promote an increase in inhibitory circuits. A recent study therefore hypothesised that patients 
with low CPM would benefit most from an enhancement of descending inhibition. This study 
investigated analgesic efficacy of duloxetine in a group of DPN patients (Yarnitsky et al. 2012). 
Duloxetine is a serotonin-noradrenaline reuptake inhibitor believed to augment descending 
pain inhibition through inhibiting reuptake of spinal NA and 5HT. The study concluded that 
CPM was indeed a predictor of duloxetine response, since those with lower  baseline CPM 
responded  better  to  duloxetine  treatment  (Yarnitsky  et  al.  2012).  Thus,  it  would  be 
interesting to explore any changes in CPM after the induction of experimental models such as 
UVBR. That is to say, if the models decrease CPM ability, perhaps there is a shift towards 
descending facilitation/ less inhibition. 
Secondly, it may be interesting to investigate the possibility of ongoing pain in the model of 
UVBR. Previous behavioural data noted that the secondary hypersensitivity post UVBR peaks 
at 48 hours (Davies et al. 2011), therefore suggesting that an ongoing drive may outlast the 
rekindling procedure itself. This possibility could be explored further, in humans with the use 
of  questionnaires  to  be  filled  in  at  set  time  points,  and  in  animals  with  the  use  of  CPP. 
Additionally, levels of spinal c-fos could be measured at 24 and 48 hours post rekindling, as 
this can be taken as a surrogate marker of ongoing activity into the DH. 264 
 
Thirdly, it is important that translational models engage mechanisms relevant to chronic pain 
patients. The symptoms can often be taken as indicators of particular mechanisms (Baron et 
al. 2012; von Hehn et al. 2012). Therefore, it will be of great use to compare the sensory 
profiles created from the preclinical models, to those from patients in the clinic. Currently the 
creation of sensory profiles focuses on neuropathic pain, however since the models in this 
thesis  share  more  in  common  with  non-neuropathic  chronic  pain  it  would  be  useful  to 
compare with more relevant populations. This will help identify which condition or subset of 
patients that the models best reflect.  
Finally, once there is a clear picture of the underlying mechanisms involved in this model and 
the clinical relevance, it may be used to for drug screening to assess analgesic efficacy. Most 
importantly, since this thesis has detailed full characterisation of the sensory changes evoked 
by  UVB  rekindling,  it  can  be  used  for  hypothesis  driven  screening/  a  mechanism  based 
approach to treatment. The identification of analgesics that are able to reduce specific signs 
and symptoms can then be tested in the appropriate subgroup of patients. 
 
7.6.   Concluding remarks 
Despite the potential drawbacks discussed, QST enables the quantitative measurement of a 
number of signs and symptoms of chronic pain in translational models. This allows for full 
characterisation of the models and understanding of the possible underlying mechanisms. By 
using animal models a long side these human studies it is possible to pry further into the 
distinct mechanisms underlying different symptoms. Taken together, these studies enable us 
to determine the suitability of each model with regards to testing specific analgesics. This can 
help bridge the gap between preclinical research and the clinic, in order to help provide better 
diagnosis and management of chronic pain in patients. 265 
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8.1.    Scientific Publications 
8.1.1.  Published Manuscripts 
O'Neill,  J.,  C.  Brock,  A.  E.  Olesen,  T.  Andresen,  M.  Nilsson  and  A.  H.  Dickenson  (2012). 
"Unravelling the mystery of capsaicin: a tool to understand and treat pain." Pharmacological 
reviews 64(4): 939-971. 
O'Neill, J., S. B. McMahon and B. J. Undem (2013). "Chronic cough and pain: Janus faces in 
sensory neurobiology?" Pulmonary Pharmacology & Therapeutics 26(5): 476-485. 
8.1.2.  Manuscripts in Preparation 
O'Neill, J., S. Sikandar, S. B. McMahon and A. H. Dickenson. “Characterisation of UVB and UVB 
rekindling induced sensitisation in rodents and healthy human volunteers” 
O'Neill,  J.,  S.  B.  McMahon  and  A.  H.  Dickenson.  “Activation  of  the  A1R  prevents  the 
development of heat hypersensitivity in a translational model of pain” 
8.1.3.  Abstracts 
O’Neill, J., G. D. Iannetti. S. B. McMahon and A. H Dickenson. (2012) “Translational Studies of 
Pain: Electrophysiological validation of capsaicin induced sensitisation and its modulation in 
rodents and healthy human volunteers” IASP, Milan. 
Lee, M., J. O’Neill, M. Laing, and  G. D. Iannett.. (2012) “ERPs recorded in the secondary area 
post capsaicin sensitisation” IASP, Milan.  
Dawes, J.M., J. O’Neill, S. Sikandar, J. R. Perkins, K. Bartus, N. D. James, R. S. Morland, A. S. Rice, 
E.  J.  Bradbury,  D  L.  Bennett,  A.  H.  Dickenson,  S.  B.  McMahon.  (2013).  “Expression  and 
Functional effects of CXCL5 in pain” BNA, London. 
O’Neill, J., S. Sikandar, S. B. McMahon and A. H Dickenson. (2013) “Translational Studies of 
Pain: Characterisation of UVB rekindling induced sensitisation in rodents and healthy human 
volunteers” SfN, San Diego. 
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